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List of Abbreviations 
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Ac acetyl 
AcOH acetic acid 
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anh. anhydrous 
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Boc tert-butyloxycarbonyl 
Boc2 tert-butyloxycarbonyl anhydride 
BOP benzotriazolyl-N-oxy-tris(dimethyl- 
 amino)phosphonium hexafluoro  
 phosphate 
bs broad singlet 
bt broad triplet 
Bu butyl 
c  concentration 
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dd doublet of doublets 
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g gram(s) 
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GEF guanine-nucleotide exchange factor 
GGPP geranylgeranyl pyrophosphate 
GTP guanosine 5’-triphosphate 
GP general procedure 








HMG-CoA  β-hydroxy-β-methylglutaryl- 
 Coenzyme A 
HOBt 1-hydroxybenzotriazole 
HR-MS high-resolution mass spectrometry 
HRP horseradish peroxidase 
Hz Hertz 
IC50 inhibitor concentration resulting in  
 50% inhibition 
i.e. id est (that is) 
IPP  isopentenyl diphosphate 
iPr isopropyl 
Icmt isoprenylcysteine carboxyl 
 methyltransferase 
IR  infrared  
J coupling constant 
kDa kiloDalton 
LC-MS liquid chromatography- 
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MS mass spectrometry 
MS4Å molecular sieves 4Å 
m/z mass to charge ratio 
n normal 
NCBP(s)  nitrogen containing 
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NMP N-methyl-2-pyrrolidinone 
NMR nuclear magnetic resonance 
nOe nuclear Overhauser effect 
NOESY nuclear Overhauser enhancement  
 spectroscopy 
NTP nucleoside triphosphate 
Ns nitrobenzenesulfonyl  
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p para 
p.a. pro analysi 
PE petroleum ether (40-60) 
PFT protein:farnesyltransferase 
PGGT-1 protein:geranylgeranyl transferase-1 
PGGT-2 protein:geranylgeranyl transferase-2 
Ph phenyl 
PP pyrophosphate 
ppm parts per million 





REP  Rab escort protein 
Ras rat sarcoma 
Rce Ras and a-factor converting enzyme 
ref. reference(s) 
Rf retardation factor 
Rt retention time 
RP-HPLC reversed phase-high performance 
 liquid chromatography 
rt room temperature 
s singlet 








SDS-PAGE sodium dodecyl sulphate-
polyacrylamide gel electrophoresis 
SPPS solid phase peptide synthesis 
Su succinimide 
t triplet 
TBAI tetra-n-butylammonium iodide 
TEMPO 2,2,6,6-tetramethyl-1-piperidinyloxy 
(free radical) 




TLC thin layer chromatography 
TMS trimethylsilyl 
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Three and one-letter codes amino acids* 
 
 
Ala  (A) Alanine 
Arg  (R) Arginine 
Asn  (N) Asparagine 
Asp   (D) Aspartic acid 
Cys   (C) Cysteine 
Gln   (Q) Glutamine 
Glu  (E) Glutamic acid 
Gly   (G) Glycine 
His   (H) Histidine 
Ile   (I) Isoleucine 
Leu   (L) Leucine 
Lys   (K) Lysine 
Met   (M) Methionine 
Phe   (F) Phenylalanine 
Pro  (P) Proline 
Ser   (S) Serine 
Thr   (T) Threonine 
Trp   (W) Thryptophan 
Tyr  (Y) Tyrosine 









































































































Dolichol; Insect Hormones; Zingiberene (ginger)






















































































































































Scheme 1.1 Biochemical pathway of isoprene metabolism. 












































































































1.0.1 Introduction  
The isoprenoids form one of the largest families of naturally occurring compounds.1 
In Scheme 1.1 a metabolic map of the isoprene metabolism is depicted.2 The biosynthesis 
of these isoprenoids starts from two common precursors, isopentenyl diphosphate (IPP) 
and its isomer dimethylallyl diphosphate (DMAPP) (Scheme 1.2). After the synthesis of 
IPP and DMAPP, which in eukaryotes are synthesised via the mevalonate pathway 
(Scheme 1.2),3 the enzyme geranyl pyrophosphate synthase (GPP synthase) catalyses the 
head-to-tail addition of IPP to DMAPP yielding geranyl pyrophosphate (GPP). 
Condensation of GPP with IPP by farnesyl pyrophosphate synthase affords farnesyl 
pyrophosphate (FPP, Figure 1.1) and subsequent condensation of FPP with IPP by GPP 
synthase affords geranylgeranyl pyrophosphate (GGPP).4 The isoprenoids FPP and GGPP 


























Scheme 1.2 A simplified representation of the IPP and DMAPP biosynthesis via the mevalonate pathway 
and their further processing (ATP= adenosine triphosphate, ADP= adenosine diphosphate). 















































1.0.2 Drug Development and the Mevalonate Pathway  
Interference in the mevalonate pathway is an attractive and rewarding approach for 
the development of drugs toward several pathological disorders that are related to 
isoprenoid functioning. 
1.0.2.1 Cholesterol Lowering Agents  
An important approach toward the treatment of elevated cholesterol levels in the 
blood plasma involves inhibition of cholesterol biosynthesis. Well known examples are 
the statins (Figure 1.2),5ab compounds that act by inhibiting HMG-CoA reductase (Scheme 
1.2). As HMG-CoA reductase is situated early in the biochemical pathway, obstruction of 
this enzyme also influences the biosynthesis of other important products of the isoprene 
pathway. Next, inhibitors of squalene synthase were envisioned as more specific 
alternatives for the development of cholesterol lowering agents.6ab Squalene synthase 
catalyses the reductive dimerisation of two FPP molecules to squalene which is further 
processed to cholesterol (Scheme 1.2). To date, however, no squalene synthase inhibitor 












Figure 1.2 Examples of statins as HMG-CoA reductase inhibitors: lovastatin (Mevacor®), simvastatin 
(Zocor®), pravastatin (Lipostat®), fluvastatin (Lescol®) and atorvastatin5cd (Lipitor®). 
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1.0.2.2 Agents against Osteoporosis  
Bones are continually remodeled by two types of cells: osteoblasts, which synthesise 
the collagen fibrils that form the scaffolding upon which the bone is formed and 
osteoclasts, which are responsible for bone resorption. During osteoporosis7 there is an 
imbalance between these two cell types, for instance enhanced activity of osteoclasts, 
which can lead to an overall breakdown of bone tissue. A recently developed approach 
toward anti-osteoporosis agents is based on nitrogen containing bisphosphonates (NCBPs, 
Figure 1.3).8 These compounds exert their activity against osteoclasts by inhibiting FPP 
synthase (Scheme 1.2) with apoptosis as effect.9 As the earlier mentioned statins inhibit 
the formation of FPP precursors, these compounds are also envisioned as effective anti-
osteoporosis agents.10 However, until now there is insufficient evidence for the clinical 
use of statins as anti-osteoporosis agents which may be attributed to the fact that statins 










Figure 1.3 The nitrogen containing bisphosphonates Risedronate (Actonel®) and Alendronate (Fosamax®)  
as agents for the treatment of osteoporosis. 
 
1.0.2.3 Anti-cancer Agents  
Protein isoprenylation11 is a post-translational modification entailing the covalent 
attachment of an isoprenoid lipid to a protein-substrate (Scheme 1.2). To date more than 
100 proteins that are involved in regulating various biological processes such as signal 
transduction,12 cell growth, differentiation, cytoskeletal function and vesicular 
trafficking,13 are known to be isoprenylated. In general, post-translational modifications 
transform a protein from a pre-mature state to a mature state by either regulating a 
proper translocation of the protein to a cellular membrane or inducing protein-protein 
interactions.14 G-proteins are GTPases (guanine triphosphatases) which are located at the 
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signalling pathways.15 Normally, they cycle between an active GTP bound state and an 
inactive GDP bound state (Figure 1.4). This process of GTP and GDP binding is regulated 
by a GTPase activating protein (GAP) and a guanine nucleotide exchange factor (GEF). 
GAP catalyses the hydrolysis of GTP and can be seen as a negative regulator of G-protein 












Figure 1.4 The GTPase cycle. GEF= guanine nucleotide exchange factor; GAP= guanine triphosphatase 
activating protein; GDP= guanosine diphosphate; GTP= guanosine triphosphate. 
 
The wide interest in the interference of isoprenylation is primarily based on the 
finding that isoprenylated G-proteins17 are involved in the malignant transformation of 
cells and that blocking these oncogenic G-proteins is a promising method for the 
development of anti-cancer agents. The involvement of G-proteins in tumorogenesis can 
be caused by the following: 1) mutations in the G-proteins themselves which invariably 
confer resistance to the binding and action of GAPs,18 leading to a situation in which the 
signal induced by the G-protein is continually in the “ON” state; 2) alterations in 
upstream tyrosine receptor kinases leading to undesired activation of the G-protein; 3) 
alterations in downstream components such as GAP proteins which ultimately leads to a 
loss of negative regulation.19  
The most important and abundant small G-proteins involved in human 
tumorogenesis20 are members of the Ras family:∗ H-Ras (Harvey-Ras), N-Ras 
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(neuroblastoma-Ras), K-Ras (Kirsten-Ras), with K-Ras existing as two isoforms, K-RasA 
and K-RasB.21 These small monomeric G-proteins (21 kDa) show a high sequence 
conservation and were first detected in human cancers in 1982. It is estimated that they 
are present in - and at least partially responsible for the proliferation of - about 30 − 40% 
of all human tumors.22 Since the finding of these oncogenic proteins in humans, there has 
been a considerable interest in the development of Ras inhibitors as anti-cancer agents.23  
A widely used approach toward the inhibition of oncogenic Ras activity comes from 
understanding of the requirements for its activity. All Ras proteins are initially 
synthesised as inactive cytosolic proteins that have to undergo post-translational 
modifications to gain full biological activity (Scheme 1.3).24 The first and most essential 
modification involves the isoprenylation of a C-terminal cysteine residue in a 
characteristic tetrapeptide motif, the “Ca1a2X-box”, of the peptide substrate. Here C stands 
for cysteine, in general the a1a2 is an aliphatic hydrophobic dipeptide and the nature of 
residue X determines substrate specificity between the two responsible isoprenylating 
enzymes,  protein:farnesyl transferase (PFT) and protein:geranylgeranyl transferase-1 
(PGGT-1). PFT preferably modifies substrates where X is Met, Ser or Gln whereas PGGT-
1 has a high propensity for modifying substrates having Leu or Phe as X residue.  
Although the isoprenylation step is the major determinant for proper functioning of 
Ras proteins, subsequent post-translational modifications are also important for full 
transforming activity.25 These post-translational modifications comprise a number of steps 
(Scheme 1.3): first, there is the proteolytic cleavage of the a1a2X tripeptide by the protease 
Rce126 which is followed by the methylation of the formed C-terminal carboxylic group 
by isoprenylcysteine carboxyl methyltransferase (Icmt).27 In the case of H-Ras,28 N-Ras 
and K-RasA, upstream cysteine residues (for H-Ras two cysteines) are then palmitoylated 
through the action of a palmitoyl transferase29 and this additional hydrophobicity 
promotes further association to the cell membrane.30 K-RasB on the other hand, contains 
a stretch of upstream located positively charged lysine residues which allow K-RasB to 
interact with the negatively charged heads of the lipid bilayer.31 It is assumed that this 
electrostatic interaction substitutes for the palmitoyl interaction present in H-Ras, N-Ras 
and K-RasA.32  
 





























































Scheme 1.3 Simplified representation of Ras processing and its role as molecular switch  
in signal transduction.  
 
 1.1 The Protein Prenyl Transferases 33 
1.1.1 Introduction  
PFT and PGGT-1 catalyse the vast majority of protein isoprenylation events 
encountered in nature. Their role in post-translational modifications was identified for 
the first time in 1990 by Brown and co-workers who noticed that [3H] labeled mevalonate 
was incorporated into polypeptides.34 In 1991 PFT was identified in the cytosolic fraction 
of bovine brain.35 Since then PFT has been isolated from rat brain,36,37,38 pig39, yeast,40 
plants41 and human.42 PGGT-1 was identified in 1991 and has since then been purified 
from bovine brain,43 yeast (Saccharomyces cerevisiae),44 rat,45 human46 and plants.47 
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α-subunit of PFT  
and PGGT-1
β-subunit of PFT β-subunit of PGGT-1
The crystal structures of PFT48 and PGGT-149 (Figure 1.5) show a heterodimeric 
metalloprotein consisting of an α-subunit (48 kDa) and a β-subunit (PFT: 46 kDa, PGGT-
1: 43 kDa). PFT and PGGT-1 share the same α-subunit while the β-subunit of PFT has 
25% homology with the β-subunit of PGGT-1. The α-subunit is build up by a set of 
helices which are arranged in α-helical hairpin pairs. This results in a crescent like shape 
which wraps extensively around the β-subunit. The β-subunit forms a globular and 
compact α-α barrel domain with a central cavity in which the active site resides. 
 
 












1.1.2 Reaction cycle and Mechanism of PFT and PGGT-1   
From steady-state kinetic studies and X-ray crystallographic studies, a general 
reaction cycle for PFT51 and PGGT-149 has been formulated. The catalytic cycle 
commences with the binding of the isoprenoid pyrophosphate substrate52 followed by 
binding of the peptide substrate (I II III, Scheme 1.4). During the following turn-over 
process, metals play an important role: a Zn2+ ion is essential for catalytic activity and 
directs the binding of the peptide substrate and enhances the nucleophilicity of the 
cysteine-thiol functionality by lowering its pKa (A B, Scheme 1.4);53 a Mg2+ ion is 
required in PFT for maximal activity by coordinating the isoprenoid pyrophosphate group 
and facilitating its nucleophilic displacement. PGGT-1 does not require any Mg2+ for 
activity, instead the active site of PGGT-1 contains a lysine residue for coordination with 
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the pyrophosphate group.54 Initially, the pyrophosphate group and the zinc coordinated 
thiolate are separated by ∼8Å. In the next step the isoprenoid substrate repositions the 
pyrophosphate group to close proximity of the thiolate allowing formation of the 
thioether  by a Sn2 like displacement of the pyrophosphate group (A B, Figure 1.6). The 
transition state of the product formation (A, Scheme 1.4) can be visualised as a metal 
bound cysteine bearing a partial negative charge on the thiol, the isoprenoid having a 
partial positive charge on C1 and the bridging oxygen between the α-phosphate and C1 
having a partial negative charge.§ Upon binding of a new isoprenoid substrate (IV II, 
Scheme 1.4) the isoprene part of the isoprenylated protein is moved to an exit groove. In 
the exit groove the conformation of the Ca1a2X part of the prenylated protein changes 
from an extended to a type 1 β-turn and this alteration is believed to be important for 




























Scheme 1.4 Reaction sequence and mechanism of isoprenylation by PFT and PGGT-1. 
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Figure 1.6 Rotation of first two isoprene units brings the isoprenoid in the productive conformation 
(exemplified for GGPP and CVIL).50 
 
1.1.3 Factors that Determine Substrate Specificity of PFT and PGGT-1  
In order to develop any substrate based prenyl transferase inhibitors it is important 
to understand the factors by which PFT and PGGT-1 discriminate between their peptide 
and isoprenoid substrate. In this section the factors governing this specificity will be 
outlined in some detail. 
1.1.3.1 Peptide substrate specificity  
The first difference between PFT and PGGT-1 concerns the selective binding of the 
peptide substrate. Beese and co-workers13 defined a set of rules directing substrate 
selectivity by crystallographic analysis of a set of eight substrate peptides. For PFT and 
PGGT-1 the a1 position is oriented toward the solvent and in theory should be able to 
accommodate any amino acid (Figures 1.7 and 1.8). In both enzymes the a2 residue binds 
in a hydrophobic pocket, excluding polar or charged residues in this position. In addition, 
too large or too small residues are also not compatible with the a2 pocket. In PFT (Figure 
1.7) the a2 pocket has a highly aromatic character and aromatic substituents at the a2 
position of the Ca1a2X-box can interact strongly with this pocket.   
 


















N specificity pocket 1
a) exposed to solvent
b) a1: any amino acid possible
a) interacts with Trp102β, Trp106β,
Tyr361β and 3rd isoprene FPP
b) a2: Ile, Val preferred over Leu, Phe, Tyr, Thr, Met
always Cys
pocket 2
a) interacts withTyr131α, Ala98β, Ser99β,
Trp102β, His149β, Ala151β,Pro152β
b) X= Met > Gln, Ser, Ala, Thr, Cys
a) interacts with Leu99β, Ser99β, Trp106β,
Ala151β, 3rd isoprene FPP






























b) X= Leu preferred over Ph, Met, Ile, Val
a) exposed to solvent
b) a1: any amino acid possible
a) interacts with Thr49β, Phe53β, Leu320β,
3rd and 4th isoprene GGPP, X-amino acid
b) a2: Ile, Val preferred over Leu, Phe, Tyr, Thr, Met
always Cys
a) interacts with Thr49β, His121β,
Ala123β, Phe174β.













Figure 1.7 Surrounding of Ca1a2X tetrapeptide motif in active site of PFT.  
 
The most important moiety governing peptide specificity for PFT and PGGT-1 is the 
side-chain of the X-residue. In the specificity pocket (pocket 1, Figure 1.7) of PFT van der 
Waals and electrostatic interactions allow the binding of Met, Gln or Ser, the X- residues 
found in the majority of mammalian PFT substrates.55 Although natural PFT substrates 
containing a Phe as X-residue are known, pocket 1 is not able to accommodate this 
residue.56 An explanation is that the Phe side-chain binds in an alternative pocket (pocket 
2, Figure 1.7) and the empty space of specificity pocket 1 is filled with two water 
molecules. This alternative pocket can also be used by PFT to accommodate a Leu, Asn or 










Figure 1.8 Surrounding of Ca1a2X tetrapeptide motif in active site of PGGT-1. 








In PGGT-1 (Figure 1.8) the hydrophobic pocket for residue a2 is smaller and has less 
aromatic character than the corresponding pocket in PFT. Stabilisation of the C-terminal 
X-residue is governed by one pocket in which hydrophobic and van der Waals 
interactions allow binding with a Leu, Phe or Met moiety in the peptide substrates. The 
majority of PGGT-1 substrates have a Leu as X-residue, but Ile57 and Val58 are also 
tolerated by PGGT-1 as X-residue.  









Figure 1.9 Left: surrounding FPP in PFT (A); right: surrounding GGPP in PGGT-1 (B). 
 
The second difference between PFT and PGGT-1 concerns the selective binding of 
the isoprenoid substrate. In PFT, the terminal isoprene in FPP is surrounded by a 
Tyr(365β) and Trp(102β) residue (A, Figure 1.9). In PGGT-1 the Trp residue is a smaller 
Thr residue and the Tyr is Phe (B, Figure 1.9). This enables accommodation of the 4th 
isoprene of GGPP and thus productive binding of GGPP. In all PGGTs-1 isolated from 
different species, the 49β residue is found to be a small amino acid (Thr, Val, Ser, Ala) 
whereas in PFT it is always Trp. To underline the importance of Trp102β in PFT, it is 
reported that when this residue is mutated in PFT to a Thr residue the corresponding PFT 
shows the same isoprenoid substrate specificity as PGGT-1.38a,46 Thus, as PFT 
discriminates between FPP and GGPP by steric factors,59 how does PGGT-1 exclude the 
binding of the smaller FPP? The mechanism by which PGGT-1 releases its product 
determines the preference for GGPP binding: the lipid binding pocket is always occupied 
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with either the isoprenoid substrate or the product (see Scheme 1.4) and GGPP is much 
more able to displace the product from the active site in PGGT-1 than PFT; thus PGGT-1 
uses its product release to direct isoprenoid specificity.13 
1.1.3.3 Substrate cross-specificity 
PFT and PGGT-1 exhibit cross-specificity that can be explained with the aid of 
structural information given in paragraph 1.1.3.1 and 1.1.3.2. First, PFT can bind C-
terminal Leu residues in pocket 2 (Figure 1.7), an alternative pocket to the one used for 
the Met residue. For example the small G-protein RhoB with CKVL as Ca1a2X sequence is 
a substrate of both PGGT-1 and PFT.60 A model composed by Beese and co-workers13 
shows that Leu can nicely be accommodated in the second binding pocket of PFT. It is 
important to mention that this type of cross-specificity is strongly regulated by the a1a2 
dipeptide sequence: some dipeptide sequences do not allow a correct positioning of the 
Leu side-chain in the alternative pocket of PFT. This is exemplified by the finding that 
Rap2b, having CVIL as Ca1a2X box, is not a substrate for PFT. Second, PGGT-1 is able to 
accommodate Met in its X-binding pocket, explaining the observed cross-specificity for 
K-RasB with Ca1a2X= CVIM and N-Ras with Ca1a2X= CVVM. Finally, in contrast to the 
peptide substrate, cross-specificity of the isoprenoid substrates appears to be less 
pronounced.61  
1.1.3.4 Protein:geranylgeranyl transferase 2  
Protein:geranylgeranyl transferase-2 (PGGT-2) is the third member of the protein 
prenyl transferases and exclusively isoprenylates Rab proteins, which are small G-
proteins involved in subcellular localisation and vesicular transport.62 In contrast to PFT 
and PGGT-1, the isoprenylation step catalysed by PGGT-2 (also called RabGGT) involves 
the transfer of two geranylgeranyl isoprenoids to two closely spaced cysteine moieties 
located at the C-terminus of the Rab proteins. These cysteines are arranged in motifs such 
as C-C, C-a-C, C-C-a, or a-a-X-X (with C= cysteine and a is any amino acid).63 An 
additional difference with PFT and PGGT-1, is the required complexation of PGGT-2 
with a Rab escort protein (REP) prior to substrate binding.64   
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1.2.1 Inhibition of PFT and PGGT-1 in Drug Development  
As Ras proteins (i.e. H-Ras, N-Ras, K-RasA and K-RasB) are normally farnesylated, 
it is not surprising that the majority of research activities aimed at disabling protein 
isoprenylation is directed at the design of PFT inhibitors. In addition, the majority of 
proteins is geranylgeranylated,11b,65 indicating that blocking of geranylgeranylation will 
affect a broader range of biological processes. However, PGGT-1 has emerged as an 
important alternative target for several reasons.66 First, there is the observation that upon 
blocking PFT, N-Ras and the most abundant human oncogenic Ras protein K-RasB are 
geranylgeranylated through the action of PGGT-1.67 This indicates that effective therapies 
based on preventing K-RasB (and N-Ras)68 functioning may require the inhibition of both 
PFT and PGGT-1. Besides K-RasB, several natural PGGT-1 substrates (e.g. RhoA) may 
also be involved in mediating oncogenesis and/or metastasis.69 Second, PGGT-1 inhibitors 
hold promise as anti-osteoporosis agents. This is based on the observation that 
geranylgeraniol (GGOH), but not FPP, was able to prevent the action of nitrogen 
containing bisphosphonates (NCBPs) on oscteoclasts.8b,70 The GGOH is transformed in 
vivo to GGPP,71 which then restores the geranylgeranylation of certain proteins 
important for osteoclast growth (such as Rab, Rho and Rac).72  
A third therapeutic field promoting the targeting of PGGT-1 entails atherosclerosis 
and restenosis. Atherosclerosis is a general term for the thickening and hardening of 
arteries while restenosis involves the rethickening of a coronary artery after percutaneous 
transluminal coronary angioplasty.73 During these processes the proliferation of vascular 
smooth muscle cells plays an important role. Because isoprenylated G-proteins are 
involved in the regulation of vascular smooth muscle cell proliferation, the inhibition of 
these proteins by blocking PFT and/or PGGT-1 is regarded to be a viable approach toward 
the development of therapeutic agents for atherosclerosis and restenosis.74 
 
1.2.2 Design and Development of PFT and PGGT-1 inhibitors  
1.2.2.1 The Ca1a2X box as lead  
Since the early 90’s it is known that PFT and PGGT-1 recognise and are inhibited by 
Ca1a2X box tetrapeptides and thus can serve as lead for the design of potential inhibitors 






























































targets PFT targets PGGT-1
(Figure 1.10). The intrinsic potency of the Ca1a2X tetrapeptide as recognition motif for the 
corresponding prenyl transferase (PFT and/or PGGT-1) is further underscored by the 
early observation that a Ca1a2X sequence such as CVLS (from PFT substrate H-Ras) is 
farnesylated by PFT.34,36,75 The presence of an N-terminal amine, for example in the case 
of CVLS, is generally tolerated by the prenyl transferase. Longer Ca1a2X containing 
peptides, e.g. SSGCVLS,35 are also farnesylated. As small peptides exhibit a low cellular 
permeability and a high sensitivity toward proteolytic degradation, this renders them 
unuseful for therapeutic applications. To overcome these obstacles the Ca1a2X motif has 
been used extensively as lead for the development of numerous Ca1a2X peptidomimetics 
aimed at inhibiting PFT (Figure 1.11) and/or PGGT-1 (Figure 1.12).76 Ca1a2M analogs 477 
and 878 illustrate an interesting feature of the Ca1a2X template: compound 4 has an 
extended conformation while 8 adopts a β-turn like conformation. As mentioned in 
paragraph 1.1.2, the Ca1a2X tetrapeptide adopts both type of conformations in both PFT 
and PGGT-1. Therefore Ca1a2X based inhibitors may adopt an extended or turn-like 
motif. Besides modification of the a1a2 part the cysteine and X-residue have also been 
replaced by non-peptidic mimics. Compounds 9–12 (Figure 1.11) and 16–20 (Figure 1.12) 
are examples in which the cysteine residue is replaced by an alternative Zn2+ chelating 
moiety, the imidazole functionality. In general, the X-residue is replaced by a 
hydrophobic residue which binds either in the pocket involved in the interaction with 
the X moiety or to other hydrophobic residues present in the active site. In compound 13 
a tetrazole79 is incorporated as a carboxylic acid isostere. Although the Ca1a2X tetrapeptide 
motif is a valuable and rewarding template for a peptidomimetic approach toward 
isoprenyl transferase inhibitors, the structural determinants of enzyme recognition and 









Figure 1.10 Ca1a2X box tetrapeptide sequences used for the development of PFT/PGGT-1 inhibitors. 












































































































































































































































Figure 1.12 PGGT-1 inhibitors which bind in the Ca1a2X pocket: 14,67c 15,81 16/17,82 18,83 19,84 20,85 2186. 













































































































1.2.2.2 The isoprenoids FPP and GGPP as lead  
Next to the Ca1a2X tetrapeptides,  FPP (Figure 1.13) and GGPP (Figure 1.14) can be 
used as templates for the development of prenyl transferase inhibitors. In general, the 
pyrophosphate is replaced by a more stabile and cell permeable isosteric group (as in 22 − 
24 and 28 − 30). Compounds 26 and 27 are examples of PFT inhibitors which were 


























Figure 1.14 Examples of PGGT-1 inhibitors based on GGPP: 28 - 3092, 3193, 3289, 3394, 3495. 























































































1.2.2.3  Bisubstrate Inhibitors  
Potential inhibitors of PFT and PGGT-1 can also be based on the characteristics of 
both the Ca1a2X and isoprenoid substrates.96 Such bisubstrate inhibitors (35–38, Figure 
1.15) offer opportunities for achieving high specificity, as combining the features of both 
substrates makes it more likely that neither component will be recognised by untargeted 
enzymes which also use the same substrate (e.g. squalene synthase).97 Note that to date 







   
 
Figure 1.15 Examples of bisubstrate inhibitors targeted at PFT: 3598, 3699, 37100, 38101. 
 
1.2.2.4  Inhibitors from library screening  
Lead compounds for the development of PFT and/or PGGT-1 inhibitors have also 
been obtained by the screening of libraries. In general, these compounds exhibit a large 
variety in structural identity.102 Compound 39 (Figure 1.16) is an example of a potent PFT 
inhibitor obtained from library screening.103 Despite a high peptidic character, kinetic 
analysis showed 39 to be competitive for FPP. The very low cell permeability of 39 led to 









Figure 1.16 Compound 39: PFT inhibitor from library screening; compound 40 is an analog of 39 with 
improved cellular permeability. 
































Androstatin A: R= CHO
Androstatin B: R= CH2OH












































1.2.2.5 Inhibitors from natural sources  
Several natural inhibitors of PFT105 (Figure 1.17) and PGGT-1106 (Figure 1.18) have 
been isolated from microorganisms, plants and soils. Natural source inhibitors are seldom 
used as lead compounds for the development of more potent analogs which may be 




























Figure 1.18 Natural inhibitors of PGGT-1. 
 
1.2.3 Inhibitors of isoprenylation in clinical trials.  
To date, four inhibitors of PFT have been subjected to evaluation in clinical trials 
(phase I-III).106e,107 Compound L-778,123 (Figure 1.19)84 was initially designated a selective 




































inhibitor of PFT (PFT: Ki= 0.9 nM, PGGT-1: Ki= 10 μM) which competes with the Ca1a2X 
peptide substrate. Later it was found that when anions (such as adenosine triphosphate, 
phosphate, sulfate) are present, L-778,123 behaves like a dual inhibitor of both PFT and 
PGGT-1 (PGGT-1: Ki= 4 nM) indicating that anions have a synergistic effect on the 









Figure 1.19 Structure of L-778,123 and its binding mode in PFT. 
 
The trihalobenzocycloheptapyridine SCH66336 (Lonafarnib/Sarasar®,Figure 1.20) is 
a selective inhibitor of PFT (IC50= 1.9 nM). The design of SCH66336 started from 
SCH44342, a compound obtained by random library screening.109 The binding mode of 
SCH66336 has been elucidated in detail by crystallographic studies110 showing that the 
upper part is involved in interactions with bound FPP while the lower part has contacts 
with amino acid residues of PFT (right part Figure 1.20). 











Figure 1.20 Left: structure of SCH44342 and SCH66336. Right: binding mode of SCH66336 in PFT. 





























BMS-214662 (Figure 1.21)111 is a selective inhibitor of PFT (IC50= 1.4 nM). 
Crystallographic studies showed that BMS-214662 binds in the Ca1a2X box binding site, in 
line with its peptide-competitive behaviour, as previously determined by kinetic 
analysis.112 The general design of this compound is based on an imidazole group for 
interaction with the Zn2+ in the active site and a core which is functionalised with 
aromatic residues for stacking interactions with aromatic residues of the a2 binding 
pocket. As for SCH66336, the inactivity of BMS-214662 against PGGT-1 is believed to be 
















Figure 1.21 Left: key interactions of BMS-214662 in PFT. Right: binding mode from X-ray studies. 
 
Finally, R115777 (Tipifarnib®, Figure 1.22)113,∗ is a selective inhibitor of PFT (IC50= 
1.4 nM) that binds to the peptide binding pocket as clarified by kinetic analysis and 
crystallographic studies.111,113 R115777 is U-shaped when bound to the active site of PFT 
and besides polar interactions, aromatic stacking of the aromatic residues are involved in 
binding. The selectivity of R115777 against PFT is also governed by the aromatic residues 
of the a2 binding pocket. 
 
                                                 
∗  As from january 24th 2005, Tipifarnib® has been submitted to the US Food and Drug Administration 
(FDA) for approval for the treatment of acute myeloid leukemia (see www.drugs.com/nda/tipifarnib 
050124.html).  




































Figure 1.22 Left: key interactions of R115777 in PFT. Right: binding mode from X-ray studies. 
 
1.2.4 Why is there selectivity for tumor cells versus normal cells? 
The phenomenon that tumor cells show an enhanced sensitivity for inhibition is 
not uncommon. At the moment the exact reasons for the observed selectivity of PFT and 
PGGT-1 inhibitors for tumor cells is not fully clear. Some observations made with PFT 
inhibitors, however, are worth mentioning.114 First, not all farnesylated proteins exhibit 
the same sensitivity to PFT inhibition in cells.78,115 Second, redundant pathways in normal 
cells may be responsible for the compensation of the functional loss of proteins.116 
Thirdly, the functions of farnesylated proteins involved with cellular transformation may 
be more susceptible to the action of PFT/PGGT-1 inhibitors than are the functions of 
those same proteins in normal cells. For example, a dominant negative form of Ras has 
been found to exhibit a much greater inhibitory effect on cellular transformation induced 
by oncogenic H-Ras function than on normal cellular Ras function.117 
 
 1.3 Outline of the Thesis 
 Van Boom and co-workers demonstrated for the first time the viability of (partially 
deoxygenated) sugar amino acids (SAAs) as peptidomimetic building blocks in the 
construction of novel PFT inhibitors based on the Ca1a2X-box.118 In line with this 
approach, Chapter 2 describes a novel route towards two dideoxy SAAs (41 and 42, Figure 
1.23) which were used to synthesise analogs of the Ca1a2L motif thereby aiming to target 
PGGT-1 (43). Next to the (stereochemical) nature of the SAA building block (i.e. R or S at 
















































R= CH(CH)3 for 
targeting PGGT-1
R= CH2SCH3 for 
targeting PFT47 X= H, H46 X= H, H
48 X= O





C6), the configuration (L or D) of the Cys and Leu pharmacophores was varied, leading to 
a set of eight Ca1a2L analogs. It is demonstrated that the nature of the SAA building block, 
in conjunction with the stereochemistry (L or D) of the Cys and Leu pharmacophores, has 









Figure 1.23 Sugar amino acids 41 and 42 as dipeptide isosters in the Ca1a2L motif. 
 
Chapter 3 describes the use of SAAs in the development of both PFT and PGGT-1 
inhibitors. It was envisioned that enhancing the hydrophobicity of the a1a2 dipeptide 
mimics might lead to hydrophobic interactions between the Ca1a2X analogs and the 
hydrophobic residues surrounding the a2 pocket. As aromatic groups reside in this pocket 
it was decided to attach a benzyl group to the C3 hydroxyl group (44, Figure 1.24). In 
addition, the importance of the amide linkage between the SAA and X-residue was 
probed by the synthesis of a set of Ca1a2X analogs (49) in which the corresponding amide 
was replaced by an amine.119 The methyl ester analog of one of the developed compounds 
was evaluated in vivo and showed inhibitory activity against protein farnesylation in 










Figure 1.24 Benzylated SAAs (44 and 45) and corresponding amine analogs (46 and 47)  
as dipeptide isosters in the Ca1a2X motif. 
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Chapter 4 presents the synthesis of lipophilic Ca1a2L analogs as potential bisubstrate 
inhibitors of PGGT-1. The general structure of the presented compounds is depicted in 
Figure 1.25 (50): Ca1a2L analogs presented in Chapter 2 are connected, directly or via a 
linker (Gly or γ-Abu), to a simple fatty chain (lauric acid or palmitic acid) which may 








Figure 1.25 General structure of lipophilic Ca1a2L  analogs presented in Chapter 4. 
 
In Chapter 5 the effect of introducing a tetrazole79 as carboxyl bioisostere in the 
Ca1a2X box is investigated (Figure 1.26). Compound 51 is an analog of the Ca1a2X box 
sequence CVIM (K-RasB) and compound 52 is derived form a potent and selective 
inhibitor of PFT presented in chapter 3. As is shown, in both compounds the C-terminal 








Figure 1.26 Tetrazole analogs of CVIM (51) and a potent PFT inhibitor presented in Chapter 3 (52).  
 
Chapter 6 presents a labeling strategy for detecting the in vivo isoprenylation of 
proteins by a Bertozzi-Staudinger reaction120 between an azide substituted FPP moiety 
(53) and phosphine reagent 54 (Scheme 1.5). After incubation of a mouse macrophage cell 
line with FPP analog 53, PFT recognises 53 as alternative substrate and consequently 
processes it. The cell lysate was then treated with reagent 54 thereby covalently binding 
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allowed detection of any azidofarnesylated proteins by chemiluminescence. Analysis by 
SDS-PAGE showed the azidofarnesylated proteins as separate bands and by addition of 
PFT inhibitors, the labeling efficiency was decreased indicating that the developed 
















Scheme 1.5 Two-step Bertozzi-Staudinger ligation for the identification of isoprenylated proteins. 
 
Chapter 7 describes a combinatorial approach toward a library of ambiphilic peptide-
based compounds of general structure in which an in silico iterative optimisation 
procedure was used for the rapid construction of potential inhibitors of PGGT-1 (Scheme 
1.6). The iterative optimisation procedure involves the arbitrary replacement of randomly 
chosen building blocks. By repetitive cycles of the process a progressive improvement of 










Scheme 1.6 Schematic presentation of optimisation procedure presented in Chapter 7.
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Abstract. A novel route towards two dideoxy sugar amino acids (SAAs) is presented. The suitably protected 
SAA building blocks were used to synthesise eight analogs of the Ca1a2L motif present in natural substrates 
of protein:geranylgeranyl transferase 1 (PGGT-1). Two Ca1a2L analogs (i.e. 2,6-trans 9 and 2,6-cis 14) which 
structurally differ at the C6 position of the central SAA residue and at Cα of the cysteine residue, show 
comparable inhibition potency against PGGT-1 (IC50= 68 ± 16 μM and 69 ± 20 μM, respectively). The results 












 2.1 Introduction 
An attractive strategy for the generation of PGGT-1 inhibitors is based on the 
design of structural analogs of the Ca1a2L motif present in natural PGGT-1 substrates (see 
Chapter 1). A generic structure of these Ca1a2L based inhibitors consists of the important 
pharmacophoric groups, i.e. the cysteine and leucine side chains, interconnected via a 
predesigned peptidomimetic linker (I, Figure 2.1). Desirable properties in terms of 
biostability (resistance towards proteolytic degradation) and bioactivity (e.g. inducement 







Figure 2.1 Peptidomimetic replacement of a1a2 dipeptide (I); schematic representation of SAA (II). 
 
Sugar amino acids (SAAs, II, Figure 2.1), modified carbohydrates featuring an amine 
and a carboxylate, have emerged as useful building blocks for the construction of a wide 
variety of potentially biologically active molecules,3 such as oligosaccharide mimetics,4 
enkephalin analogs,5 integrin inhibitors6 and scaffolds.7 Moreover, van Boom and co-
workers demonstrated the viability of partially deoxygenated gluconic amino acids 
(having either a 2,6-cis or 2,6-trans configuration) as building blocks in the construction 
of novel PFT inhibitors.8  
In this chapter the use of SAAs III (2,6-cis) and IV (2,6-trans) as an isosteric 
replacement of the a1a2 dipeptide present in the Ca1a2L motif (V, Figure 2.2) of natural 
PGGT-1 substrates is presented. Both the 2,6-cis and 2,6-trans configuration in the SAA 
building blocks were selected.9,10 Next to the (stereochemical) nature of the SAA building 
block, the configuration (L or D) of the Cys and Leu pharmacophores was varied, leading 
to eight novel tetrapeptide analogs of the general design VI (Figure 2.2). It is 
demonstrated that the nature of the SAA building block, in conjunction with the 
stereochemistry (L or D) of the Cys and Leu pharmacophores, has a distinct influence on 
































































Figure 2.2 Incorporation of SAAs III and IV as dipeptide isosters in the Ca1a2L motif (V) furnishing  
potential PGGT-1 inhibitors of type VI. 
 
 2.2 Results and Discussion 
2.2.1 Synthesis − In the first approach toward the synthesis of SAAs 3 (Scheme 2.1), 
glucal 1, readily prepared from D-(+)-glucuronic acid-γ-lactone,11 was treated with 
TMSCN and BF3·OEt2 furnishing 4,5-dideoxy glucopyranosyl cyanides 2,6-cis/trans 2 
(86%, cis/trans ∼3/5) as an inseparable mixture.12 Reduction of the olefin and cyanide 
functionalities13 in 2 followed by protection of the resulting primary amine as the tert-
butoxy carboxylate (Boc), and final saponification of the acetate gave SAA 3 as an 
inseparable mixture of diastereoisomers in 30% yield over the four steps.  
Although this route of synthesis proved to be an efficient process, the anomeric 
mixture obtained after the Ferrier rearrangement in the first step (2,6-cis/trans 2) could 
not be separated after the three subsequent transformations. Therefore the removal of the 
3-O acetate in an earlier stage of the synthetic route was investigated. Base mediated 
removal of the acetate in 2,6-cis/trans 2 is excluded because of the instability of 2 under 
these conditions.14 Gratifyingly, acid-induced hydrolysis15 of the acetate furnished a 
separable mixture of the desired 2,6-cis/trans cyanides 5.  
In an alternative approach, the individual C-glycosides 2,6-cis and 2,6-trans 5 
proved to be accessible from the known, partially deprotected methyl glucuronate-D-
glucal 4.16 Treatment of 4 with Pd(OAc)2 and TMSCN in CH3CN at 80°C gave cyanides 
2,6-cis 5 and 2,6-trans 5 in a ratio of ∼1/1 in 76% yield.17 After separation by silica gel 
chromatography, the individual isomers were transformed (10% Pd/C, H2; Boc2O, Et3N, 
DCM) into the corresponding orthogonally protected SAA building blocks (2,6-cis 3 and 
















































































aReagents and conditions. (i) 1.1 equiv. TMSCN, 0.2 equiv. BF3·OEt2, DCM (2,6-cis/trans 2: 86% ); (ii) 
(a) 10% Pd/C, MeOH/CHCl3 (10/1 v/v), H2 atm. (45 psi), 24 h, (b) Boc2O, Et3N, DCM (2,6-trans 3: 55%, 2,6-
cis 3: 51% ); (iii) KOtBu, MeOH (2,6-cis/trans 3: 87%); (iv) 0.05M HCl in MeOH, 60°C, 5 h (combined yield 
2,6-cis 5 and 2,6-trans 5: 89%); (v) 5 mol% Pd(OAc)2, 5 equiv. TMSCN, CH3CN, 80°C, 48 h (combined yield 
2,6-cis 5 and 2,6-trans 5: 76%).   
 
The general route of synthesis to the fully protected Ca1a2L mimetics is exemplified 
by the preparation of 2,6-trans 8 (Scheme 2.2). Saponification of the methyl ester in 2,6-
trans 3 and condensation of the resulting acid (2,6-trans 6)8 with Leu-OMe⋅HCl under the 
influence of PyBOP and DIPEA in DMF afforded dimer 2,6-trans 7 in 87% yield over the 
two steps. Removal of the Boc protective group in 2,6-trans 7 and condensation of the 
resulting ammonium salt with Fmoc-L-Cys(StBu)-OH gave protected 2,6-trans 8. By the 
same synthetic procedure and with comparable efficiency, protected trimers 2,6-trans 13 










2,6-trans 3  R=Me
2,6-trans 7































aReagents and conditions. (i) 1.0 equiv. LiOH (1.0M aq.), H2O/1,4-dioxane, 0°C (>99%); (ii) L-Leu-
OMe·HCl, PyBOP, DIPEA, DMF (87%); (iii) 50% TFA in DCM, iPr3SiH; (iv) Fmoc-L-Cys(StBu)-OH, 
PyBOP, DIPEA, DMF (87%). 
 
Scheme 2.3 Synthesis 2,6-cis 11 and 2,6-trans 11.a 
 
 
aReagents and conditions. (i) (a) LiOH, H2O/1,4-dioxane, 0°C (>99%), (b) D-Leu-OMe·HCl, PyBOP, 
DIPEA, DMF (combined yield 2,6-cis 10 and 2,6-trans 10: 74%); (ii) (a) TFA, DCM, iPr3SiH, (b) Fmoc-L-
Cys(StBu)-OH, PyBOP, DIPEA, DMF (2,6-cis 11: 79%, 2,6-trans 11: 77%). 
 
In an alternative route to the Ca1a2L analogs (VI, Figure 2.2), the diastereoisomeric 
mixture of SAAs 3 was used in the initial peptide formation followed by separation at a 
later stage (Scheme 2.3). Saponification of SAAs 2,6-cis/trans 3 followed by condensation 
with D-Leu-OMe⋅HCl (PyBOP, DIPEA, DMF) gave a mixture of diastereoisomeric dimers 
2,6-cis 10 and 2,6-trans 10 (cis/trans ∼3/5), which could be readily separated by silica-gel 
chromatography. Elongation of the individual isomers with Fmoc-L-Cys(StBu)-OH using 
standard condensation gave the corresponding fully protected trimers 2,6-cis 11 and 2,6-
trans 11 in good yield. According to this protocol 2,6-cis 15 and 2,6-trans 15 were 




















































In a final deprotection step, concomitant removal of the Fmoc and hydrolysis of the 
methyl ester protecting groups in the eight Ca1a2L mimetics (8, 11, 13, 15) proceeded 
smoothly with Tesser’s base mixture (MeOH/1,4-dioxane/4M aq. NaOH 15/4/1 v/v/v). 
The corresponding deprotected trimers 2,6-cis 9, 12, 14, 16 and 2,6-trans 9, 12, 14, 16 
(Scheme 2.4) were subsequently purified by RP-HPLC. 
 







































2,6-trans 8 R1= Fmoc R2= Me 2,6-cis 8 R1= Fmoc R2= Me
2,6-trans 11 R1= Fmoc R2= Me 2,6-cis 11 R1= Fmoc R2= Me
2,6-trans 13 R1= Fmoc R2= Me 2,6-cis 13 R1= Fmoc R2= Me

























































































cleaved in vitro 
with DTT
2,6-trans 9 R1= R2= H 2,6-cis 9 R1= R2= H
2,6-trans 12 R1= R2= H 2,6-cis 12 R1= R2= H
2,6-trans 14 R1= R2= H 2,6-cis 14 R1= R2= H













































2.2.2 NMR analysis − An important element in the design of the Ca1a2L mimetics 
was the absolute configuration at C2 relative to C6 of the incorporated SAA building 
block. As epimerisation may occur at various stages of the synthetic sequences employed 
to prepare the Ca1a2L analogs, various NMR techniques were applied in order to ensure 
that the individual stereochemical integrity of the SAA building blocks (2,6-cis and 2,6-
trans 3) is conserved in the final products. The initial cis/trans configuration was 
introduced into the SAA scaffold in the course of the Ferrier rearrangement. To establish 
the absolute stereochemical outcome of the reaction, nOe experiments were applied on 
the individual diastereoisomers of the SAA precursors 2,6-cis and 2,6-trans 5. Irradiation 
of H2 (δ= 4.03 ppm, Figure 2.3) in the more polar product (TLC analysis) of the 4,5-
unsaturated glycopyranosyl cyanides showed an enhancement of the signal of H6 (δ= 5.17 





   
   
 
Figure 2.3 Structural assignment of 2,6-cis and 2,6-trans 5 by nOe experiments. 
 
As expected, irradiation of H2 (δ= 4.25) and H6 (δ= 5.18) ppm) in the less polar 
product did not show a nOe, which is in agreement with the 2,6-trans configuration. 
Furthermore, the negative [α]D value found for 2,6-trans 5 ([α]D25= –134.4, c= 1.0, CHCl3) 
and positive [α]D value for 2,6-cis 5 ([α]D25= +112.2, c= 1.0, CHCl3), are consistent with 
reported data for optical rotations of 4,5-unsaturated C-glucopyranosides.18 
To ensure that the initial configuration of the incorporated SAA building blocks is 
unchanged in the final products, we subjected trimer 2,6-trans 8 to a NOESY correlation 
experiment (Figure 2.4). The anticipated axial disposition of C6 in 2,6-trans 8 was 
confirmed by the observed nOe signal between H2 (δ= 3.96 ppm) and the H7 protons (δ= 




























































Figure 2.4 Configuration of C6 in 2,6-trans 8 by NOE experiment. 
 
 
In addition to 2D-correlation 1H-NMR, simple 1D 13C-NMR provides rapid insight 
into the stereochemistry of C-glycosidic compounds. This is based on the general 
observation that the C6 carbon resonances for α-C-glycosides (2,6-trans) appear at higher 
field than those for the corresponding β-C-glycosides (2,6-cis).18 The chemical shifts of 
the pyranoid carbon atoms (i.e. C2-6) of the eight fully protected trimers are listed in Table 
2.1. The chemical shift of C6 of the 2,6-trans compounds resonates at a higher field than 
that of the 2,6-cis compounds. Interestingly, this characteristic difference in chemical 
shift is also observed for the resonances of C2, C3, C4 and C5. Analysis of the chemical 




Table 2.1 13C-NMR chemical shifts of C2, C3, C4,C5 and C6 of compounds 8, 9, 11, 13 and 15. 
                                           δ 13C (ppm)  
  
       compound  C6  C5  C4  C3  C2  
 
  2,6-trans 8a 72.5 23.8 27.2 66.3 76.5 
  2,6-trans 11a 72.3 23.3 26.4 65.4 76.1 
  2,6-trans 13a 72.1 23.6 26.3 66.1 75.0    
  2,6-trans 15a 72.5 23.6 27.1 65.8 77.1 
    2,6-trans 9b 70.9 22.3 26.2 63.3 77.5 
  
    2,6-cis 8a 77.2 27.5 31.4 68.9 78.9 
  2,6-cis 11a 76.4 27.3 30.9 68.4 78.3 
  2,6-cis 13a 76.3 27.0 30.5 67.8 78.0 
  2,6-cis 15a 76.6 27.2 30.6 68.1 78.1 
    2,6-cis 9b 75.2 27.4 31.4 67.1 80.6 
 
aMeasured in CDCl3. bmeasured in DMSO-d6. 
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2.2.3 Biological Evaluation − The eight Ca1a2L peptidomimetics were tested for their 
inhibitory activity against bovine PGGT-1 using purified enzyme in an in vitro assay as 
published previously.19 The StBu protective group in the cysteine residue is cleaved under 
the conditions of the assay (pH 7.4, DTT).20 In Table 2.2 the IC50 values of the tested 
Ca1a2L analogs are listed. As can be seen from Table 2.2, four out of the eight Ca1a2L 
mimetics (i.e. 2,6-trans 9, 2,6-trans 12, 2,6-trans 14 and 2,6-cis 14) proved to be capable of 
inhibiting PGGT-1 in the micromolar range, whereas the other four (i.e. 2,6-cis 9, 2,6-cis 
12, 2,6-cis 16 and 2,6-trans 16) showed little or no inhibition at millimolar 
concentrations. The two most potent inhibitors of the series, 2,6-trans 9 and 2,6-cis 14, 
contain a 2,6-trans and a 2,6 cis SAA residue, respectively. They further differ in the 
stereochemistry of the cysteine residue (L vs D, respectively). Incorporation of both D-
amino acids in both examples led to inactive compounds (i.e. 2,6-cis 16 and trans 16).21 
 
Table 2.2 IC50 values of tested Ca1a2L analogs.a 
 
          compound                        IC50 (μM)                                 compound                         IC50 (μM) 
 2,6-trans 9 68 ± 16  2,6-cis 9 ∼1000 
 2,6-trans 12 241 ± 75 2,6-cis 12 >1000 
 2,6-trans 14 109 ± 30 2,6-cis 14    69 ± 20  
 2,6-trans 16 >1000 2,6-cis 16 ∼1000 
 
aIC50: concentration of compound required to inhibit for 50% the PGGT-1 catalysed incorporation of 
[3H]-GGPP. All IC50 values are means of three determinations: one determination involves performing the 
assay at 5 concentrations of compound. By using a mathematical function fitting to the 
concentration/inhibition curve, the IC50 value was determined. 
 
 2.3 Conclusions 
In summary, a useful strategy for the preparation of novel PGGT-1 inhibitors is 
presented. The approach is based on the incorporation of partially deoxygenated (2,6-
cis/trans) SAA building blocks, which in turn were prepared from the common starting 
compound glucal 1 (Scheme 2.1). Variation of the SAA, in combination with the 
introduction of the cysteine and leucine pharmacophores as the D- and L amino acid 
derivatives, furnished 8 novel peptidomimetics resembling the Ca1a2X motif present in 
PGGT-1 substrate proteins. Of these, 4 were found to be inhibitors of PGGT-1 in the 
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micromolar range, whereas the other 4 showed no inhibition at millimolar 
concentrations. The two most potent inhibitors of the series, 2,6-trans 9 and 2,6-cis 14, 
differ both in the nature of the SAA building block and the stereochemistry of the 
cysteine residue. This observation indicates that both 2,6-trans 3 and 2,6 cis 3 can be used 
for the development of novel PGGT-1 inhibitors. 
 
 2.4 Experimental Section 
2.4.1 General − CH3CN, CHCl3, DCE, DCM, DMF, 1,4-dioxane, toluene were all of p.a. quality (Baker) 
and were stored on 4Å molecular sieves. Methanol (p.a. Baker) was stored on 3Å molecular sieves. PE (40-
60 fraction) and EtOAc were of technical grade and distilled before use. Et3N (99%, Acros) was distilled 
over CaH2 when necessary or used as received. DIPEA (peptide grade) and TFA were purchased from 
Biosolve and used without purification. Leu-OMe·HCl, Fmoc-Cys-(StBu)-OH and pyBOP were from 
Novabiochem. D-Leu-OMe·HCl and D-Fmoc-Cys-(StBu)-OH were from Bachem. BF3⋅OEt2 (Aldrich), 
Boc2O (Fluka), D-(+)-glucuronic acid-γ-lactone (Fluka), iPr3SiH (Aldrich), TMSCN (Fluka), Pd(OAc)2 
(Fluka) and 10% Pd/C (Aldrich) were used as received. RP-HPLC analysis and purification were performed 
on a Jasco HPLC system equipped with a Merck Lichrosphere C18 100Å column (4×250 mm). 1H-NMR and 
13C-NMR spectra were recorded with a Bruker AC-200 (1H-NMR 200 MHz, 13C-NMR 50 MHz), Bruker 
DPX-300 (1H-NMR 300 MHz; 13C-NMR 75 MHz), Bruker AV-400 (1H-NMR 400 MHz, 13C-NMR 100 MHz), 
Bruker DMX-600 (1H-NMR 600 MHz, 13C-NMR 150 MHz) or Bruker DSX-750 MHz (1H-NMR 750 MHz, 
13C-NMR 188 MHz). Chemical shifts are given in ppm (δ) relative to tetramethylsilane as internal standard. 
1H-NMR: resonance of CDCl3 at 0.00 ppm as internal standard. 13C-NMR: middle resonance of CDCl3 set at 
77.0 ppm as internal standard. MS (ESI): Perkin Elmer SCIEX API 165 quadrupole mass spectrometer, HR-
MS: API QSTARTM Pulsar (Applied Biosystems). Reactions were followed by TLC analysis on silica gel 
(Schleider & Schull, F 1500 LS 254) or HPTLC aluminium sheets (Merck, silica gel 60, F254), with detection 
by UV-absorption (254 nm) where applicable and charring at 150°C with 20% H2SO4 in ethanol (25 g L-1), 
ninhydrin (3 g L-1) in EtOH/AcOH (100/3 v/v), NH4(Mo)7O24⋅4H2O (25 g L-1) and NH4Ce(SO4)4⋅2H2O (10 g 
L-1) in 10% aq. H2SO4 or 2% KMnO4 in aq. K2CO3 (1%). Column chromatography was performed with silica 
gel (Baker; 0.063-0.200mm). 
2.4.2 General procedures − General procedure 1 (GP 1); hydrogenation and Boc protection: to a 0.25M 
solution of the 4,5-unsaturated glucopyranosyl cyanide in MeOH/CHCl3 (20 mL, 10/1 v/v) was added 10% 
palladium on activated carbon (25 mass%). The reaction mixture was shaken overnight under elevated 
hydrogen atmosphere (45 psi). After TLC analysis (EtOAc) showed complete conversion of the starting 
material into a ninhydrin positive product (base line spot), the mixture was filtrated over Celite® and the 
solution was concentrated under reduced pressure. The crude product was used without further 
purification for the next reaction. To a ∼0.1M solution of the crude amine in DCM, 1.2 equiv. of Boc2O and 
2.2 equiv. of Et3N were added. After TLC analysis showed consumption of the starting material (PE/EtOAc 
1/1 v/v), water was added. The aqueous layer was extracted with EtOAc (2×) and the combined organic 
layers were washed with brine, dried (MgSO4) and the solvent was removed in vacuo.  
General procedure 2 (GP 2); saponification methyl ester SAA Building block: to a 0.1M solution of the 

























analysis (EtOAc) showed consumption of the starting material, the reaction mixture was neutralised (pH 
≈7) by AcOH or Dowex-H+ and the solvents were removed in vacuo. The obtained residue was used 
without further purification for the amino acid coupling described in general procedure 3. 
General procedure 3 (GP 3); coupling of SAA Building block to Leu-OMe·HCl: to a 0.1M solution of the 
SAA in DMF was added 1.2 equiv. Leu-OMe·HCl, 1.2 equiv. pyBOP and 4 equiv. DIPEA. After TLC 
analysis (PE/EtOAc 1/1 v/v) showed consumption of the starting material, the DMF was removed in vacuo. 
The residue was dissolved in EtOAc and washed with water (2×), sat. aq. NaHCO3 (2×), 5% KHSO4 (2×) and 
brine (sat. aq. NaCl). The organic phase was dried (MgSO4) and the solvent was removed in vacuo. 
General procedure 4 (GP 4); removal of the Boc protective group: to a 0.05M solution of the dimer in 
DCM were added 1.3 equiv. of iPr3SiH and TFA (DCM/TFA 1/1 v/v). After TLC analysis (PE/EtOAc 1/1 v/v) 
showed consumption of the starting material, the reaction mixture was coevaporated 5× with PhMe.  
General procedure 5 (GP 5); coupling of dimer to Fmoc-Cys-(StBu)-OH: to a 0.1M solution of the 
deprotected dimer in DMF were added 4 equiv. DIPEA, 1.2 equiv. Fmoc-Cys-(StBu)-OH and 1.2-1.5 equiv. 
pyBOP. After TLC analysis (PE/EtOAc 1/1 v/v) showed consumption of the starting material, the reaction 
was worked up as described in general procedure 2. 
General procedure 6 (GP 6); Tesser’s base mediated deprotection: a 0.01M solution of the trimer in 
MeOH/1,4-dioxane/4M aq. NaOH (15/4/1 v/v/v) is stirred at 0°C and the reaction mixture was allowed to 
reach room temperature. After TLC analysis (PE/EtOAc 1/1 v/v) showed consumption of the starting 
material, the reaction mixture was diluted with water and washed with DCM (3×). The aqueous layer was 
collected and neutralised with AcOH (pH ≈7). After lyophilisation, the crude product is purified by RP-
HPLC (purity ≥95%, 10→40% linear gradient CH3CN (= eluent B) in H2O (= eluent A) and 1% aq. TFA (= 
eluent C, effective 0.1%). 
 
Methyl (3,4-di-O-acetyl-D-glucuronate) glucal (1): white crystalline compound, 90% yield over 4 steps (250 
mmol scale) from commercially available D-(+)-glucuronic acid-γ-lactone as described in reference 11. 
(±)-(2S,3S,6SR) Methyl 3-O-acetyl-6-nitrile-4,5-dideoxyhex-4-eno-D-glucopyranuronate (2,6-cis/trans 2). 
To a solution of glucal 1 (5.01 g, 19.4 mmol; 2× coevaporated with DCE) in DCM (50 
mL) was added TMSCN (2.91 mL, 23.3 mmol, 1.2 equiv.) and BF3⋅OEt2 (0.49 mL, 0.2 
equiv.). The reaction mixture was stirred for 1 h, after which TLC analysis (PE/aceton 
4/1 v/v) showed complete conversion of 1. The reaction mixture was quenched with 
sat. aq. NaHCO3 (50 mL) and diluted with EtOAc (50 mL). The water layer was extracted with EtOAc (2×50 
mL) and the combined organic phases were washed with sat. aq. NaHCO3 (50 mL) and brine (50 mL) and 
dried on MgSO4. The solvent was removed in vacuo and silica gel chromatography (PE/aceton 4/1 v/v) gave 
2,6-cis/trans 2 as a colorless oil (3.76 g, 86%). 1H-NMR (300 MHz, CDCl3) δ 6.21-5.95 (m, 2H, H4, H5), 5.55 
(m, 1H, H3), 5.34, 5.22 (2×dd, 2H, H6α/β, J= 2.6 and 7.1 Hz; J= 3.3 and 4.0 Hz), 4.47 (d, 1H, H2α, J= 6.3 Hz), 
4.44 (d, 1H, H2β, J= 4.3 Hz), 3.81, 3.79 (2×s, 2×3H, OCH3α/β), 2.12, 2.09 (2×s, 2×3H, CH3Ac, α/β); 13C-NMR (50 
MHz, CDCl3) δ 169.4 (2×C=O), 126.7, 125.7 (C5α/β), 124.8, 124.4 (C4α/β), 115.1 (C≡N), 73.4, 72.4 (C2α/β), 63.4, 
62.8 (C3α/β), 61.3, 60.9 (C6α/β), 52.3, 52.2 (OCH3α/β), 20.1 (CH3Ac); MS (ESI): m/z 248.1 (M+Na)+.  
(+)-(2S,3S,6S) Methyl 3-hydroxy-6-nitrile-4,5-dideoxyhex-5-eno-D-glucopyranuronate (2,6-trans 5); 
(-)-(2S,3S,6R) Methyl 3-hydroxy-6-nitrile-4,5-dideoxyhex-5-eno-
D-glucopyranuronate (2,6-cis 5). Method 1: To a solution of 2,6-
cis/trans 2 (2.00 g, 8.88 mmol; 2× coevaporated with 10 mL 
PhMe) was added a 0.05M methanolic HCl solution (50 mL). The reaction mixture was stirred for 5 h at 


















was quenched with sat NaHCO3 (50 mL) and diluted with EtOAc (50 mL). The water layer was extracted 
with EtOAc (50 mL). The combined organic phases were washed with sat. NaHCO3 (25 mL) and brine (25 
mL), and dried on MgSO4. The solvent was removed in vacuo and silica gel chromatography (PE/EtOAc 1/1 
v/v) gave 2,6-trans 5 and 2,6-cis 5 both as a colorless oil (1.45 g, 89%).  
Method 2: To a solution of 4 (236 mg, 1.36 mmol (2× coevaporated with PhMe) in CH3CN (20 mL) 
was added 5 mol% Pd(OAc)2 (15 mg) and 5 equiv. TMSCN (0.85 mL, 6.80 mmol). The reaction mixture was 
stirred for 72 h at 80°C after which TLC analysis showed complete conversion of the starting material. The 
reaction was quenched with 0.1 N HCl (25 mL) and diluted with EtOAc (50 mL). The water layer was 
extracted with EtOAc (2×50 mL). The combined organic phases were washed with sat. aq. NaHCO3 (50 mL) 
and brine (saturated aq. NaCl, 50 mL), and dried on MgSO4. The solvent was removed in vacuo and silica 
gel chromatography (PE/EtOAc, 1/1 v/v) yielded 2,6-trans 5 and 2,6-cis 5 (189 mg, 76%). 2,6-trans 5: [α]D25= 
–134.4 (c= 1.0, CHCl3), 1H-NMR (300 MHz, CDCl3) δ 6.12 (dt, 1H, H5, J= 2.2 Hz), 5.83 (ddd, 1H, H4, J= 2.0 
and 3.2 Hz), 5.18 (dd, 1H, H6, J= 2.3 and 5.4 Hz), 4.47-4.41 (m, 1H, H3), 4.25 (d, 1H, H2, J= 8.1 Hz), 3.87 (s, 
3H, OCH3); 13C-NMR (75 MHz, CDCl3) δ 169.7 (C=O), 131.8 (C5), 121.9 (C4), 115.4 (C≡N), 74.5 (C6), 63.7 
and 62.5 (C2 and C3), 53.0 (OCH3); MS (ESI): m/z 184.2 (M+H)+, 206.2 (M+Na)+; HR-MS: calc. 184.0609 
(C8H9NO4+H)+, found 184.0605; 2,6-cis 5: [α]D25= +112.2 (c= 1.0, CHCl3), 1H-NMR (300 MHz, CDCl3) δ 6.13 
(dt, 1H, H5, J= 2.6 Hz), 5.93 (dt, 1H, H4, J= 1.9 Hz), 5.17 (dd, 1H, H6, J= 2.5 and 4.7 Hz), 4.54-4.49 (m, 1H, 
H3), 4.03 (d, 1H, H2, J= 7.6 Hz), 3.87 (s, 3H, OCH3); 13C-NMR (50 MHz, CDCl3) δ 169.5 (C=O), 131.3 (C5), 
122.3 (C4), 115.5 (C≡N), 76.6 (C6), 63.2, 63.0 (C3 and C2), 52.9 (OCH3); MS (ESI): m/z 184.2 (M+H)+, 206.2 
(M+Na)+; HR-MS: calc. for 184.0609 (C8H9NO4+H)+, found 184.0647. 
(+)-(2S,3S,6S)-Methyl 3-hydroxy-4,5-dideoxy-7-[N-(tert-butyloxycarbonyl)amino]-D-glucopyranuronate 
(2,6-trans 3). Treatment of 2,6-trans 5 (100 mg, 0.55 mmol) according to GP 1 
followed by silica gel chromatography (PE/EtOAc 1/1 v/v) yielded the title 
compound as a colorless oil (87 mg, 55%, 2 steps). 1H-NMR (600 MHz, CDCl3) δ 
5.08 (bs, 1H, NH), 4.35 (bs, 1H, H6), 4.14 (bs, 1H, H2), 3.80 (m, 1H, H3), 3.74 (s, 3H, OCH3), 3.28 and 3.12 
(2×m, 2H, H7), 1.80, 1.70 and 1.50 (3×m, 4H, H5, H4), 1.41 (s, 9H, tBu); 13C-NMR (50 MHz, CDCl3) δ 170.7 
(C=Oester), 156.2 (C=OBoc), 79.2 (CqtBu), 75.5 (C6), 72.3 (C2), 65.1 (C3), 52.1 (OCH3), 44.4 (C7), 28.5 (tBu), 26.6 
(C4), 22.1 (C5); MS (ESI): m/z 312.1 (M+Na)+. HR-MS: calc. for [C13H23NO6+H]+ 290.15981, found 290.15945. 
[α]D20= +24.8 (CDCl3, c= 1).  
(-)-(2S,3S,6R)-Methyl 3-hydroxy-4,5-dideoxy-7-[N-(tert-butyloxycarbonyl)amino]-D-glucopyranuronate 
(2,6-cis 3). Treatment of 2,6-cis 5 (362 mg, 1.98 mmol) according to GP 1 followed 
by silica gel chromatography (PE/EtOAc 1/1 v/v) gave 2,6-cis 3 as a colorless oil 
(271 mg, 51%). 1H-NMR (400 MHz, CDCl3) δ 5.07 (bs, 1H, NH), 3.82 (s, 3H, 
OCH3), 3.80-3.60 (m, 3H, H6, H3, H2), 3.46-3.32 (m, 2H, H7), 2.20 (m, 1H, H5), 1.70, 1.59-1.48 (m, 3H, H4, 
H5), 1.45 (s, 9H, tBu); 13C-NMR (100 MHz, CD3OD) δ 172.6 (C=Oester), 158.3 (C=OBoc), 82.8, 77.8, 68.6 (C6, 
C3, C2), 80.1 (CqtBu), 52.6 (OCH3), 45.5 (C7), 32.7 (C4), 28.7 (tBu), 28.6 (C5); MS (ESI): m/z 312.1 (M+Na)+. HR-
MS: calc. for [C13H23NO6+H]+ 290.15981, found 290.15948. [α]D20= –31.8 (CDCl3, c= 1). 
(±)-(2S,3S,6RS)-Methyl 3-hydroxy-4,5-dideoxy-7-[N-(tert-butyloxycarbonyl)amino]-D-glucopyranuronate 
(2,6-cis/trans 3). Treatment of 2,6-cis/trans 2 (1.50 g, 6.67 mmol) according to GP 
1 followed by silica gel chromatography (PE/EtOAc 1/1 v/v) gave the 3-OAc 
precursor of the title compound as a colorless oil (1.26 g, 57% 2 steps). 13C-NMR 
(50 MHz, CDCl3) δ 169-168.8 (2×C=Oester), 155.7 and 155.5 (C=OBoc), 78.6, 78.5 
(CqtBu), 77.9, 76.6, 74.9, 71.8, 68.1, 68.9 (C6, C3, C2α/β), 51.8 (OCH3αβ), 44.5, 44.9 (C7α/β), 28.1, 26.5, 23.9, 22.0 
(C5, C4α/β), 27.8 (tBu), 20.6 and 20.3 (CH3Ac); MS (ESI): m/z 332.2 (M+H)+, 354.1 (M+Na)+. The isomeric 
mixture (458 mg, 1.38 mmol) was dried by coevaporation with 1,4-dioxane (3×10 mL) and dissolved in 





































showed completion, the reaction mixture was neutralised (Dowex-H+) and the solvent was removed by 
evaporation. The product was washed with water (25 mL) and brine (25 mL), extracted with EtOAc (2×25 
mL) and the collected organic phases were dried on MgSO4. Silica gel chromatography (PE/EtOAc 1/1 v/v) 
afforded the title compound as a colorless oil (346 mg, 87%). 
(+)-4,5-dideoxy-3-hydroxy-7-(tert-butyloxycarbonyl)aminomethyl-α-D-glucuronic acid (2,6-trans 6). From 
2,6-trans 3 (25 mg, 86 μmol) and aq. LiOH (1.0 M, 90 μL) according to GP 2, crude 
yield: >99%. 2,6-Trans 6 was used crude in GP 3. 1H-NMR (300 MHz, 
CDCl3/MeOD): δ 4.36-4.28, 4.22-4.13, 4.00-3.91 (3×m, 3H, H6, H3, H2), 3.24-3.17 
(m, 2H, H7), 1.89-1.72 and 1,45 (m, 3H, H5, H4), 1.44 (bs, 9H, t-Bu); 13C-NMR (50 MHz, CDCl3/MeOD): δ 
173.0 (C=O, acid), 157.6 (C=OBoc), 79.7 (Cq t-Bu), 78.2 (C6), 72.5 (C2), 65.2 (C3), 45.1 (C7), 28.6 (tBuBoc), 27.0, 
(C4), 22.4 (C5); MS (ESI): m/z 298.2 (M+Na)+. 
(-)-4,5-dideoxy-3-hydroxy-7-(tert-butyloxycarbonyl)aminomethyl-β-D-glucuronic acid (2,6-cis 6). From 
2,6-cis 3 (25 mg, 86 μmol) and aq. LiOH (1.0 M, 90 μL) according to GP 2, crude 
yield: >99%. 2,6-cis 6 was used crude in GP 3. 13C-NMR (50 MHz, MeOD): δ 173.9 
(C=O, acid), 158.0 (C=OBoc), 81.5 (C6), 77.7 (C2), 68.3 (C3), 45.1 (C7), 32.4 (C4), 28.1 
(C5), 28.7 (tBu); MS (ESI): m/z 298.2 (M+Na)+.  
N-(6-(N-tert-butyloxycarbonyl)-aminomethyl-4,5-dideoxy-α-D-aminoglucuronopyranosyl)-L-leucine methyl 
ester (2,6-trans 7). From crude 2,6-trans 6 and L-Leu-OMe⋅HCl (19 mg, 0.1 
mmol) according to GP 3, yield of the title compound after silica gel 
chromatography (EtOAc): 30 mg, 87%, 2 steps, colorless oil. 1H-NMR (300 
MHz, CDCl3): δ 7.00 (d, 1H, NHCαLeu, J= 8.3 Hz), 4.80 (bs, 1H, NHBoc), 4.62 
(m, 1H, HαLeu), 3.98 (m, 1H, H6), 3.92 (d, 1H, H2, J= 8.3 Hz), 3.74 (s, 3H, OCH3), 3.71 (m, 1H, H3), 3.47 and 
3.26 (2×m, 2H, H7), 1.95 and 1.90-1.56 (2×m, 6H, H5, H4, HβγLeu), 1.45 (s, 9H, tBu), 0.96 (dt, 6H, 2×CH3Leu, J= 
3.2 Hz, 3.3 and 6.2 Hz); 13C-NMR (50 MHz, CDCl3): δ 172.8, 171.8 (C=Oamide&ester), 155.9 (C=OBoc), 79.6 
(CqtBu), 73.5 (C6), 72.7 (C2), 67.6 (C3), 52.3 (CαLeu), 50.2 (OCH3), 41.4 (C7), 40.6 (CβLeu), 28.3 (tBu), 26.4 (C4), 
24.9 (CγLeu), 24.2 (C5), 22.7 and 21.9 (2×CH3Leu); MS (ESI): m/z 403.5 (M+H)+; 425.3 (M+Na)+. HR-MS: calc. 
for [C19H34N2O7+H]+ 403.24388, found 403.24402. [α]D20= +8.2 (CDCl3, c= 1). 
N-(6-(N-tert-butyloxycarbonyl)-aminomethyl-4,5-dideoxy-β-D-aminoglucuronopyranosyl)-L-leucine methyl 
ester (2,6-cis 7). From crude 2,6-cis 6 and L-Leu-OMe⋅HCl (19 mg, 0.1 
mmol) according to GP 3, yield of the title compound after silica gel 
chromatography (EtOAc): 32 mg, 92%, 2 steps, colorless oil. 1H-NMR (300 
MHz, CDCl3): δ 7.02 (d, 1H, NHCαLeu, J= 7.2 Hz), 4.85 (bs, 1H, NHBoc), 4.59 
(m, 1H, HαLeu), 3.75 (s, 3H, OCH3), 3.64 (d, 1H, H2, J= 9.5 Hz), 3.54 (m, 2H, H6 and H3), 3.28 (m, 2H, H7), 
2.20 (m, 1H, H4), 1.80-1.40 (m, 6H, H5, H4, HβγLeu), 1.46 (s, 9H, tBu), 0.96 (t, 6H, 2×CH3Leu, J= 5.8 Hz and J= 
11.7 Hz); 13C-NMR (50 MHz, CDCl3): δ 172.8, 172.2 (C=Oamide&ester), 156.0 (C=OBoc), 79.5 (CqtBu), 78.2 (C6), 
77.5 (C2), 68.3 (C3), 52.4 (OCH3), 50.2 (CαLeu), 44.7 (C7), 41.1 (CβLeu), 30.6 (C4), 28.4 (tBu), 27.1 (C5), 24.9 
(CγLeu), 22.7, 21.9 (2×CH3Leu); MS (ESI): m/z 403.5 (M+H)+; 425.3 (M+Na)+. HR-MS: calc. for [C19H34N2O7+H]+ 
403.24388, found 403.24338. [α]D20= –25.6 (CDCl3, c= 1).  
N-(6-(N-tert-butyloxycarbonyl)-aminomethyl-4,5-dideoxy-αβ-D-aminoglucuronopyranosyl)-L-leucine methyl 
ester (2,6-cis/trans 7). From 2,6-cis/trans 3 (204 mg, 0.71 mmol) and aq. 
LiOH (1.0 M, 0.75 mL) according to GP 2. The crude SAA was used without 
purification for the coupling with L-Leu-OMe⋅HCl (154 mg, 0.85 mmol) 
according to GP 3. Purification by silica gel chromatography (PE/EtOAc 1/1 













































ester (2,6-trans 10); N-(6-(N-tert-butyloxycarbonyl)-aminomethyl-4,5-dideoxy-β-D-aminoglucuronopyranosyl)-
D-leucine methyl ester (2,6-cis 10). From 2,6-
cis/trans 3 (75 mg, 0.26 mmol) and aq. LiOH 
(1.0 M, 0.3 mL) according to GP 2. The crude 
product was coupled to D-Leu-OMe⋅HCl (56 
mg, 0.31 mmol) according to GP 3. 
Purification and separation by silica gel chromatography (PE/EtOAc 1/1 v/v) gave 2,6-trans 10 and 2,6-cis 
10 as colorless oils: total yield 77 mg, 74%, 2 steps (cis/trans ≈3/5). 2,6-trans 10: 1H-NMR (300 MHz, CDCl3): 
δ 7.00 (d, 1H, NHCαLeu, J= 8.6 Hz), 4.78 (bs, 1H, NHBoc), 4.61 (m, 1H, Hα), 3.95 (m, 1H, H6), 3.90 (bs, 1H, 
H2), 3.82 (m, 1H, H3), 3.75 (s, 3H, OCH3), 3.53 and 3.18 (2×m, 2H, H7), 1.94, 1.79-1.45 (2×m, 16H, H5, H4, 
HβγLeu, tBu), 0.96 (d, 6H, 2×CH3Leu, J= 5.4 Hz); 13C-NMR (50 MHz, CDCl3): δ 173.1, 171.7 (C=Oamide&ester), 
155.9 (C=OBoc), 79.5 (CqtBu), 74.0 (C6), 72.7 (C2), 66.9 (C3), 52.4 (CαLeu), 50.1 (OCH3), 41.4 (C7), 41.1 (CβLeu), 
28.3 (tBu), 26.4 (C4), 24.9 (CγLeu), 23.9 (C5), 22.7, 21.8 (2×CH3Leu); MS (ESI): m/z 403.5 (M+H)+; 425.3 
(M+Na)+; 2,6-cis 10: 1H-NMR (300 MHz, CDCl3): δ 7.05 (d, 1H, NHCαLeu, J= 6.9 Hz), 4.84 (bs, 1H, NHBoc), 
4.61 (m, 1H, HαLeu), 3.76 (s, 3H, OCH3), 3.71-3.51 (m, 3H, H6, H3, H2), 3.36-3.17 (m, 2H, H7), 2.17, 1.76-1.36 
(m, 7H, H5, H4, HβγLeu), 1.46 (s, 9H, tBu), 0.96 (t, 6H, 2×CH3Leu, J= 1.9 and 3.9 Hz); 13C-NMR (50 MHz, 
CDCl3): δ 172.0, 172.4 (C=Oamide&ester), 155.2 (C=OBoc), 79.5 (CqtBu), 77.4 (C6), 76.4 (C2), 68.6 (C3), 51.5 (CαLeu), 
49.3 (OCH3), 43.8 (C7), 40.2 (CβLeu), 29.8 (C4), 27.5 (tBu), 26.1 (C5), 24.0 (CγLeu), 21.9, 21.0 (2×CH3Leu); MS 
(ESI): m/z 403.5 (M+H)+; 425.3 (M+Na)+. 
N-(6-N-[(N-(10-fluorenyl methoxycarbonyl))-S-tert-butylthio-L-cysteinyl]-aminomethyl-4,5-dideoxy-α-
D-aminoglucuronopyranosyl)-L-leucine methyl ester (2,6-trans 8). 
From 2,6-trans 7 (29 mg, 79 μmol) and Fmoc-L-Cys(StBu)-OH (37 
mg, 86 μmol) following GP 4 and GP 5. Silica gel chromatography 
(EtOAc) gave 2,6-trans 8 as a colorless oil (45 mg, 87%, 2 steps). 1H-
NMR (750 MHz, CDCl3): δ 7.76 (dd, 2H, CHFmoc, J= 2.3 and 7.2 Hz), 
7.58 (dd, 2H, CHFmoc, J= 7.2 and 16.3 Hz), 7.40 (dd, 2H, CHFmoc, J= 4.8 and 7.3 Hz), 7.30 (t, 2H, CHFmoc, J= 7.2 
and 7.3 Hz), 7.12 (d, 1H, NHCαLeu, J= 7.4 Hz), 6.79 (bs, 1H, C7NH), 6.07 (d, 1H, NHFmoc, J= 5.3 Hz), 4.61 
(m, 1H, HαLeu), 4.55 (m, 1H, HαCys), 4.44 (m, 2H, CH2Fmoc), 4.21 (t, 1H, CHFmoc), 4.02 (m, 1H, H6), 3.96 (d, 1H, 
H2, J= 7.7 Hz), 3.81 (m, 1H, H3), 3.68 (s, 3H, OCH3), 3.55, 3.39 (2×m, 2H, H7), 3.10 (m, 2H, HβCys), 1.93, 1.79 
(2×m, 2H, H5a , H4a), 1.68-1.58 (m, 5H, H5b, H4b, HβγLeu), 1.46 (s, 9H, tBu), 0.92 (dd, 6H, 2×CH3Leu, J= 2.4 and 
5.7 Hz); 13C-NMR (50 MHz, CDCl3): δ 173.3, 171.7, 170.7 (C=Oamide&ester), 156.7 (C=OFmoc), 144.7, 141.8 
(2×CqFmoc), 128.3, 127.7, 125.9, 120.5 (CHFmoc), 76.5 (C2), 72.5 (C6), 67.2 (CH2Fmoc), 66.3 (C3), 55.5 (CαCys), 52.2 
(OCH3), 50.6 (CαLeu), 48.1 (CqtBu), 47.7 (CHFmoc), 43.3 (C7), 41.8, 40.9 (CβLeu, CβCys), 29.8 (tBu), 27.2 (C4), 25.3 
(CγLeu), 23.8 (C5), 23.0, 21.5 (2×CH3Leu); MS (ESI): m/z 716.4 (M+H)+; 738.8 (M+Na)+. 
N-(6-N-[(N-(10-fluorenyl methoxycarbonyl))-S-tert-butylthio-L-cysteinyl]-aminomethyl-4,5-dideoxy-β-D-
aminoglucuronopyranosyl)-L-leucine methyl ester (2,6-cis 8). From 
2,6-cis 7 (42 mg, 104 μmol) and Fmoc-L-Cys(StBu)-OH (54 mg, 125 
μmol) according to GP 4 and GP 5. Silica gel chromatography 
(EtOAc) afforded the title compound as a colorless oil (64 mg, 86%, 
2 steps). 1H-NMR (750 MHz, CDCl3): δ 7.76 (d, 2H, CHFmoc, J= 7.4 Hz), 7.57 (d, 2H, CHFmoc, J= 7.4 Hz), 7.40 
(dd, 2H, CHFmoc, J= 7.4 and 7.5 Hz), 7.30 (t, 2H, CHFmoc, J= 3.7 and 7.0 Hz), 7.25 (bs, 1H, NHCαLeu, J= 7.4 Hz), 
6.82 (bs, 1H, C7NH), 6.24 (bs, 1H, NHFmoc), 4.66 (m, 1H, HαLeu), 4.48 (m, 1H, HαCys), 4.41, 4.30 and 4.20 (m, 
3H, CH2 and CHFmoc), 3.71 (s, 3H, OCH3), 3.54 (m, 3H, H6, H3, H2), 3.47 and 3.30 (2×m, 2H, H7), 3.07 (d, 2H, 
HβCys, J= 5.8 Hz), 2.15 (m, 1H, H4), 1.69-1.36 (m, 6H, H5, H4, HβγLeu), 1.33 (s, 9H, tBu), 0.94 (dd, 6H, 2×CH3Leu, 







































and 141.7 (2×CqFmoc), 128.4, 127.6, 125.9, 120.5 (CHFmoc), 78.9 (C2), 77.2 (C6), 68.9 (C3), 67.2 (CH2Fmoc), 55.4 
(CαCys), 52.2 (OCH3), 50.6 (CαLeu), 48.0 (CqtBu), 47.6 (CHFmoc), 43.8 (C7), 43.0 and 40.9 (CβLeu and CβCys), 31.4 
(C4), 29.8 (tBu), 27.5 (C5), 25.2 (CγLeu), 22.9, 21.6 (2×CH3Leu); MS (ESI): m/z 716.4 (M+H)+; 738.8 (M+Na)+. 
N-(6-N-[(N-(10-fluorenyl methoxycarbonyl))-S-tert-butylthio-L-cysteinyl]-aminomethyl-4,5-dideoxy-α-
D-aminoglucuronopyranosyl)-D-leucine methyl ester (2,6-trans 11). From 2,6-trans 10 (100 mg, 0.25 mmol) 
and Fmoc-L-Cys(StBu)-OH (116 mg, 0.27 mmol) according to GP 4 
and GP 5. Silica gel chromatography (EtOAc) gave 2,6-trans 11 as a 
colorless oil (137 mg, 77%, 2 steps). 1H-NMR (400 MHz, CDCl3): δ 
7.80 (d, 2H, CHFmoc, J= 7.5 Hz), 7.60 (d, 2H, CHFmoc, J= 7.5 Hz), 7.41 
(t, 2H, CHFmoc, J= 7.4 and 7.5 Hz), 7.31 (t, 2H, CHFmoc, J= 7.4 Hz), 7.10 (d, 1H, NHCαLeu, J= 8.8 Hz), 6.74 (bs, 
1H, C7NH), 5.78 (bs, 1H, NHFmoc), 4.66 (m, 1H, HαLeu), 4.45 (dd, 2H, CH2Fmoc, J= 7.2 and 10.5 Hz), 4.39 (m, 
1H, HαCys), 4.22 (t, 2H, CHFmoc, J= 7.0 Hz), 4.08 (d, 1H, H2, J= 6.4), 3.98 (m, 1H, H3), 3.89 (m, 1H, H6), 3.71 (s, 
3H, OCH3), 3.31 and 3.11 (2×m, 2H, H7), 3.05 (dd, 2H, HβCys, J= 6.9 and 13.6 Hz), 1.91 (m, 1H, H4), 1.72-1.61 
(m, 6H, H5, H4, HβγLeu), 1.34 (s, 9H, tBu), 0.93 (t, 6H, 2×CH3Leu, J= 4.2 Hz); 13C-NMR (50 MHz, CDCl3): δ 
173.4, 171.1, 170.1 (C=Oamide&ester), 156.0 (C=OFmoc), 143.6 and 141.3 (2×CqFmoc), 127.8, 127.1, 125.0, 120.0 
(CHFmoc), 75.0 (C2), 72.1 (C6), 67.3 (CH2Fmoc), 66.1 (C3), 54.8 (CαCys), 52.5 (OCH3), 50.1 (CαLeu), 48.6 (CqtBu), 47.0 
(CHFmoc), 42.1 (C7), 41.1 and 41.0 (CβLeu, CβCys), 29.8 (tBu), 26.3 (C4), 24.8 (CγLeu), 23.6 (C5), 22.8 and 21.7 
(2×CH3Leu). MS (ESI): m/z 716.4 (M+H)+; 738.8 (M+Na)+. 
N-(6-N-[(N-(10-fluorenyl methoxycarbonyl))-S-tert-butylthio-L-cysteinyl]-aminomethyl-4,5-dideoxy-β-D-
aminoglucuronopyranosyl)-D-leucine methyl ester (2,6-cis 11). 
From 2,6-cis 10 (53 mg, 132 μmol) and Fmoc-L-Cys(StBu)-OH (68 
mg, 158 μmol) according to GP 4 and GP 5. Silica gel 
chromatography (EtOAc) gave 2,6-cis 11 as a colorless oil (75 mg, 
79%, 2 steps). 1H-NMR (400 MHz, CDCl3): δ 7.77 (d, 2H, CHFmoc, J= 
7.5 Hz), 7.58 (d, 2H, CHFmoc, J= 7.4 Hz), 7.39 (t, 2H, CHFmoc, J= 7.4 and 7.5 Hz), 7.30 (m, 2H, CHFmoc), 7.20 (d, 
1H, NHCαLeu, J= 8.4 Hz), 6.97 (bs, 1H, C7NH), 5.89 (bs, 1H, NHFmoc), 4.60 (m, 1H, HαLeu), 4.45-4.25 (m, 3H, 
HαCys, CH2Fmoc), 4.21 (t, 1H, CH2Fmoc, J= 6.9 and 7.1 Hz), 3.68 (s, 3H, OCH3), 3.68-3.53 (m, 4H, H6, H3, H2 and 
H7), 3.15 (m, 1H, H7), 3.02 (dd, 2H, HβCys, J= 7.4 Hz), 2.15 (m, 1H, H4a), 1.70-1.35 (m, 6H, H5, H4b, HβγLeu), 
1.34 (s, 9H, tBu), 0.93 (t, 6H, 2×CH3Leu, J= 6.5 and 6.6 Hz); 13C-NMR (50 MHz, CDCl3): δ 173.0, 172.1, 170.3 
(C=Oamide&ester), 156.0 (C=OFmoc), 143.5, 141.1 (2×CqFmoc), 127.6, 127.0, 125.0, 119.9 (CHFmoc), 78.0 (C2), 76.3 
(C6), 67.8 (C3), 67.2 (CH2Fmoc), 54.7 (CαCys), 52.3 (OCH3), 50.1 (CαLeu), 48.3 (CqtBu), 46.9 (CHFmoc), 43.4 (C7), 
42.1, 41.0 (CβLeu, CβCys), 30.5 (C4), 26.7 (tBu), 27.0 (C5), 26.2 (CγLeu), 21.7, 20.9 (2×CH3Leu). MS (ESI): m/z 716.4 
(M+H)+; 738.8 (M+Na)+. 
N-(6-N-[(N-(10-fluorenyl methoxycarbonyl))-S-tert-butylthio-D-cysteinyl]-aminomethyl-4,5-dideoxy-α-
D-aminoglucuronopyranosyl)-L-leucine methyl ester (2,6-trans 
13). From 2,6-trans 7 (100 mg, 0.25 mmol) and Fmoc-D-Cys(StBu)-
OH (116 mg, 0.27 mmol) according to GP 4 and GP 5. Silica gel 
chromatography (EtOAc) gave 2,6-trans 13 as a colorless oil (129 
mg, 72%). 1H-NMR (300 MHz, CDCl3): δ 7.77 (d, 2H, CHFmoc, J= 7.5 
Hz), 7.60 (dd, 2H, CHFmoc, J= 2.2 and 2.3 Hz), 7.41 (t, 2H, CHFmoc, J= 7.4 and 7.5 Hz), 7.30 (m, 2H, CHFmoc), 
7.00 (d, 1H, NHCαLeu, J= 8.8 Hz), 6.70 (bs, 1H, C7NH), 6.20 (d, 1H, NHFmoc, J= 5.8 Hz), 4.64 (m, 1H, HαLeu), 
4.51 (dd, 1H, HαCys, J= 6.7 and 6.8 Hz), 4.25 (m, 3H, CH2Fmoc, CHFmoc), 4.00 (m, 2H, H2, H6), 3.87-3.72 (m, 2H, 
H3, H7a and s, 3H, OCH3), 3.11 (m, 3H, H7b, HβCys), 1.97-1.50 (m, 7H, H4, H5, HβγLeu), 1.34 (s, 9H, tBu), 0.90 
(m, 6H, 2×CH3Leu); 13C-NMR (50 MHz, CDCl3): δ 172.6, 171.6, 170.1 (C=Oamide&ester), 157.0 (C=OFmoc), 144.7, 







































(CαCys), 52.2 (OCH3), 50.7 (CαLeu), 48.1 (CqtBu), 47.7 (CHFmoc), 42.7 (C7), 42.3, 40.8 (CβLeu, CβCys), 29.9 (tBu), 27.1 
(C4), 25.4 (CγLeu), 23.6 (C5), 23.2, 21.4 (2×CH3Leu). MS (ESI): m/z 716.4 (M+H)+; 738.8 (M+Na)+. 
N-(6-N-[(N-(10-fluorenyl methoxycarbonyl))-S-tert-butylthio-D-cysteinyl]-aminomethyl-4,5-dideoxy-β-
D-aminoglucuronopyranosyl)-L-leucine methyl ester (2,6-cis 13). 
From 2,6-cis 7 (195 mg, 0.48 mmol) and Fmoc-L-Cys(StBu)-OH 
(228 mg, 0.53 mmol) according to GP 4 and GP 5. Purification by 
silica gel chromatography (EtOAc) gave 2,6-cis 13 as a colorless oil 
(262 mg, 77%, 2 steps). 1H-NMR (400 MHz, CDCl3): δ 7.76 (d, 2H, CHFmoc, J= 7.5 Hz), 7.59 (d, 2H, CHFmoc, J= 
7.5 Hz), 7.40 (t, 2H, CHFmoc, J= 7.3 and 7.6 Hz), 7.31 (m, 2H, CHFmoc), 7.19 (d, 1H, NHCαLeu, J= 8.3 Hz), 6.82 
(bs, 1H, C7NH), 5.89 (d, 1H, NHFmoc, J= 7.1 Hz), 4.60 (m, 1H, HαLeu), 4.45 (m, 3H, HαCys and CHFmoc), 4.22 
(t, 1H, CH2Fmoc, J= 7.0 and 7.1 Hz), 3.69 (s, 3H, OCH3), 3.61-3.50 (m, 3H, H6, H3, H2), 3.47 and 3.35 (2×m, 
2H, H7), 3.10 (m, 2H, HβCys), 2.16 (m, 1H, H4), 1.73-1.37 (2×m, 6H, H5, H4, HβγLeu), 1.34 (s, 9H, tBu), 0.95 (t, 
6H, 2×CH3Leu, J= 6.2 Hz); 13C-NMR (50 MHz, CDCl3): δ 173.1, 172.0, 170.4 (C=Oamide&ester), 156.0 (C=OFmoc), 
143.6 and 141.2 (2×CqFmoc), 127.7, 127.0, 125.0, 120.0 (CHFmoc), 78.1 (C2), 76.6 (C6), 68.1 (C3), 67.3 (CH2Fmoc), 
54.6 (CαCys), 52.4 (OCH3), 50.2 (CαLeu), 48.5 (CqtBu), 47.0 (CHFmoc), 43.7 (C7), 42.0, 41.1 (CβLeu, CβCys), 30.6 (C4), 
29.8 (tBu), 27.2 (C5), 24.9 (CγLeu), 22.7, 21.8 (2×CH3Leu). MS (ESI): m/z 716.4 (M+H)+; 738.8 (M+Na)+. 
N-(6-N-[(N-(10-fluorenyl methoxycarbonyl))-S-tert-butylthio-D-cysteinyl]-aminomethyl-4,5-dideoxy-α-
D-aminoglucuronopyranosyl)-D-leucine methyl ester (2,6-trans 
15). From 2,6-trans 10 (26 mg, 65 μmol) and Fmoc-D-Cys(StBu)-
OH (33 mg, 78 μmol) according to GP 4 and GP 5. Silica gel 
chromatography (EtOAc) gave the title compound as a colorless oil 
(46 mg, 99%, 2 steps). 1H-NMR (400 MHz, CDCl3): δ 7.75 (d, 2H, CHFmoc, J= 7.5 Hz), 7.57 (d, 2H, CHFmoc, J= 
7.4 Hz), 7.39 (t, 2H, CHFmoc, J= 7.3 and 7.5 Hz), 7.32-7.27 (m, 3H, CHFmoc and NHCαLeu), 7.03 (bs, 1H, C7NH), 
5.97 (d, 1H, NHFmoc, J= 7.3 Hz), 4.70 (m, 1H, HαLeu), 4.43-4.30 (m, 3H, HαCys and CH2Fmoc), 4.20 (t, 1H, 
CHFmoc, J= 7.1 Hz), 4.15-4.05 (m, 3H, H6, H3 and H2), 3.81 (m, 4H, H7 and s, 3H, OCH3), 3.22-3.09 (m, 3H, H7 
and HβCys), 1.90 and 1.73-1.50 (m, 7H, H5, H4, HβγLeu), 1.34 (s, 9H, tBu), 0.91 and 0.85 (2×d, 6H, 2×Me Leu, J= 
6.0 and 3.9 Hz); 13C-NMR (50 MHz, CDCl3): δ 174.1, 170.7, 170.6 (3×C=Oamide&ester), 156.2 (C=OFmoc), 143.6 
and 141.3 (2×CqFmoc), 127.8, 127.1, 125.1, 120.0 (CHFmoc), 76.1 (C2), 72.3 (C6), 67.4 (CH2Fmoc), 65.4 (C3), 55.0 
(CαCys), 52.5 (OCH3), 50.0 (CαLeu), 48.4 (CqtBu), 47.0 (CHFmoc), 41.8 and 41.3 (C7, CβLeu and CβCys), 29.8 (tBu), 
26.4 (C4), 24.8 (CγLeu), 23.3 (C5), 22.8 and 21.6 (2×CH3Leu). MS (ESI): m/z 716.4 (M+H)+; 738.8 (M+Na)+. 
N-(6-N-[(N-(10-fluorenyl methoxycarbonyl))-S-tert-butylthio-D-cysteinyl]-aminomethyl-4,5-dideoxy-β-
D-aminoglucuronopyranosyl)-D-leucine methyl ester (2,6-cis 15). 
From 2,6-cis 10 (39 mg, 97 μmol) and Fmoc-D-Cys(StBu)-OH (50 
mg, 116 μmol) according to GP 4 and GP 5. Purification by silica 
gel chromatography (EtOAc) afforded 2,6-cis 15 as a colorless oil 
(63 mg, 91%, 2 steps). 1H-NMR (400 MHz, CDCl3): δ 7.76 (d, 2H, CHFmoc, J= 7.6 Hz), 7.58 (d, 2H, CHFmoc, J= 
7.5 Hz), 7.40 (t, 2H, CHFmoc, J= 7.2 and 7.4 Hz), 7.30 (m, 3H, CHFmoc and NHCαLeu), 6.87 (bs, 1H, C7NH), 6.37 
(bs, 1H, NHFmoc), 4.62 (m, 1H, HαLeu), 4.49-4.40 (m, 2H, HαCys and CHFmoc), 4.29-4.18 (m, 2H, CH2Fmoc), 3.73 
(s, 3H, OCH3), 3.67 (m, 1H, H7), 3.63-3.50 (m, 2H, H6 and H2), 3.45 (m, 1H, H3), 3.18-3.12 (dt, 1H, H7, J= 5.3 
Hz), 3.11 (d, 2H, HβCys, J= 6.7 Hz), 2.07 (m, 1H, H4), 1.67-1.37 (2×m, 6H, H5, H4, HβγLeu), 1.34 (s, 9H, tBu), 
0.95 (t, 6H, 2×Me Leu, J= 6.2 and 7.3 Hz); 13C-NMR (50 MHz, CDCl3): δ 174.5, 172.9, 171.5 (3×C=Oamide&ester), 
157.0 (C=OFmoc), 144.2 and 141.8 (2×CqFmoc), 128.4, 127.7, 125.7, 120.7 (CHFmoc), 78.3 (C2), 76.4 (C6), 68.4 (C3), 
68.1 (CH2Fmoc), 55.1 (CαCys), 53.1 (OCH3), 50.7 (CαLeu), 49.0 (CqtBu), 47.5 (CHFmoc), 43.7 (C7), 42.0 and 41.7 
(CβLeu and CβCys), 30.9 (C4), 30.4 (tBu), 27.3 (C5), 25.4 (CγLeu), 23.4, 22.4 (2×CH3Leu). MS (ESI): m/z 716.4 
































































9). Treatment of 2,6-trans 8 (37 mg, 52 μmol) according to GP 6 
afforded the title compound as a white foam (8.7 mg, 45%). 1H-NMR 
(750 MHz, DMSO-d6): δ 8.63 (t, 1H, C7NH, J= 5.6 Hz), 7.95 (d, 1H, 
NHCαLeu, J= 8.0 Hz), 4.76 (bs, 2H, NH2), 4.23 (m, 1H, HαLeu), 4.08 (d, 
1H, H2, J= 3.1 Hz), 3.97 (m, 1H, H3), 3.93 (t, 1H, HαCys, J= 6.2 and 6.4 Hz), 3.75 (m, 1H, H6), 3.27 (m, 2H, H7), 
3.08-3.17 (m, 2H, HβCys), 1.51-1.66 (m, 6H, H5, H4, HβγLeu), 1.40 (m, 1H, H5), 1.31 (s, 9H, tBu), 0.90 and 0.85 
(2×d, 6H, 2×Me Leu, J= 6.3 and 6.4 Hz); 13C-NMR (100 MHz, DMSO-d6): δ 173.8, 169.9, 166.7 (3×C=O), 
77.5 (C2), 70.9 (C6), 63.3 (C3), 51.8 (CαLeu), 50.0 (CαCys), 48.0 (Cq t-butyl StBu), 42.6 (C7), 40.1 and 39.9 (CβLeu, 
CβCys), 29.4 (tBu), 26.2 (C4), 26.2 (CγLeu), 22.3 (C5), 22.8 and 21.2 (2×CH3Leu). MS (ESI): m/z 480.1 (M+H)+; 
HR-MS: calc. 480.2202 (C20H37N3O6S2+H)+, found 480.2177. 
S-tert-butylthio-L-cysteinyl-aminomethyl-4,5-dideoxy-β-D-aminoglucuronopyranosyl)-L-leucine (2,6-cis 9). 
Treatment of 2,6-cis 8 (20 mg, 28 μmol) according to GP 6 gave 2,6-cis 
9 as a foam (5.3 mg, 40%). 1H-NMR (750 MHz, DMSO-d6): δ 8.66 (t, 
1H, C7NH, J= 5.0 Hz and 5.6 Hz), 7.95 (d, 1H, NHCαLeu, J= 7.9 Hz), 4.75 
(bs, 2H, NH2), 4.28 (m, 1H, HαLeu), 3.97 (m, 1H, HαCys), 3.55 (d, 1H , H2, 
J= 9.2 Hz), 3.44-3.19 (m, 4H, H6, H3, H7), 3.12 (m, 2H, HβCys), 1.97 (m, 1H, H4), 1.51-1.75 (m, 4H, H5, HβγLeu), 
1.31 (m, 11H, tBu, H4 and H5), 0.90 and 0.87 (2×d, 6H, 2×Me Leu, J= 6.2 and 6.0 Hz); 13C-NMR (100 MHz, 
DMSO-d6): δ 173.8, 170.1, 166.7 (3×C=O), 80.6 (C2), 75.2 (C6), 67.1 (C3), 51.7 (CαLeu), 50.0 (CαCys), 48.0 
(CqtBu), 43.2 (C7), 40.9, 40.0 (CβLeu, CβCys), 31.4 (C4), 29.4 (tBu), 27.4 (C5), 24.3 (CγLeu), 22.7 and 21.5 (2×CH3Leu). 
MS (ESI): m/z 480.1 (M+H)+; HR-MS: calc. 480.2202 (C20H37N3O6S2+H)+, found 480.2145.  
S-tert-butylthio-L-cysteinyl-aminomethyl-4,5-dideoxy-α-D-aminoglucuronopyranosyl)-D-leucine (2,6-trans 
12). Treatment of 2,6-trans 11 (9 mg, 13 μmol) according to GP 6 gave 
2,6-trans 12 as a foam (1.6 mg, 26%). 1H-NMR (750 MHz, DMSO-d6): 
δ 8.70 (d, 1H, C7NH, J= 4.4 Hz), 8.00 (d, 1H, NHCαLeu, J= 8.2 Hz), 4.75 
(bs, 2H, NH2), 4.20 (m, 1H, HαLeu), 4.10 (d, 1H, H2, J= 3.2 Hz), 3.95 (m, 
2H, HαCys, H3), 3.80 (m, 1H, H1), 3.06-2.90 (m, 4H, H7, HβCys), 1.65-1.30 (2×m, 7H, H5, H4, HβγLeu), 1.27 (s, 9H, 
tBu), 0.87 (2×d, 6H, 2×CH3Leu, J= 6.6 and 6.5 Hz); MS (ESI): m/z 480.1 (M+H)+; HR-MS: calc. 480.2202 
(C20H37N3O6S2+H)+, found 480.2036. 
S-tert-butylthio-L-cysteinyl-aminomethyl-4,5-dideoxy-β-D-aminoglucuronopyranosyl)-D-leucine (2,6-cis 12). 
Treatment of 2,6-cis 11 (43 mg, 60 μmol) according to GP 6 gave 2,6-
cis 12 as a foam (10 mg, 36%). 1H-NMR (750 MHz, DMSO-d6): δ 8.77 
(t, 1H, C7NH, J= 5.9 Hz), 8.08 (d, 1H, NHCαLeu, J= 8.2 Hz), 4.80 (bs, 2H, 
NH2), 4.32 (m, 1H, HαLeu), 3.97 (t, 1H, HαCys J= 6.3 Hz), 3.53 (d, 1H, H2, 
J= 9.3 Hz), 3.43-3.30 (m, 3H, H2, H3, H7), 3.11 (m, 3H, H7, HβCys), 1.95 (m, 1H, H4), 1.70-1.50 (m, 4H, H5, 
HβγLeu), 1.35 (m, 2H, H4, H5) 1.30 (s, 9H, tBu), 0.87 (2×d, 6H, 2×CH3Leu, J= 6.6 and 6.5 Hz); MS (ESI): m/z 
480.1 (M+H)+; HR-MS: calc. 480.2202 (C20H37N3O6S2+H)+, found 480.1982. 
S-tert-butylthio-D-cysteinyl-aminomethyl-4,5-dideoxy-α-D-aminoglucuronopyranosyl)-L-leucine (2,6-trans 14). 
Treatment of 2,6-trans 13 (10 mg, 14 μmol) according to GP 6 gave 
2,6-trans 14 as a foam (2.0 mg, 30%). 1H-NMR (750 MHz, DMSO-d6): 
δ 8.62 (dd, 1H, C7NH, J= 4.6 and 4.6 Hz), 7.99 (d, 1H, NHCαLeu, J= 8.2 
Hz), 4.77 (bs, 2H, NH2), 4.26 (m, 1H, HαLeu), 4.09 (d, 1H, H2, J= 2.9 Hz), 
4.00 (m, 1H, H3), 3.95 (m, 1H, HαCys), 3.78 (m, 1H, H6), 3.36 and 3.16-3.06 (2×m, 4H, H7 and HβCys), 1.70-
1.55 (m, 6H, H4, HβγLeu), 1.40 (m, 1H, H5), 1.30 (s, 9H, tBu), 0.87 (2×d, 6H, 2×CH3Leu, J= 6.6 and 6.5 Hz); MS 







































S-tert-butylthio-D-cysteinyl-aminomethyl-4,5-dideoxy-β-D-aminoglucuronopyranosyl)-L-leucine (2,6-cis 14). 
Treatment of 2,6-cis 13 (17 mg, 24 μmol) according to GP 6 afforded 
the title compound as a foam (5.6 mg, 49%). 1H-NMR (750 MHz, 
DMSO-d6): δ 8.71 (d, 1H, C7NH, J= 6.0 Hz), 8.08 (d, 1H, NHCαLeu, J= 8.2 
Hz), 4.80 (bs, 2H, NH2), 4.30 (m, 1H, HαLeu), 3.97 (t, 1H, HαCys J= 6.3 
Hz), 3.54 (d, 1H, H2, J= 9.2 Hz), 3.44-3.35 (m, 3H, H6, H3, H7), 3.13 (m, 3H, H7 and HβCys), 1.95 (m, 1H, H4), 
1.70-1.50 (m, 4H, H5, HβγLeu), 1.35 (m, 2H, H4 and H5) 1.30 (s, 9H, tBu), 0.87 (2×d, 6H, 2×CH3Leu, J= 6.3 and 
6.4 Hz); MS (ESI): m/z 480.1 (M+H)+; HR-MS: calc. 480.2202 (C20H37N3O6S2+H)+, found 480.2159.  
S-tert-butylthio-D-cysteinyl-aminomethyl-4,5-dideoxy-α-D-aminoglucuronopyranosyl)-D-leucine (2,6-trans 
16). Treatment of 2,6-trans 15 (20 mg, 28 μmol) according to GP 6 
furnished the title compound as a foam (6.7 mg, 50%). 1H-NMR (750 
MHz, DMSO-d6): δ 8.82 (d, 1H, C7NH, J= 4.4 Hz), 8.00 (d, 1H, 
NHCαLeu, J= 8.2 Hz), 4.60 (bs, 2H, NH2), 4.28 (m, 1H, HαLeu), 4.08 (d, 
1H, H2, J= 3.2 Hz), 4.01 (m, 1H, HαCys), 3.95 (m, 1H, H3), 3.75 (m, 1H, H6), 3.37-3.14 (m, 4H, H7 and HβCys), 
1.70-1.50 (m, 6H, H5, H4, HβγLeu), 1.39 (m, 1H, H5), 1.30 (s, 9H, tBu), 0.90 and 0.86 (2×d, 6H, 2×CH3Leu, J= 6.6 
and 6.5 Hz); MS (ESI): m/z 480.1 (M+H)+; HR-MS: calc. 480.2202 (C20H37N3O6S2+H)+, found 480.2168. 
S-tert-butylthio-D-cysteinyl-aminomethyl-4,5-dideoxy-β-D-aminoglucuronopyranosyl)-D-leucine (2,6-cis 16). 
Treatment of 2,6-cis 15 (20 mg, 28 μmol) according to GP 6 afforded 
the title compound as a foam (12 mg, 60%). 1H-NMR (750 MHz, 
DMSO-d6): δ 8.84 (s, 1H, C7NH), 8.08 (d, 1H, NHCαLeu, J= 8.1 Hz), 4.83 
(bs, 2H, NH2), 4.27 (m, 1H, HαLeu), 3.93 (m, 1H, HαCys), 3.54 (d, 1H, H2, 
J= 9.2 Hz), 3.44-3.15 (m, 6H, H6, H3, H7, HβCys), 1.95 (m, 1H, H4), 1.75-1.50 (m, 4H, H5, HβγLeu), 1.35-1.31 (m, 
11H, tBu, H4 and H5), 0.87 (2×d, 6H, 2×CH3Leu, J= 6.4 and 6.5 Hz); MS (ESI): m/z 480.1 (M+H)+; HR-MS: 
calc. 480.2202 (C20H37N3O6S2+H)+, found 480.2199. 
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Abstract. Eleven peptidomimetic analogs of the C-terminal Ca1a2X motif found in natural substrates of the 
prenyl transferases PFT and PGGT-1 were synthesised and evaluated for their inhibition potency and 
selectivity against PFT and PGGT-1. Replacement of the central dipeptide part a1a2 by a benzylated sugar 
amino acid resulted in a good and selective PFT inhibitor (2,6-cis 21, IC50= 250 ± 20 nM). The methyl ester 













 3.1 Introduction 
Tetrapeptides based on the C-terminal Ca1a2X motif can function as substrate analog 
inhibitors of protein:farnesyl transferase (PFT) and protein:geranylgeranyl transferase-1 
(PGGT-1; see Chapter 1). Chapter 2 presented a new type of Ca1a2X analogs, in which a 
sugar amino acid (SAA) is incorporated as replacement of the central dipeptide a1a2. On 
the basis of this finding, it was envisaged that compounds with improved inhibitory 
potency can be obtained by modification of the SAA moieties. From literature data it is 
known that the introduction of hydrophobic aromatic residues at the a2 position has a 
beneficial effect on the inhibitory potency against both PFT and PGGT-1.1 For PFT this is 
exemplified by the potent and competitive inhibitor CVFM,2 in which the presence of 
phenylalanine at the a2 position is of prime importance. In line with this, it is reported 
that a series of Ca1a2L analogs, in which the a1a2 portion was replaced by dipeptide 
isosteric 2-aryl-4-aminobenzoic acid moieties, were effective inhibitors of PGGT-1.1de,3 
The replacement of amide linkages by amine connections in certain Ca1a2X analogs not 
only has a beneficial effect on the stability against proteolytic degradation but also 
influences the selectivity of inhibition.4 The recently developed5 synthesis of amino 
acid/carbohydrate conjugates via the Fukuyama/Mitsunobu glycosylation of amino acid 
derived ortho-nitrobenzenesulfonamides offered the opportunity to evaluate the 
inhibitory potency and selectivity of Ca1a2X analogs having an amine bond between the 





















methionine (PFT) or leucine (PGGT-1)
benzyl group as aromatic functionality
amine (X= H,H) or 
amide (X= O)
R








This chapter describes the synthesis of novel inhibitors of the prenylating enzymes 
PFT and PGGT-1 containing a benzylated SAA having a 2,6-trans or a 2,6-cis substituted 
sugar core (I, Figure 3.1). The Ca1a2L analogs 18 and 19 and the controls 2,6-cis 23 and 
2,6-cis 24∗ (Scheme 3.5) were designed to inhibit PGGT-1, while the corresponding 
Ca1a2M analogs 20 and 21 were projected to inhibit PFT. Sulfoxides 2,6-trans 22 and 2,6-
cis 22 were obtained as side products in a deprotection step. All compounds were 
evaluated on their inhibitory potency and selectivity in both a PFT and PGGT-1 enzyme 
bio-assay.6 The effect of compound 2,6-cis 25, (i.e. methyl ester of 2,6-cis 21, Figure 3.2), 
on the prenylation of proteins was investigated in cultured cells. 
 
 3.2 Results and Discussion 
3.2.1 Synthesis – The assembly of all target Ca1a2X analogs started with the synthesis 
of epimeric alcohols 2,6-trans 3 and 2,6-cis 3 (Scheme 3.1). Known7 cyanides 2,6-trans 1 
and 2,6-cis 1 were hydrogenated (45 psi H2) over Pd/C (10% Pd). Treatment of the 
resulting ammonium salts with Boc2O followed by base catalysed deacetylation gave diols 
2,6-trans 2 and 2,6-cis 2, respectively in good overall yields. The introduction of the 
benzyl group at C3 was achieved by protection of the primary hydroxyl with a trityl 
group and phase transfer catalysed benzylation of the C3 hydroxyl8 whereafter acidic 
removal of the triphenylmethyl group furnished the desired key building blocks 2,6-trans 
3 and 2,6-cis 3. 
The route of synthesis to the fully protected amine precursors (2,6-trans/cis 8 and 
2,6-trans/cis 9) is exemplified by the conversion of 2,6-trans 3 into compounds 2,6-trans 8 
and 2,6-trans 9 (Scheme 3.2). Thus, treatment of 2,6-trans 3 with either o-Ns-Leu-OMe 
(4)9 or o-Ns-Met-OMe (5)10 and PPh3/DEAD gave, after removal of the nosyl group, the 
dimers 2,6-trans 6 and 2,6-trans 7, respectively in good yield. The Boc group was removed 
and the corresponding ammonium salt was condensed with Fmoc-Cys(StBu)-OH 
furnishing the desired Ca1a2X analogs. Starting from 2,6-cis 3, the corresponding 2,6-cis 




                                                 

























2,6-trans 7  R= CH2SCH3
6 2
2,6-trans 8  R= CH(CH3)2























2,6-cis 7  R= CH2SCH3
6 2
2,6-cis 8  R= CH(CH3)2








4:  R= CH(CH3)2










































aReagents and conditions (i) (a) 10% Pd/C, H2, EtOH, MeOH, CHCl3 (b) Boc2O, Et3N, DCM (c) 
NaOMe, MeOH (2,6-trans 2: 95%, 2,6-cis 2: 70%); (ii) (a) TrCl, pyridine, 60°C (b) BnBr, Bu4NHSO4, 50% aq. 
NaOH, DCM (c) p-TsOH·H2O, DCM, MeOH (2,6-trans 3: 73%, 2,6-cis 3: 75%). 
 
 





















aReagents and conditions (i) (a) o-Ns-Leu-OMe (4) or o-Ns-Met-OMe (5), PPh3, DEAD, THF (b) 
K2CO3, PhSH, CH3CN, 50°C (2,6-trans 6: 65%, 2,6-cis 6: 92%; 2,6-trans 7: 81%, 2,6-cis 7: 99%); (ii) TFA, 
DCM, iPr3SiH or Et3SiH; (iii) Fmoc-Cys(StBu)-OH, BOP, N-ethylmorpholine, DMF (2,6-trans 8: 40%, 2,6-

























The fully protected precursor of debenzylated control compound 2,6-cis 11 (Scheme 
3.5) was obtained by the procedure depicted in Scheme 3.3. Removal of the benzyl group 
in 2,6-cis 6 furnished 2,6-cis 10 (HCl salt) which was subjected to the same sequence of 
reactions as described for the synthesis of 8, thereby affording 2,6-cis 11. 
 
 








aReagents and conditions: (i) 10% Pd/C, H2, EtOH, CHCl3 (100%); (ii) TFA, DCM, iPr3SiH or Et3SiH; 
(iii) Fmoc-Cys(StBu)-OH, BOP, N-ethylmorpholine, DMF (52%, 2 steps). 
 
The route of synthesis to the fully protected amide precursors is exemplified by the 
conversion of 2,6-cis 3 into compounds 2,6-cis 15 and 2,6-cis 16  (Scheme 3.4). Oxidation 
of 2,6-cis 3 with RuCl3⋅3H2O11 or TEMPO/[bis(acetoxy)iodo]benzene12 gave the carboxylic 
acid 2,6-cis 12. In an alternative route to the SAAs 2,6-cis 12 and 2,6-trans 12, diol 2 was 
processed as exemplified for the 2,6-cis isomer (Scheme 3.4). Treatment of 2,6-cis 2 with 
benzylidene dimethyl acetal afforded 2,6-cis 17 in good yield. Next, opening of the acetal 
by subjection of 2,6-cis 17 to excess diisobutylaluminium hydride gave 2,6-cis 3 along 
with the corresponding C1–OBn regio-isomer (C3–OBn/C1–OBn: ≈7/1).13 As separation of 
the two regio-isomers was found to be troublesome at this stage, the oxidation step was 
carried out on the mixture and the desired SAA building block 2,6-cis 12 could be isolated 
in pure form. Subsequent condensation of 2,6-cis 12 with H-Leu-OMe (HCl salt) or H-
Met-OMe (HCl salt) yielded 2,6-cis 13 and 2,6-cis 14, respectively. Deprotection of the 
Boc group and condensation with Fmoc-Cys(StBu)-OH afforded 2,6-cis 15 and 2,6-cis 
16.14 The corresponding 2,6-trans Ca1a2X analogs (2,6-trans 15 and 2,6-trans 16, Scheme 
3.4) were obtained by executing the same sequence of reactions as described for the 2,6-




























2,6-cis 13  R= CH(CH3)2
2,6-cis 3
2,6-cis 14 R= CH2SCH3
2,6-cis 15  R= CH(CH3)2









































2,6-trans 13  R= CH(CH3)2
2,6-trans 14 R= CH2SCH3
2,6-trans 15  R= CH(CH3)2



































aReagents and conditions (i) RuCl3⋅3H2O, K2S2O8, 1M KOH or TEMPO, [bis(acetoxy)iodo]benzene, 
DCM, H2O (2,6-trans 12: 85%, 2,6-cis 12: 100%); (ii) benzaldehyde dimethyl acetal, p-TsOH·H2O, CH3CN 
(2,6-trans 17: 71%, 2,6-cis 17: 77%); (iii) DIBAL-H, PhCH3, 0°C; (iv) HCl⋅H-Leu-OMe, BOP, DIPEA (2,6-
trans 13: 98%, 2,6-cis 13: 98%) or HCl⋅H-Met-OMe, EDC, HOBt, DMF (2,6-trans 14: 73%, 2,6-cis 14: 83%); 
(v) TFA, DCM, iPr3SiH or Et3SiH; (vi) Fmoc-Cys(StBu)-OH, for 15: BOP, HOBt, DIPEA (2,6-trans 15: 80%, 
2,6-cis 15: 85%), for 16: EDC, HOBt, DMF (2,6-trans 16: 79%, 2,6-cis 16: 79%). 
 
Target compounds 18−22 and 2,6-cis 23 (Scheme 3.5) were obtained by treatment of 
the fully protected precursors with Tesser’s base mixture (MeOH/1,4-dioxane/4M aq. 
NaOH, 15/4/1 v/v/v) to effect simultaneous hydrolysis of the ester and removal of the 
Fmoc group. The crude compounds were subsequently characterised by LC-MS and 
purified by RP-HPLC. In the case of 2,6-trans 21 and 2,6-cis 21, the applied deprotection 
condition gave oxidised side-products which were identified as sulfoxides 2,6-trans 22 




evaluation of their biological activity. Fortunately, base mediated deprotection under 
stringent non-aerobic conditions furnished the desired 2,6-trans 21 and 2,6-cis 21. 
 




aReagents and conditions (i) (a): MeOH/1,4-dioxane/4M NaOH (b) RP-HPLC purification; (ii) (a) 
MeOH/1,4-dioxane/4M NaOH: reaction was performed under argon with freshly distilled 1,4-dioxane 
(benzophenone ketyl) (b) RP-HPLC purification.  
 
3.2.2 Biological Evaluation – Compounds 18−22 and 2,6-cis 23 (Scheme 3.5) were 
evaluated for their in vitro inhibitory activity against PFT and PGGT-1 following 
previously described procedures (Table 3.1). The StBu protective group on the cysteine 
residue is cleaved under the conditions of the assay (pH 7.4, DTT). As a reference the 























































































































2,6-trans 21 2,6-trans 22
2,6-cis 16
i
2,6-cis 21 2,6-cis 22




R= SCH3 R= S(O)CH3 R= SCH3 R= S(O)CH3
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Table 3.1 Determined IC50 values of 18−22 and 2,6-cis 23, reference tetrapeptides CVIM and CVIL. 
 
                                               IC50 (μM)a                                                                                                                         IC50 (μM)a 
compound                PFT                      PGGT-1             compound               PFT                       PGGT-1 
2,6-trans 18 ∼1000 270 ± 122 2,6-cis 21 0.25 ± 0.02 >1000 
2,6-cis 18 >1000 464 ± 147 2,6-trans 22 91 ± 14 521 ± 75 
2,6-trans 19 321 ± 18 206 ± 34 2,6-cis 22 2.2 ± 0.6 >1000 
2,6-cis 19 57 ± 18 14 ± 6 2,6-cis 23 >1000 261 ± 55 
2,6-trans 20 ∼1000 311 ± 94 2,6-cis 24 -b ∼1000 
2,6-cis 20 >1000 500 ± 81 CVIM 0.42 ± 0.05 -b 
2,6-trans 21 42 ± 6 48 ± 11 CVIL -b 4.4 ± 0.2 
aIC50: concentration of compound required to inhibit for 50% the PGGT-1 or PFT catalysed 
incorporation of [3H]-GGPP or [3H]-PFT, respectively. All IC50 values are means of three determinations: 
one determination involves performing the assay at 5 concentrations of compound. By using a mathematical 
function fitting to the concentration/inhibition curve, the IC50 value was determined. bnot determined. 
Compound 2,6-cis 21 proved to be a good (IC50= 250 ± 20 nM) and selective PFT 
inhibitor. Furthermore, 2,6-cis 21 has a 1000-4000 fold improved inhibitory potency 
compared to the SAA based PFT inhibitors reported previously16 and was found to be 
slightly more active than the lead tetrapeptide inhibitor CVIM. When 2,6-trans 21 and 
2,6-cis 21 are compared, it becomes clear that the stereochemical identity of the SAA is 
important with respect to both potency and selectivity.  
For PGGT-1, 2,6-cis 19 was found to be the most active inhibitor (IC50= 14 ± 6 μM). 
Compound 2,6-cis 19, which only differs from 2,6-cis 21 in its X amino acid, shows no 
high selectivity for either enzyme.15 Comparing 2,6-cis 24 with 2,6-cis 19 shows that 
enhanced hydrophobicity at the a2 position has a positive effect on the inhibitory 
potency. Having an amine linkage between the dipeptide isostere and the X amino acid 
(18 and 20) proves to be detrimental for the inhibition of both enzymes, in particular for 
PFT.17 However, compound 2,6-cis 23 is ∼4 times more active against PGGT-1 than its 
amide analog 2,6-cis 24. Although introduction of a sulfoxide functionality (22) leads to a 
decrease in inhibitory potency, this modification is better tolerated by PFT than PGGT-
1.18a This is in analogy with results reported by Manne and co-workers18b who observed 
that replacement of the methionine by polar residues (e.g. carboxamide or sulfone) 
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Figure 3.2 Synthesisa of 2,6-cis 25and in vivo evaluationb of TR006, 2,6-cis 21 and 2,6-cis 25. 
 
                                                                                                                           
                                                                                                                                             
 













aReagents and conditions (i) 20% piperidine in DMF (81%). bMet-18b-2 cells were treated with [3H]-
mevalonate, simvastatin and in the absence of compound (lane 1); with TR006 (lane 2, c= 100 μM); 2,6-cis 
21 (lane 3, c= 100 μM); 2,6-cis 25 (lane 4, c= 100 μM). Monolayers of cells were dissolved in detergent 
solution and subjected to electrophoresis and autoradiography. 
 
In order to evaluate whether compound 2,6-cis 21 is able to inhibit protein 
farnesylation in cultured cells, in vivo experiments were conducted using CHO (Chinese 
Hamster Ovary) Met-18b-2 cells.19 The corresponding methylester 2,6-cis 25 was 
synthesised in order to facilitate cellular uptake by enhancing the hydrophobicity. Once 
having entered the cell, the methylester is believed to be hydrolysed by hydrolases to the 
corresponding acid. As illustrated in Figure 3.2, incubation with [3H]-mevalonate resulted 
in several radio-labelled prenylated proteins which can be roughly divided into 
farnesylated proteins at molecular weights of about 46 – 80 kDa and geranylgeranylated 
proteins at about 22 – 28 kDa.20 While incubation with 2,6-cis 21 (lane 3) did not 
influence the prenylation pattern, 2,6-cis 25 (lane 4) inhibited the incorporation of 
labelled mevalonate into the higher molecular weight bands, indicating that protein 
farnesylation was strongly decreased. The 21 – 28 kDa bands did not change supporting 
the specificity of the inhibition. As a positive control, TR006 (Figure 3.2), a potent 
inhibitor of PFT and GGPP synthase,6b,21 was shown to decrease the prenylation of both 
the higher and lower molecular weight proteins (lane 2).  
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 3.3 Conclusions 
In summary, the synthesis and biological evaluation of novel Ca1a2X analogs, in 
which the a1a2 part is replaced by benzylated SAA dipeptide isosters is described. The 
stereochemistry of the SAA residue has a pronounced effect on inhibition potency and 
selectivity. Compound 2,6-cis 21, having a 2,6-cis configuration in the SAA core and X= 
methionine, appeared to be the most potent and selective PFT inhibitor in this series. The 
corresponding diastereoisomer 2,6-trans 21 is a modestly active inhibitor of both 
enzymes. Compound 2,6-cis 19, having a 2,6-cis SAA configuration and X= leucine, was 
also found to be a modest active dual inhibitor.22 In addition, while 2,6-cis 21 was not 
active in intact cells, the corresponding methyl ester 2,6-cis 25 was shown to inhibit 
protein farnesylation in intact Met-18b-2 cells.  
 
 3.4 Experimental Section 
3.4.1 General − AcOH, CH3CN, CHCl3, DCE, DCM, DMF, 1,4-dioxane, MeOH, pyridine and toluene 
were all of p.a. quality (Baker) and stored on molecular sieves (4Å). Methanol (p.a. Baker) was stored on 
molecular sieves (3Å). PE (40-60 fraction) and EtOAc were of technical grade and distilled before use. Et3N 
(99%, Acros) was used as received or distilled, when necessary, over CaH2 and stored over KOH pellets. 
DIPEA (peptide grade) and TFA were purchased from Biosolve. HCl⋅H-Leu-OMe, HCl⋅H-Met-OMe, Fmoc-
Cys-(StBu)-OH and BOP were obtained from Novabiochem and used as received. Benzaldehyde dimethyl 
acetal (99%, Acros), BF3·OEt2 (Aldrich), CSA (Aldrich), Boc2O (Fluka), DIBAL-H (1M in cyclohexane or 
toluene, Aldrich), DOWEX® (50WX4-H+-form, Fluka), N-ethylmorpholine (Acros), 
[bis(acetoxy)iodo]benzene (Acros), KOH (Boom), K2S2O8 (Acros), 10% Pd/C (Aldrich), PhSH (Aldrich), 
RuCl3⋅3H2O (Acros), TEMPO (Acros), p-TsOH·H2O (Acros), Et3SiH (Fluka), iPr3SiH (Fluka), TMSCN 
(Fluka) and TrCl (Aldrich) were used as received. RP-HPLC analysis and purification were performed on a 
Jasco HPLC system equipped with a Merck Lichrosphere C18 100Å column (4×250 mm). 1H-NMR and 13C-
NMR spectra were recorded with a Bruker AC-200 (1H-NMR 200 MHz, 13C-NMR 50 MHz), Bruker DPX-
300 (1H-NMR 300 MHz; 13C-NMR 75 MHz), Bruker AV-400 (1H-NMR 400 MHz, 13C-NMR 100 MHz), 
Bruker DMX-600 (1H-NMR 600 MHz, 13C-NMR 150 MHz). Chemical shifts are given in ppm (δ) relative to 
tetramethylsilane as internal standard. 1H-NMR: resonance of CDCl3 at 0.00 ppm as internal standard. 13C-
NMR: CDCl3 soln.; middle resonance of CDCl3 (77.0 ppm) as internal standard. MS (ESI): Perkin Elmer 
SCIEX API 165 quadrupole mass spectrometer, HR-MS: API QSTARTM Pulsar (Applied Biosystems). ATR-
IR spectra were recorded on a Shimadzu 8300 FT-IR Spectrometer. Reactions were followed by TLC 
analysis on silica gel (Schleicher & Schuell, F 1500 LS 254) or HPTLC aluminium sheets (Merck, silica gel 
60, F254), with detection by UV-absorption (254 nm) where applicable and charring at 150°C with 20% 
H2SO4 in EtOH (25 g L-1), ninhydrin (3 g L-1) in EtOH/AcOH (100/3 v/v), NH4(Mo)7O24⋅4H2O (25 g L-1) and 
NH4Ce(SO4)4⋅2H2O (10 g L-1) in 10% aq. H2SO4 or 2% KMnO4 in 1% aq. K2CO3. Column chromatography 














3.4.2 General procedures − General procedure 1a (GP 1a); Fukuyama/Mitsunobu with o-Ns amino acids: 
One equiv. of the amino alcohol and 1.1 equiv. of the o-Ns protected amino acid were coevaporated with 
toluene (3×) and then dissolved in freshly distilled THF (∼0.01 M). At 0°C, 2.0 equiv. PPh3 and 2.0 equiv. 
DEAD (dropwise) were added. The mixture was stirred at room temperature until TLC analysis showed 
completion and subsequently concentrated in vacuo.  
General procedure 1b (GP 1b); deprotection o-Ns protective group: the crude product obtained from 
general procedure 1a is dissolved in CH3CN (c ∼0.1 M) and treated with 4 equiv. of K2CO3 and 3 equiv. of 
PhSH. The reaction mixture is stirred at 50°C for 30-60 min after which it is washed with water and brine 
(saturated aq. NaCl soln.) and extracted with EtOAc (3×).  
General procedure 2 (GP 2); coupling of HCl⋅Leu-OMe with SAA Building block: to a ∼0.1M soln. of the 
sugar amino acid in DMF were added 1.2 equiv. HCl⋅Leu-OMe, 1.2 equiv. BOP, 1.2 equiv. HOBt and 4 
equiv. DIPEA. For the synthesis of 2,6-trans 14 and 2,6-cis 14, 1.2 equiv. EDC and 1.2 equiv. HOBt were 
employed. After TLC analysis (PE/EtOAc 1/1 v/v) showed consumption of the starting material, DMF was 
removed in vacuo. The residue was dissolved in EtOAc and washed with water (2×), sat. NaHCO3 (2×), 
water (2×), 5% aq. KHSO4 (2×) and brine. The organic phase was dried (MgSO4) and concentrated in vacuo.  
General procedure 3 (GP 3); removal of Boc: to a ∼0.05M soln. of dimer in DCM were added 1.3 equiv. 
iPr3SiH or Et3SiH and TFA (→50% TFA in DCM). After TLC analysis (PE/EtOAc 1/1 v/v) showed total 
consumption of starting material (±½ h), the reaction mixture was coevaporated with anh. toluene (5×).  
General procedure 4 (GP 4); coupling with Fmoc-Cys-(StBu)-OH: to a ∼0.1M soln. of the deprotected 
dimer in DMF were added 4 equiv. DIPEA or 4 equiv. N-ethylmorpholine, 1.2 equiv. Fmoc-Cys-(StBu)-OH, 
1.2 equiv. BOP and 1.2 equiv. HOBt. After TLC analysis (Et2O/EtOH/25% ammonia 6/3/1 v/v/v) showed 
consumption of the starting material, the reaction was worked up as described in general procedure 2. For 
the synthesis of 2,6-trans 16 and 2,6-cis 16, 1.2 equiv. EDC and 1.2 equiv. HOBt were employed. 
General procedure 5 (GP 5); deprotection using Tesser’s base: a ∼0.01M solution of the trimer in 
MeOH/1,4-dioxane/4M aq. NaOH (15/4/1 v/v/v) is stirred for 45 min at rt, after which the reaction mixture 
is diluted with water and washed with DCM (3×). The combined aqueous layers are neutralised with AcOH 
(pH ∼7) and evaporation gives the crude product, which is then subjected to RP-HPLC purification using a 
linear gradient of CH3CN (= eluent B) in H2O (= eluent A) and 1% aq. TFA (= eluent C, effective 0.1%). 
 
(2R,3S,6S)-6-{N-[(tert-butyloxycarbonyl)amino]methyl}-2-hydroxymethyl-tetrahydropyran-3-ol (2,6-trans 
2). Compound 2,6-trans 1 (4.00 g, 16.7 mmol) was dissolved in EtOH/MeOH/CHCl3 
(50 mL, 5/5/1 v/v/v) and 10% Pd/C (1.00 g). After hydrogenation for 24 h under 45 
psi H2-atmosphere, the Pd/C was filtered off and the crude amine (HCl salt) was 
obtained as a foam after concentration in vacuo. To a ∼0.1M soln. of the product in 
DCM were added 1.2 equiv. of Boc2O and 2.2 equiv. of Et3N and the reaction mixture was stirred until TLC 
analysis showed total consumption of the starting material (PE/EtOAc 1/1 v/v), water was added. The aq. 
layer was extracted 2× with EtOAc and the combined organic layers were washed with brine, dried 
(MgSO4) and evaporated. Treatment of the crude diacetate with 0.3 equiv. NaOMe in MeOH (∼0.1M) gave 
after silica gel chromatography (5% MeOH/EtOAc) 2,6-trans 2 (4.16 g, 15.9 mmol, 95%, 3 steps) as an oil. 
(Rf= 0.5, 10% MeOH in EtOAc). [α]D25= +31.2 (c= 0.25, CHCl3). 1H-NMR (200 MHz, CDCl3/MeOD): δ 5.04 
(bs, NH), 3.89-3.80 (m, 1H, H6), 3.75-3.71 (m, 2H, H1ab), 3.54-3.34, 3.21-3.10 (m, 4H, H3, H2, H7ab), 1.92-1.81, 
1.78-1.68 (m, 4H, H5ab, H4ab), 1.45 (s, 9H, tBu); 13C-NMR (50 MHz, MeOD): δ 158.2 (C=OBoc), 79.8 (CqtBu), 
77.5, 71.6, 66.5 (C2, C3, C6), 62.4 (C1), 42.3 (C7), 28.7 (tBu), 28.1, 25.3 (C5, C4). IR ν (cm-1, film): 3323, 2936, 
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1688 (C=O), 1522, 1454, 1393, 1366, 1252, 1170, 1109, 1043. MS (ESI): m/z 262.1 (M+H)+, 284.1 (M+Na)+. 
HR-MS: calc. for [C12H23NO5+Na]+ 284.1468, found 284.1489. 
(2R,3S,6R)-6-{N-[(tert-butyloxycarbonyl)amino]methyl}-2-hydroxymethyl-tetrahydropyran-3-ol (2,6-cis 
2). From 2,6-cis 1 (0.79 g, 3.29 mmol) as described for the 2,6-trans isomer. Silica gel 
chromatography (5% MeOH/EtOAc) gave the title compound (0.60 g, 2.31 mmol, 
70% over three steps) as an oil (Rf= 0.5, 10% MeOH in EtOAc). [α]D25= –8.8 (c= 0.25, 
CHCl3). 1H-NMR (200 MHz, MeOD): δ 4.86 (s, 1H, NH), 3.85, 3.82 (2×d, 2H, H1ab, J= 4.4 Hz), 3.62-3.47 (m, 
2H, H2, H6), 3.41-3.27 (m, 1H, H7a), 3.27-3.17 (m, 1H, H3), 3.09-2.96 (m, 1H, H7b), 2.17-2.10 (m, 1H, H4a), 
1.73-1.53 (m, 3H, H4b, H5ab), 1.45 (s, 9H, tBu); 13C-NMR (50 MHz, MeOD): δ 158.2 (C=OBoc), 83.5 (C2), 79.8 
(CqtBu), 77.4 (C3), 67.1 (C6), 63.4 (C1), 45.8 (C7), 33.0 (C4), 29.1 (C5), 28.8 (tBu). IR ν (cm-1, film): 3340, 2936, 
1690 (C=O), 1522, 1454, 1393, 1367, 1252, 1171, 1097, 1043. MS (ESI): m/z 262.1 (M+H)+, 284.1 (M+Na)+. 
HR-MS: calc. for [C12H23NO5+Na]+ 284.1468, found 284.1474. 
(2R,3S,6S)-6-{N-[(tert-butyloxycarbonyl)amino]methyl}-2-trityloxymethyl-tetrahydropyran-3-ol (2,6-trans 
2Tr). Diol 2,6-trans 2 (2.32 g, 8.8 mmol) was coevaporated with pyridine (3×10 mL) 
and dissolved in pyridine (60 mL). TrCl (2.69 g, 9.7 mmol) was added and the 
reaction mixture was stirred at 60°C overnight. The pyridine was removed in vacuo 
and the residue was partitioned between an aq. HCl solution (20 mL, 0.1 M) and EtOAc (20 mL). The aq. 
layer was extracted with EtOAc (2×) and the combined organic layers were washed with brine, dried 
(MgSO4) and concentrated in vacuo. Silica gel chromatography (Et2O) gave the title compound (4.1 g, 8.2 
mmol, 93%) as a foam (Rf= 0.3, Et2O). [α]D25= +2.8 (c= 0.5, CHCl3). 1H-NMR (200 MHz, CDCl3): δ 7.47-7.20 
(m, 15H, HTr), 4.92 (bs, 1H, NH), 3.74-3.18 (m, 7H, H1, H2, H3, H6, H7), 1.71-1.58 (m, 4H, H4, H5), 1.42 (s, 
9H, tBu); 13C-NMR: δ 155.3 (C=OBoc), 143.1 (CqTr), 127.8-126.0 (CTr), 85.8 (CqTr), 77.6 (CqtBu), 75.1, 69.3, 64.9 
(C2, C3, C6), 62.4 (C1), 42.0 (C7), 27.4 (tBu), 26.1 (C4), 22.7 (C5). IR ν (cm-1, film): 3416, 2935, 1695, 1502, 
1448, 1364, 1250, 1171, 1053, 760, 706. MS (ESI): m/z 526.5 (M+Na)+. HR-MS: calc. for [C31H37NO5+Na]+ 
526.2563, found 526.2550. 
(2R,3S,6R)-6-{N-[(tert-butyloxycarbonyl)amino]methyl}-2-trityloxymethyl-tetrahydropyran-3-ol (2,6-cis 
2Tr). From 2,6-cis 2 (1.00 g, 3.83 mmol) as described for 2,6-trans 2Tr Silica gel 
chromatography (Et2O) afforded the title compound (1.73 g, 3.44 mmol, 90%) as a 
foam (Rf= 0.6, Et2O). [α]D25= –37.2 (c= 0.5, CHCl3). 1H-NMR (200 MHz, CDCl3): δ 
7.48-7.18 (m, 15H, HTr), 4.82 (bs, 1H, NH), 3.50 (m, 2H, H1ab), 3.34 (m, 3H, H6, H2, H7a), 3.21 (m, 1H, H3), 
2.95 (ddd, 1H, H7b), 2.09 (m, 1H, H4a), 1.67-1.31 (m, 3H, H5ab, H4b), 1.44 (s, 9H, tBu); 13C-NMR: δ 155.5 
(C=OBoc), 143.4 (CqTr), 128.5-126.6 (CTr), 86.5 (CqTr), 78.4 (CqtBu), 79.7, 75.4, 67.7 (C2, C3, C6), 65.0 (C1), 44.4 
(C7), 31.3 (C4), 27.9 (tBu), 27.3 (C5). IR ν (cm-1, film): 3427, 2930, 1695, 1493, 1448, 1365, 1169, 1099, 760, 
706. MS (ESI): m/z 526.5 (M+Na)+. HR-MS: calc. for [C31H37NO5+Na]+ 526.2563, found 526.2552. 
(2R,3S,6S)-6-{N-[(tert-butyloxycarbonyl)amino]methyl}-3-benzyloxy-2-trityloxymethyl-tetrahydropyran 
(2,6-trans 2TrBn). Compound 2,6-trans 2Tr (2.1 g, 4.3 mmol) was dissolved in DCM (50 
mL), Bu4NHSO4 (4.3 g, 12.7 mmol) and benzyl bromide (1.3 mL, 10.6 mmol) were 
added. A 50% aq. solution of NaOH (50 mL) was added and the reaction mixture was 
stirred vigorously until TLC analysis showed completion (24−48 h). Ice-water was added and the layers 
were separated. The aqueous layer was extracted with EtOAc (2×). The combined organics were 
subsequently washed with water (2×) and brine (2×), dried (MgSO4) and concentrated in vacuo. Silica gel 
chromatography (PE/Et2O 1/1 v/v) yielded the title compound (2.3 g, 3.9 mmol, 91%) as an oil (Rf= 0.8, 
Et2O). [α]D25= +22.2 (c= 1, CHCl3). 1H-NMR (200 MHz, CDCl3): δ 7.46-7.21 (m, 20H, HTr&Bn), 4.97 (bs, 1H, 
NHBoc), 4.59, 4.46 (2×d, 2H, CH2Bn, J= 11.7 Hz), 3.61-3.08 (m, 7H, H1, H2, H3, H6, H7), 1.73-1.52 (m, 4H, H5 




















126.9 (CTr&Bn), 86.5 (CqTr), 78.8 (CqtBu), 74.1 (C6), 71.8 (C3), 70.3 (C2), 70.2 (CH2Bn), 62.6 (C1), 43.2 (C7), 29.2 
(tBu), 27.9 (C4), 23.6 (C5). IR ν (cm-1, film): 2934, 1713, 1493, 1448, 1366, 1169, 1101, 748, 704. MS (ESI): 
m/z 616.3 (M+Na)+. HR-MS: calc. for [C38H43NO5+Na]+ 616.3033, found 616.3017. 
(2R,3S,6R)-6-{N-[(tert-butyloxycarbonyl)amino]methyl}-3-benzyloxy-2-trityloxymethyl-tetrahydropyran 
(2,6-cis 2TrBn). From 2,6-cis 2Tr (2.69 g, 5.34 mmol) as described for 2,6-trans 2TrBn 
Silica gel chromatography (PE/Et2O 1/1 v/v) afforded the title compound (2.57 g, 
4.33 mmol, 81%) as a foam (Rf= 0.9, Et2O). [α]D25= +1.6 (c= 0.25, CHCl3). 1H-NMR 
(200 MHz, CDCl3): δ 7.48-7.01 (m, 20HTr&Bn), 5.01 (bs, 1H, NHBoc), 4.50, 4.30 (2×d, 2H, CH2Bn, J= 11.4 Hz), 
3.56-3.03 (m, 7H, H1, H2, H3, H6, H7), 2.24 (m, 1H, H4a), 1.75-1.46 (m, 3H, H4b, H5ab), 1.46 (s, 9H, tBu); 13C-
NMR (50 MHz, CDCl3): δ 156.0 (C=OBoc), 143.3 (CqTr), 138.0 (CqBn), 128.5-127.2 (CTr&Bn), 87.3 (CqTr), 79.0 
(CqtBu), 78.9, 76.3, 69.5 (C2, C3, C6), 66.1 (CH2Bn), 60.6 (C1), 44.7 (C7), 28.3 (tBu), 27.5, 31.1 (C4, C5). IR ν (cm-1, 
film): 2930, 1716, 1493, 1448, 1366, 1171, 1099, 1028, 748, 698. MS (ESI): m/z 616.4 (M+Na)+. HR-MS: calc. 
for [C38H43NO5+Na]+ 616.3033, found 616.3033. 
(2R,3S,6S)-6-{N-[(tert-butyloxycarbonyl)amino]methyl}-2-phenyl-hexahydro-pyrano[3,2-d][1,3]-dioxine 
(2,6-trans 17). To a solution of 2,6-trans 2 (4.16 g, 15.9 mmol) in CH3CN (75 mL) 
was added benzaldehyde dimethyl acetal (2.9 mL, 2.91 mmol) and CSA (0.74 g, 
3.12 mmol). After stirring for 2 h at 65°C, TLC analysis (EtOAc) showed total 
consumption of starting material and the mixture was neutralised with Et3N (3.12 mmol) and concentrated 
in vacuo. After extraction with EtOAc and washing with 10% aq. NaHCO3 and brine, the organic layer was 
dried over MgSO4. Silica gel chromatography (PE/EtOAc 4/1 v/v) yielded the title compound (3.95 g, 11.3 
mmol, 71%) as a white crystalline compound (Rf= 0.7, EtOAc). [α]D25= +50.4 (c= 1, CHCl3). 1H-NMR (400 
MHz, CDCl3): δ 7.49-7.33 (m, 5H, HPh), 5.55 (s, 1H, PhCH), 4.79 (s, 1H, NH), 4.19 (dd, 1H, H1a, J= 5.9 and 
10.2 Hz), 3.93 (t, 1H, H1b), 3.70-3.55 (m, 4H, H6, H3, H2, H7a), 3.21 (m, 1H, H7b), 2.00, 1.75 (2×m, 4H, H4ab, 
H5ab), 1.45 (s, 9H, tBu); 13C-NMR (75 MHz, CDCl3): δ 155.6, (C=OBoc), 137.4 (CqPh), 128.70, 127.8, 125.91 
(CPh), 101.4 (PhCH), 78.8 (CqBoc), 78.3 (C6), 71.6 (C3), 69.3 (C2), 66.0 (C1), 39.4 (C7), 28.1 (tBu), 25.3, 24.3 (C5, 
C4). IR ν (cm-1, film): 3352, 2935, 1697, 1510, 1456, 1366, 1238, 1169, 1099, 1001, 750, 698. MS (ESI): m/z 
350.2 (M+H)+, 372.1 (M+Na)+. HR-MS: calc. for [C19H27NO5+Na]+ 372.1781, found 372.1833. 
(2R,3S,6R)-6-{N-[(tert-butyloxycarbonyl)amino]methyl}-2-phenyl-hexahydro-pyrano[3,2-d][1,3]-dioxine 
(2,6-cis 17). From 2,6-cis 2 (706 mg, 2.70 mmol) as described for 2,6-trans 17. Silica 
gel chromatography (PE/EtOAc 4/1 v/v) gave 2,6-cis 17 (726 mg, 2.08 mmol, 77%), 
white crystals (Rf= 0.9, EtOAc). [α]D25= –24.0 (c= 0.25, CHCl3). 1H-NMR (200 MHz, 
CDCl3): δ 7.52-7.34 (m, 5H, HPh), 5.55 (s, 1H, PhCH), 4.88 (s, 1H, NH), 4.27 (dd, 1H, H1a, J= 5.9 and 10.2 
Hz), 3.69 (m, 1H, H1b), 3.59-3.47 (m, 2H, H2, H6), 3.46-3.34 (m, 2H, H3, H7a), 3.08-2.95 (m, 1H, H7b, J= 5.1 
and 4.4 Hz), 2.15-2.05 (m, 1H, H5a), 1.84-1.53 (m, 3H, H5b, H4ab), 1.46 (s, 9H, tBu); 13C-NMR (50 MHz, 
CDCl3): δ 155.7, (C=OBoc), 137.4 (CqPh), 128.7, 128.0, 125.9 (CPh), 101.4 (PhCH), 79.0 (CqBoc), 77.9 (C2), 76.4 
(C3), 73.0 (C6), 69.0 (C1), 44.6 (C7), 28.2 (tBu), 27.9, 27.7 (C5, C4). IR ν (cm-1, film): 3375, 2933, 1715, 1510, 
1456, 1393, 1366, 1246, 1171, 1099. MS (ESI): 350.2 (M+H)+, 372.2 (M+Na)+. HR-MS: calc. for 
[C19H27NO5+Na]+ 372.1781, found 372.1801. 
(2R,3S,6S)-6-{N-[(tert-butyloxycarbonyl)amino]methyl}-3-benzyloxy-tetrahydropyran-2-ol (2,6-trans 3). 
Method 1: A solution of 2,6-trans 2TrBn (2.3 g, 3.9 mmol) and 0.3 equiv. of p-
TsOH·H2O (0.22 g) in MeOH (50 mL) and DCM (50 mL) was stirred at rt until TLC 
analysis (PE/EtOAc 1/3 v/v) showed completion. The reaction was quenched with a 
half-saturated NaHCO3 solution and extracted with EtOAc. The combined organics were washed with 
brine, dried (MgSO4) and concentrated to dryness. Silica gel chromatography (Rf= 0.7, EtOAc) yielded the 





















(283 mg, 0.81 mmol) in toluene (12 mL) under a blanket of argon was cooled to 0°C. Subsequently, 8.1 mL 
of a 1M soln. of DIBAL-H in toluene (8.1 mmol, 10 equiv.) was added and after ½h the reaction mixture 
was allowed to warm up to rt. When TLC analysis showed total consumption of starting material (12−24 h), 
the temperature was lowered to 0°C and the reaction was quenched carefully with MeOH (5 mL). After ½h 
the temperature was again brought to 0°C and 10% aq. NaOH was added. The water layer was extracted 
with EtOAc (3×) and the combined organic layers were washed with brine and dried with MgSO4. Silica gel 
chromatography yielded the title compound (198 mg, 70%) and the 1-OBn regio-isomer (39 mg, 14%, Rf= 
0.6, EtOAc). [α]D25= +68.4 (c= 1, CHCl3). 1H-NMR (200 MHz, CDCl3) δ 7.31-7.28 (m, 5HBn), 5.10 (bs, 1H, 
NHBoc), 4.59 and 4.46 (2×d, CH2Bn, J= 11.7 Hz), 3.85-3.20 (m, 7H, H6, H3, H2, H1, H7), 1.93-1.67 (m, 4H, H5ab 
and H4ab), 1.42 (s, 9H, tBu); 13C-NMR (50 MHz, CDCl3) δ 156.1 (C=OBoc), 138.2 (CqBn), 128.2, 127.5, 127.2 
(CBn), 79.1 (CqBoc), 74.3 (C2), 72.5 (C6), 70.7 (C3), 70.3 (CH2Bn), 61.6 (C1), 41.6 (C7), 28.2 (tBu), 24.2, 23.9 (C4, 
C5). IR ν (cm-1, film): 3340, 2976, 1693, 1520, 1454, 1366, 1250, 1169, 1092. 750, 698. MS (ESI): m/z 352.1 
(M+H)+, 374.1 (M+Na)+. HR-MS: calc. for [C19H29NO5+Na]+ 374.1943, found 372.1935.  
(2R,3S,6R)-6-{N-[(tert-butyloxycarbonyl)amino]methyl}-3-benzyloxy-tetrahydropyran-2-ol (2,6-cis 3). 
Following method 1 as described for the synthesis of 2,6-trans 3 using 2,6-cis 2TrBn 
(800 mg, 1.35 mmol) gave after silica gel chromatography (PE/EtOAc 1/1 v/v) the 
title compound (479 mg, 1.35 mmol, 100%) as an oil. Employing method 2 using 2,6-
cis 17 (365 mg, 4.93 mmol) gave an unseparable mixture of the title compound (Rf= 0.7, EtOAc) and the 1-
OBn regio-isomer (Rf= 0.4, EtOAc/PE 2/1 v/v) in a ∼7/1 ratio as determined by 13C-NMR (det. limit <5%), 
total yield: 292 mg, 0.83 mmol, 80%. [α]D25= +60.8 (c=0.5, CHCl3). 1H-NMR (300 MHz, CDCl3): δ 7.36-7.24 
(m, 5H, HBn), 5.34 (s, 1H, NH), 4.62, 4.46 (2×d, 2H, CH2Bn, J= 11.6 Hz), 3.88 and 3.68 (2×dd, 2H, H1ab, J= 4.4 
and 11.5 Hz), 3.50-3.41 (m, 1H, H6, J= 3.4 and 2.6 Hz), 3.37-3.30 (m, 3H, H3, H2, H7a), 3.06-2.97 (m, 1H, H7b, 
J= 4.8 Hz), 2.29-2.24 (m, 1H, H5a), 1.71-1.50 (m, 1H, H4a), 1.43 (s, 9H, tBu), 1.39-1.30 (m, 2H, H5b, H4b); 13C-
NMR (50 MHz, CDCl3): δ 156.0 (C=OBoc), 138.1 (CqBn), 128.3, 127.6, 127.2 (CBn), 80.4 (C2), 79.1 (CqBoc), 76.5 
(C6), 73.4 (C3), 70.7 (CH2Bn), 62.7 (C1), 44.7 (C7), 28.3 (tBu), 28.3, 27.5 (C5, C4). IR ν (cm-1, film): 3340, 2976, 
1693, 1520, 1454, 1366, 1250, 1169, 1092, 750, 698. MS (ESI): m/z 352.1 (M+H)+, 374.1 (M+Na)+. HR-MS: 
calc. for [C19H29NO5+Na]+ 374.1943, found 372.1938. 
(2S,3S,6S)-3-O-Benzyl-6-{N-[(tert-butyloxycarbonyl)amino]methyl}-tetrahydropyran-1-carboxylic acid 
(2,6-trans 12). Method 1: To an aq. soln. of KOH (1M, 14.2 mL) and K2S2O8 (1.69 g, 
6.25 mmol) was added 2,6-trans 3 (400 mg, 1.42 mmol) and RuCl3·3H2O (166 mg). 
The solution immediately turned black and after TLC analysis (EtOAc) showed 
completion, the brown mixture was quenched with MeOH (10 mL). Salts were 
filtered off and excess K2S2O8 was destroyed with NaSO3⋅H2O. After neutralization with AcOH (pH ≈7), the 
crude product was extracted with EtOAc, dried (MgSO4) and concentrated in vacuo. Silica gel 
chromatography (Rf= 0.7, 1% AcOH in EtOAc) gave 2,6-trans 12 (345 mg, 0.94 mmol, 66%) as an oil which 
solidified on standing. Method 2: to a solution of 2,6-trans 3 (134 mg, 381 μmol) in DCM (2 mL) was added 
water (2 mL), 2.2 equiv. [bis(acetoxy)iodo]benzene (839 μmol, 270 mg) and a cat. amount of TEMPO (10 
mg). After stirring for 12−16 h, Na2S2O3 (0.5 g) was added and the reaction was washed with 1N HCl and 
brine and extracted with EtOAc, dried (MgSO4) and concentrated in vacuo. Yield 2,6-trans 12: 118 mg, 
85%. [α]D25= +21.6 (c= 0.25, CHCl3). 1H-NMR (300 MHz, MeOD): δ 7.35 (m, 5H, HBn), 5.73 (s, 1H, NH), 4.57 
(m, 3H, CH2Bn, H2), 3.97 (m, 2H, H3, H6), 3.13 (m, 2H, H7), 2.05 (m, 2H, H5), 1.70 (m, 2H, H4), 1.42 (s, 9H, 
tBu); 13C-NMR (75 MHz, aceton-d6): δ 173.5 (C=Ocarboxyl), 158.2 (C=OBoc), 139.5 (CqBn), 129.3, 128.7, 128.6 
(CBn), 81.1 (C3), 79.9 (CqBoc), 76.2, 73.1 (C2, C6), 71.5 (CH2Bn), 45.9 (C7), 28.7 (tBu), 25.1 (C4), 23.4 (C5). IR ν 
(cm-1, film): 3363, 2926, 1773, 1709, 1522, 1452, 1367, 1271, 1250, 1165. MS (ESI): m/z 366.0 (M+H)+, 388.3 














cis 12). From 2,6-cis 3 (339 mg, 0.96 mmol) as described for 2,6-trans 12 employing 
method 1. Silica gel chromatography (Rf= 0.8, 1% AcOH/EtOAc) gave 2,6-cis 12 
(351 mg, 0.96 mmol, 100%) as an oil. Following method 2 as described for 2,6-trans 
12, employing TEMPO and [bis(acetoxy)iodo]benzene, furnished 2,6-cis 12 in 100% yield. [α]D25= +8.0 (c= 
0.5, CHCl3). 1H-NMR (200 MHz, MeOD): δ 7.25-7.05 (m, 5H, HBn), 5.12 (s, 1H, NH), 4.54, 4.44 (2×d, 2H, 
CH2Bn, J= 12.3 Hz), 4.05 (d, 1H, H2, J= 9.5 Hz), 3.58-3.29 (m, 2H, H3, H7a, J= 10.2 Hz), 3.16-3.08 (m, 2H, H6, 
H7b), 2.25-2.04 (m, 1H, H4a), 1.70-1.55 (m, 1H, H5a), 1.37-1.25 (m, 2H, H5b, H4b), 1.45 (s, 9H, tBu); 13C-NMR 
(75 MHz, MeOD): δ 173.9 (C=Ocarboxyl), 158.3 (C=OBoc), 139.4 (CqBn), 129.2, 128.7, 125.2 (CBn), 81.1 (C3), 80.0 
(CqtBu), 77.7 (C2), 76.1 (C6), 72.1 (CH2Bn), 45.2 (C7), 28.7 (tBu), 29.7, 28.0 (C4, C5). MS (ESI): m/z 366.0 
(M+H)+, 388.3 (M+Na)+. 
(2R,3S,6S)-3-O-Benzyl-6-{N-[(t-butyloxycarbonyl)amino]methyl}tetrahydropyran-1-N-L-leucine methyl ester 
(2,6-trans 6). Following GP 1a and GP 1b employing 2,6-trans 3 (44 mg, 0.13 
mmol) and o-Ns-Leu-OMe (4, 56 mg, 0.17 mmol) gave after silica gel 
chromatography (PE/EtOAc 1/1 v/v) the title compound (39 mg, 0.08 mmol, 
65%) as an oil. 1H-NMR (600 MHz, CDCl3): δ 7.34-7.10 (m, 6H, HBn and 
NHCα), 5.00 (bs, 1H, NHBoc), 4.60, 4.49 (2×d, 2H, CH2Bn, J= 11.7 and 12.4 Hz), 4.22 (m, 1H, Hα), 3.71 (s, 3H, 
OCH3), 3.38-3.23 (m, 5H, H2, H3, H6, H7), 2.70 (m, 2H, H1ab), 1.88 -1.22 (m, 7H, H4ab, H5ab, Hβγ), 1.38 (s, 9H, 
tBu), 0.89 (m, 6H, 2×CH3Leu); 13C-NMR (150 MHz, CDCl3): δ 172.6 (C=Oester), 155.6 (C=OBoc), 138.0 (CqBn), 
128.2, 127.5 (CBn), 79.0 (CqtBu), 73.6, 73.4, 70.1 (C2, C3, C6), 70.3 (CH2Bn), 59.9 (Cα), 51.5 (OCH3), 47.8 (C1), 
42.4 (C7), 42.2 (Cβ), 28.7 (tBu), 24.8 (Cγ), 24.2, 23.8 (C4 and C5), 22.6 (CH3Leu), 22.1 (CH3Leu). MS (ESI): m/z 
497.2 (M+H)+, 510.4 (M+Na)+. 
(2R,3S,6R)-3-O-Benzyl-6-{N-[(t-butyloxycarbonyl)amino]methyl} tetrahydropyran-1-N-L-leucine methyl 
ester (2,6-cis 6). Following GP 1a employing 2,6-cis 3 (347 mg, 1.0 mmol) 
and o-Ns-Leu-OMe (4, 367 mg, 1.1 mmol) and following GP 1b, gave after 
silica gel chromatography (PE/EtOAc 1/1 v/v) the title compound (439 mg, 
0.9 mmol, 92%) as an oil. 1H-NMR (200 MHz, CDCl3): δ 7.32-7.26 (m, 5HBn), 
7.05 (d, 1H, NHCα, J= 8.2 Hz), 5.09 (bs, 1H, NHBoc), 4.54 (m, 3H, Hα and CH2Bn), 4.50 (d, 1H, H2, J= 3.9 Hz), 
4.11 (bs, 1H, H3), 3.67 (s, 3H, OCH3), 3.56 (m, 1H, H6), 3.30 and 3.06 (2×m, 2H, H7), 1.71 and 1.63-1.49 (m, 
7H, H5a, H4ab, HβγLeu), 1.38 (s, 9H, tBu), 1.34 (m, 1H, H5b), 0.96 (2×d, 6H, 2×CH3Leu, J= 5.9 and 6.0 Hz); 13C-
NMR (50 MHz, CDCl3): δ 172.6 (C=Oester), 155.9 (C=OBoc), 138.2 (CqBn), 128.2, 127.5 (CBn), 78.9 (CqtBu), 80.1, 
76.4, 74.5 (C2, C3, C6), 70.7 (CH2Bn), 59.9 (OCH3), 51.4 (Cα), 47.9 (C1), 44.7 (C7), 42.7 (Cβ), 28.5 (C4), 28.2 
(tBu), 27.6 (C5), 24.7 (Cγ), 22.6, 22.1 (2×CH3Leu).  
(2R,3S,6S)-3-O-Benzyl-6-{N-[(t-butyloxycarbonyl)amino]methyl}tetrahydropyran-1-N-L-methionine methyl 
ester (2,6-trans 7). Following GP 1a and GP 1b using 2,6-trans 3 (171 mg, 
0.49 mmol) and o-Ns-Met-OMe (5, 184 mg, 0.53 mmol) yielded after silica 
gel chromatography (PE/EtOAc 1/1 v/v) the title compound (196 mg, 0.40 
mmol, 81%) as an oil. 1H-NMR (300 MHz, CDCl3): δ 7.36-7.24 (m, 6H, HBn 
and NHCα), 5.05 (bs, 1H, NHBoc), 4.63 and 4.49 (2×d, 2H, CH2Bn, J= 11.5 Hz), 3.73 (m, 5H, OCH3, H3, H2), 
3.40 (m, 2H, H6 and Hα), 3.25 (m, 2H, H7), 2.75 (m, 2H, H1ab), 2.59 (m, 1H, Hγ), 2.10 (s, 3H, SCH3), 2.00-1.55 
(m, 6H, H4, H5 and Hβ), 1.45 (s, 9H, tBu); 13C-NMR (50 MHz, CDCl3): δ 175.5 (C=Oester), 156.0 (C=OBoc), 
138.3 (CqBn), 128.3, 127.6 (CBn), 79.2 (CqtBu), 73.5, 73.3, 70.3 (C2, C3, C6), 70.5 (CH2Bn), 60.1 (Cα), 51.9 (OCH3), 
47.8 (C1), 42.0 (C7), 32.3 (Cβ), 30.4 (Cγ), 28.3 (tBu), 24.3, 23.9 (C4 and C5), 15.3 (SCH3). MS (ESI): m/z 497.4 


















































ester (2,6-cis 7). Following GP 1a and GP 1b using 2,6-cis 3 (354 mg, 1.0 
mmol) and o-Ns-Met-OMe (5, 383 mg, 1.1 mmol) gave after silica gel 
chromatography (Rf= 0.2, PE/EtOAc 2/1 v/v) 2,6-cis 7 (494 mg, 1.0 mmol, 
99%) as an oil. 1H-NMR (300 MHz, CDCl3): δ 7.37-7.25 (m, 6H, 5HBn and 
NHCα), 5.00 (bs, 1H, NHBoc), 4.61, 4.47 (2×d, 2H, CH2Bn, J= 11.5 Hz), 3.73 (s, 3H, OCH3), 3.71-3.27 (m, 5H, 
H7a, H6, H3, H2 and Hα), 3.02-2.88 (m, 2H, H7b, H1a), 2.67 (2×d, 1H, H1b, J= 5.0 and 5.1 Hz), 2.59 (t, 1H, Hγ, J= 
7.3 and 7.4 Hz), 2.20 (m, 1H, H5a), 2.07 (s, 3H, SCH3), 2.00-1.66 (m, 5H, H5b, H4ab, Hβ), 1.45 (s, 9H, tBu); 13C-
NMR (75 MHz, CDCl3): δ 175.6 (C=Oester), 156.0 (C=OBoc), 138.3 (CqBn), 128.3, 127.7 (CBn), 80.0, 76.6, 74.5 
(C2, C3 and C6), 79.2 (CqtBu), 70.9 (CH2Bn), 60.3 (Cα), 51.8 (OCH3), 49.0 (C1), 44.8 (C7), 32.7 (Cβ), 30.5 (Cγ), 28.6 
(C4), 28.4 (tBu), 27.8 (C5), 15.3 (SCH3). MS (ESI): m/z 497.4 (M+H)+, 519.4 (M+Na)+. 
(2R,3S,6S)-3-O-Benzyl-6-{(N-[(S-(tert-butyl)sulfanyl]-N-{[9H-fluoren-9-yl)methoxy]carbonyl}-L-cysteinyl) 
amino]methyl}-tetrahydropyran-1-N-L-leucine methyl ester (2,6-
trans 8). From 2,6-trans 6 (39 mg, 0.08 mmol) and N-
ethylmorpholine (42 μL, 0.33 mmol) following GP 3 and GP4. Silica 
gel chromatography (PE/EtOAc 1/1 v/v) gave 2,6-trans 8 (26 mg, 
0.03 mmol, 40%) as an oil. 1H-NMR (300 MHz, CDCl3): δ 7.75 (d, 2H, HFmoc, J= 7.5 Hz), 7.60 (d, 2H, HFmoc, J= 
7.3 Hz), 7.42-7.25 (m, 9H, HBn&Fmoc), 6.93 (bs, 1H, C7NH), 5.95 (d, 1H, CαCys, NHFmoc, J= 7.4 Hz), 4.61-4.41 (m, 
4H, HαMet, CH2Bn and HFmoc), 4.33 (t, 1H, HFmoc, J= 7.2 and 10.4 Hz), 4.23 (t, 1H, HFmoc, J= 7.1 Hz), 3.80-3.68 
(m, 5H, H2, H6 and OCH3), 3.55 (m, 1H, H7a), 3.25 (m, 2H, HαMet, H7b, H3), 3.13 (m, 2H, HβCys), 2.75 (m, 2H, 
H1ab), 1.90-1.54 (m, 5H, H4ab, H5ab, HγLeu), 1.33 (s, 9H, tBu), 0.89 (t, 6H, 2×CH3Leu, J= 6.2 and 6.3 Hz); 13C-
NMR (75 MHz, CDCl3): δ 176.5-169.9 (C=Oester&amide), 155.8 (C=OFmoc), 143.8, 141.2 (CqFmoc), 138.3 (CqBn), 
128.4, 127.6, 127.1, 125.2, 119.9 (CHBn&Fmoc), 73.4, 69.5 (C2, C3, C6), 70.5 (CH2Bn), 67.1 (CH2Fmoc), 59.5 (CαLeu), 
54.7 (CαCys), 51.9 (OCH3), 48.3 (CqtBu), 47.8 (C1), 47.1 (CHFmoc), 43.0 (CβCys), 41.9 (CβLeu), 41.4 (C7), 29.8 (tBu), 
24.8 (CγLeu), 24.3 (C4), 23.8 (C5), 22.7, 22.3 (2×CH3Leu). MS (ESI): m/z 792.6 (M+H)+, 814.4 (M+Na)+. 
(2S,3S,6R)-3-O-Benzyl-6-{(N-[(S-(tert-butyl)sulfanyl]-N-{[9H-fluoren-9-yl)methoxy]carbonyl}-L-cysteinyl) 
amino]methyl}-tetrahydropyran-1-N-L-leucine methyl ester (2,6-
cis 8). From 2,6-cis 6 (40 mg, 0.08 mmol) and N-ethylmorpholine 
(42 μL, 0.33 mmol) according to GP 3 and GP4. Silica gel 
chromatography (PE/EtOAc 1/1 v/v) gave 2,6-cis 8 (44 mg, 0.05 
mmol, 66%) as a foam. 1H-NMR (300 MHz, CDCl3): δ 7.75 (d, 2H, HFmoc, J= 7.5 Hz), 7.60 (d, 2H, CHFmoc, J= 
7.5 Hz), 7.42-7.25 (m, 9H, HBn&Fmoc), 6.93 (bs, 1H, C7NH), 5.85 (d, 1H, NHFmoc, J= 7.8 Hz), 4.61-4.41 (m, 
4H, HαMet, CH2Bn and HFmoc), 4.34 (t, 1H, HFmoc, J= 7.1 and 10.2 Hz), 4.23 (t, 1H, HFmoc, J= 7.0 and 7.1 Hz), 3.68 
(s, 3H, OCH3), 3.55 (m, 1H, H7a), 3.41 (m, 1H, H2), 3.25 (m, 3H, HαLeu, H6 and H3), 3.04-3.15 (m, 3H, HβCys 
and H7b), 2.95 (dd, 1H, H1a, J= 2.4 and 2.7 Hz), 2.95 (dd, 1H, H1b, J= 5.5 and 5.6 Hz), 2.22 (m, 1H, H4a), 1.78-
1.68 and 1.54-1.21 (2×m, 6H, H5ab, H4b, HβγLeu), 1.33 (s, 9H, tBu), 0.89 (dd, 6H, 2×CH3Leu, J= 6.7 and 6.8 Hz); 
13C-NMR (75 MHz, CDCl3): δ 176.9 and 169.9 (C=Oester&amide), 155.8 (C=OFmoc), 143.7, 141.2 (CqFmoc), 138.3 
(CqBn), 128.4, 127.7, 127.1, 125.6, 120.0 (CHBn&Fmoc), 79.6, 75.6, 74.6 (C2, C3, C6), 71.0 (CH2Bn), 67.2 (CH2Fmoc), 
60.0 (CαLeu), 54.5 (CαCys), 51.8 (OCH3), 49.4 (CβCys), 48.3 (CqtBu), 47.1 (CHFmoc), 43.9 (C7), 42.8 (CβLeu and C1), 
29.8 (tBu), 24.8 (CγLeu), 28.6 (C4), 28.0 (C5), 22.7, 22.3 (2×CH3Leu).  
(2R,3S,6S)-3-O-Benzyl-6-{(N-[(S-(tert-butyl)sulfanyl]-N-{[9H-fluoren-9-yl)methoxy]carbonyl}-L-cysteinyl) 
amino]methyl}-tetrahydropyran-1-N-L-methionine methyl ester 
(2,6-trans 9). From 2,6-trans 7 (160 mg, 0.32 mmol) N-
ethylmorpholine (164 μL, 1.3 mmol) according to GP 3 and GP4. 





































































(122 mg, 0.15 mmol, 47%) as an oil. 1H-NMR (300 MHz, CDCl3): δ 7.77 (d, 2H, HFmoc, J= 7.5 Hz), 7.62 (d, 
2H, HFmoc, J= 7.4 Hz), 7.44-7.28 (m, 9H, HBn&Fmoc), 7.01 (bs, 1H, C7NH), 6.02 (d, 1H, NHFmoc, J= 8.0 Hz), 
4.63-4.42 (m, 4H, HαMet, CH2Bn, HFmoc), 4.34 (t, 1H, HFmoc, J= 7.3 and 10.2 Hz), 4.27 (t, 1H, HFmoc, J= 6.9 and 
7.1 Hz), 3.82-3.71 (m, 5H, H2, H6 and OCH3), 3.60 (m, 1H, H7a), 3.45 (dd, 1H, HαMet, J= 5.5, 5.6 and 7.7 Hz), 
3.35-3.20 (m, 2H, H7b and H3), 3.14 (m, 2H, HβCys), 2.80 (m, 2H, H1ab), 2.55 (m, 2H, HγMet), 2.07 (s, 3H, SCH3), 
1.99-1.56 (m, 6H, H4ab, H5ab, HβMet), 1.35 (s, 9H, tBu); 13C-NMR (75 MHz, CDCl3): δ 175.9, 170.0 
(C=Oester&amide), 155.8 (C=OFmoc), 143.7, 141.2 (CqFmoc), 138.2 (CqBn), 128.4, 127.6, 127.0, 125.1, 119.9 
(CHBn&Fmoc), 73.3, 69.5 (C2, C3, C6), 70.9 (CH2Bn), 67.1 (CH2Fmoc), 59.5 (CαMet), 54.6 (CαCys), 52.1 (OCH3), 48.2 
(CqtBu), 47.6 (C1), 47.1 (CHFmoc), 42.9 (CβCys), 41.3 (C7), 32.2 (CβMet), 30.4 (CγMet), 29.8 (tBu), 24.3 (C4), 23.7 (C5), 
15.3 (SCH3). MS (ESI): m/z 810.1 (M+H)+, 832.3 (M+Na)+.  
(2R,3S,6R)-3-O-Benzyl-6-{(N-[(S-(tert-butyl)sulfanyl]-N-{[9H-fluoren-9-yl)methoxy]carbonyl}-L-cysteinyl) 
amino]methyl}-tetrahydropyran-1-N-L-methionine methyl ester 
(2,6-cis 9). From 2,6-cis 7 (131 mg, 0.26 mmol) and N-
ethylmorpholine (134 μL, 1.06 mmol) according to GP 3 and GP4. 
Silica gel chromatography (PE/EtOAc 1/1 v/v) gave 2,6-cis 9 (92 mg, 
0.11 mmol, 44%) as an oil. 1H-NMR (300 MHz, CDCl3): δ 7.75 (d, 2H, HFmoc, J= 7.5 Hz), 7.60 (d, 2H, HFmoc, J= 
7.4 Hz), 7.44-7.25 (m, 9H, HBn&Fmoc), 6.94 (bs, 1H, C7NH), 5.85 (d, 1H, CαCysNHFmoc, J= 8.0 Hz), 4.60-4.40 (m, 
4H, HαMet, CH2Bn and HFmoc), 4.34 (t, 1H, HFmoc, J= 7.1 and 10.6 Hz), 4.23 (t, 1H, HFmoc, J= 7.0 and 7.1 Hz), 
3.69 (s, 3H, OCH3), 3.55 (m, 1H, H7), 3.40 (m, 2H, HαMet and H2), 3.25 (m, 2H, H6 and H3), 3.13 (m, 3H, HβCys 
and H7b), 2.95 (dd, 1H, H1a, J= 2.1 and 2.6 Hz), 2.72 (dd, 1H, H1b, J= 5.4 and 5.5 Hz), 2.55 (t, 2H, HγMet, J= 7.1 
and 7.5 Hz), 2.24 (m, 1H, H4a), 2.05 (s, 3H, SCH3), 2.04-1.55 (m, 5H, H5ab, H4b, HβMet), 1.34 (s, 9H, tBu); 13C-
NMR (75 MHz, CDCl3): δ 169.9 (C=Oester&amide), 155.8 (C=OFmoc), 143.7, 141.2 (CqFmoc), 138.2 (CqBn), 128.4, 
127.7, 127.1, 125.1, 120.0 (CBn&Fmoc), 79.5, 75.6, 74.4 (C2, C3, C6), 71.0 (CH2Bn), 67.2 (CH2Fmoc), 60.1 (CαMet), 
54.6 (CαCys), 52.0 (OCH3), 48.3 (CqtBu), 47.1 (CHFmoc), 49.3 (C1), 43.9 (C7), 42.8 (CβCys), 32.8 (CβMet), 30.5 (CγMet), 
29.8 (tBu), 28.6 (C4), 28.0 (C5), 15.3 (SCH3). MS (ESI): m/z 810.3 (M+H)+, 832.4 (M+Na)+.  
(2R,3S,6R)-3-hydroxy-6-{N-[(t-butyloxycarbonyl)amino]methyl}-tetrahydropyran-1-N-L-leucine methyl 
ester hydrochloride (2,6-cis 10).23 Compound 2,6-cis 6 (209 mg, 0.44 mmol) 
was dissolved in EtOH/CHCl3 (5.5 mL, 10/1 v/v) and 10% Pd/C (20 mg) was 
added. The mixture was hydrogenated overnight using a balloon filled with 
hydrogen-gas. The catalyst was removed by filtration over Celite® and the 
filtrate was concentrated in vacuo to give crude 2,6-cis 10 (HCl salt, 185 mg, 0.44 mmol, 100%). 1H-NMR 
(300 MHz, MeOD): δ 4.15 (m, 1H, Hα), 3.86 (s, 3H, OCH3), 3.45 (m, 3H, H6, H2 and H7a), 3.25 (m, 2H, H3 
and H1a), 3.21 (m, 1H, H7b), 3.08 (m, 1H, H1b), 2.06, 1.71, 1.92-1.43 (2×m, 7H, H5ab, H4ab, HβγLeu), 1.42 (s, 9H, 
tBu), 0.96 (2×d, 6H, 2×CH3Leu, J= 5.8 and 6.0 Hz); 13C-NMR (150 MHz, MeOD): δ 170.6 (C=Oester), 158.4 
(C=OBoc), 80.3 (CqtBu), 78.8, 78.0, 68.8 (C2, C3, C6), 60.1 (CαLeu), 53.8 (OCH3), 49.0 (C1), 45.5 (C7), 39.6 (Cβ), 
32.8 (C4), 28.8 (tBu, C5), 26.0 (Cγ), 23.5, 21.8 (2×CH3Leu). MS (ESI): m/z 389.3 (M+H)+, 411.2 (M+Na)+. 
(2R,3S,6R)-3-hydroxy-6-{(N-[(S-(tert-butyl)sulfanyl]-N-{[9H-fluoren-9-yl)methoxy]carbonyl}-L-cysteinyl) 
amino]methyl}-tetrahydropyran-1-N-L-leucine methyl ester (2,6-cis 
11). From 2,6-cis 10 (154 mg, 0.36 mmol) and N-ethylmorpholine 
(185 μL, 1.45 mmol) according to GP 3 and GP4. Silica gel 
chromatography (PE/EtOAc 1/1 v/v) yielded the title compound 
(132 mg, 0.19 mmol, 52%). 1H-NMR (750 MHz, CDCl3): δ 7.76 (d, 
2H, HFmoc, J= 7.5 Hz), 7.60 (m, 2H, HFmoc), 7.42-7.26 (m, 9H, HFmoc), 6.93 (bs, 1H, C7NH), 6.28 (d, 1H, 
NHFmoc, J= 7.3 Hz), 4.65 (m, 1H, H3), 4.47-4.32 (m, 3H, CH2Fmoc and HαCys), 4.25 (m, 1H, CHFmoc), 3.66 (s, 


































and 2.80 (2×m, 2H, H1ab), 2.25 (m, 1H, H4a), 1.73-1.41 (m, 6H, H4b, H5ab, HβLeu, HγLeu), 1.33 (s, 9H, tBu), 0.93 
(m, 6H, 2×CH3Leu); 13C-NMR (50 MHz, CDCl3): δ 176.7, 169.9 (C=Oamide&ester), 155.8 (C=OFmoc), 143.7, 141.2 
(CqFmoc), 128.3, 127.7, 127.0, 119.9 (CHFmoc), 78.4, 75.9 and 70.8 (C2, C3, C6), 67.2 (CH2Fmoc), 54.0 (CαCys), 51.8 
(OCH3), 48.7 (C1), 48.3 (CqtBu), 47.0 (CHFmoc), 43.6 (C7), 42.6 (CβLeu, CβCys), 29.0 (tBu), 24.8 (CγLeu), 28.4, 27.7 
(C4, C5), 23.5, 21.8 (2×CH3Leu). MS (ESI): m/z 702.4 (M+H)+.  
N-[(6S)-6-({N-[(tert-Butoxy)carbonyl]amino}methyl-4,5,6-trideoxy-3-benzyloxy-1-oxo-D-arabino-hexo-pyranos 
-1-yl]-L-leucine methyl ester (2,6-trans 13). From 2,6-trans 12 (53 mg, 145 
μmol) and HCl⋅H-Leu-OMe (27 mg, 0.15 mmol) according to GP 2. Silica 
gel chromatography (Rf= 0.7, EtOAc) gave 2,6-trans 13 as an oil (70 mg, 142 
μmol, 98%). [α]D25= +16.8 (c= 0.25, CHCl3). 1H-NMR (600 MHz, CDCl3): δ 
7.29-7.19 (m, 5HBn), 7.00 (d, 1H, NHCα, J= 8.2 Hz), 5.13 (bs, 1H, NHBoc), 4.54 (m, 3H, Hα and CH2Bn), 4.50 
(d, 1H, H2, J= 3.9 Hz), 4.11 (bs, 1H, H3), 3.67 (s, 3H, OCH3), 3.56 (m, 1H, H6), 3.30 and 3.06 (2×m, 2H, H7), 
1.71 and 1.63-1.49 (2×m, 7H+9H, H5a, H4ab, HβγLeu), 1.38 (s, 9H, tBu), 1.34 (m, 1H, H5b), 0.96 (2×d, 6H, 
2×CH3Leu, J= 5.9 and 6.0 Hz); 13C-NMR (150 MHz, CDCl3): δ 172.6, 169.3 (C=Oamide&ester), 155.6 (C=OBoc), 
138.0 (CqBn), 128.0, 127.2 (CBn), 78.7 (CqtBu), 76.2 (C2), 72.9 (C6), 70.4 (CH2Bn and C3), 50.9 (OCH3), 50.1 (Cα), 
44.8 (C7), 40.8 (Cβ), 28.0 (tBu), 24.7 (Cγ), 23.5 (C4), 22.4 (CH3Leu), 22.0 (C5), 21.4 (CH3Leu). MS (ESI): m/z 515.5 
(M+Na)+. HR-MS: calc. for [C26H40N2O7+Na]+ 515.2727, found 515.2769. 
N-[(6R)-6-({N-[(tert-Butoxy)carbonyl]amino}methyl-4,5,6-trideoxy-3-benzyloxy-1-oxo-D-arabino-hexo-pyranos 
-1-yl]-L-leucine methyl ester (2,6-cis 13). From 2,6-cis 12 (53 mg, 145 μmol) 
and HCl⋅H-Leu-OMe (27 mg, 0.15 mmol) according to GP 2. Silica gel 
chromatography (Rf= 0.7, EtOAc) gave 2,6-cis 13 as an oil (70 mg, 142 μmol, 
98%). [α]D25= –22.4 (c= 0.5, CHCl3). 1H-NMR (300 MHz, CDCl3): δ 7.33-7.24 
(m, 5HBn), 6.83 (d, 1H, NHCα, J= 7.9 Hz), 5.11 (bs, 1H, NHBoc), 4.61 (m, 3H, Hα, CH2Bn), 3.78 (d, 1H, H2, J= 
9.2 Hz), 3.77 (s, 3H, OCH3), 3.53-3.40 (m, 3H, H6, H3, H7a), 3.10 (m, 1H, H7b), 2.27, 1.74-1.23 (2×m, 7H, H5ab, 
H4ab, Hβγ), 1.44 (s, 9H, tBu), 0.90 (2×d, 6H, 2×CH3Leu, J= 6.2 and 6.4 Hz); 13C-NMR (50 MHz, CDCl3): δ 173.2, 
169.8 (C=Oamide&ester), 156.0 (C=OBoc), 137.8 (CqBn), 128.3, 127.7 (CBn), 79.5 (C2), 79.3 (CqtBu), 76.8 (C6), 75.2 
(C3), 71.4 (CH2Bn), 52.1 (OCH3), 50.4 (Cα), 44.6 (C7), 41.3 (Cβ), 29.0 (C4), 28.3 (tBu), 26.9 (C5), 24.8 (Cγ), 22.7, 
21.8 (2×CH3Leu). MS (ESI): m/z 515.5 (M+Na)+. HR-MS: calc. for [C26H40N2O7+Na]+ 515.2727, found 
515.2728. 
N-[(6S)-6-({N-[(tert-Butoxy)carbonyl]amino}methyl-4,5,6-trideoxy-3-benzyloxy-1-oxo-D-arabino-hexo-pyranos 
-1-yl]-L-methionine methyl ester (2,6-trans 14). From 2,6-trans 12 (52 mg, 142 
μmol) and HCl⋅H-Met-OMe (34 mg, 170 μmol) according to GP 2. Silica gel 
chromatography (Rf= 0.9, EtOAc/AcOH 98/2 v/v) gave 2,6-trans 14 as an oil 
(53 mg, 104 μmol, 73%). [α]D25= +28.2 (c= 1, CHCl3). 1H-NMR (300 MHz, CDCl3): δ 7.61-7.10 (m, HBn and 
NHCα), 5.68 (bs, 1H, NHBoc), 5.05 (m, 1H, Hα), 4.77, 4.70 (2×d, CH2Bn, J= 7.3 Hz), 3.77 (s, 3H, OCH3), 3.46-
3.06 (m, 5H, H6, H3, H2 and H7), 2.58-2.34 (m, 2H, Hγ), 2.29-2.01 (m, 2H, Hβ), 2.11 (s, 3H, SCH3), 197-1.51 
(m, 4H, H5ab and H4ab), 1.45 (s, 9H, tBu); 13C-NMR (50 MHz, CDCl3): δ 171.8, 169.9 (C=Oamide&ester), 155.9 
(C=OBoc), 138.0 (CqBn), 128.1, 127.3 (CBn), 79.1 (CqtBu) 76.4 (C2), 73.1 (C6), 70.8 (C3), 70.7 (CH2Bn), 52.3 (OCH3), 
51.0 (Cα), 44.9 (C7), 31.2 (Cβ), 30.0 (Cγ), 28.2 (tBu), 23.6 (C4), 22.1 (C5), 15.2 (SCH3). MS (ESI): m/z 511.5 
(M+H)+, 533.3 (M+Na)+. HR-MS: calc. for [C25H38N2O7S +Na]+ 533.2291, found 533.2331. 
N-[(6R)-6-({N-[(tert-Butoxy)carbonyl]amino}methyl-4,5,6-trideoxy-3-benzyloxy-1-oxo-D-arabino-hexo-pyranos 
-1-yl]-L-methionine methyl ester (2,6-cis 14). From 2,6-cis 12 (244 mg, 0.67 
mmol) according to GP 2. Silica gel chromatography (Rf= 0.8, EtOAc/AcOH 
98/2 v/v) gave 2,6-cis 14 as an oil which solidified on standing (284 mg, 0.56 






































7.27 (m, 5HBn), 7.09 (d, 1H, NHCα, J= 7.7 Hz), 5.10 (bs, 1H, NHBoc), 4.61 (ddd, 1H, Hα, J= 5.3, 5.5, 7.4 and 
7.5 Hz), 4.58 (s, CH2Bn), 3.79 (d, 1H, H2, J= 9.2 Hz), 3.73 (s, 3H, OCH3), 3.52-3.42 (m, 3H, H6, H3, H7a), 3.08 
(m, 1H, H7b), 2.46 (t, 2H, Hγ, J= 7.4 and 7.6 Hz), 2.30-1.46 (2×m, 6H, H5ab, H4ab and Hβ), 2.03 (s, 3H, SCH3), 
1.44 (s, 9H, tBu); 13C-NMR (50 MHz, CDCl3): δ 171.9, 170.4 (C=Oamide&ester), 156.2 (C=OBoc), 137.7 (CqBn), 
128.4, 127.9 (CBn), 79.5 (CqtBu) 79.3 (C2), 77.5 (C6), 74.8 (C3), 71.2 (CH2Bn), 52.4 (OCH3), 51.3 (Cα), 44.5 (C7), 
31.3 (Cβ), 29.9 (Cγ), 29.0 (C4), 28.3 (tBu), 26.7 (C5), 15.3 (SCH3). MS (ESI): m/z 511.6 (M+H)+, 533.1 (M+Na)+. 
HR-MS: calc. for [C25H38N2O7S +Na]+ 533.2291, found 533.2297.  
N-[(6S)-6-({N-(S-[tert-Butyl)sulfanyl]-N-{[(9H-fluoren-9-yl)methoxy]carbonyl}-L-cysteinyl)amino]-methyl}-
4,5,6-trideoxy-3-benzyloxy-1-oxo-D-arabino-hexo-pyranos-1-yl]-L-leucine methyl ester (2,6-trans 15). From 
2,6-trans 13 (200 mg, 407 μmol) according to GP 3 and GP4. Silica 
gel chromatography (Rf= 0.9, PE/EtOAc 1/3 v/v) afforded the title 
compound (263 mg, 326 μmol, 80%) as an oil. [α]D25= –20.0 (c= 0.5, 
CHCl3). 1H-NMR (750 MHz, CDCl3): δ 7.76 (d, 2H, HFmoc, J= 7.6 Hz), 
7.60 (d, 2H, HFmoc, J= 7.4), 7.41-7.26 (m, 9H, HFmoc&Bn), 7.10 (d, 1H, NHFmoc, J= 8.2 Hz), 6.87 (bs, 1H, C7NH), 
6.28 (d, 1H, NHCαLeu, J= 8.2 Hz), 4.66 (m, 1H, HαLeu), 4.57-4.51 (m, 3H, CH2Bn and HαCys), 4.49-4.42 (m, 1H, 
HFmoc), 4.40 (bs, 1H, H2), 4.35 (t, 1H, HFmoc, J= 7.7 and 10.2 Hz), 4.23 (t, 1H, HFmoc, J= 7.1 and 7.2 Hz), 4.18 
(m, 1H, H3), 3.73 (s, 3H, OCH3), 3.78-3.69 (m, 2H, H6 and H7a), 3.21-3.12 (m, 2H, HβCys), 3.02 (ddd, 1H, H7b, 
J= 4.3, 4.6, 9.4 Hz and J= 4.4, 4.8, 9.2 Hz), 2.00 (m, 1H, H4a), 1.75 (m, 1H, H5a), 1.69-1.54 (m, 3H, HβγLeu), 1.51 
(m, 1H, H4b), 1.42 (m, 1H, H5b), 1.33 (s, 9H, tBu), 0.93 (d, 6H, 2×CH3Leu, J= 5.1 Hz); 13C-NMR (50 MHz, 
CDCl3): δ 173.9, 170.2, 169.0 (C=Oamide&ester), 156.3 (C=OFmoc), 143.7, 143.6, 141.2 (CqFmoc), 138.1 (CqBn), 128.3, 
127.7, 127.6, 127.0, 125.1, 125.0, 119.9 (CBn&Fmoc), 76.6 (C2), 72.2 (C6), 70.7 (CH2Bn), 70.6 (C3), 67.2 (CH2Fmoc), 
54.4 (CαLeu), 52.6 (OCH3), 50.3 (CαCys), 48.1 (CqtBu), 47.0 (CHFmoc), 44.1 (C7), 42.4, 41.6 (CβLeu and CβCys), 29.7 
(tBu), 24.9 (CγLeu), 23.7 (C4), 22.6 (CH3Leu), 22.4 (C5), 21.9 (CH3Leu). MS (ESI): m/z 828.4 (M+Na)+. HR-MS: 
calc. for [C43H55N3O8S2+H]+ 806.3503, found 806.3479. 
N-[(6R)-6-({N-(S-[tert-Butyl)sulfanyl]-N-{[(9H-fluoren-9-yl)methoxy]carbonyl}-L-cysteinyl)amino]-methyl}-
4,5,6-trideoxy-3-benzyloxy-1-oxo-D-arabino-hexo-pyranos-1-yl]-L-leucine methyl ester (2,6-cis 15). From 
2,6-cis 13 (70 mg, 142 μmol) according to GP 3 and GP4. Silica gel 
chromatography (Rf= 0.5, PE/EtOAc 1/3 v/v) gave 2,6-cis 15 (97 mg, 
120 μmol, 85%) as an oil. [α]D25= –21.2 (c= 1, CHCl3). 1H-NMR (750 
MHz, CDCl3): δ 7.74 (d, 2H, HFmoc, J= 7.5 Hz), 7.58 (d, 2H, HFmoc, J= 
7.4), 7.39-7.24 (m, 9H, HFmoc&Bn), 7.12 (bs, 1H, C7NH, 7.00 (d, 1H, NHCαLeu, J= 7.4 Hz), 6.12 (d, 1H, NHCαCys, 
J= 7.3 Hz), 4.60 (m, 1H, HαLeu), 4.50 (m, 3H, CH2Bn and HαCys), 4.42-4.30 (m, 2H, CH2Fmoc), 4.21 (t, 1H, 
CHFmoc, J= 7.3 and 7.2 Hz), 3.77 (d, 1H, H2, J= 8.7 Hz), 3.68 (s, 3H, OCH3), 3.49 (m, 2H, H6 and H7a), 3.44 
(ddd, 1H, H3, J= 4.5, 4.6 and 10.1 Hz), 3.28 (m, 1H, H7b), 3.11 (m, 2H, HβCys), 2.18 (m, 1H, H4a), 1.70 (m, 1H, 
H5a), 1.59-1.39 (m, 4H, H4b, HβγLeu), 1.38 (m, 1H, H5b), 1.32 (s, 9H, tBu), 0.88 (2×d, 6H, 2×CH3Leu, J= 5.9 and 
6.0 Hz); 13C-NMR (50 MHz, CDCl3): δ 173.6, 170.3, 169.9 (C=Oamide&ester), 156.0 (C=OFmoc), 143.7, 141.2 
(CqFmoc), 137.8 (CqBn), 129.7, 128.3, 127.8, 127.7, 127.6, 127.2, 125.1, 119.9 (CHBn&Fmoc), 79.2 (C2), 75.9 (C6), 
75.2 (C3), 71.4 (CH2Bn), 67.2 (CH2Fmoc), 54.5 (CαLeu), 52.2 (OCH3), 50.3 (CαCys), 48.2 (CqtBu), 47.0 (CHFmoc), 43.3 
(C7), 42.3, 41.1 (CβLeu and CβCys), 29.7 (tBu), 29.0 (C4), 27.1 (C5), 24.8 (CγLeu), 22.7, 21.8 (2×CH3Leu). MS (ESI): 
m/z 828.4 (M+Na)+. HR-MS: calc. for [C43H55N3O8S2+H]+ 806.3503, found 806.3479. 
N-[(6S)-6-({N-(S-[tert-Butyl)sulfanyl]-N-{[(9H-fluoren-9-yl)methoxy]carbonyl}-L-cysteinyl)amino]-methyl}-
4,5,6-trideoxy-3-benzyloxy-1-oxo-D-arabino-hexo-pyranos-1-yl]-L-
methionine methyl ester (2,6-trans 16). From 2,6-trans 14 (367 mg, 
0.72 mmol) according to GP 3 and GP4. Silica gel chromatography 








































79%) as an oil. [α]D25= –8.0 (c= 0.5, CHCl3). 1H-NMR (750 MHz, CDCl3): δ 7.71 (d, 2H, HFmoc, J= 7.5 Hz), 7.61 
(d, 2H, HFmoc, J= 7.4 Hz), 7.41-7.25 (m, 10H, HFmoc&Bn, NHCαLeu), 6.86 (bs, 1H, C7NH), 6.26 (d, 1H, NHFmoc, 
J= 8.3 Hz), 4.61 (m, 1H, HαMet), 4.62-4.45 (m, 4H, HαCys, CH2Bn, CHFmoc), 4.42 (s, 1H, H2), 4.35 (t, 1H, CHFmoc, 
J= 7.4 and 10.1 Hz), 4.24 (t, 1H, CHFmoc, J= 7.0 Hz), 4.18 (m, 1H, H3), 3.75 (m, 5H, H6, H7a, OCH3), 3.17 (m, 
2H, HβMet), 3.03 (m, 1H, H7b), 2.49 (t, 2H, HγMet, J= 7.3 and 7.7 Hz), 2.20 (m, 1H, H4a), 2.07 (s, 3H, SCH3), 
2.10-1.99 (m, 4H, H5a, HβγLeu), 1.77 (m, 2H, H5b, H4b), 1.33 (s, 9H, tBu). 13C-NMR (50 MHz, CDCl3): δ 172.4, 
169.9, 169.2 (C=Oamide&ester), 155.9 (C=OFmoc), 143.4, 140.8 (CqFmoc), 137.8 (CqBn), 127.9-126.7, 124.7 and 119.6 
(CFmoc&Bn), 76.3, 72.0, 70.3 (C2, C3, C6), 70.3 (CH2Bn), 66.8 (CH2Fmoc), 54.2 (CαMet), 52.4 (OCH3), 50.9 (CαCys), 
47.7 (CqtBu) , 46.7 (CHFmoc), 44.0 (C7), 42.2 (CβCys), 30.9, 29.9 (CβγMet), 29.9 (tBu), 23.4 (C4), 22.3 (C5), 15.0 
(SCH3). MS (ESI): m/z 824.6 (M+H)+. HR-MS: calc. for [C42H53N3O8S3+H]+ 824.3073, found 824.3097. 
N-[(6R)-6-({N-(S-[tert-Butyl)sulfanyl]-N-{[(9H-fluoren-9-yl)methoxy]carbonyl}-L-cysteinyl)amino]-methyl}-
4,5,6-trideoxy-3-benzyloxy-1-oxo-D-arabino-hexo-pyranos-1-yl]-L-
methionine methyl ester (2,6-cis 16). From 2,6-cis 14 (50 mg, 98 
μmol) following GP 3 and GP4. Silica gel chromatography (Rf= 0.6, 
EtOAc) gave 2,6-cis 16 (64 mg, 77 μmol, 79%) as a white foam. 
[α]D25= +6.8 (c= 0.5, CHCl3). 1H-NMR (400 MHz, CDCl3): δ 7.76, 7.52 (2×d, 4H, HFmoc, J= 7.5 Hz), 7.39 (t, 2H, 
HFmoc, J= 7.2 and 7.4 Hz), 7.36-7.25 (m, 9H, HFmoc&Bn), 7.10 (t, 1H, NHCαMet, J= 6.2 and 7.6 Hz), 6.77 (bs, 1H, 
C7NH), 5.98 (m, 1H, NHFmoc, J= ∼6 Hz), 4.70 (ddd, 1H, HαLeu, J= 5.2, 7.6 and 12.9 Hz), 4.60, 4.54 (2×d, 2H, 
CH2Bn, J= 1.9 and 2.1 Hz), 4.46 (m, 1H, HαCys), 4.42 (dd, 1H, CHFmoc, J= 7.3 Hz), 4.33 (t, 1H, CHFmoc, J= 7.4 and 
10.1 Hz), 4.35 (t, 1H, CHFmoc, J= 7.0 and 7.1 Hz), 3.80 (m, 1H, H2), 3.75 (s, 3H, OCH3), 3.59-3.40 (m, 3H, H6, 
H3, H7a), 3.25 (m, 1H, H7b), 3.07 (m, 2H, HβMet), 2.47 (m, 2H, HγMet), 2.21-2.04 (m, 2H, H4a, HβCys), 2.04 (s, 3H, 
SCH3), 2.00-1.86 (m, 1H, HβCys), 1.74 (m, 1H, H5a), 1.58 (m, 1H, H4b), 1.44 (m, 1H, H5b), 1.33 (s, 9H, tBu). 13C-
NMR (50 MHz, CDCl3): δ 172.4, 170.2, 169.9 (C=Oamide&ester), 156.0 (C=OFmoc), 143.7, 141.2 (CqFmoc), 137.8 
(CqBn), 129.0, 128.3, 128.1, 127.9, 127.7, 127.1, 125.1, 119.9 (CFmoc&Bn), 79.4 (C2), 76.0 (C6), 75.0 (C3), 71.3 
(CH2Bn), 67.2 (CH2Fmoc), 54.6 (CαMet), 52.5 (OCH3), 51.1 (CαCys), 48.3 (CqtBu), 47.0 (CHFmoc), 43.3 (C7), 42.4 
(CβCys), 29.9 (tBu), 31.5, 29.9 (CβγMet), 29.0 (C4), 27.1 (C5), 15.3 (SCH3). MS (ESI): m/z 824.6 (M+H)+. HR-MS: 
calc. for [C42H53N3O8S3+H]+ 824.3073, found 824.3103. 
(2R,3S,6S)-3-O-Benzyl-6-{(N-[(S-(tert-butyl)sulfanyl]-L-cysteinyl)amino]methyl}-tetrahydropyran-1-N-L-
leucine (2,6-trans 18). From 2,6-trans 8 (20 mg, 25 μmol) according to 
GP 5. RP-HPLC purification (linear gradient B) afforded the title 
compound (2.4 mg, 4.2 μmol, 17%). 1H-NMR (600 MHz, MeOD): δ 
7.35-7.29 (m, 5H, HBn), 4.65 and 4.48 (2×d, 2H, CH2Bn, J= 11.6 Hz), 4.08 
(m, 2H, HαCys and H2), 3.91 (m, 2H, H3 and H6), 3.73 (m, 1H, HαLeu), 3.60 (m, 1H, H7a), 3.38 (m, 1H, H3), 3.30 
(m, 1H, H7b), 3.25-3.13 (m, 4H, H1ab and HβCys), 2.00 (m, 1H, H4a), 1.79-1.70 (m, 4H, HβγLeu and H5a and H4b), 
1.58 (m, 1H, H5b), 1.37 (s, 9H, tBu), 0.98 (t, 6H, 2×CH3Leu, J= 5.7 and 5.8 Hz). HR-MS: calc. for 
[C26H43N3O5S3+H]+ 556.28789, found 556.28408. 
(2R,3S,6R)-3-O-Benzyl-6-{(N-[(S-(tert-butyl)sulfanyl]-L-cysteinyl)amino]methyl}-tetrahydropyran-1-N-L-
leucine (2,6-cis 18). From 2,6-cis 8 (10 mg, 13 μmol) according to GP 5. 
RP-HPLC purification (linear gradient B) afforded the title compound 
(4.9 mg, 8.5 μmol 67%). 1H-NMR (600 MHz, MeOD): δ 7.34-7.29 (m, 
5H, HBn), 4.68 and 4.45 (2×d, 2H, CH2Bn, J= 11.5 Hz), 4.15 (t, 1H, HαCys, 
J= 6.5 and 6.6 Hz), 3.55 (m, 1H, HαLeu), 3.55 (m, 2H, H2 and H6), 3.39 (m, 1H, H1a), 3.34-3.23 (m, 4H, H7ab, H3 
and HβCys), 3.15 (dd, 1H, HβCys, J= 7.2, 7.3 and 14.1 Hz), 3.06 (dd, 1H, H1b, J= 9.2, 9.3, 12.8 and 13.0 Hz), 2.42 
(m, 1H, H4a), 1.80 (m, 3H, HβγLeu and H5a), 1.65 (m, 1H, HβLeu), 1.49-1.39 (m, 2H, H5b and H4b), 1.36 (s, 9H, 







































(C=Oamide&carboxyl), 137.5 (CqBn), 77.6, 76.3, 75.9 (C2, C3, C6), 71.5 (CH2Bn), 54.3 (CαLeu), 49.6-48.4 (CαCys, CqtBu 
and C7, obscured by MeOD peak), 44.7 (C1), 42.5, 40.5 (CβLeu and CβCys), 30.1 (tBu), 29.2, 28.6 (C5, C4), 26.1 
(CγLeu), 23.1, 22.6 (2×CH3Leu). HR-MS: calc. for [C26H43N3O5S3+H]+ 556.28789, found 556.28440. 
N-[(6S)-6-({N-(S-[tert-Butyl)sulfanyl]-L-cysteinyl)-amino]-methyl}-4,5,6-trideoxy-3-benzyloxy-1-oxo-D-
arabino-hexopyranos-1-yl]-L-leucine (2,6-trans 19). Compound 2,6-
trans 15 (20 mg, 25 μmol) was deprotected according to GP 5. The 
crude product was divided in 2 portions and 1 portion was purified by 
RP-HPLC (linear gradient B, 20→70%) affording 2,6-trans 15 (3.0 mg, 
5.3 μmol, 42%) as a white foam. LC-MS Rt= 14.9 min (lin. gradient B, 26 min). 1H-NMR (600 MHz, 
D2O/CD3CN): δ 7.62 (d, 1H, NHCαLeu, J= 7.3 Hz), 7.32-7.27 (m, 6H, HBn and C7NH), 4.50 (2×d, 2H, CH2Bn, J= 
11.9 and 12.0 Hz), 4.27 (m, 1H, HαLeu), 4.06 (m, 1H, HαCys), 3.94 (m, 3H, H2, H3 and H6), 3.28 (m, 2H, H7ab), 
3.02 (d, 2H, HβCys, J= 6.3 Hz), 1.88 (m, 1H, H4a), 1.63-1.40 (m, 6H, H4b, H5ab, HβγLeu), 1.25 (s, 9H, tBu), 0.80 
(2×d, 6H, 2×CH3Leu, J= 6.0 and 6.1 Hz); 13C-NMR (50 MHz, D2O/CD3CN): δ 179.9–171.6 (C=Oamide&carboxyl), 
139.0 (CqBn), 128.0-127.3 (CBn), 75.6, 71.1, 70.5 (C2, C3, C6), 69.8 (CH2Bn), 52.6 (CαLeu, CαCys), 47.4 (CqtBu), 43.0–
40.8 (C7, CβLeu and CβCys), 28.4 (tBu), 24.2 (CγLeu), 22.5, 21.0 (C4, C5), 22.0, 20.4 (2×CH3Leu). MS (ESI): m/z 
570.4 (M+H)+. HR-MS: calc. for [C27H43N3O6S2+H]+ 570.2666, found 570.2631. 
N-[(6R)-6-({N-(S-[tert-Butyl)sulfanyl]-L-cysteinyl)-amino]-methyl}-4,5,6-trideoxy-3-benzyloxy-1-oxo-D-
arabino-hexopyranos-1-yl]-L -leucine (2,6-cis 19). Compound 2,6-cis 
15 (37 mg, 46 μmol) was deprotected according to GP 5. RP-HPLC 
purification of 23 μmol crude product (linear gradient B, 20→70%) 
gave 2,6-cis 19 (5.6 mg, 9.8 μmol, 43%) as a white foam. LC-MS Rt= 
14.9 min (lin. gradient B, 26 min). 1H-NMR (600 MHz, D2O/CD3CN): δ 7.56-7.20 (m, 5H, CBn), 4.42 (t, 2H, 
CH2Bn, J= 12.4 Hz), 4.09 (m, 1H, HαLeu), 3.85 (m, 1H, HαCys), 3.60 (d, 1H, H2, J= 9.3 Hz), 3.47 (m, 1H, H6), 3.44 
(dt, 1H, H3, J= 9.5, 10.3 and J= 9.6, 10.4 Hz), 3.23 (m, 2H, H7ab), 3.02 (m, 2H, HβCys), 2.11 (m, 1H, H4a), 1.65 
(m, 1H, H5a), 1.49-1.27 (m, 5H, H4b, H5b, HβγLeu), 1.22 (s, 9H, tBu), 0.80 (d, 6H, 2×CH3Leu, J= 3.8 Hz); 13C-NMR 
(50 MHz, D2O/CD3CN/MeOD): δ 181.0, 175.0, 171.6 (C=Oamide&carboxyl), 139.1 (CqBn), 129.7-127.3 (CBn), 81.2, 
77.1, 76.8 (C2, C3, C6), 72.2 (CH2Bn), 55.1, 54.2 (CαLeu, CαCys), ∼48.0 (CqtBu, obscured by MeOD signal), 45.7, 
44.0, 42.9 (C7, CβLeu and CβCys), 30.1 (tBu), 30.0, 27.9 (C4, C5), 25.8 (CγLeu), 23.8, 22.3 (2×CH3Leu). MS (ESI): m/z 
570.4 (M+H)+. HR-MS: calc. for [C27H43N3O6S2+H]+ 570.2666, found 570.2646.  
(2R,3S,6S)-3-O-Benzyl-6-{(N-[(S-(tert-butyl)sulfanyl]-L-cysteinyl)amino]methyl}-tetrahydropyran-1-N-L-
methionine (2,6-trans 20). From 2,6-trans 9 (20 mg, 12.3 μmol) 
according to GP 5. RP-HPLC purification (linear gradient B) gave 
the title compound (6.4 mg, 11.1 μmol, 90%) as a white foam. 1H-
NMR (600 MHz, MeOD): δ 7.35-7.29 (m, 5H, HBn), 4.65, 4.48 (2×d, 
2H, CH2Bn, J= 11.6 Hz), 4.10 (m, 2H, HαMet and H2), 3.91 (m, 2H, HαCys and H6), 3.54 (m, 1H, H7a), 3.36 (m, 
2H, H1a and H7b), 3.26-3.15 (m, 4H, HβCys and H3,1b), 2.68 (m, 2H, HγMet), 2.20, 2.10 (m, 2H, HβMet), 2.10 (s, 
3H, SCH3), 2.06 (m, 1H, H4a), 1.79-1.70 (m, 3H, H5ab and H4b), 1.36 (s, 9H, tBu); 13C-NMR (100 MHz, 
MeOD): δ 173.0, 169.6 (C=Oamide&carboxyl), 139.5 (CqBn), 129.5-128.9 (CBn), 75.1 72.7, 71.7 (C2, C3, C6), 71.4 
(CH2Bn), 61.1 (CαMet), 52.4 (CαCys), 46.8 (CqtBu), 42.3, 41.8 (C7 and CβCys), 30.9, 29.1 (CβγMet), 30.6 (tBu), 25.2, 
24.6 (C4, C5), 15.0 (SCH3). HR-MS calc. for [C26H43N3O5S3+Na]+ 596.22626, found 596.19714. 
(2R,3S,6R)-3-O-Benzyl-6-{(N-[(S-(tert-butyl)sulfanyl]-L-cysteinyl)amino]methyl}-tetrahydropyran-1-N-L- 
methionine (2,6-cis 20). From 2,6-cis 9 (20 mg, 12.3 μmol) according to 
GP 5. RP-HPLC purification (linear gradient B) gave 2,6-cis 20 (4.7 mg, 
8.2 μmol 67%). 1H-NMR (600 MHz, MeOD): δ 7.60-7.50 (m, 5HBn), 



















































6.5 and 6.6 Hz), 3.79 (m, 1H, HαMet), 3.54 (m, 2H, H2 and H6), 3.44 (m, 1H, H1a), 3.34 (m, 2H, H7ab), 3.26 (m, 
1H, H3), 3.23-3.13 (2×dd, 2H, HβCys, J= 6.0, 6.1 Hz and 7.2, 7.3 Hz), 3.07 (m, 1H, H1b), 2.66 (m, 2H, HγMet), 
2.43 (m, 1H, H4a), 2.17-2.11 (m, 2H, HβMet), 2.09 (s, 3H, SCH3), 1.80 (m, 1H, H5a), 1.52-1.36(m, 2H, H5b and 
H4b), 1.36 (s, 9H, tBu). HR-MS calc. for [C26H43N3O5S3+H]+ 574.24431, found 574.21685. 
N-[(6S)-1-({N-(S-[tert-Butyl)sulfanyl]-L-cysteinyl)-amino]-methyl}-4,5,6-trideoxy-3-benzyloxy-1-oxo-D-arabino 
-hexopyranos-1-yl]-L-methionine (2,6-trans 21). Compound 2,6-trans 16 
(121 mg, 146 μmol) was deprotected according to GP 5. The employed 
1,4-dioxane was freshly distilled over Na/K and benzophenon. The 
crude product was dissolved in 13 mL H2O/CH3CN (10/3 v/v) and 3 mL 
(∼34 μmol of crude compound) was used for RP-HPLC (linear gradient B, 20→70%) affording the title 
compound (7.1 mg, 12 μmol, 35%) as a white foam. LC-MS Rt= 15.4 min (lin. gradient B, 26 min). 1H-NMR 
(600 MHz, D2O/CD3CN): δ 7.60-7.50 (m, 5H, HBn), 4.77 (partly obscured by solvent, 2H, CH2Bn), 4.71 (m, 
1H, HαMet), 4.59 (d, 1H, H2, J= 2.8 Hz), 4.35 (t, 1H, HαCys, J= 6.2 Hz), 4.17 (m, 1H, H3), 3.98 (m, 1H, H6), 3.75, 
3.40 (2×m, 2H, H7ab), 3.08-3.17 (dd, 2H, HβCys, J= 2.8 and 3.3 Hz), 2.80-2.64 (2×m, 2H, HγMet), 2.45–2.14, 
1.86–1.70 (2×m, 6H, HβMet, H5ab, H4ab), 2.25 (s, 3H, SCH3), 1.47 (s, 9H, tBu); 13C-NMR (50 MHz, 
D2O/CD3CN): δ 179.7, 176.2, 169.0 (C=Oamide&carboxyl), 137.5 (CqBn), 128.1, 127.6, 127.5 (CBn), 75.9 (C2), 71.1, 
70.7 (C6 and C3), 70.0 (CH2Bn), 53.5 (CαMet), 52.5 (CαCys), 47.7 (CqtBu), 43.6 (C7), 41.0 (CβCys), 31.1, 28.9 (CβγMet), 
28.5 (tBu), 22.8 (C4), 21.5 (C5), 13.9 (SCH3). MS (ESI): m/z 588.2 (M+H)+. HR-MS: calc. for 
[C26H41N3O6S3+H]+ 588.2230, found 588.2227. 
N-[(6R)-1-({N-(S-[tert-Butyl)sulfanyl]-L-cysteinyl)-amino]-methyl}-4,5,6-trideoxy-3-benzyloxy-1-oxo-D-
arabino-hexopyranos-1-yl]-L-methionine (2,6-cis 21). From 2,6-cis 16 
(30 mg, 36 μmol) according to GP 5. The employed 1,4-dioxane was 
bubbled through with argon by sonification before use in the Tesser’s 
base mixture. RP-HPLC purification (linear gradient B, 05→95%) 
afforded 2,6-cis 21 (4.6 mg, 7.8 μmol, 21%) as a white foam. LC-MS Rt= 13.4 min (lin. gradient B, 26 min). 
LC-MS still showed presence of 2,6-cis 22 (2,6-cis 22/2,6-cis 21: ∼3/7). 1H-NMR (600 MHz, D2O/CD3CN): δ 
7.40-7.33 (m, 5H, HBn), 4.59 (d, 1H, PhCHH, J= 12.1 Hz), 4.51 (partly obscured by watersignal: 2H, PhCH 
and HαMet), 4.35 (t, 1H, HαCys, J= 6.3 Hz), 3.78 (d, 1H, H2, J= 9.4 Hz), 3.61-3.53 (m, 2H, H6 and H7a), 3.47 
(ddd, 1H, H3, J= 4.5, 6.0 and 10.3 Hz), 3.21 (2×d, 1H, HβCys, J= 5.8 and 5.9 Hz), 3.14 (m, 2H, HβCys and H7b), 
2.52 (m, 2H, HγMet), 2.30 (m, 1H, H4a), 2.11, 1.94 (2m, 2H, HβMet), 2.05 (s, 3H, SCH3), 1.76 (m, 1H, H5a), 1.53 
(m, 1H, H4b), 1.40 (m, 1H, H5b), 1.32 (s, 9H, tBu); 13C-NMR (50 MHz, D2O/CD3CN): δ 179.7, 176.2, 169.0 
(C=Oamide&carboxyl), 137.5 (CqBn), 128.1, 127.6, 127.5 (CBn), 75.9, 71.1, 70.7 (C2, C3, C6), 70.0 (CH2Bn), 53.5 (CαMet), 
52.5 (CαCys), 47.7 (CqtBu), 43.6 (C7), 41.0 (CβCys), 31.1, 28.9 (CβγMet), 28.5 (tBu), 22.8, 21.5 (C4, C5), 13.9 (SCH3). 
MS (ESI): m/z 588.2 (M+H)+. HR-MS: calc. for [C26H41N3O6S3+H]+ 588.2230, found 588.2165. 
N-[(6S)-1-({N-(S-[tert-Butyl)sulfanyl]-L-cysteinyl)-amino]-methyl}-4,5,6-trideoxy-3-benzyloxy-1-oxo-D-
arabino-hexopyranos-1-yl]-L-methionine sulfoxide (2,6-trans 22). 
From 2,6-trans 16 (27 mg, 33 μmol) according to GP 5. RP-HPLC 
purification (linear gradient B, 20→70%) gave 2,6-trans 22 (3.6 mg, 6.0 
μmol, 18%), white foam. LC-MS Rt= 11.8 min (lin. gradient B, 26 min). 
1H-NMR (600 MHz, D2O/MeOD): δ 7.38-7.33 (m, 5H, HBn), 4.60 (dd, 2H, CH2Bn, J= 11.9 Hz), 4.71 (dd, 1H, 
HαMet, J= 5.3 and 5.4 Hz), 4.45 (s, 1H, H2), 4.18 (t, 1H, HαCys, J= 6.2 Hz), 4.02 (m, 1H, H3), 3.98 (m, 1H, H6), 
3.70, 3.48 (2×m, 2H, H7ab), 3.08-3.17 (d, 2H, HβCys, J= 6.2 Hz), 2.97-2.87 (2×m, 2H, HγMet), 2.70 (s, 3H, 
MeS=O), 2.36 (m, 1H, H4a), 2.22 (m, 1H, H5a), 1.99 (m, 1H, H4b), 1.71 (m, 2H, HβMet), 1.55 (m, 1H, H5b), 1.31 












































arabino-hexopyranos-1-yl]-L-methionine sulfoxide (2,6-cis 22). From 
2,6-cis 16 (17 mg, 21 μmol) according to GP 5. RP-HPLC purification 
(linear gradient B, 20→70%) afforded the title compound (3.0 mg, 5 
μmol, 24%) as a white foam. LC-MS Rt= 11.6 min (lin. gradient B, 26 
min). 1H-NMR (600 MHz, D2O/CD3CN): δ 7.32-7.24 (m, 5H, HBn), 4.51 (partly obscured by solvent: 1H, 
PhCH), 4.42 (m, 2H, PhCH and HαMet), 4.09 (t, 1H, HαCys, J= 6.2 and 6.3 Hz), 3.71 (d, 1H, H2, J= 9.5 Hz), 3.51 
(m, 1H, H6), 3.43 (m, 2H, H3 and H7a), 3.16-3.04 (m, 3H, HβCys and H7b), 2.75 (m, 2H, HγMet), 2.52 (s, 3H, 
MeS=O), 2.20 (m, 2H, H4a and HβMet), 2.02 (m, 1H, HβMet), 1.68 (m, 1H, H5a), 1.42 (m, 1H, H4b), 1.33 (m, 1H, 
H5b), 1.23 (s, 9H, tBu); 13C-NMR (50 MHz, D2O/CD3CN, signals marked an * appear double due to chiral 
sulfoxide): δ 176.8, 171.8, 168.7 (C=Oamide&carboxyl), 138.5 (CqBn), 129.4-128.9 (CBn), 81.5, 75.5, 74.0, 80.6, 76.4, 
76.0 (C2*, C3* and C6*), 71.7, 71.4 (CH2Bn*), 54.0, 53.3 (CαMet*, CαCys*), 50.0 (CγS(O)CH3), 49.2 (CqtBu), 44.0, 
41.3 (C7 and CβCys), 37.5 (MeS=O). 29.8 (tBu), 29.4 (CβMet), 27.6, 26.2 (C4, C5). MS (ESI): m/z 604.4 (M+H)+. 
HR-MS: calc. for [C26H41N3O6S3+H]+ 604.2179, found 604.2180.  
(2S,3S,6R)-3-hydroxy-6-{(N-[(S-(tert-butyl)sulfanyl]-L-cysteinyl)amino]methyl}-tetrahydropyran-1-N-L-leucine 
(2,6-cis 23). From 2,6-cis 11 (20 mg, 28.4 μmol) according to GP 5. RP-
HPLC purification (linear gradient B) gave the title compound (2.7 mg, 
5.7 μmol, 20%). 1H-NMR (600 MHz, MeOD): δ 4.85 (bs, 1H, HαLeu), 
3.51 (m, 2H, HαLeu and H2), 3.41 (m, 1H, H1a), 3.34–3.25 (m, 4H, H7ab, H6 
and H3), 3.25-3.15 (m, 3H, HβCys and H1b), 2.12 (m, 1H, H4a), 1.85 (m, 2H, HβLeu and HγLeu), 1.77 (m, 1H, H5a), 
1.68 (m, 1H, HβLeu), 1.52-1.41 (m, 2H, H5b and H4b), 1.36 (s, 9H, tBu), 1.02 (m, 6H, 2×CH3Leu). MS (ESI): m/z 
466.4 (M+H)+, 488.4 (M+Na)+. HR-MS calc. for [C26H43N3O5S3+Na]+ 488.222886, found 488.222886. 
N-[(6R)-6-({N-(S-[tert-Butyl)sulfanyl]-L-cysteinyl)-amino]methyl}-4,5,6-trideoxy-3-benzyloxy-1-oxo-D-
arabino-hexo pyranos-1-yl]-L-methionine methyl ester (2,6-cis 25). A 
solution of 2,6-cis 16 (83 mg, 102 μmol) in DMF (4 mL) and 1 mL of 
piperidine was stirred for ½h, after which TLC analysis (PE/EtOAc 
1/3 v/v) showed total consumption of 2,6-cis 16. The reaction mixture 
was concentrated in vacuo and the residue was dissolved in EtOAc, washed with 1N HCl and brine, the 
combined organic phases were dried (MgSO4) and concentrated in vacuo. Silica gel chromatography (Rf= 
0.5, EtOAc/MeOH 4/1 v/v) gave 2,6-cis 25 as an oil (50 mg, 81 μmol, 81%). 1H-NMR (300 MHz, CDCl3): δ 
7.74 (t, C7NH, 1H), 7.34-7.27 (m, 5H, HBn), 7.05 (d, 1H, NHCαMet, J= 7.8 Hz), 4.71 (dd, 1H, HαMet, J= 7.5 and 
12.8 Hz), 4.59 (s, 2H, CH2Bn), 3.79 (d, 1H, H2, J= 9.1 Hz), 3.74 (s, 3H, OCH3), 3.66 (dd, 1H, H7a, J= 3.6 and 3.7 
Hz), 3.58-3.47 (m, 3H, H6 and H3 and HβMet), 3.27 (dd, 1H, H7b, J= 3.7 Hz), 3.16 (m, 1H, HβMet), 2.49 (m, 2H, 
HγMet), 2.25-1.96 (m, H4a and HβCys), 2.06 (s, 3H, SCH3), 1.75 (m, 1H, H5a), 1.55 (m, 1H, H4b), 1.39 (m, 1H, 
H5b), 1.34 (s, 9H, tBu); 13C-NMR (50 MHz, CDCl3): δ 178.7, 173.4, 172.6 (C=Oamide&ester), 139.6 (CqBn), 129.3, 
129.0, 128.6 (CBn), 81.4, 77.2, 76.1 (C2, C3, C6), 72.2 (CH2Bn), 55.2 (CαMet), 52.9 (OCH3), 52.5 (CαCys), ∼49 (CqtBu, 
obscured by solvent), 45.2, 44.3 (C7 and CβCys), 30.2 (tBu), 31.9, 31.0, 30.0, 28.2 (CβγMet, C4, C5), 15.2 (SCH3). 
MS (ESI): m/z 602.4 (M+H)+. HR-MS: calc. for [C27H43N3O6S3+H]+ 602.2392, found 602.2370. 
 
Procedure Protein prenylation in Met-18b-2 CHO cells − Method according to Cohen et al.:6 Met-
18b-2 CHO cells19 were grown in HamF12/DMEM (1:1) medium supplemented with 5% FCS. The cells 
were incubated in the same medium containing 5% dialysed FCS and 5 μM simvastatin in the presence or 
absence of 100 μM of 2,6-cis-25 for 2 h at 37°C and the incubation was continued after addition of [3H]-








































After the cell lysates had been sheared and heated for 5 min at 95°C, proteins were separated by 
electrophoresis on 12.5% polyacrylamide-SDS gels. Subsequently the gel was impregnated with EN3HANCE 
(NEN), dried and the radiolabeled bands were made visible by exposure to Kodak X-omat AR film for 6 
days at –80°C.  
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of 2,6-cis 10 (Scheme 3.3), gave poor results. This may be accounted to poisoning of the Pd/C by the 
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Abstract. The attachment of lipids, with or without a linker, to several of the SAA modified Ca1a2L analogs 
presented in Chapter 2 and 3 gave lipophilic Ca1a2L analogs as potential bisubstrate inhibitors of PGGT-1. 
The inhibitory potency toward PGGT-1 of these lipophilic Ca1a2L analogs was improved in comparison 











 4.1 Introduction  
The reported strategies aimed at the development of PFT and PGGT-1 inhibitors are 
generally based on either of the two substrates, that is, the isoprenyl pyrophosphate 
entity or the Ca1a2X tetrapeptide, as a lead structure. A relatively unexplored area of 
research entails the design of bisubstrate analog inhibitors,1 containing elements from 
both the tetrapeptide and isoprenyl moiety. The idea that product analogs might be 
effective PFT/PGGT-1 inhibitors originates from the finding that isoprenyl transferases 
exhibit an unusually high affinity for their two substrates and especially for the turnover 
product. Isoprenylated proteins are removed from the active site only when a new 
isoprenyl pyrophosphate enters the active site.2 Based on these considerations, several 
research groups have reported on the development of bisubstrate inhibitors against PFT.3 
In line with these studies, lipophilic Ca1a2L analogs were constructed as potential 




















Figure 4.1 Lipophilic Ca1a2L analogs as potential bisubstrate inhibitors of PGGT-1. 
 
The discovery of new PGGT-1 inhibitors4 out of a series of Ca1a2L analogs featuring 
sugar amino acid (SAA) based dipeptide isosters as replacement of the central a1a2 
dipeptide was presented in Chapters 2 and 3. The Ca1a2L analog 2,6-trans 1 (Figure 4.1), in 
which the amino acids cysteine and leucine are arranged in a 2,6-trans fashion on the 
pyranoid SAA core, was found to inhibit PGGT-1 with an IC50-value of 68 ± 16 µM. In 
contrast, the corresponding 2,6-cis analog (2,6-cis 1), with the stereochemistry at C6 
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inverted, was found to be much less active against PGGT-1, with an IC50-value of ≈1000 
µM.5 On the basis of these results, the preparation of a set of lipophilic Ca1a2L analogs 
with general structure 2 (Figure 4.1) was undertaken. The potential bisubstrate inhibitors 
are composed of Ca1a2L analogs 2,6-cis 1 or 2,6-trans 1 which are connected, either 
directly or via a linker (C2: glycine or C4: 4-aminobutyric acid), to lauric acid (C12) or 
palmitic acid (C16). It should be noted that a saturated fatty acid is known to be well 
tolerated by PFT and PGGT-1 as an isoprenyl analog.6 
 
 4.2 Results and Discussion 
4.2.1 Synthesis – The synthesis of the partially protected precursors of the projected 
inhibitors, having a 2,6-trans or 2,6-cis relationship in the central SAA residue, is shown 
in Schemes 4.1 and 4.2, respectively. TFA/DCM mediated removal of the Boc group in 
compounds 2,6-trans 3 and 2,6-cis 3, the syntheses of which are reported in Chapter 2, 
and condensation of the free amine with Boc-Cys(StBu)-OH (BOP, HOBt, DIPEA) 
furnished suitably protected Ca1a2L analogs 2,6-trans 4 and 2,6-cis 4, respectively, both in 
72% overall yield. Next, unmasking the amine in 2,6-trans 4 and 2,6-cis 4 followed by 
condensation with either lauric [CH3(CH2)10CO2H] or palmitic acid [(CH3(CH2)14CO2H] 
with BOP/HOBt gave 2,6-trans 7 and 2,6-trans 8 and 2,6-cis 7 and 2,6-cis 8, respectively 
(84%−100%, 2 steps). The synthesis of lipophilic Ca1a2L analogs provided with a linker 
started with condensation of Boc-Gly-OH or Boc-4-aminobutyric acid with the 
ammonium salt of 2,6-trans 4 or 2,6-cis 4 to give the desired 2,6-trans 5 and 2,6-trans 6 
and 2,6-cis 5 and 6, respectively (70%−75%, 2 steps). Finally, these intermediates were 
elongated with lauric or palmitic acid according to the same procedure as described for 7 
and 8, furnishing 2,6-trans 9 – 12 (64−95%, 2 steps) and 2,6-cis 9 – 12 (78%−100%, 2 
steps).  
The partially protected precursors 2,6-trans 7 – 12 and 2,6-cis 7 – 12 were converted 
to the target bisubstrate analogs (2,6-trans 19 – 24 and 2,6-cis 19 – 24, respectively) by a 
two step deprotection procedure (Scheme 4.3): aq. LiOH mediated saponification of the 
methyl ester released the acid (13 – 18) and treatment with DTT resulted in cleavage of 

























































2,6-trans   9: n=1, m= 10
2,6-trans 7: m=10
2,6-trans 8: m=14
2,6-trans 10: n=3, m= 10
2,6-trans 11: n=1, m= 14

































Scheme 4.2 Synthesis of lipophilic Ca1a2L analogs based on 2,6-cis 1.a 
 
 
aReagents and conditions. (i) (a) TFA/DCM, iPr3SiH (b) Boc-Cys(StBu)-OH, BOP, DIPEA, HOBt, 
DMF/DCM (72%, over 2 steps); (ii) (a) TFA/DCM, iPr3SiH (b) for 2,6-trans 7 and 2,6-cis 7: 
CH3(CH2)10CO2H, for 2,6-trans 8 and 2,6-cis 8: CH3(CH2)14CO2H, BOP, DIPEA, HOBt, DMF/DCM (2,6-trans 
7: 100%, 2,6-trans 8: 87%, 2,6-cis 7: 91%, 2,6-cis 8: 84%, 2 steps); (iii) (a) TFA/DCM, iPr3SiH (b) for 2,6-
trans 5 and 2,6-cis 5: Boc-Gly-OH, for 2,6-trans 6 and 2,6-cis 6: Boc-4-aminobutyric acid, BOP, DIPEA, 
HOBt, DMF/DCM (2,6-trans 5: 75%, 2,6-trans 6: 75%, 2,6-cis 5: 72%, 2,6-cis 6: 70%, 2 steps); (iv) (a) 
TFA/DCM, iPr3SiH (b) for 2,6-trans 9, 2,6-trans 10, 2,6-cis 9 and 2,6-cis 10: CH3(CH2)10CO2H, for 2,6-trans 
11, 2,6-trans 12, 2,6-cis 11 and 2,6-cis 12: CH3(CH2)14CO2H, BOP, DIPEA, HOBt, DMF/DCM (2,6-trans 9: 
95%, 2,6-trans 10: 64%, 2,6-trans 11: 90%, 2,6-trans 12: 85%, 2,6-cis 9: 100%, 2,6-cis 10: 92%, 2,6-cis 11: 



































































2,6-cis   9: n=1, m= 10
2,6-cis 7: m=10
2,6-cis 8: m=14
2,6-cis 10: n=3, m= 10
2,6-cis 11: n=1, m= 14
























































































































































2,6-trans 13: R1= H; R2= StBu
2,6-trans 19: R1= R2= H
2,6-trans   8: R1= CH3 R2= StBu
2,6-trans 14: R1= H; R2= StBu
2,6-trans 20: R1= R2= H
2,6-trans   9: R1= CH3 R2= StBu
2,6-trans 15: R1= H; R2= StBu
2,6-trans 21: R1= R2= H
2,6-trans 12: R1= CH3 R2= StBu
2,6-trans 18: R1= H; R2= StBu































2,6-trans 11: R1= CH3 R2= StBu
2,6-trans 17: R1= H; R2= StBu
2,6-trans 23: R1= R2= H
2,6-trans 10: R1= CH3 R2= StBu
2,6-trans 16: R1= H; R2= StBu
2,6-trans 22: R1= R2= H
2,6-cis   7: R1= CH3 R2= StBu
2,6-cis 13: R1= H; R2= StBu
2,6-cis 19: R1= R2= H
2,6-cis   8: R1= CH3 R2= StBu
2,6-cis 14: R1= H; R2= StBu
2,6-cis 20: R1= R2= H
2,6-cis   9: R1= CH3 R2= StBu
2,6-cis 15: R1= H; R2= StBu
2,6-cis 21: R1= R2= H
2,6-cis 12: R1= CH3 R2= StBu
2,6-cis 18: R1= H; R2= StBu
2,6-cis 24: R1= R2= H
2,6-cis 11: R1= CH3 R2= StBu
2,6-cis 17: R1= H; R2= StBu
2,6-cis 23: R1= R2= H
2,6-cis 10: R1= CH3 R2= StBu
2,6-cis 16: R1= H; R2= StBu











































Scheme 4.3 Deprotection 2,6-trans 7-12 and 2,6-cis 7-12.a  
Biological evaluation of target compounds 2,6-trans 19-24 and 2,6-cis 19-24.b 
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a(i) 1M LiOH, H2O/1,4-dioxane, 0°C→rt; (ii) (a) DTT, Tris buffer (pH 7.4), MeOH or EtOH (b) RP-
HPLC purification. bActivity of PGGT-1 at 10 or 100 µM of compound: expressed as % of control activity 




4.2.2 Biological Evaluation – All compounds (2,6-trans 19 – 24 and 2,6-cis 19 – 24) 
were evaluated for their inhibitory potency against PGGT-1 (Scheme 4.3) by determining 
the residual enzyme activity in vitro at 2 different concentrations (10 and 100 µM) 
according to a procedure previously described.4d The results of the biological evaluation 
are presented in Scheme 4.3. Similar to the monosubstrate analogs (2,6-trans 1 and 2,6-cis 
1, Figure 4.1 and Scheme 4.3), the most potent compounds 2,6-trans 23 and 2,6-trans 24 
feature a 2,6-trans substitution pattern on the SAA moiety. Determination of the IC50-
values revealed that 2,6-trans 23 (IC50= 12.7±1.3 µM) and 2,6-trans 24 (IC50= 12.3±1.0 
µM), differing in the nature of the linker, inhibit PGGT-1 with equal efficacy, 
representing a ≈6-fold improvement in potency compared to the corresponding 
monosubstrate 2,6-trans 1 (IC50= 68±16 µM). 
Whereas monosubstrate 2,6-cis 1 showed little activity below 1000 µM, compounds 
2,6-cis 19 – 24, featuring an isoprenyl analog, all appeared to exhibit an enhanced 
activity. The most potent member of the 2,6-cis series was found to be 2,6-cis 20, in 
which the C16 palmitic acid is directly connected to the cysteine. In contrast to the 2,6-
trans series, where the introduction of a longer alkyl chain and linker gradually increases 
the inhibitory potency, introduction of a linker or increasing the length of the alkyl chain 
in the 2,6-cis series seems to have no additional effect on the potency. Although 
inhibitors based on 2,6-cis 1 yielded (slightly) less potent inhibitors, the gain of inhibition 
potency is more pronounced in comparison with the series based on 2,6-trans 1. 
 
 4.3 Conclusions 
Summarizing, it has been shown that the attachment of simple lipids such as lauric 
or palmitic acid (with or without a linker) to the previously presented Ca1a2L analogues 
2,6-trans and 2,6-cis 1, is a promising approach to increase their inhibition potency 
against PGGT-1. The most potent compounds (2,6-trans 23 and 2,6-trans 24) were found 
to inhibit PGGT-1 in the low micromolar range (≈6 fold improvement over the 
corresponding monosubstrate analogs). At the moment there is no experimental prove 
that the inhibitors presented in this chapter actually act by occupying the peptide and 
isoprenyl pyrophosphate pocket of the enzyme. Due to the presence of different 
hydrophobic pockets in the active site of PGGT-1, in which the introduced acyl residues 
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could bind, alternative binding modes are feasible. Furthermore, as the lipophilic Ca1a2L 
analogs are provided with the zinc-binding thiol function, it is unlikely that they adopt a 
product-like conformation in the active site of the enzyme.2bf  
 
 4.4 Experimental Section 
4.4.1 General − 1H NMR and 13C NMR spectra were recorded with a Bruker AC-200 (200, 50.1 MHz), a 
Bruker DPX-300 (300, 75 MHz), a Bruker Avance-400 (400, 100 MHz) or a Bruker DMX-600 (600, 150 
MHz). Chemical shifts are given in ppm (δ) relative to tetramethylsilane as internal standard. Mass spectra 
were recorded with a Perkin Elmer/SCIEX API 165 mass instrument and HR-Mass spectra were recorded 
with an API QSTAR
tm
 Pulsar (Applied Biosystems). LC-MS analysis was performed on a Jasco HPLC system 
(detection simultaneously at 214 and 254 nm) coupled to the Perkin Elmer/SCIEX API 165 mass 
instrument. Column chromatography was performed on silica gel 60 (0.04–0.063 mm, Fluka). DMF 
(Biosolve p.a.), 1,4-dioxane (Biosolve p.a.), DCM (Biosolve, p.a.) and toluene (Biosolve, p.a.) were stored 
over molecular sieves (4Å). EtOAc and PE (40-60) were of technical grade and distilled before use. Leu-
OMe·HCl (Nova Biochem), BOP (Nova Chemicals), DIPEA (Biosolve), iPrSi3H (Aldrich), TFA (Biosolve), 
Boc-Cys(StBu)-OH (NovaBiochem), Boc-Gly-OH (Bissendorf Biochemicals), Boc-4-aminobutyric acid 
(NeoSystems), palmitic acid (Janssen Chimica), lauric acid (Acros), Boc2O (Fluka) were used as received. 
Reactions were followed by TLC analysis on silicagel (Schleicher & Schuell, F 1500 LS 254) or HPTLC 
aluminium sheets (Merck, silicagel 60, F254), with detection by UV-absorption (254 nm) where applicable 
and charring at 150°C with 20% H2SO4 in EtOH (25 g L-1), ninhydrin (3 g L-1) in EtOH/AcOH (100/3 v/v), 
NH4(Mo)7O24⋅4H2O (25 g L-1) and NH4Ce(SO4)4⋅2H2O (10 g L-1) in 10% aq. H2SO4 or KMnO4 (2%) in 1% aq. 
K2CO3. Column chromatography was performed with silica gel (Fluka; 0.063-0.200 mm). 
4.4.2 General procedures − General procedure 1a (GP 1a); removal of the Boc protective group: to a 
∼0.05M soln. of the dimer in DCM were added 1.3 equiv. iPr3SiH or Et3SiH and TFA (→TFA/DCM 1/1 v/v). 
After TLC analysis (PE/EtOAc 1/1 v/v) showed consumption of the starting material, the TFA was 
coevaporated with toluene (5×10 mL). The free amine can be visualised with TLC analysis by employing 
Et2O/EtOH/25% aq. ammonia (6/3/1 v/v/v) and spraying with ninhydrin. 
General procedure 1b (GP 1b); condensation with RCO2H: to a ∼0.1M soln. of the amine in DMF were 
added 1.2 equiv. of the appropriate acid, 1.2 equiv. BOP and 4 equiv. DIPEA. After TLC analysis 
(DCM/MeOH 9/1 v/v KMnO4) showed consumption of the starting material, DMF was removed in vacuo. 
The residue was dissolved in EtOAc and washed with water (2×), sat. aq. NaHCO3 (2×), 5% KHSO4 (2×) and 
brine. The organic phase was dried (MgSO4) and concentrated in vacuo.  
General procedure 2 (GP 2); saponification methyl ester: to a stirred solution of the methyl ester in 1,4-
dioxane/H2O (1/1 v/v) at 0°C was added aq. LiOH (1.0 M, 1.0 equiv.) and the temperature was allowed to 
rise to room temperature. After TLC analysis (DCM/MeOH 9/1 v/v) showed consumption of the starting 
material (30-45 min) the reaction mixture was neutralised (pH ∼7) by addition of Amberlite-H+. The 
Amberlite-H+ was filtered off and the solvents were removed in vacuo by co-evaporation with toluene. 
Dissolving the crude acid in DCM allowed precipitation of the product in cold petroleum ether. For LC-MS 
analysis eluent A: 50% aq. MeOH, B: CH3CN and C: 0.1% methanolic TFA were employed. 
General procedure 3 (GP 3); DTT mediated removal of StBu group: to a solution of the disulfide in 




degassed with argon. Subsequently DTT (25-50 equiv.) is added and the reaction mixture is stirred under 
argon for 24 h. Next, the reaction mixture is diluted with tBuOH/CH3CN/H2O (1/1/1 v/v/v, c= 5 – 10 mg 
mL-1) and the crude thiol is purified by RP-HPLC employing a linear gradient of CH3CN (= eluent B) in 
50% aq. MeOH (= eluent A) and 0.1% methanolic TFA (= eluent C).  
 
N-(6-[(N-tert-butyloxycarbonyl)-S-tert-butylthio-L-cysteinyl]-aminomethyl-4,5-dideoxy-α-D-glucurono 
pyranosyl)-L-leucine methyl ester (2,6-trans 4). Following GP 1a 
and 1b employing 2,6-trans 3 (1.8 g, 4.6 mmol) and Boc-Cys(StBu)-
OH (1.7 g, 5.5 mmol) gave after purification by silica gel 
chromatography the title compound (Rf= 0.5, EtOAc) in 72% yield 
as a colorless oil. 1H-NMR (400 MHz, CDCl3) δ 7.57, 7.40 (2m, 2H, 
NHCαLeu, NHC7), 5.89 (bs, 1H, NHBoc), 4.60 (bs, 1H, HαLeu), 4.39 (bs, 1H, HαCys), 4.06 (d, 1H, H6, J= 7.2 Hz), 
3.97 (bs, 1H, H6), 3.87 (bs, 1H, H3), 3.76 (s, 3H, OCH3), 3.43-3.38 (m, 2H, H7), 3.10 (m, 2H, HβCys), 1.90, 1.73-
1.68 (m, 7H, H4&5, HβγLeu), 1.46, 1.34 (2×s, 18H, 2×tBu), 0.96 (m, 6H, 2×CH3Leu); 13C-NMR (75 MHz, CDCl3) δ 
173.2-171.0 (C=Oester&amide), 154.7 (C=OBoc), 79.1 (Cq tBuBoc), 73.5, 71.6, 66.2 (C2, C3, C6), 54.1, 51.7, 49.6 (CαLeu, 
CαCys, OCH3), 47.2 (C7), 41.8, 39.5 (Cq StBu , CβLeu, CβCys), 29.0, 27.4 (2×tBu), 26.1, 23.2 (C4, C5), 24.1 (CγLeu), 
22.1, 20.8 (2×CH3Leu). MS (ESI): m/z 594.5 (M+H)+, 616.4 (M+Na)+. HR-MS: calc. for [C26H47N3O8S2+H]+ 
594.28773, found 594.28674. [α]D20= +2.0 (CHCl3, c= 0.5). 
N-(6-[(N-tert-butyloxycarbonyl)-S-tert-butylthio-L-cysteinyl]-aminomethyl-4,5-dideoxy-β-D-glucurono 
pyranosyl)-L-leucine methyl ester (2,6-cis 4). Following GP 1a and 
1b using 2,6-cis 3 (0.8 g, 2.1 mmol) and Boc-Cys(StBu)-OH (0.8 g, 
2.5 mmol) gave after purification by silica gel chromatography the 
title compound (Rf= 0.5, EtOAc) in 72% yield as a colorless oil. 1H-
NMR (400 MHz, CDCl3) δ 7.13 (d, 1H, NH, J= 7.2 Hz), 6.80 (t, 1H, 
NH, J= 4.8 and 5.6 Hz), 5.53 (bs, 1H, NHBoc), 4.51 (m, 1H, HαLeu), 4.29 (dd, 1H, HαCys, J= 6.6 and 6.9 Hz), 
3.95 (d, 1H, H2, J= 8.0 Hz), 3.88 (m, 1H, H6), 3.71 (m, 1H, H3), 3.67 (s, 3H, CH3O), 3.64 (m, 1H, H7a), 3.17 (m, 
1H, H7b), 3.05 (m, 2H, HβCys), 1.84 (m, 1H, H4a), 1.69 (m, 1H, H5a), 1.57 (m, 5H, H4b, H5b, HβγLeu), 1.37, 1.25 
(2×s, 18H, 2×tBu), 0.86 (dd, 6H, 2×CH3Leu J= 6.2 and 6.5 Hz); 13C-NMR (100 MHz, CDCl3) δ 172.8-170.9 
(C=Oester&amide), 155.4 (C=OBoc), 79.7 (CqtBu Boc), 77.8, 76.6, 67.9 (C2, C3, C6), 53.8, 52.0, 49.7 (CαLeu, CαCys, OCH3), 
47.7 (C7), 43.2, 41.7, 40.7 (CqStBu, CβLeu, CβCys), 30.4, 26.8 (C4, C5), 29.4, 27.9 (2×tBu), 24.5 (CγLeu), 22.4, 21.5 
(2×CH3Leu). MS (ESI): m/z 594.4 (M+H)+, 616.4 (M+Na)+. HR-MS: calc. for [C26H47N3O8S2+H]+ 594.28773, 
found 594.28687. [α]D20= −42 (CHCl3, c= 0.5). 
N-(6-[(N-(N-tert-Butyloxycarbonyl-glycine))-S-tert-butylthio-L-cysteinyl]-aminomethyl-4,5-dideoxy-α-D-
glucuronopyranosyl)-L-leucine methyl ester (2,6-trans 5). 
Following GP 1a and 1b using 2,6-trans 4 (94 mg, 0.16 mmol) 
and Boc-Gly-OH (33.3 mg, 0.19 mmol) gave the title 
compound (Rf= 0.5, EtOAc/acetone 1/1 v/v) in 75% yield. 1H-
NMR (400 MHz, CDCl3) δ 7.40 (d, 1H, NH, J= 7.4 Hz), 7.30 (m, 1H, NH), 5.40 (bs, 1H, NHBoc), 4.78 (dt, 1H, 
HαCys, J= 5.5, 5.6 and 5.7 Hz), 4.65 (m, 1H, HαLeu), 4.13 (m, 1H, H6), 4.02 (d, 1H, H2, J= 8.5 Hz), 3.85 (dd, 1H, 
HαGly, J= 5.7 Hz), 3.76 (m, 5H, H3, HαGly, OCH3), 3.57, 3.45 (2×m, 2H, H7ab), 3.34 (m, 1H, HβCys), 3.06 (dd, 1H, 
HβCys J= 5.1 Hz), 1.95 (m, 1H, H4a), 1.85 (m, 1H, H5a), 1.67 (m, 5H, H4b5b, HβγLeu), 1.45, 1.33 (2×s, 18H, 2×tBu), 
0.86 (m, 6H, 2×CH3Leu); 13C-NMR (100 MHz, acetone-d6) δ 173.5-170.6 (C=Oester&amide), 157.2 (C=OBoc), 79.7 
(CqtBu Boc), 76.2 (C2), 72.5 (C6), 66.7 (C3), 54.0, 52.4 (OCH3, CαCys), 50.8 (CαLeu), 48.3 (CqtBu), 44.8 (C7), 42.8 
(CαGly), 41.6 (CβCys), 40.9 (CβLeu), 30.5, 29.2 (2×tBu), 27.4 (C4), 25.4 (CγLeu), 24.0 (C5), 23.3, 21.6 (2×CH3Leu). MS 
(ESI): m/z 651.4 (M+H)+, 673.5 (M+Na)+. HR-MS: calc. for [C28H50N4O9S2+H]+ 651.30920, found 651.30963. 




































glucuronopyranosyl)-L-leucine methyl ester (2,6-cis 5). 
Following GP 1a and 1b using 2,6-cis 4 (70 mg, 0.12 mmol) 
and Boc-Gly-OH (25 mg, 0.14 mmol) gave 2,6-cis 5 (Rf= 0.56, 
EtOAc/acetone 1/1 v/v) in 72% yield. 1H-NMR (400 MHz, 
CDCl3) δ 7.40 (d, 1H, NH, J= 7.3 Hz), 7.17 (m, 1H, NH), 5.41 
(bs, 1H, NHBoc), 4.78 (dd, 1H, HαCys, J= 6.6 and 6.7 Hz), 4.66 (m, 1H, HαLeu), 3.76 (m, 5H, HαGly, CH3O), 3.63 
(d, H2, 1H, J= 9.3 Hz), 3.54 (m, H3, H6), 3.46 (m, 1H, H7a), 3.28, 3.25 (2×dd, 1H, H7b, J= 2.2, 2.5 and 2.6 Hz), 
3.20 (dd, 1H, HβCys, J= 6.0 and 6.4 Hz), 3.06 (dd, 1H, HβCys, J= 6.4 and 6.5 Hz), 2.17 (m, 1H, H4a), 1.67 (m, 4H, 
H4b, HβγLeu), 1.55–1.40 (m, 2H, H4b&5b), 1.45, 1.33 (2×s, 18H, 2×tBu), 0.86 (dd, 6H, 2×CH3Leu, J= 6.1 Hz); 13C-
NMR (100 MHz, CDCl3) δ 173.7, 172.2, 170.3 (C=Oester&amide), 156.1 (C=OBoc), 80.1 (CqtBu Boc), 77.7 (C2), 76.7 
(C6), 68.2 (C3), 53.0, 52.4 (CαLeu, OCH3), 49.7 (CαCys), 48.1 (CqtBu), 44.1 (CαGly), 43.6 (C7), 41.1, 40.8 (CβLeu, 
CβCys), 30.5 (C4), 29.6, 28.2 (2×tBu), 27.1 (C5), 24.7 (CγLeu), 22.6, 21.6 (2×CH3Leu). MS (ESI): m/z 650.3 (M+H)+, 
673.5 (M+Na)+. HR-MS: calc. for [C28H50N4O9S2+H]+ 651.30920, found 651.31061. [α]D20= −67 (CHCl3, c= 1). 
N-(6-[(N-(4-N-tertButyloxycarbonyl-aminobutyric acid))-S-tert-butylthio-L-cysteinyl]-aminomethyl-4,5-
dideoxy-α-D-glucuronopyranosyl)-L-leucine methyl ester 
(2,6-trans 6). Following GP 1a and 1b using 2,6-trans 4 (254 
mg, 0.43 mmol) and Boc-4-aminobutyric acid (104 mg, 0.51 
mmol) gave the title compound (Rf= 0.7, EtOAc/acetone 1/1 
v/v) in 75% yield. 13C-NMR (50 MHz, acetone-d6) δ 173.4, 
172.2, 170.7 (C=Oester&amide), 157.0 (C=OBoc), 78.5 (CqtBu Boc), 76.1 (C2), 72.4 (C6), 66.9 (C3), 54.2, 52.2 (CαLeu, 
OCH3), 50.7 (CαCys), 48.1 (Cq, StBu), 42.8, 41.4. 40.7, 39.8 (C7, CβLeu, CβCys, CH2), 33.0, 27.2, 26.6, 24.0 (C4, C5, 
2×CH2), 29.9, 28.5 (2×tBu), 25.3 (CγLeu), 23.2, 21.4 (2×CH3Leu). MS (ESI): m/z 679.5 (M+H)+, 701.4 (M+Na)+. 
HR-MS: calc. for [C30H54N4O9S2+H]+ 679.34050, found 679.34375. [α]D20= −16 (CHCl3, c= 1). 
N-(6-[(N-(4-N-tertButyloxycarbonyl-aminobutyric acid))-S-tert-butylthio-L-cysteinyl]-aminomethyl-4,5-
dideoxy-β-D-glucuronopyranosyl)-L-leucine methyl ester 
(2,6-cis 6). Following GP 1a and 1b using 2,6-cis 4 (0.25 g, 
0.42 mmol) and Boc-4-aminobutyric acid (0.10 g, 0.51 mmol) 
gave 2,6-cis 6 (Rf= 0.65, EtOAc/acetone 1/1 v/v) in 70% yield. 
δ 7.21 (m, 1H, NH, J= 7.3 Hz), 7.12 (m, 1H, NH), 4.80 (bs, 1H, 
NHBoc), 4.63 (m, 2H, HαCys, HαLeu), 3.71 (s, 3H, CH3O), 3.49–3.42 (m, 3H, H2, H3, H6), 3.09–3.01 (m, 4H, H7, 
HβCys), 2.20 (2×CH2), 2.10 (m, 1H, H4a), 1.74 (m, 2H, CH2), 1.63 (m, 4H, H4b, HβγLeu), 1.49–1.27 (m, 2H, H4b, 
H5b), 1.38, 1.27 (2×s, 18H, 2×tBu), 0.86 (dd, 6H, 2×CH3Leu, J= 6.1 Hz); 13C-NMR (100 MHz, CDCl3) δ 174.3, 
173.6, 172.4, 171.3 (C=Oester&amide), 156.4 (C=OBoc), 79.5 (CqtBu Boc), 77.8 (C6), 76.9 (C2), 68.2 (C3), 52.9, 52.3 
(CαLeu, OCH3), 49.7 (CαCys), 47.8 (Cq, StBu), 43.4, 41.0. 40.7, 39.3 (C7, CβLeu, CβCys, CH2), 29.6, 28.2 (2×tBu), 
32.9, 30.4, 27.0, 26.1 (C4, C5, 2×CH2), 24.7 (CγLeu), 22.6, 21.5 (2×CH3Leu). MS (ESI): m/z 677.7 (M+H)+, 701.4 
(M+Na)+. HR-MS: calc. for [C30H54N4O9S2+H]+ 679.34050, found 679.34039. [α]D20 = −69 (CHCl3, c= 1).  
N-(6-[(N-(N-lauric acid))-S-tert-butylthio-L-cysteinyl]-aminomethyl-4,5-dideoxy-α-D-glucuronopyranosyl)-
L-leucine methyl ester (2,6-trans 7). Following GP 1a and 1b using 2,6-trans 4 (44 mg, 0.07 mmol) and lauric 
acid (18 mg, 0.09 mmol) gave 2,6-trans 7 (Rf= 0.5, DCM/MeOH 9/1 
v/v) in 100% yield. 1H-NMR (600 MHz, CDCl3) δ 7.30 (d, 1H, NH, 
J= 8.4 Hz), 6.97 (m, 1H, NH), 6.77 (d, 1H, NH, J= 7.5 Hz), 4.77 (dd, 
1H, HαCys, J= 7.0 Hz), 4.65 (m, 1H, HαLeu), 4.04 (m, 1H, H6), 3.99 (d, 
1H, H2, J= 7.9 Hz), 3.84 (m, 1H, H3), 3.76 (s, 3H, OCH3), 3.76 (m, 1H, H7a), 3.31 (m, 1H, H7b), 3.20, 3.08 (m, 






























































1.75−1.58 (m, 6H, HβγLeu, H5a, CH2lipid), 1.42–1.27 (m, tBu, H4b&5b, CH2lipid), 0.95 (t, 6H, 2×CH3Leu, J= 6.2 and 
6.3 Hz), 0.88 (t, 3H, CH3lipid, J= 6.8 and 7.1 Hz); 13C-NMR (150 MHz, CDCl3) δ 174.0, 173.4, 171.9, 170.5 
(C=Oester&amide), 73.4 (C6), 71.7 (C2), 67.4 (C3), 52.9, 52.5 (CαLeu, OCH3), 50.1 (CαCys), 48.5 (CqtBu), 42.0 (CβCys), 
41.0 (CβLeu), 39.6 (C7), 36.5, 33.8, 31.9 (3×CH2lipid), 29.6 (tBu), 29.6 (CH2lipid), 26.5, 25.6, 24.0, 24.8, 22.7 (C4, 
C5, 3×CH2lipid), 24.8 (CγLeu), 22.8, 21.7 (2×CH3Leu), 14.0 (CH3lipid). MS (ESI): m/z 676.5 (M+H)+. HR-MS: calc. 
for [C33H61N3O7S2+H]+ 676.40237, found 676.40063. [α]D20= −2.4 (CHCl3, c= 0.25). 
N-(6-[(N-(N-lauric acid))-S-tert-butylthio-L-cysteinyl]-aminomethyl-4,5-dideoxy-β-D-glucuronopyranosyl)-
L-leucine methyl ester (2,6-cis 7). Following GP 1a and 1b using 2,6-
cis 4 (53 mg, 0.09 mmol) and lauric acid (21.5 mg, 0.11 mmol) gave 
2,6-cis 7 (Rf= 0.4, DCM/MeOH 9/1 v/v) in 91% yield. 1H-NMR (400 
MHz, CDCl3) δ 7.35 (d, 1H, NH, J= 8.9 Hz), 7.10 (bt, 1H, NH), 4.73 
(dd, 1H, HαCys, J= 7.2 and 7.4 Hz), 4.69 (dd, 1H, HαCys, J= 7.3 and 8.3 
Hz), 3.77 (s, 3H, CH3O), 3.62–3.42 (m, 4H, H2, H3, H6, H7a), 3.12 (m, 1H, H7b), 3.02 (dd, 2H, HβCys, J= 6.9, 7.2 
and 7.3 Hz), 2.32−2.17 (m, 4H, 2×CH2lipid), 1.70−1.32 (m, HβγLeu, H4, H5, CH2lipid), 1.34–1.20 (m, tBu, CH2lipid), 
0.95 (dd, 6H, 2×CH3Leu, J= 5.9 Hz), 0.89 (t, 3H, CH3lipid, J= 6.8 and 7.1 Hz); 13C-NMR (150 MHz, CDCl3) δ 
175.3, 175.2, 173.1, 172.4 (C=Oester&amide), 78.8 (C6), 78.2 (C2), 69.2 (C3), 53.4, (CαLeu, OCH3), 50.6 (CαCys), 49.0 
(CqtBu), 44.4, (C7), 42.0. 41.5 (CβLeu, CβCys), 37.1, 32.8, 31.5, 31.0– 30.0 (CH2lipid), 30.2 (tBu), 28.0, 26.6 (C4, C5), 
23.5 (CH2lipid), 25.8 (CγLeu), 23.7, 22.6 (2×CH3Leu), 15.0 (CH3lipid). MS (ESI): m/z 676.3 (M+H)+, 698.5 (M+Na)+. 
HR-MS: calc. for [C33H61N3O7S2+H]+ 676.40237, found 676.40149. [α]D20= −115.2 (CHCl3, c= 0.25). 
N-(6-[(N-(N-palmitic acid))-S-tert-butylthio-L-cysteinyl]-aminomethyl-4,5-dideoxy-α-D-glucurono pyranosyl)-
L-leucine methyl ester (2,6-trans 8). Following GP 1a and 1b using 
2,6-trans 4 (91 mg, 0.15 mmol) and palmitic acid (47.2 mg, 0.18 
mmol) gave the title compound (Rf= 0.67, EtOAc/acetone 1/1 v/v) in 
87% yield. 1H-NMR (400 MHz, CDCl3) δ 7.30 (m, 2H, 2×NH), 7.00 
(d, 1H, NH, J= 7.8 Hz), 4.77 (m, 1H, HαCys), 4.62 (m, 1H, HαLeu), 4.06 (m, 2H, H6, H2), 3.84 (m, 1H, H3), 3.76 
(s, 3H, CH3O), 3.60, 3.30 (2×m, 2H, H7), 3.14 (m, 2H, HβCys), 2.27 (m, 2H, CH2lipid), 1.95 (m, 1H, H4a), 1.75, 
1.55 (m, 6H, HβLeu, HγLeu, H5a, CH2lipid), 1.42–1.20 (m, tBu, H4b5b, CH2lipid), 0.95 (t, 6H, 2×CH3Leu, J= 5.8 and 5.9 
Hz), 0.88 (t, 3H, CH3lipid, J= 6.6 and 7.0 Hz); 13C-NMR (100 MHz, CDCl3) δ 174.1, 173.4, 171.9, 170.7 
(C=Oester&amide), 74.2 (C6), 71.3 (C2), 66.6 (C3), 53.3, 52.6 (CαLeu, OCH3), 50.7 (CαCys), 48.2 (CqtBu), 42.0 (CβCys), 
40.8 (CβLeu), 39.7 (C7), 36.3, 31.8 (2×CH2lipid), 29.6 (tBu), 29.6 (CH2lipid), 26.5, 25.6, 24.0. 22.6 (C4, C5, 
2×CH2lipid), 25.1 (CγLeu), 22.6, 21.3 (2×CH3Leu), 14.0 (CH3lipid). MS (ESI): m/z 733.9 (M+H)+, 754.6 (M+Na)+. 
HR-MS: calc. for [C37H69N3O7S2+H]+ 732.46497, found 732.46338. [α]D20= −2.0 (CHCl3, c= 0.5). 
N-(6-[(N-N-(palmitic acid))-S-tert-butylthio-L-cysteinyl]-aminomethyl-4,5-dideoxy-β-D-glucurono pyranosyl)-
L-leucine methyl ester (2,6-cis 8). Following GP 1a and 1b using 
2,6-cis 4 (76 mg, 0.13 mmol) and palmitic acid (39.4 mg, 0.15 
mmol) gave the title compound (Rf= 0.8, EtOAc/acetone 1/1 v/v) 
in 84% yield. 1H-NMR (400 MHz, CDCl3) δ 7.37 (1H, NH), 7.20 
(1H, NH), 7.12 (1H, NH), 4.70 (m, 2H, HαCys, HαLeu), 3.76 (s, 3H, 
CH3O), 3.53 (m, 4H, H2, H3, H6, H7a), 3.20 (m, 1H, H7b), 3.00 (m, 2H, HβCys), 2.40−2.17 (m, 3H, CH2lipid, H4a), 
1.50−1.40 (m, 6H, HβLeu, HγLeu, H5a, CH2lipid), 1.40–1.20 (m, tBu, H4b5b, CH2lipid), 0.95 (dd, 6H, 2×CH3Leu, J= 6.1 
and 6.0 Hz), 0.88 (t, 3H, CH3lipid, J= 6.6 and 7.0 Hz); 13C-NMR (100 MHz methanol-d4) δ 174.4, 172.2, 171.4 
(C=Oester&amide), 77.9 (C6), 77.4 (C2), 68.3 (C3), 53.6, 52.4 (CαLeu, OCH3), 50.7 (CαCys), 48.2 (Cq, StBu), 43.9, (C7), 
42.7. 41.0 (CβLeu, CβCys), 36.5, 32.5, 31.5, 30.0–29.0 (CH2lipid), 30.2 (tBu), 27.1, 25.7, 24.8, 22.7 (C4, C5, CH2), 
24.8 (CγLeu), 22.7, 21.7 (2×CH3Leu), 14.1 (CH3lipid). MS (ESI): m/z 732.5 (M+H)+, 754.8 (M+Na)+. HR-MS: calc. 














































pyranosyl)-L-leucine methyl ester (2,6-trans 9). Following 
GP 1a and 1b using 2,6-trans 5 (34 mg, 0.05 mmol) and 
lauric acid (12.5 mg, 0.06 mmol) gave 2,6-trans 9 (Rf= 0.5, 
DCM/MeOH 9/1 v/v) in 52% yield. 13C-NMR (50 MHz, 
CDCl3) δ 174.4, 173.5, 171.9, 169.7 (C=Oester&amide), 73.0, 70.9 
(C2, C6), 67.1 (C3), 53.0, 52.3 (Cα, OCH3), 49.6 (Cα), 48.2 (CqtBu), 43.3, 42.0, 41.7, 39.5 (CβCys, CβLeu, CH2Gly, C7), 
35.9, 31.6 (2×CH2lipid), 29.5 (tBu), 29.6 (CH2lipid), 26.3, 25.3, 23.7, 22.4 (C4, C5, CH2lipid), 24.6 (CγLeu), 22.6, 21.4 
(2×CH3Leu), 13.8 (CH3lipid). MS (ESI): m/z 733.5 (M+H)+, 755.5 (M+Na)+. HR-MS: calc. for [C35H64N4O8S2+H]+ 
733.42383, found 733.42206. 
N-(6-[(N-(N-(lauric acid)-glycine))-S-tert-butylthio-L-cysteinyl]-aminomethyl-4,5-dideoxy-β-D-glucurono 
pyranosyl)-L-leucine methyl ester (2,6-cis 9). Following GP 1a and 1b using 2,6-cis 5 (64 mg, 0.10 mmol) 
and lauric acid (23.6 mg, 0.12 mmol) gave 2,6-cis 9 (Rf= 
0.54, DCM/MeOH 9/1 v/v) in 100% yield. 1H-NMR (400 
MHz, CDCl3) δ 7.42 (dd, 2H, 2×NH, J= 5.7 and 6.5 Hz), 7.18 
(t, 1H, NH, J= 5.8 Hz), 6.54 (t, 1H, NH, J= 5.1 Hz), 4.70 (m, 
2H, HαCys, HαLeu), 3.92 (dd, 2H, CH2Gly, J= 2.9 and 3.0 Hz), 3.77 (s, 3H, OCH3), 3.66 (m, 1H, H6), 3.55 (m, 2H, 
H2, H3), 3.43, 3.26 (2×m, 2H, H7), 3.14, 3.00 (2×m, 2H, HβCys), 2.64–2.14 (m, 4H, 2×CH2lipid), 1.72–1.32 (m, 
HβγLeu, H4, H5, CH2lipid), 1.32 (s, 9H, tBu), 1.32–1.17 (m, CH2lipid), 0.95 (dd, 6H, 2×CH3Leu, J= 6.0 Hz), 0.88 (t, 
3H, CH3lipid, J= 6.6 and 7.0 Hz); 13C-NMR (100 MHz, CDCl3) δ 174.3, 174.1, 172.3, 170.2, 169.7 
(C=Oester&amide), 77.6, 76.5 (C2, C6), 68.3 (C3), 53.2, 52.6 (CαLeu, OCH3), 49.6 (CαCys), 48.4 (CqtBu), 43.8, 43.4, 41.3, 
41.0 (CβCys, CβLeu, CH2Gly, C7), 36.2, 31.9, 30.7 (3×CH2lipid), 29.6 (tBu), 29.3 (CH2lipid), 27.3, 25.6, 22.6 (C4, C5, 
CH2lipid), 24.9 (CγLeu), 22.8, 21.8 (2×CH3Leu), 14.1 (CH3lipid). MS (ESI): m/z 733.5 (M+H)+, 755.5 (M+Na)+. HR-
MS: calc. for [C35H64N4O8S2+H]+ 733.42383, found 733.42236. [α]D20= −55.6 (CHCl3, c= 0.5). 
N-(6-[(N-(N-4-(N-lauric acid)-aminobutyric acid))-S-tert-butylthio-L-cysteinyl]-aminomethyl-4,5-dideoxy-
α-D-glucuronopyranosyl)-L-leucine methyl ester. (2,6-trans 
10). Following GP 1a and 1b using 2,6-trans 6 (73 mg, 0.11 
mmol) and lauric acid (26.0 mg, 0.13 mmol) gave the title 
compound (Rf= 0.5, DCM/MeOH 9/1 v/v) in 64% yield. 1H-
NMR (600 MHz, CDCl3) δ 7.66 (m, 1H, NH), 7.27 (m, 1H, 
NH), 7.17 (d, 1H, NH, J= 8.1 Hz), 5.88 (m, 1H, NH), 4.96 (m, 1H, HαCys), 4.85−4.60 (m, 3H, HαLeu, CH2), 4.17 
(m, 1H, H6), 4.10 (d, 1H, H2, J= 8.2 Hz), 4.06 (m, CH2), 3.80 (m, 1H, H3), 3.75 (s, 3H, CH3O), 3.71–3.25 (m, 
H7, CH2), 3.32 (dd, HβCys, J= 6.5 Hz), 3.12 (m, HβCys), 2.31 (m, CH2), 2.13 (m, CH2), 1.91 (m, H4a, CH2), 1.77 (m, 
1H, H5a), 1.97−1.55 (m, HβγLeu, H4, H4,CH2), 1.40 (CH2), 1.33 (s, 9H, tBu), 1.25 (m, CH2), 0.95 (m, 6H, 
2×CH3Leu), 0.88 (t, 3H, CH3lipid, J= 6.8 and 7.1 Hz); 13C-NMR (150 MHz, CDCl3) δ 174.2, 173.6, 173.0, 172.4, 
170.5 (C=Oester&amide), 72.9, 71.9 (C2, C6), 70.7 (C3), 53.0, 52.3 (CαLeu, OCH3), 50.1 (CαCys), 48.3 (CqtBu), 42.8, 
42.8, 40.9, 39.6, 38.0, 36.9 (CβCys, CβLeu, CH2, C7), 32.5, 31.9 (CH2), 29.6 (tBu), 29.6 (CH2), 26.7, 26.6, 26.0, 
25.9 (C4, C5, CH2), 24.8 (CγLeu), 22.9, 21.6 (2×CH3Leu), 14.0 (CH3lipid). MS (ESI): m/z 761.7 (M+H)+, 783.5 
(M+Na)+. HR-MS: calc. for [C37H68N4O8S2+H]+ 761.45513, found 761.45355. [α]D20= −8 (CHCl3, c= 0.25). 
N-(6-[(N-(N-4-(N-lauric acid)-aminobutyric acid))-S-tert-butylthio-L-cysteinyl]-aminomethyl-4,5-dideoxy-
β-D-glucuronopyranosyl)-L-leucine methyl ester (2,6-cis 10). 
Following GP 1a and 1b using 2,6-cis 6 (55 mg, 0.08 mmol) 
and lauric acid (19.5 mg, 0.10 mmol) gave 2,6-cis 10 (Rf= 
0.50, DCM/MeOH 9/1 v/v) in 92% yield. 1H-NMR (600 






































































NH), 4.72–4.62 (m, 2H, HαCys, HαLeu), 3.76 (s, 3H, OMe), 3.61–3.46 (m, 5H, H2, H3, H6, H7a), 3.25 (m, 2H, 
CH2), 3.17 (m, 1H, H7b), 3.06 (m, 2H, HβCys), 2.27 (m, 2H, CH2), 2.17 (t, 2H, CH2, J= 7.7 and 7.2 Hz), 1.90 (m, 
2H, CH2), 1.82–1.39 (m, HβγLeu, CH2lipid, H45), 1.33 (s, 9H, tBu), 1.26 (m, CH2lipid), 0.88 (dd, 6H, 2×CH3Leu, J= 5.8 
and 5.6 Hz), 0.87 (t, 3H, CH3lipid, J= 6.7 and 7.2 Hz); 13C-NMR (50 MHz, CDCl3) δ 173.8, 173.6, 173.3, 172.1, 
170.9 (C=Oester&amide), 77.7 (C6), 76.7 (C2), 68.1 (C3), 52.8, 52.3 (OCH3, CαCys), 49.7 (CαLeu), 47.9 (CqtBu), 43.4 
(C7), 40.7, 40.6 (CβLeu, CβCys), 38.2, 36.5, 33.0, 31.6, 30.3 (CH2), 29.6 (tBu), 29.3, 29.1 (CH2lipid), 27.2, 25.8, 22.7 
(C45, CH2), 24.8 (CγLeu), 24.1, 21.7 (2×CH3Leu), 14.1 (CH3lipid). MS (ESI): m/z 761.8 (M+H)+, 783.6 (M+Na)+. 
HR-MS: calc. for [C37H68N4O8S2+H]+ 761.45513, found 761.45288. [α]D20= −59.2 (CHCl3, c= 0.25). 
N-(6-[(N-(N-(palmitic acid)-glycine))-S-tert-butylthio-L-cysteinyl]-aminomethyl-4,5-dideoxy-α-D-glucurono 
pyranosyl)-L-leucine methyl ester (2,6-trans 11). Following GP 
1a and 1b using 2,6-trans 5 (50 mg, 0.08 mmol) and palmitic 
acid (23.6 mg, 0.09 mmol) gave 2,6-trans 11 (Rf= 0.7, 
EtOAc/acetone 1/1 v/v) in 90% yield. 1H-NMR (400 MHz, 
CDCl3) δ 7.40 (d, 1H, NH, J= 8.2 Hz), 7.30 (m, 2H, 2×NH), 6.56 (t, 1H, NH, J= 5.0 Hz), 4.77 (dd, 1H, HαCys, J= 
5.8 and 6.0 Hz), 4.66 (m, 1H, HαLeu), 4.10 (m, 1H, H6), 4.06 (d, 1H, H2, J= 8.2 Hz), 3.92 (ddd, 2H, CH2Gly, J= 
5.0 and 5.4 Hz), 3.77 (m, 4H, H3, OCH3), 3.54 (m, 1H, H7a), 3.38 (m, 2H, H7b, HβCys), 3.09 (dd, 1H, HβCys, J= 
5.1 and 5.2 Hz), 2.36–2.22 (m, 2H, CH2lipid), 1.94 (m, 1H, H4a), 1.80 (m, 1H, H5a), 1.70−1.55 (m, 9H, HβγLeu, 
H4b, H5b, 2×CH2lipid), 1.33 (s, 9H, tBu), 1.39–1.15 (m, CH2lipid), 0.95 (t, 6H, 2×CH3Leu, J= 3.9), 0.88 (t, 3H, 
CH3lipid, J= 6.6 and 7.0 Hz); 13C-NMR (100 MHz, CDCl3) δ 174.6, 173.8, 172.2, 169.9 (C=Oester&amide), 73.0, 71.0 
(C2, C6), 67.5 (C3), 53.2, 52.6 (CαLeu, OCH3), 49.9 (CαCys), 48.5 (CqtBu), 43.7, 42.3, 41.0, 39.6 (CβCys, CβLeu, CH2Gly, 
C7), 36.1, 31.9 (2×CH2lipid), 29.6 (tBu), 29.6 (CH2lipid), 26.6, 25.5, 24.0, 22.6 (C4, C5, 2×CH2lipid), 24.1 (CγLeu), 
22.6, 21.6 (2×CH3Leu), 14.1 (CH3lipid). MS (ESI): m/z 789.5 (M+H)+, 811.6 (M+Na)+. HR-MS: calc. for 
[C37H72N4O8S2+H]+ 789.48643, found 789.48407. [α]D20= −17.6 (CHCl3, c= 0.5). 
N-(6-[(N-(N-(palmitic acid)-glycine))-S-tert-butylthio-L-cysteinyl]-aminomethyl-4,5-dideoxy-β-D-glucurono 
pyranosyl)-L-leucine methyl ester (2,6-cis 11). Following 
GP 1a and 1b using 2,6-cis 5 (63 mg, 0.10 mmol) and 
palmitic acid (29.8 mg, 0.12 mmol) gave 2,6-cis 11 (Rf= 0.8, 
EtOAc/acetone 1/1 v/v) in 98% yield. 1H-NMR (400 MHz, 
CDCl3) δ 7.77 (m, 1H, NH), 7.61 (d, 1H, NH, J= 7.8 Hz), 7.52 (d, 1H, NH, J= 8.7 Hz), 7.00 (m, 1H, NH), 4.66 
(m, 2H, HαCys, HαLeu), 3.90 (dd, 2H, CH2Gly), 3.76 (s, 3H, CH3O), 3.76–3.27 (m, 4H, H2, H3, H6, H7, HβCys), 3.09 
(dd, 1H, HβCys, J= 1.6, 1.9 and 6.4, 6.7 Hz), 2.27 (m, 2H, CH2lipid), 2.15 (m, 1H, H4a), 1.74–1.38 (m, 10H, HβLeu, 
HγLeu, H4b, H5, 2×CH2lipid), 1.32 (s, 9H, tBu), 1.32–1.15 (m, CH2lipid), 0.95 (m, 6H, 2×CH3Leu), 0.88 (t, 3H, 
CH3lipid, J= 6.6 and 7.0 Hz); 13C-NMR (100 MHz, CDCl3) δ 174.7, 173.9, 172.4, 170.3, 169.7 (C=Oester&amide), 
78.0, 76.7 (C2, C6), 68.3 (C3), 53.1, 52.5 (CαLeu, OCH3), 49.9 (CαCys), 48.2 (CqtBu), 43.7, 42.0, 41.6, 40.8 (CβCys, 
CβLeu, CH2Gly, C7), 36.1, 31.8 (2×CH2lipid), 29.6 (tBu), 29.6 (CH2lipid), 27.1, 25.5, 23.8, 21.6 (C4, C5, 2×CH2lipid), 
24.8 (CγLeu), 22.7, 21.6 (2×CH3Leu), 14.0 (CH3lipid). MS (ESI): m/z 789.5 (M+H)+, 811.6 (M+Na)+. HR-MS: calc. 
for [C37H72N4O8S2+H]+ 789.48643, found 789.48444. [α]D20= −55 (c= 0.5,CHCl3). 
N-(6-[(N-(N-(palmitic acid)-4-aminobutyric acid))-S-tert-butylthio-L-cysteinyl]-aminomethyl-4,5-dideoxy-
α-D-glucuronopyranosyl)-L-leucine methyl ester (2,6-trans 
12). Following GP 1a and 1b using 2,6-trans 6 (57 mg, 0.08 
mmol) and palmitic acid (26 mg, 0.1 mmol) gave 2,6 trans 
12 (Rf= 0.5, EtOAc/acetone 1/1 v/v) in 85% yield. 1H-NMR 
(600 MHz, CDCl3) δ 7.66 (m, 1H, NH), 7.29 (m, 1H, NH), 7.17 (d, 1H, NH, J= 7.9 Hz), 5.97 (m, 1H, NH), 
4.82 (m, 1H, HαCys), 4.67 (m, 1H, HαLeu), 4.16 (m, 1H, H6), 4.10 (d, 1H, H2, J= 8.0 Hz), 4.05 (m, CH2), 3.81 (m, 




















































CH2), 2.35 (m, CH2), 2.15 (m, CH2), 1.91 (m, H4a, CH2), 1.77 (m, 1H, H5a), 1.68−1.54 (m, HβγLeu,H4b, H5b, CH2), 
1.33 (s, 9H, tBu), 1.39–1.15 (m, CH2), 0.95 (t, 6H, 2×CH3Leu, J= 5.8 and 5.4 Hz), 0.88 (t, 3H, CH3lipid, J= 6.9 and 
7.1 Hz); 13C-NMR (150 MHz, CDCl3) δ 176.9, 174.2, 173.1, 172.3, 170.5 (C=Oester&amide), 73.0, 70.7 (C2, C6), 
67.4 (C3), 53.0, 52.4 (CαLeu, OCH3), 49.8 (CαCys), 48.3 (CqtBu), 42.7, 40.7, 39.6, 37.8 (CβCys, CβLeu, CH2, C7), 33.9, 
32.5, 31.8 (CH2), 29.6 (tBu), 29.6 (CH2), 26.5, 26.0, 25.8, 22.6, 21.6 (C4, C5, CH2), 24.8 (CγLeu), 22.8, 21.5 
(2×CH3Leu), 14.0 (CH3lipid). MS (ESI): m/z 817.8 (M+H)+, 839.6 (M+Na)+. HR-MS: calc. for [C41H76N4O8S2+H]+ 
817.51773, found 817.51459. [α]D20= −7.6 (CHCl3, c= 0.5). 
N-(6-[(N-(N-(palmitic acid)-4-aminobutyric acid))-S-tert-butylthio-L-cysteinyl]-aminomethyl-4,5-dideoxy-
β-D-glucuronopyranosyl)-L-leucine methyl ester (2,6-cis 12). 
Following GP 1a and 1b using 2,6-cis 6 (44 mg, 0.07 mmol) 
and palmitic acid (20 mg, 0.08 mmol) gave the title 
compound (Rf= 0.54, EtOAc/acetone 1/1 v/v) in 78% yield. 
1H-NMR (600 MHz, CDCl3) δ 7.34–7.39 (m, 3H, NH), 6.11 (m, 1H, NH), 4.70 (m, 1H, HαCys), 4.64 (m, 1H, 
HαLeu), 4.00 (m, CH2), 3.76 (s, 3H, CH3O), 3.50–3.57 (m, H2, H3, H6, CH2), 3.36–3.18 (m, H7, CH2), 3.06 (m, 
HβCys, CH2), 2.33–2.22 (m, CH2), 2.16 (m, CH2), 1.80 (m, CH2), 1.69 (m, HβγLeu, H4a, H5a, CH2), 1.33 (s, 9H, 
tBu), 1.50–1.32 (m, H4b, H5b, CH2), 1.25 (m, CH2), 0.95 (t, 6H, 2×CH3Leu, J= 5.4 and 5.5 Hz), 0.88 (t, 3H, 
CH3lipid, J= 6.8 and 7.1 Hz); 13C-NMR (150 MHz, CDCl3) δ 175.0, 174.6, 174.5, 173.2, 171.9 (C=Oester&amide), 
79.0, 77.7 (C2, C6), 69.2 (C3), 54.7, 53.3 (CαLeu, OCH3), 49.0 (CαCys), 48.3 (CqtBu), 44.5, 41.9, 41.8, 39.4, 37.6, 
34.1, 32.8, 31.5 (CβCys, CβLeu, CH2, C7), 29.6 (tBu), 30.0 (CH2), 28.1, 26.7, 26.6, 23.5 (C4, C5, CH2), 24.8 (CγLeu), 
22.8, 21.5 (2×CH3Leu), 14.0 (CH3lipid). MS (ESI): m/z 817.8 (M+H)+, 839.6 (M+Na)+. HR-MS: calc. for 
[C41H76N4O8S2+H]+ 817.51773, found 817.51849. [α]D20= −50.8 (CHCl3, c= 0.5). 
N-(6-[(N-(N-lauric acid))-S-tert-butylthio-L-cysteinyl]-aminomethyl-4,5-dideoxy-α-D-glucurono pyranosyl)-
L-leucine (2,6-trans 13). From 2,6-trans 7 (31 mg, 0.05 mmol) 
according to GP 2. Crude yield: 100%. 1H-NMR (400 MHz, 
methanol-d4) δ 4.54 (dd, 1H, J= 5.6 Hz, HαCys), 4.36 (m, 1H, HαLeu), 
4.10 (d, 1H, J= 3.6 Hz, H2), 4.02 (m, 1H, H3), 3.69 (m, 1H, H6), 3.26 
(m, 2H, H7), 3.06 (1H, HβCys), 2.88 (dd, 1H, J= 6.0 Hz, HβCys), 2.16 (m, 2H, CH2), 1.69-1.42 (m, CH2lipid, HβγLeu, 
H4&5), 1.30-1.10 (m, tBu, CH2lipid), 0.85 (t, 6H, J= 6.4 Hz, 2×CH3Leu), 0.79 (t, 3H, J= 6.8 Hz, CH3lipid); 13C-NMR 
(50 MHz, methanol-d4) δ 175.2-170.5 (C=Oamide&carboxyl), 73.8 (C6), 72.0 (C2), 66.7 (C3), 52.7, 50.2 (CαLeu, CαCys), 
48.1 (C7), 41.7 (CqtBu), 40.2, 36.2 (CβLeu, CβCys), 29.5 (tBu), 29.4 (CH2lipid), 25.4 (C4), 24.7 (CγLeu), 22.6 (CH3Leu), 
22.4 (C5), 21.3 (CH3Leu), 13.8 (CH3lipid). MS (ESI): m/z 684.6 (M+Na)+. HR-MS: calc. for [C32H59N3O7S2+H]+ 
662.3867, found 662.3922.  
N-(6-[(N-(N-lauric acid))-L-cysteinyl]-aminomethyl-4,5-dideoxy-α-D-glucuronopyranosyl)-L-leucine (2,6-
trans 19). From 2,6-trans 13 (7 mg, 11 µmol) according to GP 3. LC-MS analysis: Rt 16.3 min, m/z 574.5 
(M+H)+. Linear gradient of B (30→90%) in 26 min. 
N-(6-[(N-(N-lauric acid))-S-tert-butylthio-L-cysteinyl]-aminomethyl-4,5-dideoxy-β-D-glucuronopyranosyl)-L-
leucine (2,6-cis 13). From 2,6-cis 7 (55 mg, 0.08 mmol) according to 
GP 2. Crude yield: 100%. 1H-NMR (400 MHz, methanol-d4) δ 4.60 
(t, 1H, J= 6.8 and 7.2 Hz, HαCys), 4.24 (m, 1H, HαLeu), 3.52 (m, 3H, H2, 
H3, H7a), 3.35 (m, 1H, H6), 3.10 (m, 1H, H7b), 3.00 (dd, 1H, J= 6.0 Hz, 
HβCys), 2.84 (dd, 1H, J= 6.0 Hz, HβCys), 2.14 (m, 2H, CH2), 2.00 (m, 1H, H4a), 1.69-1.42 (m, CH2lipid, HβγLeu, H4b, 
H5), 1.30-1.10 (m, tBu, CH2lipid), 0.83 (bs, 6H, 2×CH3Leu), 0.76 (t, 3H, J= 6.4 and 6.8 Hz, CH3lipid). 13C-NMR (50 
MHz, methanol-d4) δ 176.0-172.5 (C=Oamide&carboxyl), 80.8 (C6), 77.6 (C2), 69.2 (C3), 54.0, 51.3 (CαLeu, CαCys), 

















































21.7 (2×CH3Leu), 14.2 (CH3lipid). MS (ESI): m/z 662.3 (M+H)+, 684.6 (M+Na)+. HR-MS: calc. for 
[C32H59N3O7S2+H]+ 662.3867, found 662.3909. 
N-(6-[(N-(N-lauric acid))- L-cysteinyl]-aminomethyl-4,5-dideoxy-β-D-glucuronopyranosyl)-L-leucine (2,6-
cis 19). From 2,6-cis 13 (12 mg, 18 µmol) according to GP 3. LC-MS analysis: Rt 4.8 min, m/z 574.5 (M+H)+. 
Linear gradient of B (10→90%) in 26 min. 
N-(6-[(N-(N-palmitic acid))-S-tert-butylthio-L-cysteinyl]-aminomethyl-4,5-dideoxy-α-D-glucurono pyranosyl)-
L-leucine (2,6-trans 14). From 2,6-trans 8 (98 mg, 0.13 mmol) according to GP 2. Crude yield: 100%. 1H-
NMR (400 MHz, methanol-d4) δ 4.50 (dd, 1H, J= 5.6 Hz, HαCys), 4.40 
(m, 1H, HαLeu), 4.06 (d, 1H, J= 3.6 Hz, H2), 4.01 (m, 1H, H3), 3.68 (m, 
1H, H6), 3.25 (m, 2H, H7), 3.14 (dd, 1H, HβCys, J= 5.6 Hz), 2.85 (m, 1H, 
HβCys), 2.15 (m, 2H, CH2), 1.68-1.29 (m, CH2lipid, HβγLeu, H4&5), 1.22-
1.17 (m, tBu, CH2lipid), 0.86-0.77 (m, 9H, 2×CH3Leu), 0.88 (m, 3H, 
CH3lipid); 13C-NMR (50 MHz, methanol-d4) δ 176.0-172.3 (C=Oamide&carboxyl), 78.1 (C6), 72.8 (C2), 65.8 (C3), 
54.0, 51.5 (CαLeu, CαCys), 43.5 (C7), 43.3 (CqtBu), 41.4, 36.9 (CβLeu, CβCys), 30.6 (CH2lipid), 30.2 (tBu), 26.7 (C4), 
26.1 (CγLeu), 23.7 (C5), 23.5, 21.8 (2×CH3Leu), 14.4 (CH3lipid). LC-MS analysis: Rt 24.4 min, m/z 718.6 (M+H)+. 
Linear gradient of B (10→95%) in 26 min. HR-MS: calc. for [C36H67N3O7S2+H]+ 718.4493, found 718.4442. 
N-(6-[(N-(N-palmitic acid))-L-cysteinyl]-aminomethyl-4,5-dideoxy-α-D-glucuronopyranosyl)-L-leucine (2,6-
trans 20). From 2,6-trans 14 (25 mg, 35 µmol) according to GP 3. LC-MS analysis: Rt 7.0 min, m/z 630.6 
(M+H)+. Linear gradient of B (10→90%) in 26 min.  
N-(6-[(N-(N-palmitic acid))-S-tert-butylthio-L-cysteinyl]-aminomethyl-4,5-dideoxy-β-D-glucurono pyranosyl)-
L-leucine (2,6-cis 14). From 2,6-cis 8 (79 mg, 0.11 mmol) according 
to GP 2. Crude yield: 100%. 1H-NMR (400 MHz, methanol-d4) δ 
4.53 (dd, 1H, J= 6.0 and 6.4 Hz, HαCys), 4.44 (t, 1H, J= 6.4 and 7.6 Hz, 
HαLeu), 3.51 (d, 1H, J= 9.6 Hz, H2), 3.43-3.36 (m, 2H, H3, H7a), 3.27 
(dd, 1H, J= 3.0 and 3.6 Hz, H6), 3.17 (m, 1H, H7b), 3.14 (dd, 1H, J= 6.0 Hz, HβCys), 2.85 (dd, 1H, J= 8.0 and 9.2 
Hz, HβCys), 2.15 (m, 2H, CH2), 2.00 (m, 1H, H4a), 1.64−1.60 (m, 4H, HβγLeu, H5a), 1.50−1.27 (m, CH2lipid, H4b&5b), 
1.27−1.17 (m, tBu, CH2lipid), 0.85−0.77 (dd, 6H, J= 6.0 Hz, 2×CH3Leu), 0.79 (t, 3H, J= 6.4 Hz, CH3lipid); 13C-
NMR (50 MHz, methanol-d4) δ 176−170 (C=Oamide&carboxyl), 80.8 (C6), 77.6 (C2), 69.2 (C3), 54.0, 51.4 (CαLeu, 
CαCys), 44.1 (C7), 42.8 (CqtBu), 41.5, 36.7 (CβLeu, CβCys), 30.5 (CH2lipid), 30.0 (tBu), 28.1 (C4), 26.7 (C5), 25.9 
(CγLeu), 23.1, 21.7 (2×CH3Leu), 14 (CH3lipid). LC-MS analysis: Rt 23.6 min, m/z 718.6 (M+H)+. Linear gradient of 
B (10→90%) in 26 min. HR-MS: calc. for [C36H67N3O7S2+H]+ 718.4493, found 718.4420. 
N-(6-[(N-(N-palmitic acid))-L-cysteinyl]-aminomethyl-4,5-dideoxy-β-D-glucuronopyranosyl)-L-leucine (2,6-cis 
20). From 2,6-cis 14 (8 mg, 11 µmol) according to GP 3. LC-MS analysis: Rt 7.0 min, m/z 630.7 (M+H)+. 
Linear gradient of B (10→90%) in 26 min. 
N-(6-[(N-(N-(lauric acid)-glycine))-S-tert-butylthio-L-cysteinyl]-aminomethyl-4,5-dideoxy-α-D-glucurono 
pyranosyl)-L-leucine (2,6-trans 15). From 2,6-trans 9 (20 mg, 
0.03 mmol) following GP 2. Crude yield: 100%. 1H-NMR 
(400 MHz, methanol-d4) δ 4.51 (dd, 1H, J= 5.2 and 5.6 Hz, 
HαCys), 4.40 (dd, 1H, J= 4.0 and 4.4 Hz, HαLeu), 4.10 (d, 1H, J= 
3.6 Hz, H2), 4.03 (m, 1H, H3), 3.77 (s, 2H, HαGly), 3.71 (m, 1H, 
H6), 3.25 (bt, 2H, J= 5.2 and 5.6 Hz, H7), 3.11 (dd, 1H, J= 5.2 Hz, HβCys), 2.94 (dd, 1H, J= 8.4 Hz, HβCys), 2.17 
(t, 2H, CH2, J= 7.2 and 8.0 Hz), 1.68-1.29 (m, CH2lipid, HβγLeu, H4&5), 1.28-1.15 (m, tBu, CH2lipid), 0.85 (dd, 6H, 
2×CH3Leu, J= 5.6 and 6.0 Hz), 0.80 (t, 3H, J= 7.2 and 7.6 Hz, CH3lipid); 13C-NMR (50 MHz, methanol-d4) δ 
172.4-171.4 (C=Oamide&carboxyl), 78.2 (C6), 72.7 (C2), 65.7 (C3), 54.3, 51.4 (CαLeu, CαCys), 43.6 (C7), 42.8 (CqtBu), 















































(2×CH3Leu), 14.4 (CH3lipid). LC-MS analysis: Rt 19.9 min, m/z 719.5 (M+H)+. Linear gradient of B (05→95%) 
in 26 min. HR-MS: calc. for [C34H62N4O8S2+H]+ 719.4081, found 719.4051.  
N-(6-[(N-(N-(lauric acid)-glycine))-L-cysteinyl]-aminomethyl-4,5-dideoxy-α-D-glucuronopyranosyl)-L-leucine 
(2,6-trans 21). From 2,6-trans 15 (20 mg, 28 µmol) according to GP 3. LC-MS analysis: Rt 4.3 min, m/z 631.7 
(M+H)+. Linear gradient of B (00→90%) in 26 min. 
N-(6-[(N-(N-(lauric acid)-glycine))-S-tert-butylthio-L-cysteinyl]-aminomethyl-4,5-dideoxy-β-D-glucurono 
pyranosyl)-L-leucine (2,6-cis 15). From 2,6-cis 9 (44 mg, 0.07 
mmol) following GP 2. Crude yield: 100%. 1H-NMR (400 
MHz, methanol-d4) δ 4.59 (t, 1H, J= 6.4 and 7.2 Hz, HαCys), 
4.27 (dd, 1H, J= 4.0 Hz, HαLeu), 3.77 (dd, 2H, J= 16.4 Hz, 
HαGly), 3.52 (d, 1H, J= 9.6 Hz, H2), 3.47 (m, 2H, H6, H7a), 3.37 
(m, 1H, H4), 3.07 (m, 2H, H7b, HβCys), 2.94 (dd, 1H, J= 7.6 and 8.0 Hz, HβCys), 2.18 (t, 2H, J= 7.6 Hz, CH2lipid), 
2.02 (m, 1H, H4a), 1.61-1.40 (m, 8H, HβγLeu, H5ab, CH2lipid, H4b), 1.25-1.19 (m, tBu, CH2lipid), 0.87 (d, 6H, J= 6.0 
Hz, 2×CH3Leu), 0.80 (t, 3H, J= 6.8 and 7.2 Hz, CH3lipid); 13C-NMR (50 MHz, methanol-d4) δ 175.3-170.1 
(C=O), 78.0 (C6), 76.7 (C2), 68.3 (C3), 53.4, 50.1 (CαLeu, CαCys), 48.4 (C7), 43.9 (CqtBu), 43.3, 41.5 (CβLeu, CβCys), 
36.2 (CαGly), 30.9 (tBu), 29.8 (CH2lipid), 25.6 (C4), 24.9 (CγLeu), 22.8 (CH3Leu), 22.6 (C5), 21.8 (CH3Leu), 14.1 
(CH3lipid). MS (ESI): m/z 719.4 (M+H)+. HR-MS: calc. for [C34H62N4O8S2+H]+ 719.4081, found 719.4105. 
N-(6-[(N-(N-(lauric acid)-glycine))-L-cysteinyl]-aminomethyl-4,5-dideoxy-β-D-glucuronopyranosyl)-L-leucine 
(2,6-cis 21). From 2,6-cis 15 (12 mg, 17 µmol) according to GP 3. LC-MS analysis: Rt 8.7 min, m/z 631.7 
(M+H)+. Linear gradient of B (60→90%) in 26 min.  
N-(6-[(N-(N-(lauric acid)-4-aminobutyric acid))-S-tert-butylthio-L-cysteinyl]-aminomethyl-4,5-dideoxy-α-
D-glucuronopyranosyl)-L-leucine (2,6-trans 16). From 2,6-
trans 10 (29 mg, 0.04 mmol) according to GP 2. Crude yield: 
100%. 1H-NMR (400 MHz, methanol-d4) δ 4.82 (dd, 1H, J= 
7.6 Hz, HαCys), 4.28 (m, 1H, HαLeu), 4.14 (m, 2H, H2&3), 3.73 
(m, 1H, H6), 3.44 (m, 1H, H7a), 3.29-3.13 (m, 4H, CH2lipid, H7a, HβCys), 3.00 (dd, 1H, J= 7.6 and 8.0 Hz, HβCys), 
2.30, 2.16 (2×m, 4H, 2×CH2), 1.82-1.50 (m, CH2lipid, HβγLeu, H4, H5), 1.35-1.20 (m, tBu, CH2lipid), 0.85 (m, 9H, 
2×CH3Leu, CH3lipid); 13C-NMR (50 MHz, methanol-d4) δ 176.2-171.8 (C=Oamide&carboxyl), 78.6 (C6), 73.7 (C2), 
65.5 (C3), 53.9, 53.6 (CαLeu, CαCys), 44.5 (C7), 43.8 (CqtBu), 43.5, 39.4 (CβLeu, CβCys), 37.0, 33.3, 32.8 (CH2), 30.5 
(tBu), 30.2 (CH2lipid), 27.6 (C4), 26.8 (C5), 26.1 (CγLeu), 23.4, 22.2 (2×CH3Leu), 14 (CH3lipid). LC-MS analysis: Rt 
24.6 min, m/z 747.5 (M+H)+. Linear gradient of B (00→95%) in 26 min. HR-MS: calc. for [C36H66N4O8S2+H]+ 
747.4394, found 747.4446. 
N-(6-[(N-(N-(lauric acid)-4-aminobutyric acid))-L-cysteinyl]-aminomethyl-4,5-dideoxy-α-D-glucurono 
pyranosyl)-L-leucine (2,6-trans 22). From 2,6-trans 16 (8 mg, 11 µmol) according to GP 3. LC-MS analysis: 
Rt 4.6 min, m/z 659.6 (M+H)+. Linear gradient of B (10→90%) in 26 min. 
N-(6-[(N-(N-(lauric acid)-4-aminobutyric acid))-S-tert-butylthio-L-cysteinyl]-aminomethyl-4,5-dideoxy-β-
D-glucuronopyranosyl)-L-leucine (2,6-cis 16). From 2,6-cis 
10 (40 mg, 0.06 mmol) according to GP 2. Crude yield: 100%. 
1H-NMR (400 MHz, methanol-d4) δ 4.61 (t, 1H, J= 6.8 and 
7.2 Hz, HαCys), 4.43 (dd, 1H, J= 3.6 Hz, HαLeu), 3.52 (d, 1H, J= 
9.2 Hz, H2), 3.46 (m, 2H, H3, H7a), 3.36 (m, 1H, H6), 3.20-3.02 (m, 4H, CH2lipid, H7b, HβCys), 2.90 (dd, 1H, J= 4.8 
and 5.2 Hz, HβCys), 2.20 (t, 2H, J= 7.2 CH2), 2.08 (t, 2H, J= 7.6 Hz, CH2), 2.02 (m, 1H, H4a), 1.70 (m, 2H, 
CH2lipid), 1.64-1.60 (m, HβγLeu, H5a), 1.52-1.30 (m, CH2lipid, H4b&5b), 1.30-1.10 (m, tBu, CH2lipid), 0.87 (m, 6H, 
2×CH3Leu), 0.80 (t, 3H, J= 7.2 Hz, CH3lipid); 13C-NMR (50 MHz, methanol-d4) δ 174.9-170.6 (C=Oamide&carboxyl), 






















































38.8, 36.4 (3×CH2), 29.3 (tBu), 29.1 (CH2lipid), 25.5 (C4), 24.7 (CγLeu), 22.6 (CH3Leu), 22.4 (C5), 21.6 (CH3Leu), 
13.8 (CH3lipid). LC-MS analysis: Rt 25.0 min, m/z 747.5 (M+H)+. Linear gradient of B (10→90%) in 26 min. 
HR-MS: calc. for [C36H66N4O8S2+H]+ 747.4394 (M+H)+, found 747.4411. 
N-(6-[(N-(N-(lauric acid)-4-aminobutyric acid))-L-cysteinyl]-aminomethyl-4,5-dideoxy-β-D-glucurono 
pyranosyl)-L-leucine (2,6-cis 22). From 2,6-cis 16 (20 mg, 27 µmol) according to GP 3. LC-MS analysis: Rt 
4.7 min, m/z 659.6 (M+H)+. Linear gradient of B (10→90%) in 26 min. 
N-(6-[(N-(N-(palmitic acid)-glycine))-S-tert-butylthio-L-cysteinyl]-aminomethyl-4,5-dideoxy-α-D-glucurono 
pyranosyl)-L-leucine (2,6-trans 17). From 2,6-trans 11 (74 
mg, 0.09 mmol) according to GP 2. Crude yield: 100%. 1H-
NMR (400 MHz, methanol-d4) δ 4.50 (dd, 1H, J= 6.4 Hz, 
HαCys), 4.40 (dd, 1H, J= 4.0 and 4.4 Hz, HαLeu), 4.10 (d, 1H, J= 
3.6 Hz, H2), 4.01 (m, 1H, H3), 3.75 (s, 2H, HαGly), 3.70 (m, 1H, H6), 3.25 (m, 2H, H7), 3.10 (dd, 1H, J= 5.2 Hz, 
HβCys), 2.94 (dd, 1H, HβCys, J= 1.2 Hz), 2.16 (t, 2H, CH2, J= 7.2 and 8.0 Hz), 1.68-1.29 (m, CH2lipid HβγLeu, H4&5), 
1.26-1.10 (m, tBu, CH2lipid), 0.85 (dd, 6H, 2×CH3Leu, J= 5.6 and 6.0 Hz), 0.79 (t, 3H, CH3lipid, J= 6.8 Hz); 13C-
NMR (50 MHz, methanol-d4) δ 176.8-171.4 (C=Oamide&carboxyl), 78.3 (C6), 72.7 (C2), 65.7 (C3), 54.3, 51.4 (CαLeu, 
CαCys), 43.6 (C7), 42.7 (CqtBu), 41.2, 36.6 (CβLeu, CβCys), 32.8 (CαGly), 30.5 (CH2lipid), 30.0 (tBu), 26.6 (C4), 25.9 
(CγLeu), 23.6 (C5), 23.3, 21.5 (2×CH3Leu), 14.2 (CH3lipid). MS (ESI): m/z 775.5 (M+H)+, 797.4 (M+Na)+. HR-MS: 
calc. for [C38H70N4O8S2+H]+ 775.4707, found 775.4756. 
N-(6-[(N-(N-(palmitic acid)-glycine))-S-tert-butylthio-L-cysteinyl]-aminomethyl-4,5-dideoxy-α-D-glucurono 
yranosyl)-L-leucine (2,6-trans 23). From 2,6-trans 17 (19 mg, 28 µmol) according to GP 3. LC-MS analysis: 
Rt 8.6 min, m/z 687.6 (M+H)+. Linear gradient of B (80→90%) in 26 min. 
N-(6-[(N-(N-(palmitic acid)-glycine))-S-tert-butylthio-L-cysteinyl]-aminomethyl-4,5-dideoxy-β-D-glucurono 
pyranosyl)-L-leucine (2,6-cis 17). From 2,6-cis 11 (48 mg, 0.06 
mmol) according to GP 2. Crude yield: 100%. 1H-NMR (400 
MHz, methanol-d4) δ 4.55 (dd, 1H, J= 6.0 Hz, HαCys), 4.47 (dd, 
1H, J= 6.8 and 7.6 Hz, HαLeu), 3.76 (s, 2H, HαGly), 3.53 (d, 1H, 
J= 9.2 Hz, H2), 3.40 (m, 2H, H3, H7a), 3.29 (dd, 1H, J= 3.2 Hz, H6), 3.18 (1H, H7b), 3.09 (dd, 1H, J= 5.6 and 6.0 
Hz, HβCys), 2.92 (dd, 1H, J= 7.6 and 8.0 Hz, HβCys), 2.15 (t, 2H, J= 7.2 and 7.6 Hz, CH2), 2.01 (m, 1H, H4a), 
1.64-1.60 (m, 4H, HβγLeu, H5a), 1.50-1.27 (m, CH2lipid, H4b&5b), 1.25-1.19 (m, tBu, CH2lipid), 0.87 (dd, 6H, J= 6.0 
Hz, 2×CH3Leu), 0.80 (t, 3H, J= 7.2 Hz, CH3lipid); 13C-NMR (50 MHz, methanol-d4) δ 176-170 (C=Oamide&carboxyl), 
80.6 (C6), 77.6 (C2), 69.3 (C3), 54.2, 51.2 (CαLeu, CαCys), 44.3 (C7), 43.5 (CqtBu), 42.6, 41.4 (CβLeu, CβCys), 36.6 
(CαGly), 30.5 (CH2lipid), 30.0 (tBu), 26.5 (C4), 25.8 (CγLeu), 23.5 (C5), 23.2, 21.7 (2×CH3Leu), 15.2 (CH3lipid). MS 
(ESI): m/z 775.6 (M+H)+, 797.4 (M+Na)+. HR-MS: calc. for [C38H70N4O8S2+H]+ 775.4707, found 775.4690. 
N-(6-[(N-(N-(palmitic acid)-glycine))-S-tert-butylthio-L-cysteinyl]-aminomethyl-4,5-dideoxy-β-D-glucurono 
pyranosyl)-L-leucine (2,6-cis 23). From 2,6-cis 17 (10 mg, 15 µmol) according to GP 3. LC-MS analysis: Rt 
6.8 min, m/z 687.6 (M+H)+. Linear gradient of B (10→90%) in 26 min. 
N-(6-[(N-(N-4-(palmitic acid)-aminobutyric acid))-S-tert-butylthio-L-cysteinyl]-aminomethyl-4,5-dideoxy 
-α-D-glucuronopyranosyl)-L-leucine (2,6-trans 18). From 
2,6-trans 12 (58 mg, 0.07 mmol) following GP 2. Crude yield: 
100%. 1H-NMR (400 MHz, methanol-d4) δ 4.50 (dd, 1H, J= 
5.2 Hz, HαCys), 4.40 (m, 1H, HαLeu), 4.11 (d, 1H, J= 3.6 Hz, H2), 
4.03 (m, 1H, H3), 3.72 (m, 1H, H6), 3.26 (m, 2H, H7), 3.12-
3.06 (m, 3H, CH2lipid, HβCys), 2.92 (dd, 1H, J= 6.0 Hz, HβCys), 2.16, 2.06 (2×t, 4H, J= 7.2 and 7.6 Hz, 2×CH2), 
1.73-1.42 (m, CH2lipid, HβγLeu, H4, H5), 1.30-1.10 (m, tBu, CH2lipid), 0.85 (dd, 6H, J= 5.6 and 6.0 Hz, 2×CH3Leu), 




















































72.7 (C2), 65.7 (C3), 54.2, 51.4 (CαLeu, CαCys), 43.5 (C7), 43.0 (CqtBu), 41.1, 39.3 (CβLeu, CβCys), 37.0, 33.7, 32.8 
(CH2), 30.5 (CH2lipid), 30.0 (tBu), 26.4 (C4), 26.0 (CγLeu), 23.6 (C5), 23.3, 21.5 (2×CH3Leu), 14.2 (CH3lipid). MS 
(ESI): m/z 803.5 (M+H)+. HR-MS: calc. for [C40H74N4O8S2+H]+ 803.5020 (M+H)+, found 803.4991. 
N-(6-[(N-(N-4-(palmitic acid)-aminobutyric acid))-L-cysteinyl]-aminomethyl-4,5-dideoxy-α-D-glucurono 
pyranosyl)-L-leucine (2,6-trans 24). From 2,6-trans 18 (17 mg, 21 µmol) according to GP 3. LC-MS analysis: 
Rt 6.6 min, m/z 715.5 (M+H)+. Linear gradient of B (10→95%) in 26 min. 
N-(6-[(N-(N-4-(palmitic acid)-aminobutyric acid))-S-tert-butylthio-L-cysteinyl]-aminomethyl-4,5-dideoxy 
-β-D-glucuronopyranosyl)-L-leucine (2,6-cis 18). From 2,6-
cis 12 (44 mg, 0.05 mmol) according to GP 2. Crude yield: 
100%. 1H-NMR (400 MHz, methanol-d4) δ 4.54 (dd, 1H, J= 
6.0 Hz, HαCys), 4.43 (t, 1H, J= 6.8 and 7.2 Hz, HαLeu), 3.50 (d, 
1H, J= 9.2 Hz, H2), 3.42 (m, 2H, H3, H7a), 3.29 (dd, 1H, J= 3.2 and 3.6 Hz, H6), 3.18 (1H, H7b), 3.12-3.02 (m, 
2H, CH2lipid), 3.09 (dd, 1H, J= 8.0 Hz, HβCys), 2.92 (dd, 1H, J= 7.6 and 8.0 Hz, HβCys), 2.18 (t, 2H, J= 7.2 and 7.6 
Hz, CH2), 2.08 (t, 2H, J= 7.2 and 8.0 Hz, CH2), 2.01 (m, 1H, H4a), 1.70 (m, 2H, CH2lipid), 1.64-1.60 (m, HβγLeu, 
H5a), 1.52-1.30 (m, CH2lipid, H4b&5b), 1.25-1.19 (m, tBu, CH2lipid), 0.87 (dd, 6H, J= 5.2 and 5.6 Hz, 2×CH3Leu), 
0.80 (t, 3H, J= 6.4 and 7.2 Hz, CH3lipid); 13C-NMR (50 MHz, methanol-d4) δ 176.0-172.5 (C=Oamide&carboxyl), 
80.7 (C6), 77.6 (C2), 69.3 (C3), 54.2, 51.6 (CαLeu, CαCys), 44.2 (C7), 42.8 (CqtBu), 42.3, 41.6 (CβLeu, CβCys), 39.4, 
36.9, 33.8 (3×CH2), 30.5 (CH2lipid), 30.0 (tBu), 26.4 (C4), 25.9 (CγLeu), 23.5 (C5), 23.2, 21.2 (2×CH3Leu), 14.4 
(CH3lipid). LC-MS analysis: Rt 23.1 min, m/z 803.5 (M+H)+. Linear gradient of B (10→90%) in 26 min. HR-
MS: calc. for [C40H74N4O8S2+H]+ 803.5020, found 803.5039 (M+H)+.  
N-(6-[(N-(N-4-(palmitic acid)-aminobutyric acid))-S-tert-butylthio-L-cysteinyl]-aminomethyl-4,5-dideoxy 
-β-D-glucuronopyranosyl)-L-leucine (2,6-cis 24). From 2,6-cis 18 (11 mg, 14 µmol) according to GP 3. LC-
MS analysis: Rt 7.0 min, m/z 715.6 (M+H)+. Linear gradient of B (70→90%) in 26 min.  
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Tetrazole as Carboxyl Bioisostere in the Development of Ca1a2X 




Abstract. A suitably protected tetrazole analog of methionine (10) was synthesised and subsequently used to 
evaluate whether the tetrazole moiety can be used as a carboxyl isostere in the Ca1a2X based approach 
toward PFT inhibitors as presented in Chapter 3. Biological evaluation of the tetrazole analogs of reference 
compound CVIM (15) and the previously presented PFT inhibitor 1 (19) shows that both selectivity and 
significant inhibitory potency against PFT are preserved, indicating that the tetrazole is a suitable 
















 5.1 Introduction 
A well established approach (see Chapter 1) toward the development of inhibitors 
of the prenylating enzymes PFT and PGGT-1 entails the development of analogs of the 
tetrapeptide sequence Ca1a2X (Figure 5.1, C= cysteine, a1= any (aliphatic) amino acid, a2= 
any aliphatic amino acid (e.g. Val, Ile), X= Leu for PGGT-1 inhibitors and X= Met (or Ser) 
for PFT inhibitors. A new type of inhibitors based on the replacement of the central two 
amino acids by a sugar amino acid (SAA) is described in Chapters 2 and 3. Compound 1 
(figure 5.1), having a 2,6-cis arrangement of the SAA part and a benzyl ether substituent 
on C3, was found to be a highly selective (PGGT-1: IC50 > 1000 μM) and potent inhibitor 
of PFT (IC50= 250 ± 20 nM). The leucine derivative of 1 is compound 2 and this Ca1a2X 
mimic was found to inhibit PFT with an IC50 value of 57 ± 18 μM and PGGT-1 with an 
IC50 value of 14 ± 6 μM.  
 
Figure 5.1 Isosteric replacement of the carboxyl group by a tetrazole (3↔4) in Ca1a2X mimics 1 and 2. 
 
Besides the substitution of the a1a2 part in the Ca1a2X sequence, several research 
groups have investigated whether the C or X residues can be modified. As the side chain 
of the X-residue is an important structural recognition element attaining both inhibitory 
action and selectivity between PFT and PGGT-1, the application of a suitable carboxylic 
acid isostere was considered. Based on this, the resemblance of the tetrazole group (3↔4 , 
Figure 5.1) with the carboxylic acid functionality in terms of acidity, planarity, 









































































































al.2 have demonstrated that the use of a tetrazole as a carboxyl isostere has a beneficial 
effect on the potency of their type of PFT inhibitors. In this chapter the synthesis and 
biological evaluation of Ca1a2X analogs 15 and 19 (Scheme 5.3 and 5.4, respectively) is 
described. 
 
 5.2 Results and Discussion 
5.2.1 Synthesis − First, the synthesis of the appropriate tetrazole analogs of 
methionine and leucine (Scheme 5.1) was investigated. For this purpose, the method of 
Duncia et al.3 was employed, as the thus synthesised tetrazoles are protected at the N1 
position (Figure 5.1) with the base labile propionitrile group. 
Boc-Leu-OH (5) and Boc-Met-OH (6) were converted into the corresponding 
cyanoethyl amides (6 and 9, respectively) in good yield. Treatment of 9 with PPh3, 
TMSN3 and DIAD and ensuing removal of the Boc group afforded tetrazole compound 10 
(TFA salt) in >99% from 9. Unfortunately, conversion of 6 into 7 failed under several 
conditions (elevated temperature, various amounts of reagents). The sensitivity of the 
tetrazole formation to steric hindrance in combination with the bulky leucine side chain4 
probably prevents formation of the tetrazole ring (Scheme 5.2).5 
 















aReagents and conditions. (i) fumarate•H2NCH2CH2C≡N, EDC, HOBt, DMF/DCM (5: 73%; 9: 67%); (ii) 





Scheme 5.2 Proposed mechanism of tetrazole formation from an amide with N3– and species V. 
 
CVIM-1H-tetrazole (15, Scheme 5.3) was synthesised by Boc chemistry as follows. 
Thus, amino tetrazole 10 was condensed with Boc-Val-OH (BOP, HOBt) affording dimer 
11 in 61% yield. Treatment of 11 with TFA and subsequent coupling with Boc-Ile-OH 
furnished trimer 12 in 54% over 2 steps. Following the same procedure, Boc-Cys(Tr)-OH 
was incorporated leading to the fully protected tetramer 13 (70% from 12). Treatment of 
13 with excess DBU (7 equiv.) led to removal of the propionitrile group (yield 95%) and 
finally deprotection of the cysteine residue (TFA, DCM and R3SiH) afforded CVIM analog 
15 (Scheme 5.3) which after purification by RP-HPLC (purity ≥95%) was isolated in 28% 
overall yield starting from 13. 
Although both the propionitrile group and Fmoc group can be removed by base 
mediated β-elimination, the Fmoc group is much more labile.6 This offered the 
opportunity to explore the use of Fmoc protected SAA 16b in the synthesis of target 
molecule 19 (Scheme 5.4). SAA 16b was readily obtained from the corresponding Boc 
derivative 16a of which the synthesis is presented in Chapter 3. Coupling of 10 and 16b 
gave dimer 17 in 71% yield. Selective removal of the Fmoc group in 17 with 1.0 equiv. 
DBU in DCM was complete after 30 min (TLC analysis). Subsequent addition of HOBt 
(2.0 equiv.) and coupling of the released amine with Fmoc-Cys(StBu)-OH gave fully 
protected 18 in a two-step one-pot procedure. After purification by silica gel 
chromatography compound 18 was isolated in 83% yield from 17. Treatment of 18 with 
excess DBU caused deprotection of the tetrazole and cysteine residue to furnish 19, which 



































































































Scheme 5.3 Synthesis of CVIM analog 15.a 
 
 
aReagents and conditions. (i) Boc-Ile-OH, BOP, HOBt, DIPEA, DMF (11: 61%); (ii) TFA, DCM, iPr3SiH 
or Et3SiH; (iii) Boc-Val-OH, BOP, HOBt, DIPEA, DMF (12: 54%, 2 steps); (iv) Boc-Cys(Tr)-OH, BOP, 
HOBt, DIPEA, DMF (13: 70%, 2 steps); (v) 7 equiv. DBU, DCM; (vi) RP-HPLC (15: 28% from 13).  
 

















aReagents and conditions. (i) (a) TFA, DCM, iPr3SiH (b) FmocOSu, NaHCO3, H2O (16b: 92%, 2 steps); 
(ii) 10, HCTU, DIPEA, DMF (17: 71%); (iii) (a) DBU (1.0 equiv.), DCM (b) HOBt (c) Fmoc-Cys(StBu)-OH, 


















































































5.2.2 Biological Evaluation − Compounds 15 and 19 were evaluated for their in vitro 
inhibitory activity against pure PFT and PGGT-1.7 The tetrapeptide CVIM8 was evaluated 
as a reference. The StBu protective group is cleaved under the conditions of the assay 














Figure 5.2 Results biological evaluation of 15, 19 and CVIM against PFT. aActivity of PFT at a certain 
concentration of compound: expressed as % of control activity (i.e. without test compound). 
 
In line with their carboxylic analogs (Chapter 3), compounds 15 and 19 did not 
show any inhibitory potency against PGGT-1. The inhibitory action of 15 and 19 toward 
PFT was slightly reduced in comparison with their carboxylic counterparts.  
 
 5.3 Conclusions 
This chapter describes the concise synthesis of Ca1a2X analogs 15 and 19. Their 
biological evaluation shows that tetrazole can be incorporated as a suitable carboxylic acid 
isostere in the SAA based development of PFT inhibitors. Unfortunately, as the targeted 
tetrazole analog of leucine (7) could not be synthesised according to the method 
employed in this chapter, it is uncertain whether Ca1a2X analogs targeted at inhibiting 
PGGT-1 can be provided with this carboxylic acid isostere (see Chapter 8).  
 
        c inhibitor (μM) 























 5.4 Experimental Section 
5.4.1 General - 1H NMR and 13C NMR spectra were recorded with a Bruker AC-200 (200, 50.1 MHz), a 
Bruker DPX-300 (1H: 300, 13C: 75 MHz), a Bruker Avance-400 (1H: 400, 13C: 100 MHz) or a Bruker DMX-
600 (1H: 600, 13C: 150 MHz). Chemical shifts are given in ppm (δ) relative to tetramethylsilane as internal 
standard. Mass spectra were recorded with a Perkin Elmer/SCIEX API 165 mass instrument and HR-MS 
spectra were recorded with an API QSTARtm Pulsar (Applied Biosystems). Eluents were of technical grade 
and distilled before use. DMF (Biosolve p.a.), DCM (Biosolve p.a.) and toluene (Biosolve p.a.) were stored 
over molecular sieves (4Å). EtOAc and PE (40-60) were of technical grade and distilled before use. MeOH 
(Biosolve), HCl (Acros), DIC (Fluka), iPr3SiH (Aldrich), EDC (Aldrich), TFA (Biosolve), Boc-Leucine 
(Novabiochem), Boc-Methionine (Novabiochem), 3-aminopropionitrile fumarate (Aldrich), PPh3 (Acros), 
DIAD (Acros), TMSN3 (Fluka), THF (Biosolve), PMe3 (Aldrich), Et3N (Acros) were used as received. 
Reactions were followed by TLC analysis on silica gel (Schleicher & Schuell, F 1500 LS 254) or HPTLC 
aluminium sheets (Merck, silica gel 60, F254), with detection by UV-absorption (254 nm) where applicable 
and charring at 150°C with 20% H2SO4 in EtOH (25 g L-1), ninhydrin (3 g L-1) in EtOH/AcOH (100/3 v/v), 
NH4(Mo)7O24⋅4H2O (25 g L-1) and NH4Ce(SO4)4⋅2H2O (10 g L-1) in 10% aq. H2SO4 or 2% KMnO4 in 1% aq. 
K2CO3. Column chromatography was performed with silica gel (Fluka; 0.063-0.200 mm). RP-HPLC analysis 
and purification were performed on a Jasco HPLC system equipped with a Merck Lichrosphere C18 100Å 
column (4×250 mm). The applied solvents were H2O (eluent A), CH3CN (eluent B) and 1% aq. TFA 
(effective 0.1%, eluent C). 
5.4.2 General procedures - General procedure 1 (GP 1): a ≈0.01M solution of the amino acid in 
DCM/DMF (1/1, v/v) was cooled to 0°C and 1.1 equiv. EDC and 1.1 equiv. HOBt were added. After 30 min 
of stirring at 0°C, 3-aminopropionitrile fumarate (1.2 equiv.) was added and the mixture is stirred overnight 
during which the temperature is allowed to rise to room temperature. After TLC analysis (DCM/MeOH: 9/1 
v/v, ninhydrine) showed consumption of starting material, the DCM was evaporated under reduced 
pressure and the mixture was taken up in EtOAc, washed with saturated aq. KHSO4, aq. NaHCO3 and brine. 
The organic phase was dried (MgSO4), concentrated and subjected to silica gel column chromatography.  
General procedure 2 (GP 2): to a stirred solution of the coupled amino acid in CH3CN, PPh3 (2.5 equiv.) 
was added at 0°C, DIAD (2.5 equiv.) was added slowly, followed by TMSN3 (10 equiv.), which was added 
over 20 min The mixture was stirred overnight at 0−4°C, after which it was cooled to 0°C and a solution of 
NaNO2 (1 equiv.) in H2O was added. After 30 min a solution of ceric-ammonium nitrate (1 equiv.) in H2O 
was added over 10 min. After 20 min ice-cold water was added and the aqueous solution was extracted with 
EtOAc (3×). The combined organic phases were washed with brine, dried (MgSO4) and concentrated.  
General procedure 3a (GP 3a): to a ∼0.05M solution of the dimer in DCM were added iPr3SiH (1.3 
equiv.) or Et3SiH (1.3 equiv.) and TFA (→50% TFA in DCM). After TLC analysis (PE/EtOAc 1/1 v/v) 
showed total consumption of starting material, the reaction mixture was coevaporated 5× with anh. 
toluene. 
General procedure 3b (GP 3b): to a ∼0.1M solution of the amine in DMF was added the appropriate 
amino acid (1.1 equiv.), BOP (1.1 equiv.), HOBt (1.1 equiv.) and DIPEA (4 equiv.). After TLC analysis 
(PE/EtOAc 1/1 v/v) showed consumption of the starting material, DMF was removed in vacuo. The residue 
was dissolved in EtOAc and washed with water (2×), sat. aq. NaHCO3 (2×), water (2×), 5% aq. KHSO4 (2×) 




Boc-Leu-aminopropionitrile (6). Following GP 1 using Boc-Leu-OH (1.01 g, 4.36 mmol) gave 6 (73% yield, 
white solid). 1H-NMR (400 MHz, CDCl3): δ 7.26, 5.53 (2×bs, 2×NH), 4.16 (bs, 1H, 
HαLeu), 4.57-4.43 (m, 2H, CH2), 3.16 (t, 2H, NCH2, J= 6.4 Hz), 1.69-1.48 (2×m, 3H, 
HβγLeu), 1.45 (s, 9H, tBu), 0.94 (t, 6H, 2×CH3, J= 6.6 and 6.7 Hz). 13C-NMR (100 MHz, 
CDCl3) δ 173.6 (C=Oamide), 155.8 (C=OBoc), 117.9 (C≡N), 80.1 (CqBoc), 53.0 (CαMet), 41.2 
(CH2), 35.5 (CβLeu), 28.3 (tBu), 23.4 (CγLeu), 22.8, 21.8 (2×CH3Leu), 18.1 (CH2), MS (ESI): m/z 284.0 (M+H)+, 
306.2 (M+Na)+. HR-MS: calc. for [C14H25N3O3+H]+ 284.19687, found 284.19678. [α]D25= −40 (c= 1, CHCl3).   
Boc-Met-aminopropionitrile (9). Following GP 1 and using Boc-Met-OH (8, 750 mg, 3.00 mmol) gave 9 
(67% yield, white solid). 13C-NMR (50 MHz, CDCl3): δ 172.0 (C=Oamide), 154.8 
(C=OBoc), 117.36 (C≡N), 78.4 (CqBoc), 52.8 (CαMet), 34.6 (CH2), 31.3, 29.2 (CβγMet), 27.4 
(tBu), 17.0 (CH2), 14.2 (SCH3). MS (ESI): m/z 302.1 (M+H)+, 324.0 (M+Na)+. HR-MS: 
calc. for [C13H23N3O3S+H]+ 302.15329, found 302.15283. [α]D25= −18 (c= 1, CHCl3). 
H-Met-1H-propionitrile-tetrazole (10). Compound 9 (100 mg, 0.31 mmol) was treated according to GP 2. 
The crude product can be applied to a silica gel column (EtOAc) affording Boc-Met-1H-
propionitrile-tetrazole as a white solid. 1H-NMR (200 MHz, CDCl3): δ 6.85 (s, 1H, 
NHBoc), 4.93-5.02 (m, 1H, HαMet), 4.82-4.90 (m, 2H, CH2C≡N), 3.12-3.19 (m, 2H, NCH2), 
2.66 (m, 2H, HβMet), 2.43 (m, 2H, HγMet), 2.09 (s, 3H, SCH3), 1.41 (s, 9H, tBu). 13C-NMR (50 
MHz, CDCl3): δ 164.6 (C=Ntetrazole), 155.6 (C=OBoc), 115.9 (C≡N), 80.9 (CqtBu), 42.8 (CαMet), 
42.7 (CH2), 32.0, 29.9 (CβγMet), 28.1 (tBu), 18.4 (CH2), 15.0 (SCH3). MS (ESI): m/z 348.9 (M+Na)+. HR-MS: 
calc. for [C13H22N6O2S+H]+ 327.15977, found 327.16174. Next, crude Boc-Met-1H-propionitrile-tetrazole 
was deprotected with TFA/DCM/Et3SiH (25/75/2.5 v/v/v) for 30 min. Evaporation and silica gel purification 
(Rf= 0.5, 25% MeOH in EtOAc) gave 10 as a dark-brown oil (yield >99% from 9). 1H-NMR (200 MHz, 
MeOD): δ 5.12 (m, 1H, HαMet), 4.85 (m, 2H, CH2C≡N), 3.30 (m, 2H, NCH2), 2.64-2.45 (m, 4H, HβγMet), 2.06 (s, 
3H, SCH3); 13C-NMR (75 MHz, MeOD): δ 154.3 (C=Ntetrazole), 118.2 (C≡N), 44.5 (CαMet and CH2C≡N), 33.0, 
29.7 (CβγMet), 18.8 (CH2), 14.8 (SCH3). IR ν (cm-1, film): 3425, 2924, 2361, 1674, 1551, 1435, 1196, 1134. MS 
(ESI): m/z 227.1 (M+H)+, 248.9 (M+Na)+. HR-MS: calc. for [C8H14N6S+H]+ 227.10734, found 227.10713.   
Boc-Ile-Met-1H-propionitrile-tetrazole (11). Compound 10 (0.49 g, 2.15 mmol) was treated according to GP 
3b. Purification by silica gel chromatography (Rf= 0.4, EtOAc/PE 1/1) gave 11 in 
61% yield (0.57 g, 1.3 mmol) as a white solid. 1H-NMR (400 MHz, CDCl3): δ 
7.27 (d, 1H, NHC=O), 5.47 (dd, 1H, HαMet, J= 7.2 Hz), 5.11 (d, 1H, NHBoc, J= 7.2 
Hz), 4.90, 4.75 (2×dt, 2H, CH2C≡N), 3.12 (m, 2H, CH2CH2C≡N), 2.57 and 2.38 
(2×m, 4H, HβγMet), 2.01 (s, 3H, SCH3), 1.70 (bs, 3H, HβγIle), 1.32 (s, 9H, tBu), 1.02 
and 0.86−0.80 (2×m, 6H, 2×CH3Ile); 13C-NMR (50 MHz, CDCl3): δ 172.8 (C=Oamide), 155.6, 155.2 (C=Ntetrazole 
and C=OBoc), 116.2 (C≡N), 79.3 (CqtBu), 58.6 (CαIle), 42.6 (CH2C≡N), 40.9 (CαMet), 36.2 (CβIle), 31.1, 29.3 
(CβγMet), 27.6 (tBu), 24.2 (CγIle), 17.8 (NCH2), 14.7, 13.4, 10.2 (SCH3 and 2×CH3Ile). MS (ESI): m/z 440.3 
(M+H)+, 462.2 (M+Na)+, 478.1 (M+K)+. HR-MS: calc. for [C19H33N7O3S+H]+ 440.24384, found 440.24355; 
calc. for [C19H33N7O3S+NH4]+ 457.27038, found 457.27008. [α]D25= −36 (c= 0.86, MeOH). 
Boc-Val-Ile-Met-1H-propionitrile-tetrazole (12). Compound 11 (0.52 g, 1.19 mmol) was treated according 
to GP 3a and 3b. Silica gel chromatography (EtOAc, Rf= 0.4) gave 12 
(0.34 g, 0.64 mmol) as a white solid in 54% yield. 13C-NMR (50 MHz, 
CDCl3): δ 172.6, 172.0 (C=Oamide), 155.3, 155.2 (C=Ntetrazole and C=OBoc), 
116.2 (C≡N), 80.0 (CqtBu), 60.3, 57.6 (CαIle and CαVal), 42.9 (CH2C≡N), 41.2 
(CαMet), 36.1, 30.1 (2×CβIle,Val), 31.5, 29.7 (CβγMet), 28.0 (tBu), 24.5 (CγIle), 
18.2 (NCH2), 19.0, 17.8, 15.1, 14.7, 10.6 (SCH3 and CH3Ile,Val). IR ν (cm-1, film): 2963, 2361, 1690, 1643, 1528, 








































Boc-Cys(Tr)-Val-Ile-Met-1H-propionitrile-tetrazole (13). Compound 7 (100 mg, 186 μmol) was treated 
according to GP 3a and 3b. Silica gel chromatography (EtOAc/PE 
5/2, Rf= 0.5) gave the title compound as a white solid (115 mg, 130 
μmol) in 70% yield. 1H-NMR (400 MHz, CDCl3): δ 7.45–7.18 (m, 
NHC=O and 15×HTr), 6.70 (d, 1H, NHC=O, J= 8.2 Hz), 6.30 (d, 1H, 
NHC=O, J= 4.6 Hz), 5.54 (m, 1H, HαMet), 4.74 (t, 2H, CH2C≡N, J= 
6.7 and 7.2 Hz), 4.62 (d, 1H, NHBoc), 4.36 (dd, 1H, Hα, J= 5.3 Hz), 3.83 (t, 1H, Hα, J= 4.2 Hz), 3.49 (m, 1H, 
Hα), 3.12 (t, 2H, NCH2, J= 3.5 and 4.1 Hz), 2.72 and 2.60 (dd, J= 5.0 Hz and m, 4H, HβγMet and HβCys), 2.07 (s, 
3H, SCH3), 2.01 (m, 1H, HβVal), 1.72 (bs, 3H, HβγIle), 1.40 (s, 9H, tBu), 0.94−0.79 (m, 12H, 4×CH3Ile). 13C-NMR 
(100 MHz, CDCl3/MeOD)∗: δ 171.9-171.2 (C=Oamide*), 156.0, 155.0 (C=Ntetrazole and C=OBoc), 144.4, 144.1 
(CqTr), 129.5-126.8 (CTr*), 116.3 (C≡N), 80.9 (CqtBu), 59.8, 58.3, 54.1 (3×CαIle, Val, Cys*), 42.9 (CH2C≡N), 41.5 
(CαMet*), 37.5, 35.7 (2×CβIle,Val*), 32.5, 31.5, 29.7 (CβγMet, CβCys), 28.1 (tBuBoc*), 24.6 (CγIle*), 18.2 (NCH2), 19.1, 
17.4, 15.4, 15.0, 10.9 (SCH3 and CH3Ile,Val*). IR ν (cm-1, film): 3865, 3742, 3611, 2970, 2322, 1697, 1643, 1520, 
1458. MS (ESI): m/z 884.6 (M+H)+, 906.5 (M+Na)+. HR-MS: calc. for [C46H61N9O5S2+H]+ 884.43098, found 
884.43110. [α]D25= −49 (c= 0.46, MeOH). 
H-Cys-Val-Ile-Met-1H-tetrazole (15). Compound 13 (57 mg, 65 μmol) was dissolved in DCM (4 mL) and 
treated with DBU (7 equiv., 455 μmol, 68 μL) until TLC analysis showed 
completion (baseline spot, orange color upon spraying with molybdenum 
solution). Next, the reaction mixture was diluted with EtOAc and 
washed with 1N HCl and brine. After drying of the organic layer 
(MgSO4) and concentration in vacuo, the crude product (14, white solid, 
crude yield: 49 mg, 59 μmol, 91%) was analyzed by 13C-NMR and mass spectroscopy. No appearance of the 
propionitrile group was detected by NMR and mass spectroscopy showed the desired mass peaks: MS (ESI) 
m/z 831.5 (M+H)+ and 853.5 (M+Na)+; HR-MS: calc. for [C43H58N8O5S2+H]+ 831.40443, found 831.40564. 
Treatment of the crude product according to GP 3a afforded the fully deprotected title compound. After 
evaporation of the volatiles, the reaction mixture was diluted with water and washed with DCM. The aq. 
layer was concentrated by lyophilisation to afford the crude product as a white powder. Purification by RP-
HPLC (linear gradient B, 10→90%) afforded the title compound (8 mg, 16 μmol, 28%) as a white powder. 
LC-MS analysis: Rt = 9.1 min (linear gradient B 10→90%, 26 min), 489.3 (M+H)+. 1H-NMR (400 MHz, 
D2O/CD3CN): δ 7.43 (d, 1H, NH, J= 8.8 Hz), 5.52 (dd, 1H, Hα, J= 6.0 and 6.8 Hz), 4.45 (apparent t, 1H, Hα, J= 
7.2 and 7.6 Hz), 4.28 (dt, 1H, Hα, J= 8.4 and 8.8 Hz), 3.46 (m, 1H, Hα), 3.30, 3.00 (2×m, 2H, HβCys), 2.52 (m, 
2H, HγMet), 2.27 (m, 2H, HβMet), 2.03 (s, 3H, SCH3 and m, 1H, HβVal), 1.68, 1.30 (2×m, 3H, HβγIle), 0.90 (dd, 6H, 
2×CH3), 0.75 (t, 3H, CH3). 0.63 (d, 3H, CH3).  
(2S,3S,6R)-3-O-Benzyl-1-{N-[(9-fluorenyl-methoxycarbonyl)aminomethyl}-tetrahydropyran-1-carboxylic 
acid (16b). To a solution of SAA 16a (0.74 g; 2.03 mmol) in DCM (15 mL) were 
added TFA (15 mL) and 1.1 equiv. Et3SiH. After stirring for 4 h at rt, TLC 
analysis (EtOAc) indicated complete conversion of the starting. The solvent was 
removed in vacuo, the crude product was coevaporated to dryness with anh. 
toluene (3×15 mL) and dissolved in dioxane (15 mL). A solution of NaHCO3 (4 
equiv.) in H2O (30 mL) was added to the reaction mixture followed by a solution 
of FmocOSu (1.1 equiv.) in dioxane (15 mL). After stirring overnight at rt, the reaction mixture was washed 
2× with 1N HCl and extracted 2× with DCM. The organic layer was washed with brine and dried over 
MgSO4. After removal of the solvent under reduced pressure, the mixture was purified by silica gel 
                                                          
*  In the case of compound 13 some 13C-NMR resonances appear double - probably due to conformational 







































chromatography (1% AcOH in PE/EtOAc 1/1 v/v) furnishing 16b (Rf= 0.4, EtOAc) as a white foam (0.92 g, 
1.88 mmol, 92%). 1H-NMR (CDCl3, 400 MHz): δ 7.73 (d, 2H, 2×HFmoc, J= 7.6 Hz), 7.57 (d, 2H, 2×HFmoc, J= 7.6 
Hz), 7.37 (t, 2H, 2×HFmoc, J= 7.2 and 7.6 Hz), 7.30 (m, HFmoc&Bn), 5.40 (t, 1H, NH), 7.57 (d, 2H, 2×HFmoc, J= 5.2 
and 6.0 Hz), 4.59 (m, 3H, HFmoc&Bn), 4.37 (d, 1H, HFmoc, J= 7.2 Hz), 4.19 (bt, 1H, HFmoc, J= 6.8 Hz), 3.51−3.42 
(d, 1H, H2, J= 9.2 Hz), 3.59-3.42 (m, 3H, H3, H6, H7a), 3.13-3.1 (m, 1H, H7b), 2.31 (m, 1 H, H4a), 1.73 (m, 1H, 
H5a), 1.52, 1.37 (2×m, 2H, H4b&5b); 13C-NMR (400 MHz, CDCl3): δ 172.9 (C=Oacid), 156.5 (C=OFmoc), 143.5, 
140.9 (CqFmoc), 137.4 (CqBn), 128.0, 127.4 126.7, 124.8, 119.6, (CHFmoc&Bn), 79.0, 76.3, 74.2 (C2, C3, C6), 70.9 
(CH2Bn), 66.5 (CH2Fmoc), 46.8 (CHFmoc), 44.5 (C7), 28.3, 26.5 (C4, C5). MS (ESI): m/z 488.4 [M+H]+. IR ν (cm-1, 
thin film): 3018, 2930, 2870, 1719, 1522, 1250, 1221, 1099. [α]D20= +3 (c= 1, CHCl3).  
N-[(6R)-6-({N-[9H-fluoren-9-ylmethoxycarbonyl-amino}methyl-4,5,6-trideoxy-3-benzyloxy-1-oxo-D-arabino-
hexo-pyranos-1-yl]-L-methionine-1H-propionitrile-tetrazole (17). A 
solution of SAA 16b (1 equiv., 168 mg, 345 μmol) and 10 (2.2 equiv., 56 
mg, 246 μmol) in DMF (5 mL) was treated with HCTU (2.2 equiv., 0.76 
mmol, 0.31 g), (2.2 equiv., 0.76 mmol, 0.10 g) and DIPEA (6 equiv., 0.35 
mL). After TLC analysis (1% AcOH/EtOAc, Rf= 0.9) showed 
completion, the reaction mixture was concentrated in vacuo and 
washed with sat. NaHCO3, KHSO4 (5%) and brine. The organic phase 
was dried (MgSO4) and evaporated in vacuo. Purification by silica gel chromatography (EtOAc/drop AcOH) 
furnished 17 as a foam (170 mg, 245 μmol, 71%). 1H-NMR (400 MHz, CDCl3) δ 7.76 (d, 2H, HFmoc, J= 7.4 
Hz), 7.60-7.24 (m, NHCα and HFmoc&Bn), 5.43 (m, 2H, NHFmoc, HαMet), 4.78 (m, 2H, CH2C≡N), 4.55–4.30 (m, 
4H, PhCH2 and CH2Fmoc), 4.18 (t, 1H, CHFmoc), 3.72 (d, 1H, H2, J= 9.2 Hz), 3.35 (m, 3H, H6, H3, H7a), 3.05 (m, 
3H, CH2CH2C≡N and H7b), 2.54–2.27 (m, 6H, HβγMet, H4a, H5a), 2.01 (s, 3H, SCH3), 1,60–1.40 (m, 2H, H4b&5b). 
13C-NMR (50 MHz, CDCl3): δ 170.6 (C=Oamide), 156.9, 155.1 (C=OFmoc and C=Ntetrazole), 143.8, 143.7, 141.1 
(CqFmoc), 137.3 (CqBn), 128.4-126.9, 125.0, 119.8 (CHFmoc&Bn), 116.3 (C≡N), 78.8 (C2), 77.2 (C6), 74.3 (C3), 70.9 
(CH2Bn), 66.6 (CH2Fmoc), 47.0 (CHFmoc), 44.5 (C7), 42.8 (CH2), 41.2 (CαMet), 31.3 (CβMet), 29.8 (CγMet), 28.6 (C4), 
28.3 (C5), 18.2 (CH2), 14.9 (SCH3). HR-MS: calc. for [C37H41N7O5S+H]+ 696.29626, found 696.29617; calc. for 
[C37H41N7O5S+Na]+ 718.27821, found 718.27773. [α]D25= −17 (c= 1, CHCl3). 
N-[(6R)-6-({N-(S-[tert-Butyl)sulfanyl]-N-{[(9H-fluoren-9-yl)methoxy]carbonyl}-L-cysteinyl)amino]-methyl}-
4,5,6-trideoxy-3-benzyloxy-1-oxo-D-arabino-hexo-pyranos-1-yl]-
L-methionine-1-propionitrile-tetrazole (18). Compound 17 (96 
mg, 138 μmol) was dissolved in DCM (2 mL) and treated with 
1.0 equiv. DBU (138 μmol, 21 μL). After TLC analysis showed 
completion, HOBt (37 mg, 2 equiv.) was added followed by a 
solution of HCTU (69 mg, 166 μmol, 1.2 equiv.), DIPEA (70 μL, 
3 equiv.) and Fmoc-Cys(StBu)-OH (72 mg, 166 μmol, 1.2 equiv.) 
in DMF (2 mL). After stirring overnight at rt, the reaction mixture was concentrated in vacuo and washed 
with sat. aq. NaHCO3, aq. KHSO4 (5%) and brine. The organic phase was dried (MgSO4) and evaporated in 
vacuo. Purification by silica gel chromatography (Rf= 0.7, EtOAc) gave 18 as a white foam (102 mg, 115 
μmol, 83%). 1H-NMR (400 MHz, CDCl3/MeOD): δ 7.73-7.62 (m, 4H, CHFmoc), 7.45 (t, 2H, CHFmoc, J= 7.2 and 
7.6 Hz), 7.30–7.11 (m, CHFmoc&Bn, NH), 7.14 (bs, 1H, NH), 6.10 (bs, 1H, NHFmoc), 5.34 (m, 1H, HαMet), 4.73 
(m, 2H, CH2), 4.49–4.30 (m, 4H, CH2Bn and CH2Fmoc), 4.18 (m, 2H, CHFmoc and HαCys), 3.69 (d, 1H, H2, J= 9.2 
Hz), 3.49 (m, 1H, H1), 3.37–3.25 (m, 3H, H3 and H7ab), 3.12–2.92 (m, 4H, CH2 and HβCys), 2.53–2.30 (m, 4H, 
HβγMet), 2.21 (m, 1H, H4a), 2.05 (s, 3H, SCH3), 1.60 (m, 1H, H5a), 1.40 (m, 2H, H4b&5b), 1.30 (s, 9H, tBu); 13C-
NMR (100 MHz, MeOD/CDCl3): δ 170.6, 170.7 (2×C=Oamide), 156.5, 155.5 (C=OFmoc and C=Ntetrazole), 143.9, 
143.7, 141.3 (4×CqFmoc), 137.6 (CqBn), 128.5-127.2, 125.2, 120.0 (CHBn&Fmoc), 116.1 (C≡N), 78.8 (C2), 76.5 (C6), 





























41.2 (CαMet), 31.3, 30.1 (CβγMet), 29.9 (tBu), 28.9, 26.9 (C4, C5), 18.5 (CH2), 15.2 (SCH3). IR ν (cm-1, film): 3300, 
2924, 1670, 1508, 1450, 1234, 1090. HR-MS: calc. for [C44H54N8O6S3+NH4]+ 904.36667, found 904.36603. 
[α]D25= −21 (c= 0.5, CHCl3). 
N-[(6R)-6-({N-(S-[tert-Butyl)sulfanyl]-L-cysteinyl)-amino]-methyl}-4,5,6-trideoxy-4-benzyloxy-1-oxo-D-
arabino-hexopyranos-1-yl]-L-methionine-1H-tetrazole (19). A 
solution of 18 (25 mg, 28 μmol) in DCM (4 mL) was treated dropwise 
with 8 equiv. DBU (224 μmol, 34 μL) until TLC analysis (EtOAc) 
showed completion. Next, the reaction mixture was diluted with 
water and organic impurities were removed by washing with DCM. 
The aq. layer was lyophilised and purification by RP-HPLC (linear 
gradient B, 7→54%) gave 19 (3.5 mg, 5.7 μmol, 20%) as a white 
powder. 1H-NMR (400 MHz, D2O/CD3CN): δ 7.43 (dd, 3H, CHBn, J= 1.2 and 2.4 Hz), 7.27 (2×d, 2H, CHBn, J= 
2.8 and 3.6 Hz), 5.55 (dd, 1H, HαMet, J= 6.4 Hz), 4.55 and 4.42 (2×d, 2H, CH2Bn, J= 11.6 Hz), 4.25 (dd, 1H, 
HαCys, J= 5.6 Hz), 3.81 (d, 1H, H2, J= 9.6 Hz), 3.71–3.61 (m, 2H, H6, H7a), 3.56–3.50 (dt, 1H, H3, J= 3.6 and 4.4 
Hz), 3.28 (dd, 1H, HβCys, J= 6.4 Hz), 3.20 (m, 2H, HβCys and H7b), 2.59–2.55 (m, 2H, HγMet), 2.43 (m, 1H, H4a), 
(m, 2H, HβMet), 2.12 (s, 3H, SCH3), 1.80 (m, 1H, H5a), 1.59–1.49 (m, 2H, H4b&5b), 1.33 (s, 9H, tBu); 13C-NMR 
(100 MHz, D2O/CD3CN): δ 171.5, 167.8 (2×C=Oamide), 156 (C=Ntetrazole), ∼138 (CqBn, due to low concentration 
difficult to detect), 128.8, 128.4, 128.3 (CHBn), 79.9 (C2), 75.8, 75.1 (C3, C6), 71.0 (CH2Bn), 52.8 (CαCys), 48.7 
(CqtBu), 43.5, 40.5 (C7, CβCys), 42.3 (CαMet), 31.2, 29.4 (CβγMet), 29.1 (tBu), 28.5, 26.8 (C4, C5), 14.4 (SCH3). LC-
MS analysis Rt= 11.4 min (linear gradient B 10→90%, 26 min); m/z 612.3 (M+H)+. 
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Incorporation of an Azide in Farnesyl Pyrophosphate Enables 
Bioorthogonal Labeling of Farnesylated Proteins  




Abstract. A novel labeling strategy for visualising farnesylated proteins from living cells is presented. The 
strategy uses the FPP analog azidoFPP (2) as alternative substrate for PFT. The azidofarnesylated proteins 
are modified by means of a Bertozzi-Staudinger ligation between phosphine reagent 1 (containing a biotin 
as identification tool) and the azide group. SDS-PAGE analysis and avidin-horseradish peroxidase 
chemiluminescence enables visualisation of the isolated proteins. Co-treatment with PFT inhibitors 
















 6.1 Introduction 
In recent years, several strategies for the chemical tagging of proteins with 
bioorthogonal functional groups have come to the fore.1 In general, a chemical probe that 
has the property to modify distinct protein families is equipped with a small, 
physiologically inert functionality and applied to a relevant tissue culture. In a later stage, 
the bioorthogonal group is targeted through a chemoselective reaction, enabling labeling 
of the modified proteins with biotin or fluorescent groups. Two reactions that are 
exceptionally suitable for this purpose are the copper-catalysed Huisgen cycloaddition of 
an azide and an acetylene,2,3 and the Bertozzi modification of the Staudinger reaction.4 
Two-step labeling techniques have been applied for the tagging of a number of 
cysteine, serine and threonine dependent enzymatic activities.5,6 Further, Bertozzi and co-
workers developed the two-step labeling, by metabolic oligosaccharide engineering, of 
cell surface glycoproteins.3 In this pioneering report, N-azidoacetyl-D-mannosamine 
proved to be a suitable substrate in the sialic acid biosynthetic pathway, resulting, 
eventually, in the decoration of cell surface sialic acid residues with azides for subsequent 
functionalisation by a modified Staudinger reaction. More recently, the same group 
revealed that a similar strategy but with azidoacetyl glucosamine as a modified metabolite 
proved to be viable in the tagging of nuclear O-GlcNAcylated proteins.7 These results 
were an incentive to investigate whether two-step labeling using modified metabolites 
can be applied to the farnesylation of proteins by protein:farnesyl transferase (PFT).8  
The following strategy was devised for the two-step labeling of farnesylated 
proteins (Scheme 6.1).9,∗After addition of azidofarnesyl pyrophosphate 210 to living cells it 
is transferred, through the action of PFT, to proteins susceptible to farnesylation. After 
the culture is lysed and denatured, biotinylated phosphine reagent 111 is added, resulting 
in selective biotinylation through a Bertozzi-Staudinger reaction. At this stage, the 
selectivity of the two-step labeling can be ascertained by the addition of PFT specific 
inhibitors (Figure 6.1).  
 
                                                 
∗ It should be noted that a related strategy employing azidofarnesyl pyrophosphate, but using both 






















































































It should be noted that the viability of this strategy relies on the following issues. 
First, the phosphine functionality is a biologically inert species.12 Although azides are 
reduced by thiols in vivo,13 this process is too slow to interfere under the timecourse of 
the employed in vivo experiments and thus can be regarded as biologically inert species. 
Second, the relatively small size and nonpolar character of the azide group make it suited 
to function as tagging handle and to date it is has not been identified in any known 





































 6.2 Results and Discussion 
6.2.1 Synthesis – The synthesis of azidofarnesyl pyrophosphate 2 was accomplished 
as follows (Scheme 6.2). Known THP-protected farnesol 5,14 obtained from farnesol 4 by 
treatment with dihydropyran and acid, was reacted with selenoxide, tert-butyl 
hydroperoxide and salicylic acid15 to afford allylic alcohol 616 in 32% yield (5 recovered in 
30% yield). Treatment of 6 with (PhO)2P(O)N3 and subsequent unmasking of the 
remaining primary alcohol afforded azidofarnesol 8 in good yield (85% from 6).17 The 
pyrophosphate moiety was now introduced following a well established procedure, by 
treating 8 with PBr3 furnishing allylic bromide 9 in 77% yield.18 Treatment with tetra-n-
butylammonium pyrophosphate furnished 2 as the tris(tetra-n-butylammonium) salt. 
Consecutive exposure to Dowex-NH4+ and lyophilisation afforded the product as the 
tris(ammonium) salt which could be purified by RP-HPLC, providing homogeneous 
azidofarnesyl pyrophosphate 2 (50% from 9).  
 




aReagents and conditions: (i) DHP, PPTS, DCM (5: >99%); (ii) SeO2·H2O (cat), tBuOOH, salicylic acid, 
DCM (6: 32%, recovered 5: 30%); (iii) (PhO)2P(O)N3, DBU, toluene (7: >99%); (iv) PPTS, EtOH, 60°C (8: 
85%); (v) PBr3, pentane, 0−4°C (9: 77%); (vi) (a) (nBu4N)3HP2O7, CH3CN, 0°C→rt (b) Dowex-NH4
+, (c) RP-











8 R = OH


















 20-25 kDa 
6.2.2 Labeling Experiment − The efficacy of the Staudinger ligation pair 111 and 2 in 
the selective labeling of farnesylated proteins was established in the following 
experiment. Cultured J774 cells, a mouse macrophage cell line, incubated with the HMG-
CoA reductase inhibitor simvastatin (10) to suppress endogenous farnesyl pyrophosphate, 
were treated with azidofarnesyl pyrophosphate 2 (100 μM final concentration). 
 






















aJ774 cells were incubated with 5 μM simvastatin 10, (lanes 1 – 8), 100 μM 2 (lanes 2 – 4), 100 μM 8 
(lanes 6 – 8), 100 μM 2 and 100 μM 11 (lanes 3 & 7), 100 μM 2 and 100 μM 12 (lanes 4 & 8). EtOH, the 
solvent of 8, was present at the latter 4 incubation conditions (lanes 5 – 8). After incubation for 24 h at 
37°C, the cells were lysed, treated with 1 (final concentration 333 μM) prior to SDS-PAGE resolvement of 
the protein content and avidin-HRP chemiluminescence identification of the modified proteins. 
 
After incubating for 24 hours, the cells were lysed, treated with an excess of reagent 1, 
and applied to SDS-PAGE separation. Biotinylated proteins were visualised by an avidin-
horseradish peroxidase (HRP) chemiluminescence assay19 and the results were compared 
with those of cells which were incubated without azide 2, but with Staudinger reagent 1 
(Figure 6.1, lanes 1 and 2). As can be seen in lane 2 (see arrows), at least five bands appear 
over the background, four in the region corresponding to 45 – 70 kDa proteins and one 
band at around 23 kDa. The lamin proteins, which are known to be PFT substrates, reside 








 10:      +     +     +      +     +     +   +    +
 11:       -      -     +      -       -      -      +     - 
 12:       -      -      -      +      -      -      -     + 
   EtOH:    -      -      -      -      +     +     +     + 
 2:      -     +      +      +    -      -      -     - 


































in the 67 – 80 kDa region, (nuclear lamin B2 is a 68 kDa protein and probably 
corresponds to the upper band detected), whereas at 20 – 25 kDa small GTP-binding 
proteins such as Ras are expected.  
Addition of pyrophosphonate 11, next to azide 2, to the tissue medium almost 
completely abolished labeling (lane 3). Compound 11 (TR006),20 developed by van Boom 
and co-workers is a potent inhibitor of PFT (IC50= 0.16 µM); this result clearly 
demonstrates the selectivity of probe 2 to be processed by PFT. Application of the less 
potent PFT inhibitor tetrapeptide mimetic 12 (see Chapter 3) also resulted in a decrease of 
labeling intensity, but with lower efficiency. Lanes 5 – 8 entail a repetition of the 
experiments, but with azidofarnesol 8 as the chemoselective probe and in the presence of 
0.1% of ethanol, the solvent of azidofarnesol. As can be seen, labeling efficiency drops 
(lane 6), however, longer exposure reveals a similar labeling pattern. This result indicates 
that azidofarnesol is transformed to the pyrophosphate within the cell and that 11 and 12 
prevented the protein farnesylation from azidofarnesol (lanes 7, 8). This is in line with 
metabolic labeling experiments which showed that the isoprenoid alcohols farnesol and 











Scheme 6.3 Proposed salvage pathway for the in vivo transformation of isoprenoid alcohol in the 
corresponding pyrophosphate (NTP= nucleoside triphosphate). 
 
The exact salvage pathway by which the isoprenoid alcohols are converted into the 
corresponding pyrophosphates has not been clarified yet. However, in rat liver 
microsomes it is has been shown that two subsequent kinases utilizing a nucleoside 
triphosphate (adenine triphosphate or cytosine triphosphate), transform the hydroxyl 
OH
F-OH (4, n= 1) or GG-OH (n= 2)
n
OPP













first into a monophosphate and finally into the pyrophosphate (Scheme 6.3).22 In contrast 
to FPP and GGPP, which are conventionally synthesised via the mevalonate pathway,∗ 
the isoprenoid alcohols are derived from either dephosphorylation of the corresponding 
pyrophosphate isoprenoid23 or degradation of isoprenylated proteins.21,22 
 
 6.3 Conclusions 
In conclusion, this chapter presents a novel labeling strategy for visualising 
farnesylated proteins from living cells. The strategy does not rely on the use of radiolabels 
and has the advantage of being rapid, efficient and selective (detection through [3H] 
labeled mevalonate or farnesylpyrophosphate normally takes up to several weeks). The 
here presented methodology may find application for the assessment of the characteristics 
of PFT and PGGT-1 inhibitors within the context of the living cell. Additionally, these 
techniques will enable the isolation/further characterisation and subcellular localisation 
of prenylated proteins. Finally, it is obvious that the here presented strategy but with an 
azidogeranygeranyl pyrophosphate probe instead of N3FPP should be of great value in 
terms of obtaining non-radioactively, biotin labeled geranylgeranylated proteins (See 
Future Prospects, Chapter 8). 
 
 6.4 Experimental Section 
6.4.1 General − 1H-NMR and 13C-NMR spectra were recorded with a Bruker AC-200 (1H-NMR 200 
Mhz, 50.1 MHz), Bruker DPX-300 (1H-NMR 300 Mhz, 75 MHz), Bruker Avance-400 (1H-NMR 400 Mhz, 
13C-NMR 100 MHz) or Bruker DMX-600 (1H-NMR 600 Mhz, 13C-NMR 150 MHz). Chemical shifts are given 
in ppm (δ) relative to tetramethylsilane as internal standard. Mass spectra were recorded with a Perkin 
Elmer/SCIEX API 165 mass instrument and HR-MS spectra were recorded with an API QSTARtm Pulsar 
(Applied Biosystems). Eluents were of technical grade and distilled before use. DMF, DCM, MeOH and 
toluene (all from Biosolve, p.a.) were stored over MS4Å. EtOAc and PE (40-60) were of technical grade and 
distilled before use. DBU (Fluka), PPTS (Acros), SeO2⋅HO2 (Aldrich) and farnesol (all trans, Aldrich) were 
used as received. Commercial tetra-n-butylammonium pyrophosphate (Fluka) was purified by 
recrystallisation.24 Reactions were followed by TLC analysis on silica gel (Schleicher & Schuell, F 1500 LS 
254) or HPTLC aluminium sheets (Merck, silica gel 60, F254), with detection by UV-absorption (254 nm) 
where applicable and charring at 150°C with 20% H2SO4 in EtOH (25 g L-1), ninhydrin (3 g L-1) in 
EtOH/AcOH (100/3, v/v), NH4(Mo)7O24⋅4H2O (25 g L-1) and NH4Ce(SO4)4⋅2H2O (10 g L-1) in 10% aq. H2SO4 
or 2% KMnO4 in 1% aq. K2CO3. Column chromatography was performed with silica gel (Fluka; 0.063-0.200 
mm). RP-HPLC analysis and purification were performed on a Jasco HPLC system equipped with a Merck 
Lichrosphere C18 100Å column (4×250 mm).  
                                                 




(E,E,E)-3,7,11-trimethyl-O-tetrahydropyranyl-2,6,10-dodecatrien-12-ol (6). The known THP-ether 5 (23 
mmol, 7.0 g, PE/Et2O 4/1 v/v, Rf= 0.7) was added dropwise to a 
cooled (0°C) solution of SeO2⋅HO2 (1.2 mmol, 128 mg, 0.05 equiv.), 
salicylic acid (2.3 mmol, 317 mg, 0.1 equiv.) and tBuOOH (80% 
soln, 10 mL, 3.5 equiv.) in DCM (23 mL). The reaction mixture was stirred for 4 days,25 diluted with toluene 
and concentrated in vacuo. After dilution with ether, the organic layer was washed with sat. aq. NaHCO3 
and brine and evaporated. The crude product was dried by coevaporation with anh. toluene, dissolved in 
MeOH (50 mL), cooled to –15°C and treated in portions with NaBH4 (4.6 mmol, 174 mg, 0.2 equiv.).26 After 
15 min, acetone was added to destroy any excess NaBH4 followed by evaporation of the MeOH. The residue 
was dissolved in EtOAc and washed with sat. aq. NH4Cl and brine. Silica gel chromatography (EtOAc/PE 
v/v 1/1) gave 6 (PE/Et2O 4/1 v/v, Rf= 0.2) as an oil (2.35 g, 7.3 mmol, 32%) along with recovered 5 (2.15 g, 
7.0 mmol, 30%). MS (ESI): m/z 345.0 (M+Na)+, 361.2 (M+K)+. 
(E,E,E)-3,7,11-trimethyl-O-tetrahydropyranyl-2,6,10-dodecatrien-12-azide (7).10 Allylic alcohol 6 (1.7 g, 
5.3 mmol) and diphenylphosphoryl azide (2.5 equiv., 13.3 mmol, 2.9 
mL) were dissolved in anh. toluene (25 mL) and cooled on ice. DBU 
(2.5 equiv., 13.3 mmol, 2.0 mL) was added dropwise during which the 
reaction solidified partially. After ½h the reaction mixture was 
allowed to warm to rt and stirr overnight (reaction mixture turned 
light pink). After TLC analysis showed completion the reaction was quenched by addition of water and 
extracted with EtOAc, washed with brine and 1N HCl and dried over MgSO4. The crude product was 
purified by silica gel chromatography (PE/EtOAc 4/1 v/v, Rf= 0.7, isomeric mixture co-spotted on TLC) to 
give 7 as an oil (1.8 g, 5. 3 mmol, 100%). 1H-NMR (300 MHz CDCl3) δ 5.38 (m, 2H), 5.11–4.93 (m, 2H), 4.62 
(d, 1H, J= 2.9 Hz), 4.23 (dd, 1H, J= 6.1 and 6.3 Hz), 4.03 (dd, 1H, J= 6.9 and 7.6 Hz), 3.89–3.77 (m, 2H), 3.50 
(dd, 1H, J= 4.1 and 5.3 Hz), 2.27–1.97, 1.82–1.41 (2×m, CH2 and CH3); 13C-NMR (50 MHz CDCl3): δ 149.3–
133 (Cq), 130–120 (=CH), 113.7 (H2C=C), 96.8 (CHTHP), 67.2 (H2C-C(CH3)CH(N3)), 62.7–61.2 (N3CH2 and 
CH2OTHP), 38.8, 35.2, 30.0, 25.5, 25.0, 18.8 (CH2), 15–20 (CH3). MS (ESI): m/z 370.1 (M+Na)+. HR-MS: 
calculated for [C20H33N3O2+NH4]+ 365.29110, found 365.29123.  
(E,E,E)-3,7,11-trimethyl-1-ol-2,6,10-dodecatrien-12-azide (8). To a solution of 7 (998 mg, 2.87 mmol) in 
EtOH (14 mL) was added PPTS (0.2 equiv., 0.6 mmol, 144 mg). The 
reaction mixture was stirred at 60°C until TLC analysis showed completion 
(6–12 hrs) and concentrated in vacuo. Silica gel chromatography (PE/Et2O 
3/1 v/v, Rf= 0.4, isomeric mixture co-spotted on TLC) gave 8 as a 
yellow/brown oil (643 mg, 2.44 mmol, 85%). 1H-NMR (300 MHz CDCl3) δ 
5.40 (m, 2H, =CHCH2), 5.12 (m, 1H, =CHCH2), 4.97 (m, 1H, H2C=C), 4.13 (d, 2H, CH2OH, J= 6.8 Hz), 3.80 
(dd, 1H , H2C=CHN3, J= 7.2 and 6.8 Hz), 3.65 (m, 2H, CH2N3), 2.20–1.94, 1.78–1.60 (2×m, CH2 and CH3); 
13C-NMR (50 MHz CDCl3): δ 142.1, 139.0, 138.8, 134.3, 133.7 (Cq), 129.5, 129.3, 125.1, 124.8, 124.2, 123.5, 
123.4 (=CH), 114.3 (H2C=C), 67.7 (H2C-C(CH3)CH(N3)), 59.2, 59.0 (N3CH2 and CH2OTHP), 39.2, 39.0, 35.7, 
30.3, 26.1 (CH2), 17.4, 16.0, 15.7 (CH3). IR ν (cm-1, film): 3348, 2924, 2091 (N3), 1443, 1381, 1242. MS (ESI): 
m/z 286.0 (M+Na)+. HR-MS: calculated for [C15H25N3O+NH4]+ 281.23359, found 281.23342.  
(E,E,E)-3,7,11-trimethyl-1-bromide-2,6,10-dodecatrien-12-azide (9). Azide 8 (91 mg, 347 µmol) was 
dissolved in pentane (1 mL) and the solution was cooled on ice (0−4 °C). 
Next, PBr3 (1.1 equiv., 380 µmol, 103 µl) was added slowly and after 
stirring for 1 h, TLC analysis showed completion (EtOAc/DCM 2/8 v/v, 
Rf= 0.9). MeOH (3.3. equiv., 1.16 mL) was added in order to quench any 



















with Et2O (10 mL) and 1× washing with water, 2× with 10% aq. NaHCO3 and 1× with water gave, after 
drying (MgSO4) and concentration in vacuo at 0−4 °C (flask was kept cold in ice-bath) compound 9 as a 
brown oil (87 mg, 268 µmol, 77%). Bromide 9 can be purified by flash silica gel chromatography (Et2O, Rf= 
0.9), however, due to their reactive character, allylic bromides are commonly used directly without 
purification. MS (ESI): m/z 326.0 (M+H)+. 1H-NMR (200 MHz, CDCl3) δ 5.40 (m, 1H, =CHCH2), 5.12–4.93 
(m, =CHCH2, H2C=C), 4.00 (d, 2H, CH2OH, J= 8.0 Hz), 3.81 (m, 1H , H2C=CHN3), 3.63 (bs, 2H, CH2N3), 
2.26–1.90, 1.81–1.50 (2×m, CH2, CH3); 13C-NMR (50 MHz CDCl3): δ 143.3, 142.3, 134.8, 134.3 (Cq), 130.2, 
129.7, 125.2, 124.4, 123.9, 121.4, 120.6, 120.0 (C=CH), 114.5 (H2C=C), 68.0 (H2C-C(CH3)CH(N3), 59.4 
(N3CH2), 39.3, 39.1, 35.8, 30.5, 29.6, 29.5, 29.3, 26.3, 26.0 (CH2), 17.6, 15.9, 14.6 (CH3). 
(E,E,E)-3,7,11-trimethyl-1-yl diphosphate-2,6,10-dodecatrien-12-azide, tris ammonium salt (2). Recrystallised 
tetra-n-butylammonium pyrophosphate24 (2.0 equiv., 284 
µmol, 256 mg) was dissolved in dry CH3CN (1 mL) and cooled 
in an ice-bath. Next, a solution of bromide 9 (46 mg, 142 
µmol) in dry CH3CN (2 mL) was added after which stirring is 
continued at rt for 2 h. The reaction mixture was 
subsequently concentrated in vacuo and the tetra-n-
butylammonium salt of N3FPP was dissolved in 2 mL 
NH4HCO3 chromatography buffer (i.e. 2 g NH4HCO3 in 1000 mL iPrOH/H2O 1/49 v/v) and loaded onto an 
ion-exchange column (Dowex® 50×4, NH4+ form).27 Next, eluting the column with buffer (10 mL) and 
lyophilisation of the crude ammonium salt of compound 2 gave a white solid. RP-HPLC purification (linear 
gradient B 05→90%, 26 min) in H2O (eluent A) and 0.1M NH4Ac (eluent C) gave compound 2 as a white 
powder in 50% yield. LC-MS Rt (2)= 9.9 min.28 MS (ESI): m/z 441.2 (M+NH4)+. 1H-NMR (600 MHz, DMSO-
d6) δ 5.40 (m, 1H, C=CHCH2), 5.28, 5.11, 4.99 (3×m, 3H, C=CHCH2 and H2C=C(CH3)), 4.25 (bs, 2H, 
CH2OH), ∼3.55 (H2C=CHN3 and CH2N3): obscured by DMSO peak, 2.12-1.90, 1.68–1.54 (m, CH2 and CH3). 
31P-NMR (133 MHz, 25 mM NH4HCO3 in D2O): δ –5.5 and –9.8.  
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A Combinatorial and Optimisation Approach toward 





Abstract. An in silico iterative optimisation procedure is presented that was used in a combinatorial 
approach (Fmoc based solid phase synthesis) toward a library of ambiphilic peptide-based compounds as 
potential PGGT-1 inhibitors. Starting with 16 randomly synthesised compounds, their structures were 
artificially evolved into a new set of compounds which then were synthesised and evaluated for their 
inhibitory activity against PGGT-1. Each cycle afforded a new generation of compounds and a progressive 
improvement of the average inhibitory activity was observed until the fifth generation (seven generations 
were synthesised). The obtained compounds were found to inhibit PGGT-1 in the low micromolar range 













 7.1 Introduction 
Most isoprenyl pyrophosphate mimic inhibitors contain a hydrophobic tail 
(isoprenyl mimic) connected to a negatively charged region (pyrophosphate mimic). The 
allowance of amide bonds in farnesyl pyrophosphate based PFT inhibitors1 in 
combination with the promiscuous nature of PGGT-1 indicate that ambiphilic peptide-
based compounds, having a negatively charged C-terminus and a hydrophobic cap 
connected via spacer molecules (Figure 7.1), can serve as novel lead compounds for the 
development of PGGT-1 inhibitors. A suitably large set of different building blocks and a 
parallel solid phase approach offers the opportunity to construct a large library of 
ambiphilic peptides. However, the combination of large sets of building blocks (important 
for a broad screening of possible leads) gives rise to such large libraries that synthesis 
becomes nearly impossible. The substantial effort that is required to construct and 
evaluate a library of enormous size can be diminished by using an optimisation 
procedure. The purpose of such a procedure is to guide the synthesis of a manageable 
library with a greater probability of obtaining good (not necessarily the best) hits for a 




Figure 7.1 Ambiphilic peptides as potential GGPP analogs. 
 
Several optimisation methods, mainly in silico, have been described in the 
literature.2 In this chapter the use of an optimisation procedure involving single building 
block mutations of selected inhibitors was investigated. In Scheme 7.1 a schematic 
representation of the followed procedure is depicted. The approach comprised the 
following steps. Initially (step 1, Scheme 7.1), 30 ambiphilic peptides, designated as 
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SPPS from a set of building blocks having a variety of structural characteristics.3 The 
target peptides were released from the resin with concomitant deprotection by acidolysis, 
analysed by LC-MS and purified by RP-HPLC. After screening (step 2, Scheme 7.1) in a 
PGGT-1 bioassay (see Experimental Section) using a pilot screening method 
(determination of % inhibition at a predefined concentration), the 16 most potent 
inhibitors of this initial set of compounds were selected (step 3), ranked with decreasing 
inhibitory potency and assigned as generation 0 (Table 7.1a). Next, in silico (step 4: see 
Scheme 7.2 for a schematic outline), one arbitrarily chosen building block of each of these 
16 selected compounds was chosen for replacement by a new randomly chosen building 
block (see 7.4 and the example in Scheme 7.2). This gives a new set of 16 mutant 
compounds which are then synthesised, purified and screened following the same 
procedure (Tables 7.1a and 7.1b). From the combined results of both sets of compounds, 
that is generation 0 and their mutants, the 16 best inhibitors were selected to make up 
generation 1. This procedure of single building block mutation in silico, synthesis, 
purification, screening and selection was repeated several times. Thus, overall one first 
evaluates the molecular diversity of a given library prior to synthesis allowing the 






Scheme 7.1 Schematic presentation of the followed optimisation procedure. 
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Scheme 7.2 Schematic example of one building mutation procedure performed in silico. G01-07= compound 
from generation 1 (G1) ranked #7 according to inhibitory potency. 
 7.2 Results and Discussion 
The assembly of the projected potential inhibitors of PGGT-1 (AwBxCyDz, Figure 7.1) 
started with the selection of commercially available building blocks for the hydrophobic 
N-terminal and hydrophilic C-terminal subunits (Aw and Dz, respectively) as well as two 
spacer moieties (Bx and Cy). 24 Building blocks make up set Aw (Chart 7.1), 22 building 
blocks make up set Bx (Chart 7.2), 24 building blocks make up set Cy (Chart 7.3) and 18 
building blocks make up set Dz (Chart 7.4). As can be seen, mainly aromatic building 
blocks were selected for the hydrophobic N-terminal part (Aw set). The number of 
available protected acidic amino acids suitable for incorporation as C-terminal building 
blocks (Dz set) was extended with residues, having uncharged or basic side-chains. Based 
on the assumption that the length of the hydrophobic tail in the ambiphiles AwBxCyDz is 
important with regard to inhibitory potency,6 spacer molecules that vary in length and 
conformational restriction were selected with the option to omit (B01 and C01) one or 
both of these building blocks. Note that after incorporation of a building block via amide 
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Figure 7.2 Average inhibitory percentage of the 16 best inhibitors per generation depicted with spreading of 
inhibitory percentage value of the best (▲) and worst (■) inhibitor. 
 
 
The efficacy of the iterative optimisation procedure was evaluated by calculation of 
the average inhibitory percentage of the 16 best inhibitors of a generation (Figure 7.2). As 
can be seen in Figure 7.2, the average inhibitory percentage first increased rapidly with 
already in the second generation (Table 7.1a), compound A03B02C14D16 was found to 
inhibit PGGT-1 for ≈95% at 100 μM concentration. After 5 generations (Table 7.1a) no 
significant improvement (not depicted in Figure 7.2) was obtained. A different ranking of 
the 16 best inhibitors of generation 5 is obtained by looking at the percentage inhibition 
of the 10 μM concentration data points (Table 7.1a). Two additional generations 
(generations 6 and 7, Table 7.1b) were synthesised during which no increase in average 
inhibitory potency was observed. A slightly more potent inhibitor A03B10C14D16 holds 
the first place in this ranking with 97% inhibition of enzyme activity. The related 
compound A03B02C14D16 is now second with 81% inhibition of PGGT-1 activity. The 
inaccurate pilot screening data could be replaced by the more accurate IC50-values as 
selection criterium instead.4 Therefore, the IC50 value of A03B10C14D16 and 
A03B02C14D16 against PGGT-1 was determined: A03B02C14D16 and A03B10C14D16 
were found to inhibit PGGT-1 with an IC50-value of 8.1±1.2 μM and 3.8±0.9 μM, 
respectively. In Scheme 7.3 the mutational pathway to these two compounds is shown 
and note that only the central two building blocks are transformed.  
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Chart 7.1 Set of A building blocks (A01-A24).a 
 
Chart 7.2 Set of B building blocks (B01-B22).a 
 
aProtective groups which are removed during the TFA mediated release of the product from the solid 






































































































































































































Chart 7.3 Set of C building blocks (C01-C24).a 
 




aProtective groups which are removed during the TFA mediated release of the product from the solid 









































































































































































































    Best 16 of generation 0                           Mutants (G1) 
Code ABCD-code 
A (%) at 
100μM 
 Code ABCD-code 
A (%) at 
100μM 
G0-01 A21B21C01D15 71 → G1-01 A21B21C01D09 0 
G0-02 A04B07C05D11 63 → G1-02 A04B17C05D11 10 
G0-03 A19B12C01D15 55 → G1-03 A19B12C01D12 24 
G0-04 A02B07C24D01 50 → G1-04 A02B17C24D01 0 
G0-05 A02B06C21D01 49 → G1-05 A18B06C21D01 7 
G0-06 A03B02C07D07 49 → G1-06 A03B02C14D07 39 
G0-07 A10B03C04D15 48 → G1-07 A10B03C04D06 26 
G0-08 A21B01C02D18 41 → G1-08 A21B22C02D18 0 
G0-09 A21B21C01D04 40 → G1-09 A21B21C24D04 48 
G0-10 A07B07C07D01 30 → G1-10 A07B07C07D08 0 
G0-11 A16B11C21D11 29 → G1-11 A16B05C21D11 32 
G0-12 A07B11C24D05 25 → G1-12 A07B11C22D05 0 
G0-13 A04B03C05D11 23 → G1-13 A04B03C17D11 11 
G0-14 A15B03C10D01 21 → G1-14 A15B03C05D01 19 
G0-15 A10B04C05D03 20 → G1-15 A10B04C05D08 41 























   
Table 7.1a Results of the one-building mutation procedure for generation 1-5. Activity (A) of PGGT-1 at 
100 μM or 10 μM of compound: expressed as % of control activity. 
  Best 16 after 1 generation                          Mutants (G2) 
Code ABCD-code 
A (%) at 
100μM 
 Code ABCD-code 
A (%) at 
100μM 
G0-01 A21B21C01D15 71 → G2-01 A21B21C20D15 62 
G0-02 A04B07C05D11 63 → G2-02 A04B07C21D11 22 
G0-03 A19B12C01D15 55 → G2-03 A19B12C01D09 0 
G0-04 A02B07C24D01 50 → G2-04 A02B07C12D01 22 
G0-05 A02B06C21D01 49 → G2-05 A02B06C15D01 29 
G0-06 A03B02C07D07 49 → G2-06 A03B02C12D07 53 
G0-07 A10B03C04D15 48 → G2-07 A10B13C04D15 0 
G1-09 A21B21C24D04 48 → G2-08 A21B02C24D04 0 
G1-15 A10B04C05D08 41 → G2-09 A10B14C05D08 75 
G0-08 A21B01C02D18 41 → G2-10 A05B01C02D18 51 
G0-09 A21B21C01D04 40 → G2-11 A21B20C01D04 4 
G1-06 A03B02C14D07 39 → G2-12 A03B02C14D16 95 
G1-11 A16B05C21D11 32 → G2-13 A16B05C03D11 0 
G0-10 A07B07C07D01 30 → G2-14 A07B07C10D01 18 
G0-11 A16B11C21D11 29 → G2-15 A16B11C09D11 0 
G1-07 A10B03C04D06 26 → G2-16 A10B06C04D06 0 
 Best 16 after 2 generations                        Mutants (G3) 
Code ABCD-code 
A (%) at 
100μM 
 Code ABCD-code 
A (%) at 
100μM 
G2-12 A03B02C14D16 95 → G3-01 A03B08C14D16 57 
G2-09 A10B14C05D08 75 → G3-02 A10B11C05D08 20 
G0-01 A21B21C01D15 71 → G3-03 A21B11C01D15 0 
G0-02 A04B07C05D11 63 → G3-04 A04B07C05D01 59 
G2-01 A21B21C20D15 62 → G3-05 A21B10C20D15 21 
G0-03 A19B12C01D15 55 → G3-06 A19B12C01D16 44 
G2-06 A03B02C12D07 53 → G3-07 A10B02C12D07 73 
G2-10 A05B01C02D18 51 → G3-08 A05B01C04D18 22 
G0-04 A02B07C24D01 50 → G3-09 A02B07C24D02 0 
G0-05 A02B06C21D01 49 → G3-10 A02B06C21D18 2 
G0-06 A03B02C07D07 49 → G3-11 A03B16C07D07 20 
G0-07 A10B03C04D15 48 → G3-12 A10B16C04D15 62 
G1-09 A21B21C24D04 48 → G3-13 A21B21C24D02 0 
G1-15 A10B04C05D08 41 → G3-14 A07B04C05D08 0 
G0-08 A21B01C02D18 41 → G3-15 A21B01C02D10 65 
G0-09 A21B21C01D04 40 → G3-16 A21B21C12D20 62 
Best 16 after 3 generations                          Mutants (G4) 
Code ABCD-code 
A (%) at 
100μM 
 Code ABCD-code 
A (%) at 
100μM 
G2-12 A03B02C14D16 95 → G4-01 A03B13C14D16 0 
G2-09 A10B14C05D08 75 → G4-02 A10B14C04D08 73 
G3-07 A10B02C12D07 73 → G4-03 A10B02C07D07 41 
G0-01 A21B21C01D15 71 → G4-04 A21B20C01D15 71 
G3-15 A21B01C02D10 65 → G4-05 A21B05C02D10 0 
G0-02 A04B07C05D11 63 → G4-06 A24B07C05D11 7 
G2-01 A21B21C20D15 62 → G4-07 A13B21C20D15 87 
G3-12 A10B16C04D15 62 → G4-08 A10B14C04D15 87 
G3-16 A21B21C12D04 62 → G4-09 A20B21C12D04 0 
G3-04 A04B07C05D01 59 → G4-10 A22B07C05D01 0 
G3-01 A03B08C14D16 57 → G4-11 A03B22C14D16 0 
G0-03 A19B12C01D15 55 → G4-12 A19B12C16D15 67 
G2-06 A03B02C12D07 53 → G4-13 A03B02C12D03 26 
G2-10 A05B01C02D18 51 → G4-14 A05B01C16D18 0 
G0-04 A02B07C24D01 50 → G4-15 A02B07C06D01 0 
G0-05 A02B06C21D01 49 → G4-16 A02B19C21D01 21 
    Best 16 after 4 generations                            Mutants (G5)           Best 16 after 5 generations 
Code ABCD-code 
A (%) at 
100μM 
 Code ABCD-code 
A (%) at 
100μM 
Code ABCD-code 
A (%) at 
100μM 
A (%) at 
10μM 
G2-12 A03B02C14D16 95 → G5-01 A03B10C14D16 68 G2-12 A03B02C14D16 95 81 
G4-07 A13B21C20D15 87 → G5-02 A17B21C20D15 72 G4-07 A13B21C20D15 87 53 
G4-08 A10B14C04D15 87 → G5-03 A10B14C04D09 0 G4-08 A10B14C04D15 87 26 
G2-09 A10B14C05D08 75 → G5-04 A10B14C15D08 73 G5-07 A02B20C01D15 80 60 
G3-07 A10B02C12D07 73 → G5-05 A09B02C12D07 58 G2-09 A10B14C05D08 75 37 
G4-02 A10B14C04D08 73 → G5-06 A10B10C04D08 1 G5-04 A10B14C15D08 73 0 
G4-04 A21B20C01D15 71 → G5-07 A02B20C01D15 80 G3-07 A10B02C12D07 73 22 
G0-01 A21B21C01D15 71 → G5-08 A21B10C01D15 48 G4-02 A10B14C04D08 73 26 
G4-12 A19B12C16D15 67 → G5-09 A19B04C16D15 50 G5-02 A17B21C20D15 72 64 
G3-15 A21B01C02D10 65 → G5-10 A21B01C03D10 17 G4-04 A21B20C01D15 71 39 
G0-02 A04B07C05D11 63 → G5-11 A04B07C19D11 10 G0-01 A21B21C01D15 71 40 
G2-01 A21B21C20D15 62 → G5-12 A21B21C04D15 43 G5-01 A03B10C14D16 68 97 
G3-12 A10B16C04D15 62 → G5-13 A10B16C18D15 35 G4-12 A19B12C16D15 67 32 
G3-16 A21B21C12D04 62 → G5-14 A21B05C12D04 54 G3-15 A21B01C02D10 65 18 
G3-04 A04B07C05D01 59 → G5-15 A04B07C05D07 0 G0-02 A04B07C05D11 63 40 






Table 7.1b Results of the one-building mutation procedure for generations 6 and 7. Activity (A) of PGGT-1 




Scheme 7.3 Mutational development of A03B02C14D16 and A03B10C14D16. 
 
Although the mode of action of A03B02C14D16 and A03B10C14D16 is not known 
at the moment, it is not excluded that these compounds act as a bisubstrate inhibitor in 
which the lipid part functions as isoprenyl mimic.5 The presence of two amines in these 
compounds (i.e. in building blocks B10, B02 and C14) indicates the possibility of H-
bonding in the active site of PGGT-1.6  
          Mutants (G6)                         Best 16 after 6 generations 
Code ABCD-code 
A (%) at 
10μM 
 Code ABCD-code 
A (%) at 
10μM 
G6-01 A03B10C24D16 27  G5-01 A03B10C14D16 97 → 
G6-02 A03B02C13D16 38  G2-12 A03B02C14D16 81 → 
G6-03 A17B21C20D01 5  G5-02 A17B21C20D15 64 → 
G6-04 A02B20C12D15 0  G5-07 A02B20C01D15 60 → 
G6-05 A11B08C14D16 0  G3-01 A03B08C14D16 57 → 
G6-06 A13B17C20D15 18  G4-07 A13B21C20D15 53 → 
G6-07 A21B21C01D17 6  G0-01 A21B21C01D15 40 → 
G6-08 A04B07C22D11 1  G0-02 A04B07C05D11 40 → 
G6-09 A21B20C01D05 0  G4-04 A21B20C01D15 39 → 
G6-10 A07B07C10D15 14  G2-14 A07B07C10D01 39 → 
G6-11 A10B14C05D10 9  G6-02 A03B02C13D16 38 → 
G6-12 A11B04C16D15 0  G2-09 A10B14C05D08 37 → 
G6-13 A21B21C09D15 0  G5-09 A19B04C16D15 37 → 
G6-14 A19B09C16D15 0  G5-12 A21B21C04D15 33 → 
G6-15 A03B22C02D16 0  G4-12 A19B12C16D15 32 → 
G6-16 A21B21C12D15 18  G4-11 A03B22C14D16 32 → 
           Mutants (G7)                          Best 16 after 7 generations 
Code ABCD-code 
A (%) at 
10μM 
 Code ABCD-code 
A (%) at 
10μM 
G7-01 A03B10C02D16 0  G5-01 A03B10C14D16 97 
G7-02 A03B14C14D16 0  G2-12 A03B02C14D16 81 
G7-03 A02B21C20D15 9  G5-02 A17B21C20D15 64 
G7-04 A20B20C01D15 36  G5-07 A02B20C01D15 60 
G7-05 A03B08C14D05 0  G3-01 A03B08C14D16 57 
G7-06 A13B16C20D15 23  G4-07 A13B21C20D15 53 
G7-07 A21B14C01D15 1  G7-16 A03B22C23D16 44 
G7-08 A06B07C05D11 0  G0-01 A21B21C01D15 40 
G7-09 A10B20C01D15 0  G0-02 A04B07C05D11 40 
G7-10 A07B07C11D01 0  G4-04 A21B20C01D15 39 
G7-11 A03B02C13D03 0  G2-14 A07B07C10D01 39 
G7-12 A10B14C21D08 28  G6-02 A03B02C13D16 38 
G7-13 A19B04C15D15 0  G2-09 A10B14C05D08 37 
G7-14 A21B21C24D15 0  G5-09 A19B04C16D15 37 
G7-15 A19B18C16D15 0  G7-04 A20B20C01D15 36 





















































 7.3 Conclusions 
The in silico optimisation procedure (Schemes 7.1 and 7.2) presented in this chapter 
gave a cut-off inhibition value after 5 of the total 7 synthesised generations of ambiphilic 
peptides (Tables 7.1a and 7.1b). The most potent PGGT-1 inhibitors found in these 7 
generations, A03B02C14D16 and A03B10C14D16, have IC50-values of 8.1±1.2 μM and 
3.8±0.9 μM, respectively.7 Thus by synthesizing a fraction (≈ 0.06%)* of the total possible 
library population, already lead compounds which exhibit low micromolar inhibitory 
potency against PGGT-1 are obtained. Obviously, it is not known whether more active 
inhibitors of PGGT-1 can be found with the given set of building blocks Aw-Dz (Charts 
7.1–7.4), however, the library obtained here can be further optimised by either 
introducing new building blocks or increasing the number of mutations. Altogether, the 
peptide analogs described in this chapter represent novel lead compounds for the 
construction of a conventional library using rational design. Because both selective and 
dual inhibitors8 of PFT and PGGT-1 show promise as therapeutics or as tools to 
investigate the biological functioning of isoprenylating processes (proteomics, see Chapter 
6), the selectivity of PGGT-1 inhibitors of the type presented in this chapter may also be 
used as a selection criterium. This can either be based on selecting for high selectivity 
(selective inhibitors) or low selectivity (dual inhibitors).9  
 
 7.4 Experimental Section 
7.4.1 General − 1H-NMR and 13C-NMR spectra were recorded with a Bruker AV-400 (1H-NMR: 400, 
13C-NMR: 100 MHz) or a Bruker DMX-600 (1H-NMR: 600, 13C-NMR: 150 MHz). Chemical shifts are given 
in ppm (δ) relative to tetramethylsilane (1H-NMR δ= 0 ppm; 13C-NMR middle resonance δ= 77.0 ppm) as 
internal standard. Mass spectra were recorded with a Perkin Elmer/SCIEX API 165 mass instrument and 
HR-MS spectra were recorded with a API QSTARtm Pulsar (Applied Biosystems). RP-HPLC analysis was 
performed on a Jasco HPLC system equipped with an Alltima C18 100Å 5 μm column (4.6×150 mm). 
Purifications were performed on a BioCad Vision (Applied Biosystem) HPLC system equipped with an 
Alltima C18 100Å 5 μm column (10×150 mm). The applied eluent systems were I: H2O (eluent A), linear 
gradient of CH3CN (eluent B), 1% aq. TFA (effective 0.1%, eluent C) or II: H2O (eluent A), linear gradient 
of CH3CN (eluent B), 0.1M NH4Ac (effective 0.01M, eluent C). In the case of compounds containing 
building blocks D04, D15 or D18, the best results were obtained with system II. All solvents were of HPLC 
quality (Biosolve). All employed building blocks (Charts 7.1-7.4) were purchased from commercial suppliers 
and were of the highest quality available. The SPPS was performed on a LaMOSS2 (Labotec Modular 
Organic Synthesis System 2) robotic synthesiser using standard Fmoc chemistry and Wang solid support 
(loading 0.5–1.1 mmol g-1, Novabiochem, 100-200 mesh). 
                                                          
*  Total library= 24×22×24×18= 228096 compounds; 30+6×16= 126 compounds synthesised= ≈0.04%.  
Chapter 7 
 137
A300 × V 
7.8 × wt 
7.4.2 General procedure for manual coupling of building blocks D01, D03, D04, D15 and D18: 1.0 g 
Wang resin (0.81 mmol) was coevaporated 3× with anh. 1,4-dioxane (10 mL) and treated with a solution of 
the amino acid (2.0 equiv., 1.6 mmol) in DCM/DMF (3/1 v/v; c= 0.1–0.15M), DIC (2.4 equiv., 1.9 mmol, 0.3 
mL) and DMAP (0.04 equiv., 5 mg). After shaking the mixture under argon for 6 h, the resin was washed 
with DCM, DMF, MeOH, DCM and finally Et2O. A second coupling step was performed employing 1.0 
equiv. of amino acid and the reaction mixture was shaken overnight. The resin was washed (DCM and 
DMF), capped (0.5M Ac2O, 0.125M DIPEA and 0.015M HOBt in NMP), washed (DMF, MeOH, DCM and 
Et2O) and dried in vacuo. The loading of the resin (0.3–0.5 mmol g-1) was determined as follows: to a sample 
of the resin (1–2 mg) in a volumetric flask (10 mL) was added a solution of piperidine/DMF (1/4 v/v, 1.0 
mL) and the mixture was left for 15 min. Next, the volume was adjusted to 10 mL by addition of EtOH 
(HPLC grade) and the UV absorption was measured between 250 and 350 nm. The loading could then be 
calculated using formula A (A300= absorption at 300 nm; EtOH as reference); V= volume of sample (= 10 
mL); wt= weight of employed resin (= 1–2 mg):  
                                                  
                                            loading (mmol g-1) =                                                                                  (A) 
 
7.4.3 General synthetic protocol LaMOSS2 robot.  
[a]  Coupling building block D: Wang resin (50 μmol) was swollen with 2×2 mL DCM and treated with 5.0 
equiv. of a building block D (0.25M solution in NMP, 1.0 mL), 5.0 equiv. DIC (0.5 mL, 0.5M solution in 
DCM) and 0.25 equiv. DMAP (0.5 mL, 0.025M solution in NMP). The reaction mixture was flushed 
with N2 for 3 h after which the reagents were removed. This procedure was repeated, however this 
time the reaction mixture was allowed to react for 16 h instead of 3 h. After a washing with NMP (1×3 
and 3×2 mL), the resin was capped with 2 mL of 0.5M Ac2O, 0.125M DIPEA and 0.015M HOBt in NMP 
(2×5 min) and washed with NMP (1×3 and 3×2 mL). 
[b] Removal Fmoc group: the resin was treated with 2 mL 20% piperidine in NMP (4×2 min) and washed 
with NMP (1×3 and 3×2 mL).10 
[c] Coupling of a building block B or C: to the resin were added 5.0 equiv. of building block B or C (0.25M 
in NMP, 1.0 mL), 5.0 equiv. BOP/HOBt (1/1, 0.5 mL, 0.5M in NMP) and 10 equiv. DMAP (0.5 mL, 
1.0M in NMP). The reaction mixture is flushed with N2 for 45 min after which the reagents are 
removed. In the case of building blocks which are known to couple difficult (e.g. B06 or C05) the 
coupling procedure was repeated. The resin was washed (1×3 and 3×2 mL NMP), capped with 2×2 mL 
of 0.5M Ac2O, 0.125M DIPEA and 0.015M HOBt in NMP and washed again (1×3 and 3×2 mL NMP).  
[d] Coupling building block A: to the resin were added 5.0 equiv. of a building block A (0.25M solution in 
NMP, 1.0 mL), 5.0 equiv. BOP/HOBt (0.5 mL, 0.5M solution in DCM) and 10 equiv. DMAP (0.5 mL, 
1.0M solution in NMP). After flushing with N2 for 45 min all reagents are removed and the resin was 
washed (1×3 mL and 3×2 mL NMP), capped (2×2 mL 0.5M Ac2O, 0.125M DIPEA and 0.015M HOBt in 
NMP) and washed again (2 mL DCM and 2 mL MeOH (3×); 1×3 mL and 3×2 mL DCM).  
[e] Cleavage of product from resin: to the resin was added 3 mL TFA/H2O/iPr3SiH (95/4/1 v/v/v) under N2 
flushing. After 2 h the TFA solution was collected in a tube and the resin was rinsed 2× with 2 mL 
TFA/H2O/iPr3SiH (95/4/1 v/v/v). 
[f]  Work-up procedure: The filtrate was concentrated in vacuo, dissolved in 4 mL H2O/CH3CN/tBuOH 
(1/1/1 v/v/v), analysed by LC-MS and purified by RP-HPLC (Tables 7.3–7.5 list LC-MS data for 





Table 7.2 Initial pool of compounds (16 most potent compounds= generation 0), synthesised via the 
general procedures described in §7.4.2 and §7.4.3 using a diverse range of building blocks (Chart 7.1–7.4). 
A= activity of enzyme at 100 μM of compound: expressed as % of control activity. 
 
7.4.5 Tables 7.3-7.5 list MS (ESI, m/z) data and Rt values of compounds from generation 1– 5. 
 
 
Table 7.3 LC-MS data (Rt and [M+H]+) of compounds from generation 1 (G1) and 2 (G2). 
aLinear gradient B 05→90%, 26 min. bNon-optimised yields. All compounds were ≥95% pure as determined 
by LC-MS. cUnless stated otherwise: linear gradient B 05→50%, 26 min.  
compound 
A (%) at 
100μM 
  compound 
A (%) at 
100μM 
       compound 
A (%) at 
100μM 
A21B21C01D15 71 A16B11C21D11 29 A24B21C04D18 10 
A04B07C05D11 63 A07B11C24D05 25 A04B13C24D01 9 
A19B12C01D15 55 A04B03C05D11 23 A04B03C19D11 9 
A02B07C24D01 50 A15B03C10D01 21 A01B03C24D01 4 
A02B06C21D01 49 A10B04C05D03 20 A21B12C01D03 3 
A03B02C07D07 49 A24B01C23D01 20 A19B15C02D10 0 
A10B03C04D15 48 A21B16C09D01 19 A15B02C21D01 0 
A21B01C02D18 41 A21B03C24D01 16 A07B11C05D13 0 
A21B21C01D04 40 A16B03C19D11 16 A12B03C10D03 0 
A07B07C07D01 30 A10B02C24D03 14 A24B01C08D03 0 
compound (G1)    [M+H]+    Rt  (min)a      yield (%)b    compound (G2)        [M+H]+    Rt  (min)c      yield (%)b 
A21B21C01D09 392,2 8,2 42 A21B21C20D15 680,4 10,2 1 
A04B17C05D11 519,4 9,8 54 A04B07C21D11 533,4 12,2a 98 
A19B12C01D12 463,2 9,0 56 A19B12C01D09 414,2 8,6 94 
A02B17C24D01 495,3 10,2 89 A02B07C12D01 583,5 13,6 34 
A18B06C21D01 374,1 7,9 28 A02B06C15D01 541,4 10,9 79 
A03B02C14D07 671,8 13,8 38 A03B02C12D07 702,6 25,9a 22 
A10B03C04D06 531,3 10,6 38 A10B13C04D15 853,6 6,9 1 
A21B22C02D18 587,5 8,9 1 A21B02C24D04 607,4 8,0 35 
A21B21C24D04 463,2 10,2 1 A10B14C05D08 678,4 11,5 60 
A07B07C07D08 657,7 12,4 45 A05B01C02D18 424,1 2,3 28 
A16B05C21D11 432,2 2,4 98 A21B20C01D04 567,2 9,3 14 
A07B11C22D05 536,2 11,5 49 A03B02C14D16 618,6 12,7a 66 
A04B03C17D11 477,3 8,5 42 A16B05C03D11 460,2 2,1 89 
A15B03C05D01 500,4 20,5 68 A07B07C10D01 594,4 15,5 38 
A10B04C05D08 678,3 8,4 48 A16B11C09D11 519,4 7,9 71 






   compound (G3)  [M+H]+       Rt (min)a   yield (%)b       compound (G4)     [M+H]+      Rt (min)a      yield (%)b    
A03B08C14D16 644,5 18,8 30 A03B13C14D16 643,3 22.6 98 
A10B11C05D08 706,4 13,1 81 A10B14C04D08 664,2 12.2 98 
A21B11C01D15 471,3 11,8 6 A10B02C07D07 687,5 11.2 60 
A04B07C05D01 534,3 17,5 89 A21B20C01D15 491,2 13.0 70 
A21B10C20D15 667,3 13,1 4 A21B05C02D10 529,5 9.9 98 
A19B12C01D16 433,1 15,6 62 A24B07C05D11 541,3 12.7 98 
A10B02C12D07 735,4 12,6 37 A13B21C20D15 712,5 11.1 6c 
A05B01C04D18 382,1 1,9 35 A10B14C04D15 639,2 8.8 31 
A02B07C24D02 536,2 12,4 98 A20B21C12D04 695,4 11.7 98 
A02B06C21D18 491,1 9,0 34 A22B07C05D01 490,2 13.9 98 
A03B16C07D07 615,5 27,0 64 A03B22C14D16 646,5 16.7 54 
A10B16C04D15 585,2 9,0 14 A19B12C16D15 650,3 12.0 13 
A21B21C24D02 505,3 11,8 51 A03B02C12D03 645,4 20.1 80 
A07B04C05D08 601,3 16,9 81 A05B01C16D18 494,2 10.4 15 
A21B01C02D10 416.1 12.0 37 A02B07C06D01 553,3 12.6 98 
A21B21C12D20 680,4 13,9 48 A02B19C21D01 469,1 11.6 37 
Table 7.4 LC-MS data (Rt and [M+H]+) of compounds from generation 3 (G3) and 4 (G4). 
aLinear gradient B 05→90%, 26 min. bNon-optimised yields. All compounds were ≥95% pure as determined 
by LC-MS.   
 
 
    compound           [M+H]+    Rt (min)a   yield (%)b     compound               [M+H]+         Rt (min)a      yield (%)b   
A03B10C14D16 618,6 17.5 76 A19B04C16D15 628,5 14.9 7 
A17B21C20D15 930,5 13.7 4 A21B01C03D10 401,1 10.6 98 
A10B14C04D09 586,3 9.6 98 A04B07C19D11 601,5 14.0 97 
A10B14C15D08 780,4 15.0 96 A21B21C04D15 516,2 11.4 10 
A09B02C12D07 582,3 14.1 17 A10B16C18D15 683,4 8.9 26 
A10B10C04D08 653,6 11.3 98 A21B05C12D04 681,4 11.1 18 
A02B20C01D15 494,1 10.8 7 A04B07C05D07 605,5 19.2 13 
A21B10C01D15 432,1 9.2 11 A20B08C14D16 567,3 8.7 98 
Table 7.5 LC-MS data [Rt and (M+H)+] of compounds from generation 5 (G5).aLinear gradient B 






7.4.6  Spectroscopic and spectrometric data of compounds from the pool of synthesised compounds.  
A03B02C14D16 (G02-12): 1H-NMR (400 MHz, DMSO-d6): δ 8.86 (d, 1H, J= 7.6 Hz), 8.73 (m, 1H), 8.03 (d, 
J= 4.0 Hz), 7.81 (m), 7.36 (m, 5H, Ph), 7.07 (d, 1H, J= 8.0 Hz), 
6.96 (d, 1H, J= 8.4 Hz), 6.82 (d, 1H, J= 6.8 Hz), 6.62 (d, 1H, J= 
8.4 Hz), 5.36 (d, 1H, J= 7.6 Hz), 5.29 (d, 1H, J= 7.2 Hz), 4.47 (m, 
1H), 4.16–3.96 (m, 6H), 3.72 (m, 1H), 3.32, 3.12 (2×s), 2.76–
2.67 (2×m), 2.49 (s), 2.06 (dd, 2H, J= 6.8 and 7.2 Hz), 1.76 (m, 
3H), 1.56, 1.50 (2×m), 1.22 (bs), 1.10 (s), 0.86 (apparent t, 3H, J= 6.0 and 6.8 Hz). Purity >95%, 20.4 mg (66% 
yield). LC-MS analysis: Rt= 12.7 min (linear gradient B 05→90%, 26 min), m/z 618.5 (M+H)+. HR-MS: calc. 
for [C34H59N5O5+H]+ 618.45945, found 618.45972. 
A03B10C14D16 (G05-01): 1H-NMR (400 MHz, DMSO-d6): δ 8.80 (d, 1H, J= 8.0 Hz), 8.66 (d, 1H, J= 7.2 Hz), 
8.07 (m, 4H), 7.81 (m), 7.35 (m, 5HPh), 7.07 (d, 1H, J= 8.0 Hz), 6.96 
(d, 1H), 6.82 (d, 1H, J= 7.2 Hz), 6.64 (d, 1H, J= 8.4 Hz), 5.35 (d, 1H, 
J= 8.0 Hz), 5.27 (d, 1H, J= 7.2 Hz), 4.37 (m, 2H), 4.17–3.96 (m, 
3H), 3.34 and 3.16 (2×s), 2.88–2.67 (m, 4H), 2.49 (s), 2.09 (m, 2H), 
1.90–1.71 (m, 3H), 1.54–1.36 (m), 1.22 (bs), 1.10 (s), 0.84 (apparent t, 3H, J= 6.0 and 6.8 Hz). Purity >95%, 
23.5 mg, (76% yield). LC-MS analysis: Rt= 17.5 min (linear gradient B 05→90%, 26 min), m/z 618.6 (M+H)+. 
HR-MS: calc. for [C34H59N5O5+H]+ 618.45945, found 618.45953. 
A10B11C05D08 (G03-02): 1H-NMR (400 MHz, DMSO-d6): δ 8.93 (s), 8.10 (d, J= 8.4 Hz), 7.94 (apparent t, J= 
5.6 and 6.0 Hz), 7.71 (s), 7.60 (dd, J= 8.0 and 8.4 Hz), 7.47 (d, J= 8.8 
Hz), 7.38–7.28 (m), 5.00 (2×d, 2H, J= 12.8 Hz), 4.47 (dt, J= 4.8, 8.0 
and 8.4 Hz), 4.30 (m), 3.23 (dd, J= 4.4 and 4.8 Hz), 3.09 (m), 2.96–
2.85 (m), 2.02 (apparent bt, J= 11.6 and 12.0 Hz), 1.63 (bt, J= 14.4 
and 15.2 Hz), 1.26 (s), 1.17 (m), 1.11 (s), 0.78 (dd, J= 12.4 and 12.8 Hz). Purity >95%, 28.6 mg, (81% yield).  
LC-MS analysis: Rt= 13.1 min (linear gradient B 05→90%, 26 min), m/z 706.4 (M+H)+.  
A21B21C24D02  (G03-13): 1H-NMR (400 MHz, DMSO-d6): δ 7.76 (m), 7.27 (m), 7.17 (m), 6.54 (s), 3.00 (m), 
2.52 (m), 2.04 (m), 1.77 (m), 1.45 (m), 1.37 (m), 1.20 (m). 
Purity >95%, 12.9 mg (51% yield). LC-MS analysis: Rt= 11.8 
min (linear gradient B 05→90%, 26 min), m/z 505.3 
 (M+H)+. 
A07B04C05D08 (G03-14): 1H-NMR (400 MHz, DMSO-d6): δ 8.10 (2×d, 2H, J= 2.0 Hz), 7.85 (d, 1H, J= 5.6 
Hz), 7.62 (dd, 1H, J= 8.0 and 12.8 Hz), 7.47 (dd, 2H, J= 3.2 and 8.4 Hz), 
4.50–4.39 (m, 2H), 3.53 (d, 1H, J= 13.6 Hz), 3.22 (m, 1H), 3.08 (m, 2H), 2.91 
(m, 1H), 2.44 (m, 1H), 1.78 (bd, J= 13.2 Hz), 1.63 (bt, J= 10.4 Hz), 1.44–1.30 
(m, 8H), 1.10 (s, 1H); 13C-NMR (100 MHz, DMSO-d6): δ 174.4, 173.6, 172.9, 156.2, 146.6, 131.1, 123.5, 56.2, 
53.3, 46.3, 41.6, 41.5, 36.8, 29.3, 28.5, 25.5, 25.2. Purity >95%, 24.3 mg (81% yield). LC-MS analysis: Rt= 
16.9 min (linear gradient B 05→90%, 26 min), m/z 601.3 (M+H)+. 
A02B17C24D01 (G01-04): 1H-NMR (400 MHz, DMSO-d6): δ 8.76 (d, 1H, J= 8.0 Hz), 8.30 (d, 2H, J= 7.2 Hz), 
8.12 (d, 3H, J= 7.2 Hz), 8.00 (t, 1H, J= 5.6 Hz), 4.49 (dd, 1H, J= 6.4 and 6.8 
Hz), 4.38 (m, 1H), 3.10–3.01 (m, 2H), 2.65 (2×d, 1H, J= 6.0 Hz), 2.50 (m, 
obscured by solvent peak), 2.10 (t, 2H, J= 7.2 Hz), 1.74 (m, 2H), 1.51–1.20 
(m, 9H), 0.85 (apparent t, 3H, J= 6.0 and 6.8 Hz); 13C-NMR (100 MHz, DMSO-d6): δ 173.0, 172.2, 171.8, 
165.2, 149.5, 140.4, 129.6, 123.8, 54.2, 49.0, 38.8, 36.7, 35.1, 31.9, 29.0, 28.4, 23.0, 22.3, 14.4. Purity >95%, 




















































































A16B11C09D11 (G02-15): 1H-NMR (400 MHz, DMSO-d6): δ 8.53 (d, 1H, J= 8.0 Hz), 8.33 (t, 1H, J= 6.0 Hz), 
7.82 (d, 3H, J= 8.4 Hz), 7.70 (bs, 3H), 7.30 (d, 2H, J= 8.0 Hz), 4.35 (m, 
1H), 4.30 (d, 2H, J= 5.6 Hz), 2.89 (apparent t, 2H, J= 6.0 and 6.4 Hz), 
2.78 (bs, 2H), 2.41 (apparent t, 2H, J= 6.4 and 7.2 Hz), 2.31 (apparent 
t, 2H, J= 6.4 and 7.2 Hz), 2.12 (bt, 1H, J= 12.0 Hz), 1.79 (m, 6H), 1.59 (m, 2H), 1.52–1.25 (m, 6H), 0.85 (m, 
2H); 13C-NMR (100 MHz, DMSO-d6): δ 174.4, 174.2, 171.3, 166.8, 144.0, 132.8, 128.0, 127.1, 52.7, 45.2, 
44.5, 42.0, 37.6, 30.5, 30.1, 29.7, 29.3, 27.0, 23.3. Purity >95%, 18.4 mg (71% yield). LC-MS analysis: Rt= 7.9 
min (linear gradient B 05→50%, 26 min), m/z 519.4 (M+H)+. 
A15B03C05D01 (G01-14): 1H-NMR (400 MHz, DMSO-d6): δ 7.92 (s, 1H), 7.73 (apparent t, 1H, J= 4.8 and 
5.2 Hz), 7.52 (d, 1H, J= 8.0 Hz), 4.42 (d, 1H, J= 5.6 Hz), 3.00 (m, 
2H), 2.60 (m, 2H), 2.04 (m, 4H), 1.46 (m, 5H), 1.40–1.10 (m), 0.86 
(apparent t, 3H, J= 6.0 and 6.8 Hz); 13C-NMR (100 MHz, DMSO-
d6): δ 174.1, 173.0, 172.6, 172.4, 56.1, 48.9, 38.6, 35.9, 35.5, 31.8, 29.5, 29.2, 25.8, 25.1, 23.0, 22.6, 14.1. 
Purity >95%, 17.0 mg (68% yield). LC-MS analysis: Rt= 20.5 min (linear gradient B 05→90%, 26 min), m/z 
500.4 (M+H)+. 
A16B05C21D11 (G01-11): 1H-NMR (400 MHz, DMSO-6): δ 8.44 (d, 1H, J= 6.0 Hz), 8.23 (dd, 2H, J= 8.0 and 
8.4 Hz), 7.76 (bs), 4.71 (m, 1H), 4.60 (m, 1H), 4.37 (d, 1H, J= 17.2 Hz), 4.17 
(m, 2H), 4.10 (d, 1H, J= 16.0 Hz), 3.88 (dd, 2H, J= 16.0 and 17.2 Hz), 3.02 (s, 
3H), 2.38 (m), 1.76–1.20 (m). Purity >95%, 21.1 mg (98% yield). LC-MS 
analysis: Rt= 2.4 min (linear gradient B 05→90%, 26 min), m/z 432.2 (M+H)+. 
 
7.4.5 Procedure Pilot Assay11,† – Determination of PGGT-1 activity was performed by using a sepharose-
coupled octapeptide as substrate. The amino acid sequence of the peptide was Met-Gly-Leu-Pro-Cys-Val-
Val-Leu containing the C-terminal Ca1a2L-box, which is the consensus sequence for geranylgeranylation by 
PGGT-1. This substrate has been designated as pepCsep. PepDsep, another sepharose-coupled peptide, 
which is non-isoprenylatable by replacing Cys by Ala, was used as control to measure non-specific 
association of radiolabeled GGPP. A partial purified PGGT-1 enzyme preparation, isolated from bovine 
brain,12 was used in the assay. The incubation mixture (25 μL) contained 2.5 μL of pepCsep or pepDsep (1 
nmol of peptide), 3 μL of PGGT-1 (bovine brain), 1 μM of [3H]-GGPP (spec. radioactivity 15 Ci mmol-1, 
American Radiolabeled Chemicals, USA), 50 μM ZnCl2, 0.5 mM MgCl2, 1 mM DTT, 0.004% Triton X-100, 
50 mM Tris-HCl (pH 7.4). For the determination of the inhibitory potencies of the various compounds, 
three different concentrations were used (in duplo) in the mixture (generations 0 – 4: 10, 100 and 1000 μM; 
generation 5 – 7: 3, 10 and 100 μM). The incubation was performed at 37°C for 40 min under continuous 
shaking. The reaction was terminated by addition of 1 mL of 2% (w/v) of SDS, the beads were spun down 
and washed successively 3× with 2% (w/v) SDS under shaking for 45 min at 50°C. The remaining adhering 
radioactivity was counted in a Liquid Scintillation Counter. For the calculation of PGGT-1 activity the [3H]-
counts bound to pepDsep were subtracted from the counts bound to pepCsep. For the determination of the 
IC50-values of the test compounds the assay was repeated at least two times in the presence of the various 
concentrations of the compounds and the concentration at 50% inhibition was determined using a 
mathematical function fitting to the concentration/inhibition curves. 
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Chapter 8  
Summary and Future Prospects 
 
Since the observation that oncogenic small G-proteins belonging to the Ras family play a 
major role in tumorogenesis, the blocking of the functioning of these oncoproteins has emerged as 
one of the main strategies in the field of anti-cancer research. In this context, prevention of 
maturation of Ras proteins by inhibition of the required post-translational isoprenylation 
mediated by the transferases PFT (protein:farnesyl transferase) and PGGT-1 
(protein:geranylgeranyl transferase-1) is recognised as a promising approach to prevent oncogenic 
Ras functioning. Since the early 90’s numerous PFT and PGGT-1 inhibitors have been reported 
and tested on their capacity to function as anti-cancer agents. Besides this, some inhibitors of PFT 
and/or PGGT-1 show potency against a range of pathological disorders (multiple sclerosis, 
osteoporosis, atherosclerosis and restenosis) and parasitic infections such as malaria. The major 
part of the research described in this Thesis was devoted to the development of PFT and PGGT-1 
inhibitors, the design of which was based on the individual substrates of PFT and PGGT-1 
(Chapters 2 – 5 and 7). Chapter 6 presents the development of a novel methodology to label and 
isolate farnesylated proteins from cells as a potential proteomic analytical tool.1   
In Chapter 1 an introduction is presented on the isoprene metabolism, a pathway 
which accounts for the biosynthesis of numerous biologically important compounds. 
After an overview of some therapies which are based on the inhibition of some key 
enzymes of the isoprene metabolism, attention is focused on the isoprenyl transferases 
PFT and PGGT-1. The mode of action, the molecular basis for substrate specificity and 
the structural design behind the development of PFT and PGGT-1 inhibitors is described. 
As four PFT inhibitors of PFT are and were the subject of ongoing clinical trials, these 









Figure 8.1 Sugar amino acid building blocks 1 – 4. 
 
Chapter 2 presents a novel route toward two dideoxy sugar amino acids (SAAs 1 and 
2, Figure 8.1) which were used in the construction of a set of Ca1a2L based 
peptidomimetics as potential PGGT-1 inhibitors. In the design the characteristic cysteine 
and leucine residues were preserved for recognition by PGGT-1 and the a1a2 dipeptide 
part was replaced by an isosteric SAA. To probe the influence of the nature of the 
cysteine and leucine residues on inhibition potency against PGGT-1, both the D and L 









































enantiomers were used. Two Ca1a2L analogs, which structurally differ in the 
configuration of both the C6 position of the central SAA residue (Figure 8.1) and the Cα of 
the cysteine residue were found to inhibit PGGT-1 with equal potency (IC50= 68 µM). As 
these results indicated that the developed SAA building blocks showed potential to 
function as dipeptide isosteres in the development of PGGT-1 inhibitors, this strategy was 
explored further.  
Chapter 3 describes the synthesis of a set of Ca1a2L and Ca1a2M based analogs in 
which the a1a2 dipeptide was replaced by hydrophobic sugar amino acids. As hydrophobic 
interactions govern the binding of the central dipeptide part a1a2  in the active site of the 
isoprenyl transferases, it was envisioned that masking of the hydroxyl group of the SAAs 
presented in Chapter 2 with a benzyl group (3 and 4, Figure 8.1), could increase 
inhibitory potency and selectivity. In order to increase the stability against proteolytic 
degradation, Ca1a2L and Ca1a2M analogs in which the amide bond between the SAA and  
the C-terminal X-residue was replaced by an amine were constructed. It appeared that 
the C6 stereochemistry of the SAA residue had a pronounced effect on both inhibitory 
potency and selectivity. Furthermore, incorporation of an amine bond between the 
dipeptide isostere and the X amino acid proved to be detrimental for the inhibition of 
both enzymes, in particular for PFT. From the Ca1a2M analogs a potent and selective PFT 
inhibitor (IC50= 250±20 nM) was obtained. The corresponding methylester of this PFT 
inhibitor exhibited in vivo inhibitory potency against PFT. From the Ca1a2L analogs, a 
modest dual inhibitor of PFT and PGGT-1 was obtained (IC50= 14 μM). The a1a2 binding 
cavity in PGGT-1 is smaller and less aromatic,2 and therefore it is envisioned that 
introduction of a smaller and non-aromatic group (such as Me or Et) at C-3 may be a 









Scheme 8.1 Alternative modification of central SAA in Ca1a2L analogs presented in Chapter 2.  
 
Reduction of the amide bond between the dipeptide isostere and the cysteine 
residue (Scheme 8.2) is another promising modification aimed at enhancing potency and 
selectivity. It is known from crystallographic studies that in the parent Ca1a2X 
tetrapeptide sequence this amide bond is not involved in any interaction with the 
enzyme. Two elegant approaches toward construction of the amine can be envisioned. 
First, by reductive amination of amine 8 with known amino cysteine aldehyde 93 
(Scheme 8.2). Second, by the Fukuyama/Mitsunobu glycosylation of ortho-
nitrobenzenesulfonamides 11 and readily available cysteinol 12.4   































R= Bn, Me, Et



















































Scheme 8.2 Reduction of amide bond between cysteine and SAA residue in Ca1a2X analogs of Chapter 3.    
 
Chapter 4 describes the design, synthesis and evaluation of lipophilic Ca1a2L analogs 
as potential bisubstrate inhibitors of PGGT-1. On the basis of the finding that isoprenyl 
transferases exhibit an unusual high affinity for their two substrates and especially for the 
turnover product, Ca1a2L analogues presented in Chapter 2 were connected either directly 
or via a linker (C2: glycine or C4: 4-aminobutyric acid) to the fatty acids lauric (C12) or 
palmitic acid (C16). Biological evaluation of the lipophilic Ca1a2L analogues against PGGT-
1 showed that the introduced lipophilicity had a positive effect on the inhibition potency. 
The gain in potency was found to depend on the type of SAA residue incorporated in the 
Ca1a2L part. Similarly to the PGGT-1 inhibitors of Chapters 2 and 3 it is not excluded that 
the inhibitory action of these lipophilic Ca1a2L analogs can be improved by executing the 






Figure 8.2 General structure of potential bisubstrate inhibitors of PGGT-1. 
 
Chapter 5 describes the evaluation of tetrazole as potential carboxyl bioisostere in 
the design of Ca1a2M based PFT inhibitors. The potent PFT inhibitor arising from Chapter 
3 and the parent PFT Ca1a2X sequence CVIM were used as lead compounds. A properly 
protected tetrazole analog of methionine was synthesised and used for the construction of 
the target compounds. Biological evaluation revealed that tetrazole is a suitable carboxylic 
acid isostere in SAA based PFT inhibitors. Unfortunately, the tetrazole analog of leucine 
could not be synthesised following a similar synthetic protocol. An alternative synthesis 
toward the targeted leucine tetrazole is shown in Scheme 8.3. With iodine and aqueous 
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(16).5 Subsequent treatment with zinc bromide and sodium azide under reflux conditions 
should subsequently furnish tetrazole 17.6 Although unprotected tetrazoles have been 
used under peptide coupling conditions,7 subsequent protection of 17 would be 
advantageous during the following synthetic steps. Alternatively, the introduction of the 
tetrazole could also take place at a later stage of the synthesis (16 → 18 → 19). 
 
Scheme 8.3 Alternative synthetic routes toward the synthesis of Ca1a2L of type 19.  
 
A promising substitution for the thiol group8 in the SAA based Ca1a2X analogs, 
presented in this Thesis, is the imidazole group. The zinc-chelating properties of the 
imidazole group have been successfully exploited in the design of inhibitors for several 
Zn2+-containing enzymes,9 including PFT and PGGT-1 (see Chapter 1). Combining all 
proposed structural prospects of this Thesis offers an interesting opportunity to construct 
SAA based Ca1a2X analogs with a high peptidomimetic character (23a, Scheme 8.4). Note 
that the amine functionality does not present an essential feature of the Ca1a2X box and 
may be deleted (23b).10     
 
 
Scheme 8.4 Imidazole as replacement for the thiol function in SAA based Ca1a2X analogs (22). 
 
Chapter 6 describes a novel labeling approach which enables the identification of 
farnesylated proteins in living cells. After addition of azidofarnesyl pyrophosphate to 
living cells, PFT recognises this farnesyl pyrophosphate analog as substrate and 
consequently modifies proteins susceptible to farnesylation. After lysis of the cells a 
biotinylated phosphine reagent (25, Scheme 8.5) is added, resulting in selective 














R3= Bn, Me or Et





















































X= O or H,H
















































23: R = H






(1) 2D gel MS, 
(2) multipledimensional MS
(3) isotope coded 
     affinity tagging/MS
Next, by using SDS-PAGE analysis and avidin-horseradish peroxidase (HRP) 
chemiluminescence, the isolated proteins could be visualised. When selective inhibitors 
of PFT were added to the cell culture, a decrease in labeling efficacy was observed. 
Analogously, labeling and isolation of PGGT-1 transformed proteins can be attained using 
azidogeranylgeranyl pyrophosphate (25, Scheme 8.5) as potential alternative substrate for 
PGGT-1. Ultimately, by employing current available proteomic tools,11 the here 











Scheme 8.5 Azidogeranylgeranyl pyrophosphate for the in vivo labeling of geranylgeranylated proteins. 
 
Chapter 7 describes a combinatorial approach toward a library of ambiphilic 
peptide-based compounds as potential inhibitors of PGGT-1. To circumvent the synthesis 
of large numbers of compounds, an in silico iterative optimization procedure was used. 
This comprises the arbitrarily rearrangement of individual building blocks of a set of 
compounds. The newly formed compounds were then synthesised and evaluated for their 
inhibitory activity against PGGT-1. After each synthesis and evaluation cycle, the 16 
most potent inhibitors were selected for the next optimization procedure. A total of 7 
generations of compounds were constructed and a progressive improvement of the 
average inhibitory activity was observed for 5 generations. IC50-values of the most active 
compounds were found to reside in the low micromolar range. The obtained lead 
compounds can be further developed using a classical structure based approach or the in 
silico iterative optimization procedure can be continued. This option requires an 
enhancement of the number of structurally divers building blocks. Additionally, diversity 
may also be enhanced by increasing the number of altered building blocks from one to 
two compounds per cycle. This means that per cycle two building blocks are replaced by 
a different building block.  
 
Finally, molecular modeling techniques represent, besides structure-activity 
relationship studies and X-ray crystallography, an important alternative tool for the 
understanding and improvement of the peptidomimetic design of isoprenyl transferase 





























inhibitors presented in this Thesis.12 As the isoprenyl transferases bind two different 
substrates in a relative big active site, kinetic analysis can be used in order to determine 
whether a compound is competitive for the Ca1a2X part, the isoprenyl part or both 
(bisubstrate inhibitor). In the case of a Ca1a2X analog, it is important to take into account 
that the isoprenyl substrate binds prior to the Ca1a2X moiety and thus should be included 
as a part of the active site. In general, two strategies can be envisioned during the 
modeling process (Figure 8.3). During the first and most widely used approach, the thiol 
group is “fixed” to the active site by its interaction with the Zn2+ ion while the remainder 
of the molecule is allowed to find an optimal binding mode. In the second approach, only 
the active site residues are fixed and the whole peptidomimetic inhibitor is allowed to 
find an optimal binding mode. In the case of a prenyl analog the amount of spacial 






   
 
Figure 8.3 Approaches toward molecular modeling of SAA based Ca1a2X analogs. 
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“Design, Synthesis and Biological Evaluation of Peptidomimetic Prenyl 
Transferase Inhibitors” 
 
In elke cel vervullen signaaltransductie-eiwitten een zeer belangrijke rol. Een bekende 
familie van signaaltransductie-eiwitten zijn G-eiwitten. De term G-eiwit is afgeleid van het feit 
dat deze eiwitten GTP (guanosine trifosfaat) binden en hydrolyseren. Deze membraangebonden 
eiwitten kunnen beschouwd worden als schakelaars en zijn betrokken bij het reguleren van 
talrijke belangrijke processen zoals celgroei, celdifferentiatie en transport. Begin jaren ’80 werd 
voor het eerst in ratten ontdekt dat bepaalde gemuteerde G-eiwitten betrokken zijn bij het 
ontwikkelen van kanker. Deze gemuteerde G-eiwitten bleken niet meer in staat om stop gezet te 
worden. Op grond van dit gegeven werden verscheidene onderzoeken gestart om deze 
gemuteerde G-eiwitten te remmen en op deze wijze anti-kanker middelen te ontwikkelen. In dit 
kader werd ontdekt dat G-eiwitten als precursor eiwitten worden gesynthetiseerd in het cytosol 
en door post-translationele veranderingen actief worden. De eerste essentiële stap in deze reeks 
van veranderingen is isoprenylering, een modificatie die nodig is voor aanhechting van de G-
eiwitten aan (de binnenzijde van) membranen waar zij hun biologische rol kunnen uitoefenen. 
Bij isoprenylering brengen de enzymen protein:farnesyl transferase (PFT) of 
protein:geranylgeranyl transferase-1 (PGGT-1) een covalente binding tot stand tussen een 
farnesyl (F) of geranylgeranyl (GG) koolstofketen en de C-terminus van het nog onvolwassen G-
eiwit. De primaire structuur van de laatste vier C-terminale aminozuren bepaalt of een G-eiwit 
wordt gefarnesyleerd of gegeranylgeranyleerd. Deze keten van vier aminozuren is bekend als de 
Ca1a2X-box en is voldoende om door PFT of PGGT-1 als substraat te worden herkend. In de 
Ca1a2X-box staat C voor de cysteine waaraan de isopreen wordt verbonden, a1a2 is een dipeptide 
keten die over het algemeen hydrofoob van karakter is. X staat voor het laatste C-terminale 
aminozuur en de stelregel is dat wanneer dit een methionine of serine is wordt het G-eiwit 
gefarnesyleerd. Wanneer X een leucine is wordt het G-eiwit gegeranylgeranyleerd. Farnesyl 
pyrofosfaat (FPF) en geranylgeranyl pyrofosfaat (GGPF), de substraten die de enzymen PFT en 
PGGT-1 in deze reactie gebruiken, zijn op hun beurt producten van het isopreen metabolisme in 
de cel. Een veel onderzochte benadering om gemuteerde G-eiwitten te blokkeren is gericht op het 
voorkomen van de localizatie van deze eiwitten in het celmembraan door het remmen van PFT 
en/of PGGT-1. Het belang van het ontwikkelen van PFT en PGGT-1 remmers is de laatste jaren 
toegenomen omdat er duidelijke aanwijzingen zijn dat naast anti-kanker therapieën, andere 
therapeutische toepassingen in het vooruitzicht liggen. Hierbij gaat het om bestrijding van 
botontkalking (osteoporose), vernauwingen in het vasculaire systeem (atherosclerose/restenose), 




De algemene inleiding (Hoofdstuk 1) begint met een korte uiteenzetting van het 
isopreen metabolisme en zijn produkten. Verschillende therapieën, die zijn gebaseerd op 
het ingrijpen in enzymatische processen aan het begin van het isopreen metabolisme 
worden opgesomd. Hierbij worden de enzymen PFT en PGGT-1 in detail besproken en 
wordt een selectie gegeven van relevante PFT en PGGT-1 remmers, waaronder vier 
verbindingen die momenteel klinisch getest worden. Aan de hand van de gekozen 
remmers worden de verschillende strategieën, die gebruikt worden om PFT en PGGT-1 
remmers te ontwikkelen, uiteengezet. Een van deze strategieën maakt gebruik van het 
gegeven dat tetrapeptiden gebaseerd op de Ca1a2X-box keten PFT en/of PGGT-1 kunnen 
remmen. Korte peptidefragmenten zijn echter niet geschikt voor therapeutische 
doeleinden, omdat zij in het lichaam meestal snel enzymatisch worden afgebroken en 
bovendien in het algemeen slecht door cellen worden opgenomen. De nadelen van 
natuurlijk voorkomende peptiden kunnen worden ondervangen door verbindingen die de 
structuur van peptiden nabootsen, de zogenaamde peptidomimetica.  
In Hoofdstuk 2 wordt beschreven dat (dideoxy) suikeraminozuren (SAAs= “sugar 
amino acids”) als dipeptide isosteer kunnen dienen in de ontwikkeling van potentiële 
remmers van PGGT-1. Suikeraminozuren zijn monosaccharide derivaten die ten minste 
één amine- en één carbonzuurgroep bevatten. Suikeraminozuren verhogen na inbouw in 
een peptide de enzymatische stabiliteit en kunnen een bepaalde conformatie induceren. 
Twee verschillende SAA bouwstenen, met de amine en de carboxyl groep aan de 
pyranose suikerring in een cis of trans relatie, werden gesynthetiseerd en ingebouwd in 
de Ca1a2X-box ter vervanging van het centrale a1a2 dipeptide gedeelte. Naast de SAAs 
werden zowel de natuurlijke L-configuratie en de onnatuurlijke D-configuratie van de 
aminozuren cysteine (C) en leucine (L) in de Ca1a2L analoga ingebouwd. Twee van de 8 
gesynthetiseerde verbindingen bleken actieve remmers van het enzym PGGT-1 te zijn. 
De synthese en inbouw van hydrofobe SAAs in Ca1a2X analoga als potentiële PFT en 
PGGT-1 remmers wordt in Hoofdstuk 3 besproken. Deze SAAs bevatten een extra 
benzylgroep in vergelijking met de SAAs van Hoofdstuk 2. Tevens werd de amide binding 
tussen het C aminozuur (cysteine) en het suikeraminozuur vervangen door een amine 
binding. Uit de biologische evaluatie bleek dat deze amine verbindingen veel minder 
actief waren en dat de amide band tussen de cysteine en SAA een belangrijke rol speelt. 
De Ca1a2X analoga met de gebenzyleerde SAAs bleken, na biologische evaluatie tegen PFT 




en selectiviteit (voor PFT of PGGT-1) van de Ca1a2X analoga sterk werd beïnvloed door 
de cis of trans relatie van de ingebouwde SAA bouwsteen. Ten slotte werd een sterke en 
selectieve remmer van PFT geselecteerd voor biologische evaluatie in een levende 
celcultuur. Daarvoor was het noodzakelijk om de eindstandige zuurgroep van het M 
aminozuur (methionine) om te zetten in een methylester. Door deze hydrofobe 
verandering passeert de remmer gemakkelijker het celmembraan om vervolgens in de cel 
door enzymen te worden gehydrolyseerd tot het oorspronkelijke zuur. Uit de 
testresultaten bleek de remmer ook in levende cellen als een potente PFT remmer te 
fungeren.  
In Hoofdstuk 4 wordt de bereiding van lipofiele Ca1a2L analoga als potentiële 
bisubstraat remmers van PGGT-1 gepresenteerd. PGGT-1 en PFT hebben een zeer grote 
affiniteit voor hun geïsoprenyleerde produkt. Door de remmers uit de Hoofdstukken 2 en 
3 aan het amino-uiteinde te voorzien van een alkylstaart worden lipofiele Ca1a2L analoga 
verkregen, die zowel met de peptide als isopreen pocket van het enzym interactie kunnen 
hebben. De lipofiele Ca1a2L analoga bleken een positieve invloed op de remmende 
werking te hebben. De toename in activiteit bleek wel afhankelijk van het type SAA. Er 
werd echter niet onomstotelijk bewezen dat de verbindingen echte bisubstraat remmers 
waren. 
In Hoofdstuk 5 wordt de vraag beantwoord of tetrazool gebruikt kan worden als 
vervanging van de carboxyl functie in PFT remmers. Eerst werd de tetrazool derivaat van 
methionine gesynthetiseerd en vervolgens ingebouwd in zowel de meest actieve PFT 
remmer uit Hoofdstuk 3 als het referentie peptide CVIM. Uit de testresultaten bleek dat 
de activiteit van deze remmers slechts marginaal was afgenomen, waarmee is aangetoond 
dat tetrazool een geschikte vervanger is van de carboxyl functie. Een overeenkomstige 
procedure voor PGGT-1 remmers was niet succesvol, omdat de synthese van de tetrazool 
derivaat van leucine niet mogelijk bleek volgens de methode gepresenteerd in dit 
hoofdstuk.  
In Hoofdstuk 6 wordt aandacht besteed aan een nieuwe methode om gefarnesyleerde 
eiwitten in de levende cel te detecteren. Het aantonen van elke familie van eiwitten in 
levende cellen is van groot belang om biologische processen onder normale en 
pathologische omstandigheden te begrijpen alsmede om het effect van geneesmiddelen op 
deze processen te onderzoeken en kwantificeren. De gebruikte methode omvatte de 




biologisch inerte azide groep. Het derivaat bleek niet alleen de celwand te passeren maar 
tevens te worden ingebouwd in gefarnesyleerde eiwitten. Dit kon na lysering van de cel 
worden bewezen omdat de azide functie met behulp van een selectieve reactie kan 
worden voorzien van een biotine-label. Na scheiding van de gemarkeerde eiwitten met 
behulp van SDS polyacrylamide gel electroforese worden de eiwitten op de gel zichtbaar 
gemaakt door middel van een “avidine-horseradish peroxidase” behandeling. Ook het 
effect van in dit proefschrift beschreven remmers op het farnesyleren van eiwitten in 
levende cellen kon zichtbaar worden gemaakt. 
Ten slotte beschrijft Hoofdstuk 7 een combinatoriële benadering om PGGT-1 
remmers te ontwikkelen. De bindingsplaats van geranylgeranyl pyrofosfaat in het enzym 
werd als doel gekozen zodat de algemene structuur van de potentiële remmers lipofiel 
met een polair uiteinde moest zijn. De verbindingen werden met behulp van peptide 
chemie gemaakt via een vaste drager procedure. Om een grote diversiteit te krijgen 
werden vier verschillende groepen van commercieel verkrijgbare bouwstenen 
geselecteerd. Om het aantal te synthetiseren en te testen verbindingen te beperken werd 
tevens een rekenmethode gebruikt waarmee de doelverbindingen werden geselecteerd. 
Na vijf cycli van zestien verbindingen gesynthetiseerd en getest te hebben, bleek de 
gemiddelde activiteit van de remmers niet meer toe te nemen. In totaal werden zeven 
cycli uitgevoerd en bleken de beste remmers een laag micromolaire IC50 waarde te 
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